{"NCT01500577": {"age": ["65 Years", "18 Years"], "eligibility": ["Current use of statins", "CNS diseases and major psychiatric diseases or inability to comply to the protocol procedures;", "Performance Status (SWOG) = 0;", "Evidence of residual disease as documented by mammograms, histologic confirmation of margin involvement or distant disease;", "Cardiac failure, class I-IV ;", ">10% probability of being a BRCA1/2 mutation carrier, according to Berry Parmigiani and/or Couch model;", "Proven hypersensitivity to nimesulide and/or simvastatin;", "Willingness to sign the informed consent form", "Histologic confirmation of hormone non-responsive DCIS (ER<5%, PgR<5%), or AH or LIN, radically excised in the previous 12 months;", "Current childbearing and inability to prevent it during the intervention period and for at least 3 months after cessation of treatment;", "Severe gastrointestinal disorders;", "Positivity for BRCA1 mutation;", "Current lactation.", "Active infections;", "Current use of NSAIDs;", "Current use of fibrates", "Current anticoagulant or antiplatelet aggregation therapy;", "Mitral and/or tricuspid valvulopathy or valvular prosthesis; Angina; Severe arterial hypertension; Chronic and/or paroxysmal atrial fibrillation; Previous myocardial infarction;", "Mild or higher alterations of hematologic, liver and renal function (i.e., WBC <3,500/mm3, Plt <120,000/mm3, HgB <10 g/dL, AST >45 U/L, ALT >45 U/L, creatinin >1.5 mg/dL, bilirubin >1.15 mg/dL, CPK 250 mg/dL);", "Current use of potent CYP3A4 inhibitors (ciclosporin, mibefradil, itraconazole, ketoconazole, erythromycin, clarithromycin)", "Previous or concurrent malignancy (with the exception of basal cell carcinoma and CIN);", "Unwillingness to be pregnant during the study and three months after drug suspension. Women will be informed that the use of contraceptive pill is contraindicated because it may interfere with the study drugs and may be harmful to a woman who has been diagnosed with breast cancer;", "Female, 18-65 years old inclusive"], "condition": ["Breast Cancer"], "location": ["Italy", "European Institute of Oncology", "Milan"], "intervention": ["Placebo", "Simvastatin", "nimesulide", "Sivastin", "Aulin"], "outcome": ["plasma IGF-I, IGFBP-1-2-3, estradiol, estrone sulphate, DHEA-sulphate, SHBG, C-reactive protein, prolactin", "Ki 67 variation"]}, "NCT01536314": {"age": ["18 Years"], "eligibility": ["Patient receiving treatment with amantadine, ketamine, dextrometorphan, L-Dopa, dopaminergic, anticholinergic agonists, barbiturate, neuroleptic, IMAO, antispastic agents, dantrolen or baclofen, phenitoin, cimetidine, ranitidine, procainamide, quinidine, quinine, nicotine, hydrochlorothiazide, warfarine", "18 years old", "Against-indication at memantine administration : hypersensitivity at active substance or excipients, hypertension, antecedent cerebrovascular accident, severe cardiac insufficiency", "Patient with alcohol addiction", "Patient with medical or surgical antecedents", "Woman in childbearing age not using effective contraceptive method, pregnant or lactating woman", "Diabetic patient (Type I and II)"], "condition": ["Neuropathic Pain"], "location": ["France", "CHU Clermont-Ferrand", "Clermont-Ferrand"], "intervention": ["Memantine EBIXA\u00ae"], "outcome": ["Evaluation of pain by numerical scale", "analgesic consumption", "Average painful", "average painful intensity"]}, "NCT00127205": {"iv-bin-abs": ["88", "92", "87", "93"], "iv-cont-count_of_participants": ["36", "55", "41"], "iv-cont-number": ["1", "3"], "age": ["18 Years"], "eligibility": ["No concurrent enrollment in clinical trials with bone density as an endpoint", "Stage I-III disease", "Antiangiogenics allowed", "Negative pregnancy test", "Sex", "Patients with skeletal pain are eligible provided bone scan and/or roentgenological exam are negative for metastatic disease", "Prior bisphosphonates for bone density allowed", "No history of esophageal stricture or motility disorders", "Female", "Creatinine clearance >= 30 mL/min", "Endocrine therapy", "Surgery", "Prior or concurrent hematopoietic growth factors allowed", "Menopausal status", "HER-2-targeted therapies allowed", "Neoadjuvant therapy or hormonal therapy alone is allowed provided study entry occurs >= 12 weeks after completion of surgery", "Patients who are at low risk for disease recurrence and for whom adjuvant systemic therapy will not be prescribed are not eligible", "Not pregnant or nursing", "Renal", "Hematopoietic", "18 and over", "Hepatic", "No renal failure", "Biologic therapy", "Fertile patients must use effective contraception", "Histologically confirmed primary adenocarcinoma of the breast", "Gastroesophageal reflux disorder allowed", "Creatinine <= 2 times upper limit of normal", "Prior neoadjuvant therapy allowed", "Age", "Suspicious findings must be confirmed as benign by x-ray, MRI, or biopsy", "No evidence of metastatic disease", "Axillary evaluation per institutional standards", "Performance status", "Zubrod 0-2", "Life expectancy"], "condition": ["Breast Cancer"], "intervention": ["clodronate disodium", "Arm I Zoledronate", "Arm III Ibandronate", "Arm II Clodronate"], "outcome": ["Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs", "Distributions of Sites of First Recurrence on the Three Arms.", "Overall Survival", "Disease-free Survival"], "outcome-Measure": ["Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs", "Distributions of Sites of First Recurrence on the Three Arms.", "Overall Survival", "Disease-free Survival"]}, "NCT00540800": {"age": ["70 Years"], "eligibility": ["Histological diagnosis of breast cancer", "Any concomitant pathology that would, in the investigator's opinion, contraindicate the use of the drugs in this study", "Creatinine > 1.25 x the upper normal limits", "Inability to comply with follow-up", "Symptomatic brain metastases", "Inability to provide informed consent", "ECOG performance status < 2", "Previous or concomitant malignant neoplasm (excluding adequately treated baso or spinocellular skin carcinoma or carcinoma in situ of the cervix)", "Previous treatment with docetaxel", "Neutrophil < 2000/mm3, platelets < 100,000/mm3, haemoglobin < 10 g/dl", "GOT and/or GPT > 1.25 x the upper normal limits in absence of hepatic metastases", "GOT and/or GPT > 2.5 x the upper normal limits in presence of hepatic metastases", "Written informed consent", "Bilirubin > 1.5 x the upper normal limit", "Age < 70 years"], "condition": ["Breast Cancer"], "location": ["Italy", "Ospedale S. Luca ASL SA 3", "Istituto Nazionale dei Tumori , Divisione di Oncologia Medica B", "Napoli", "Vallo della Lucania", "Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C"], "intervention": ["docetaxel"], "outcome": ["overall survival", "Toxicity", "Response rate", "quality of life"]}, "NCT00003906": {"age": ["35 Years"], "eligibility": ["No uncontrolled diabetes", "SGOT or SGPT normal", "No restricted normal activity for a significant portion of each day", "No evidence of suspicious or malignant disease on bilateral mammogram within the past year", "No prior systemic adjuvant therapy for breast cancer", "No clinical evidence of malignancy on physical exam within the past 180 days", "Female", "No deep vein thrombosis", "At least 10 years", "Prior documented hysterectomy and bilateral salpingo-oophorectomy", "No clinical depression, psychiatric condition, or addictive disorder", "No cerebral vascular accident, transient ischemic attack, atrial fibrillation, or uncontrolled hypertension", "Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of ovaries unknown with documented follicle-stimulating hormone level demonstrating elevation in postmenopausal range", "No concurrent nonmalignant disease that would preclude administration of tamoxifen or raloxifene", "Complete blood count and differential normal", "Concurrent Estring allowed", "Granulocyte count at least 1,500/mm^3", "Creatinine normal", "At least 12 months since spontaneous menstrual bleeding", "Platelet count normal", "Alkaline phosphatase normal", "35 and over", "Concurrent calcitonin or nonhormonal medication (e.g., cholecalciferol, fluoride, or bisphosphonates) allowed", "No concurrent warfarin or cholestyramine", "No bilateral or unilateral prophylactic mastectomy", "Bilirubin normal", "At least 55 years of age with prior hysterectomy with or without oophorectomy", "No prior invasive breast cancer or intraductal carcinoma in situ", "No pulmonary embolus", "NSABP-P-1 patients who received placebo are eligible", "Histologically confirmed lobular carcinoma in situ treated by local excision only OR a minimum projected 5 year probability of invasive breast cancer of at least 1.66%, using Breast Cancer Risk Assessment Profile", "At least 3 months since prior estrogen or progesterone replacement therapy, oral contraceptives, androgens, luteinizing hormone-releasing hormone analogs, prolactin inhibitors, or antiandrogens"], "condition": ["Breast Cancer"], "location": ["Jennie Edmundson Memorial Hospital", "Baystate Regional Cancer Program at Baystate Medical Center", "Manchester Memorial Hospital", "CCOP - Northwest", "Phoenix", "Women's College Ambulatory Care Center, Sunnybrook and Women's College Health Science Center", "Ames", "New London", "Holden Comprehensive Cancer Center at University of Iowa", "Pasadena", "Stanford Cancer Center at Stanford University Medical Center", "Greenebaum Cancer Center at University of Maryland Medical Center", "Canton", "Mercy Health Center", "Clinton", "Baylor Medical Center at Garland", "Fairview Hospital", "Coast Oncology/Hematology, P.L.L.C.", "Advocate South Suburban Hospital", "Fort Collins", "West Plains", "U.T. Cancer Institute at University of Tennessee Medical Center", "Oak Lawn", "Atlantic City Medical Center", "Bethlehem", "Danville", "Roper St. Francis Healthcare - Roper Hospital", "Peabody", "Flint", "Warren Hospital", "Miami", "Charleston", "CCOP - Upstate Carolina", "Findlay", "Northwestern Connecticut Oncology-Hematology Associates", "Dallas", "Hennepin County Medical Center - Minneapolis", "Southfield", "Kearney", "Creighton University Medical Center", "San Juan", "Mission Cancer Center at Mission Hospital", "Kalamazoo", "Greensboro", "Port Huron", "Baton Rouge", "Keesler Medical Center - Keesler Air Force Base", "Cedar Valley Medical Specialists, P.C.", "Valley Hospital", "Saint Louis Park", "Oxnard", "Ingalls Memorial Hospital", "McFarland Clinic, P.C.", "Mills-Peninsula Health Services", "Roswell Park Cancer Institute", "Allegheny General Hospital", "Waukesha", "Doylestown", "Albert Einstein Cancer Center", "Honolulu", "Saint Vincent Catholic Medical Center of New York", "Cincinnati", "Independence", "Roanoke", "Munster", "Center for Cancer Care at Goshen Health System", "Abilene", "Medical Associates", "Durham", "H. Lee Moffitt Cancer Center and Research Institute", "Baptist Regional Cancer Institute - Jacksonville", "CCOP - Columbia River Oncology Program", "CCOP - Wichita", "Iowa City", "Cooper Cancer Institute", "MBCCOP - Hawaii", "Florence", "Coldwater", "Oncology Alliance, S.C.", "Fairfield", "Norwich", "Lewes", "Richardson", "Roseville", "Fox Chase - Temple Cancer Center", "Burbank", "Marquette", "Capital Health System at Mercer", "Pueblo", "Muskogee", "Wellspan Health - York Cancer Center", "Presbyterian Healthcare", "CCOP - Atlanta Regional", "Valley Tumor Medical Group", "University of Texas Health Science Center at San Antonio", "Rockford", "CCOP - Dayton", "Pacific Shores Medical Group Comprehensive Hematology-Oncology Services - Long Beach", "Cedar Rapids", "Sacred Heart Hospital", "Crozer-Chester Medical Center", "Hemet Valley Medical Center", "Wauseon", "Wilford Hall Medical Center", "Traverse City", "Santa Fe", "Community Cancer Center at Rutland Regional Medical Center", "Hazel Crest", "Baylor/Richardson Cancer Center", "Minneapolis", "Hershey", "Frank C. Love Cancer Institute at St. Anthony Hospital", "Albuquerque", "Camden-Clark Memorial Hospital", "Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center", "Ella Milbank Foshay Cancer Center at Jupiter Medical Center", "Monroe", "Bergan Mercy Medical Center", "Underwood Memorial Hospital", "Pardee Memorial Hospital", "Suburban Hospital", "Hospital of St. Raphael", "North York General Hospital, Ontario", "CCOP - Northern Indiana CR Consortium", "Cancer Research Center at Boston Medical Center", "Drexel Hill", "New Britain", "John H. Stroger, Jr. Hospital of Cook County", "Concord", "Lufkin", "Royal Oak", "Easton", "CCOP - Christiana Care Health Services", "Jewish General Hospital - Montreal", "Philadelphia", "Mason City", "Bellingham", "Wilmington", "Glendale Memorial Hospital Comprehensive Cancer Center", "Sutter Roseville Medical Center", "Anaheim", "Mountainview Medical", "Julie and Ben Rogers Cancer Center", "Kaiser Permanente Medical Cener - Woodland Hills", "Geisinger Medical Center", "Siouxland Hematology-Oncology", "Plantation", "Firelands Regional Medical Center", "Vancouver", "Familial Oncology Program", "Meriden", "Fort Worth", "Chapel Hill", "Lapeer Regional Hospital", "Waterloo", "Parma Community General Hospital", "Scripps Memorial Hospitals-Stevens Cancer Center - Encinitas", "Evanston", "Virginia Oncology Associates - Newport News", "Park Ridge", "Lapeer", "Marshfield", "Bon Secours-Holy Family Health System", "Jamaica", "Baton Rouge General Medical Center", "Washington Hospital Center", "Tom Baker Cancer Center - Calgary", "Community Hospital", "Panorama City", "MBCCOP - Gulf Coast", "Lawrence and Memorial Hospital", "Pinnacle Health Regional Cancer Center at Pinnacle Health System", "Oakwood Hospital and Medical Center", "Paoli", "Edgewood", "Urbana", "CCOP - North Shore University Hospital", "Pottstown", "Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital", "Methodist Dallas Medical Center", "Northeast Arkansas Clinic", "Stanford", "Windham Community Memorial Hospital", "University of Chicago Cancer Research Center", "Tampa", "Todd Cancer Institute at Long Beach Memorial Medical Center", "Kalispell Regional Medical Center", "Santa Clarita Valley Cancer Center - UCLA", "New Hampshire Oncology-Hematology, PA - Hooksett", "Dearborn", "Yakima", "Cancer Research Network Inc.", "Bangor", "Penn State Cancer Institute at Milton S. Hershey Medical Center", "Fargo", "Anderson", "CCOP - Merit Care Hospital", "Columbia", "New Haven", "CCOP - Marshfield Clinic Research Foundation", "New Mexico Cancer Care Associates", "Santa Rosa", "Baptist Hospital East - Louisville", "Sacramento", "Charlottesville", "Statesville", "University of Miami Sylvester Cancer Center", "Corona", "Lima", "Mission Hospitals", "Columbus", "Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center", "Annapolis", "Lovelace Medical Center at Lovelace Sandia Health System", "CCOP - Oklahoma", "Frankfort", "St. John Health System", "Ireland Cancer Center", "Adrian", "Hattiesburg Clinic, P.A.", "Hematology-Oncology Associates, PC", "Mayo Clinic - Jacksonville", "Moses Cone Regional Cancer Center at Wesley Long Community Hospital", "Raleigh", "Mercy Medical Center", "Hartford", "Buffalo", "Saskatoon", "Palm Beach Cancer Institute", "Worcester", "Kaiser Permanente Medical Center - Riverside", "Somerville", "Hollings Cancer Center at Medical University of South Carolina", "CCOP - Montana Cancer Consortium", "St. Francis Hospital and Medical Center", "Flower Hospital - ProMedica Health System", "Louisville", "Ochsner Clinic of Baton Rouge", "Fall River", "Saginaw", "Cape Fear Valley Health System", "Fulton County Health Center", "Arkansas Cancer Research Center at University of Arkansas for Medical Sciences", "Edmonton", "Wichita", "Cross Cancer Institute", "Herbert Irving Comprehensive Cancer Center at Columbia University", "Torrance", "Akron General Medical Center", "Fontana", "CCOP - Virginia Mason Research Center", "Lubbock", "CCOP - Columbus", "Rush Cancer Institute at Rush University Medical Center", "Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute", "Red Bank", "Reading Hospital and Medical Center", "Greenbrae", "CCOP - Kalamazoo", "Baldwin Park", "La Jolla", "Thunder Bay", "Cooperstown", "Lancaster", "Farmington", "Chicago", "Charles M. Barrett Cancer Center at University Hospital", "Warrensville Heights", "Decatur", "Hinsdale Hematology Oncology Associates", "Erie", "Caritas Norwood Hospital", "Spartanburg", "Newport News", "Saint Anthony Memorial Health Centers", "Canada", "Cecilia Gonzalez De La Hoya Cancer Center at White Memorial Medical Center", "Lackland Air Force Base", "Mount Clemens", "Memorial Healthcare", "Willmar", "Pittsburgh", "Camden", "Cancer Treatment Center at Christus Schumpert St. Mary Place", "Rice Memorial Hospital", "Rockwood Clinic P.S.", "Edward H. Kaplan MD and Associates", "Gastonia", "Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center", "Flint Hematology Oncology", "New Orleans", "Kaiser Permanente Medical Center - Anaheim/Orange County", "Oceanside", "Mercy Fitzgerald Hospital", "Kingsport", "Northwestern Ontario Regional Cancer Care", "Naperville", "Missouri Cancer Care, P.C. - St. Charles", "Louis Busch Hager Cancer Center at Mary Imogene Bassett Hospital", "Sylvania", "High Point", "Green Mountain Oncology Group", "Oncology Institute of Greater Lafayette", "Tucson", "Clinical Research Center of South Florida", "Alegent Health - Immanuel Medical Center", "Swedish-American Regional Cancer Center", "Henrico Doctors' Hospital - Parham Campus", "Nanticoke Memorial Hospital", "Lansing", "Hooksett", "UW Cancer Center Wausau Hospital", "AnMed Health", "Enloe Cancer Center at Enloe Medical Center", "Olympic Hematology and Oncology", "Kaiser Permanente Medical Center - Baldwin Park", "Hartford Hospital", "Yale Comprehensive Cancer Center", "Nashua", "York", "Jacksonville", "Advocate Christ Medical Center", "Goodall Hospital", "Warren", "Irving", "CCOP - Grand Rapids", "Glendale", "Palm Springs", "CCOP - Duluth", "St. Francis Hospital", "Fayetteville", "Aurora Sinai Medical Center", "Hattiesburg", "Marin General Hospital Cancer Institute", "University Hospital - U.B.C. Site", "Munson Medical Center", "Tulane Cancer Center at Tulane University Hospital and Clinic", "Ottawa Regional Cancer Centre", "CCOP - Metro-Minnesota", "South Bend", "Southwestern Vermont Regional Cancer Center", "The Bronx", "Houston", "Torrance Memorial Medical Center", "University of Minnesota", "Maumee", "Great Falls", "University of Texas - MD Anderson Cancer Center", "Hinsdale", "Beth Israel Deaconess Medical Center", "Ann Arbor", "Cancer Center of Santa Barbara", "Saint Francis Medical Center", "Biloxi", "Manchester", "Montreal General Hospital", "Jonsson Comprehensive Cancer Center, UCLA", "South Jersey Regional Cancer Center", "Long Beach", "Missouri Baptist Cancer Center", "Leavey Cancer Center at Northridge Hospital Medical Center", "Rock Island", "Cancer Resource Center - Lincoln", "UCSF Comprehensive Cancer Center", "Poughkeepsie", "Anne Arundel Medical Center", "Cancer Center at Iredell Memorial Hospital", "University Hospital at State University of New York - Upstate Medical University", "Eastern Maine Medical Center", "United States", "Penrose Cancer Center", "St. John's Regional Health Center", "San Diego", "Stamford", "Oklahoma University Medical Center at University of Oklahoma Health Sciences Center", "St. Charles Medical Center", "Vallejo", "Montreal", "Doylestown Hospital", "Duarte", "Cleveland Clinic Taussig Cancer Center", "Credit Valley Hospital", "Houma", "Owosso", "Quain & Ramstad Clinic", "Regional Cancer Center - Erie", "Alta Bates Comprehensive Cancer Center", "Council Bluffs", "Berkeley", "Blue Water Oncology PC, Port Huron", "Maywood", "Langhorne", "Scottsdale", "Northridge", "Breast Health Center", "Saint Anthony Medical Center", "Atlanta", "Hurley Medical Center", "Huntsville", "Raleigh Hematology/Oncology Associates, P.A. - Rex Cancer Center", "Rebecca and John Moores UCSD Cancer Center", "Medical College of Georgia", "Edward Hospital Cancer Center", "Royal Victoria Hospital - Montreal", "Center for Hematology/Oncology", "Ephrata Community Hopital", "Seaford", "North Bay Cancer Center", "Ottawa", "CCOP - Evanston", "Kettering", "Long Branch", "CCOP - Scott and White Hospital", "HCA Kings Daughters Memorial Hospital", "Grand Blanc", "Mission Viejo", "Blanchard Valley Medical Associates", "St. Vincent Hospital and Health Care Center", "Mobile", "Huntington Cancer Center at Huntington Hospital", "Eastern Connecticut Hematology and Oncology Associates", "CCOP - Beaumont", "Bremerton", "Providence Saint Joseph Medical Center - Burbank", "University Hospital - Stony Brook", "Goshen", "Indiana Community Cancer Care, Incorporated", "Hematology Oncology, P.C.", "Our Lady of the Resurrection Medical Center", "Surgical Associates", "Temple", "Rutland", "Somerset Medical Center", "CCOP - Cedar Rapids Oncology Project", "University of Michigan Comprehensive Cancer Center", "New York Oncology Hematology, P.C. - Latham", "Mount Diablo Medical Center", "Lima Memorial Hospital", "Sandusky", "Chico", "Vermont Cancer Center at University of Vermont", "Huntsman Cancer Institute", "Flynn Cancer Center at Providence Everett Medical Center - Pacific Campus", "Kimmel Cancer Center at Thomas Jefferson University - Philadelphia", "Augusta", "Joliet Oncology Hematology Associates, Limited - Joliet", "Norfolk", "Granada Hills", "Sanchez Cancer Center", "Waukesha Memorial Hospital Regional Cancer Center", "Muskogee Regional Medical Center", "Kaiser Permanente Medical Center - Bellflower", "New Mexico Oncology-Hematology Consultants, Limited", "Phelps County Regional Medical Center", "Ridgewood", "Modesto", "NSMC Cancer Center", "Chester County Hospital", "Richmond", "North Valley Breast Clinic", "Providence", "Michigan City", "Parkersburg", "Vassar Brothers Medical Center", "Cancer Centers of the Carolinas - Eastside", "Frederick Memorial Hospital Regional Cancer Therapy Center", "Oncology/Hematology Associates", "Norton Healthcare Cancer Center", "New York Oncology Hematology, P.C. - Albany Regional Cancer Center", "CCOP - Central Illinois", "Toms River", "Minnesota Cooperative Group Program", "Arlington Heights", "Rochester", "Hendersonville", "CCOP - Ochsner", "Ephrata", "CCOP - Kansas City", "Tacoma", "Loma Linda University Cancer Institute at Loma Linda University Medical Center", "Boston", "North Mississippi Hematology and Oncology Associates, Limited", "CCOP - Mount Sinai Medical Center", "Saint Mary's Seton Cancer Institute", "Northwest Community Hospital", "Palmetto Richland Memorial Hospital", "Holland", "Cancer Center of the Piedmont, Inc.", "Jackson", "Sutter Gould Medical Foundation", "St. Elizabeth Medical Center", "MBCCOP - University of Illinois at Chicago", "Tupelo", "Hackensack", "Thompson Cancer Survival Center", "Burlingame", "Monmouth Medical Center", "Michigan State University Department of Surgery", "Community Health Center of Branch County", "Denver", "Community Cancer Care Specialist", "Sherman Hospital", "Skokie", "Poudre Valley Hospital", "Cancer Institute of New Jersey", "Burlington", "Jordan Hospital Club Cancer Center", "La Crosse", "Centre Hospitalier de l'Universite de Montreal", "Cancer Center at Christ Hospital", "Salt Lake City", "Lankenau Cancer Center at Lankenau Hospital", "Upland", "Corona Regional Medical Center", "Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill", "Normal", "Sanford", "Parma", "Saint Luke's Hospital", "Aurora", "Syracuse", "Arthur G. James Cancer Hospital - Ohio State University", "Baylor College of Medicine", "Sioux City", "Pottstown Memorial Regional Cancer Center", "Kaiser Foundation Hospital - West Los Angeles", "Grand Rapids", "Springfield", "CCOP - Mayo Clinic Scottsdale Oncology Program", "Lombardi Cancer Center at Georgetown University Medical Center", "St. Joseph Hospital Regional Cancer Center - Orange", "Albany", "McLeod Regional Medical Center", "Cancer Institute at Oregon Health and Science University", "Kaiser Permanente Medical Group", "Fleurimont", "Palo Alto", "Qu\u00e9bec", "Genesys Regional Medical Center", "Frederick", "Rolla", "CCOP - St. Louis-Cape Girardeau", "Yakima Regional Cancer Care Center", "Tyler", "Marquette General Hospital", "Knoxville", "West Chester", "Charles A. Sammons Cancer Center", "Mount Holly", "Florida Hospital Medical Center", "Franklin Square Hospital Center", "Chestnut Hill Healthcare", "Harrisburg", "Pensacola", "Newark Beth Israel Medical Center", "Methodist Cancer Center at Methodist Hospital", "Fremont Memorial Hospital", "JFK Medical Center", "Wendt Regional Cancer Center of Finley Hospital", "Winston-Salem", "Los Angeles", "Kaiser Permanente Medical Center - Vallejo", "Battle Creek", "Phillipsburg", "Beaumont", "Ottumwa", "Cancer Care Northwest - Spokane North", "Millville", "Arizona Cancer Center at University of Arizona Health Sciences Center", "St. Luke's Medical Clinic", "New Brunswick", "Markey Cancer Center at University of Kentucky Chandler Medical Center", "New York", "Saint James Hospital and Health Centers Comprehensive Cancer Institute", "Duke Comprehensive Cancer Center", "Amarillo", "Creticos Cancer Center at Advocate Illinois Masonic Medical Center", "Cardinal Bernardin Cancer Center at Loyola University Medical Center", "Joe Arrington Cancer Research and Treatment Center", "Abington", "Presbyterian Hospital of Dallas", "James Graham Brown Cancer Center at University of Louisville", "Rockford Clinic", "Charlotte", "St. Francis Hospital and Health Centers", "St. John's Regional Medical Center", "Baptist Cancer Institute - Memphis at Baptist Memorial Hospital - Memphis", "University of Wisconsin Comprehensive Cancer Center", "Memorial Health System of East Texas", "University of New Mexico Cancer Research and Treatment Center", "University of Massachusetts Memorial Medical Center - University Campus", "Bethesda North Hospital", "Bennington", "Milwaukee", "Little Rock", "CHUS-Hopital Fleurimont", "Charles R. Wood Foundation Cancer Center at Glens Falls Hospital", "Asheville", "Wellmont Holston Valley Hospital and Medical Center", "Jackson Oncology Associates, PLLC", "CCOP - Southeast Cancer Control Consortium", "Indianapolis", "Hickman Cancer Center at Bixby Medical Center", "Resurrection Medical Center", "Saint Anne's Hospital", "University of Texas Health Center at Tyler", "Ellis Fischel Cancer Center at University of Missouri - Columbia", "Kansas City", "Des Moines", "Rapid City", "Aultman Hospital Cancer Center at Aultman Health Foundation", "CCOP - Colorado Cancer Research Program, Incorporated", "Ball Memorial Hospital Cancer Center", "Miami Beach", "Las Vegas", "Orange", "Memorial Sloan-Kettering Cancer Center", "CCOP - Santa Rosa Memorial Hospital", "Woodland Hills", "CCOP - Iowa Oncology Research Association", "St. Charles Hospital", "St. Joseph Hospital Community Cancer Center", "California Pacific Medical Center - California Campus", "Swedish Cancer Institute at Swedish Medical Center - First Hill Campus", "Medical College of Ohio Cancer Institute", "Calgary", "Fred Hutchinson Cancer Research Center", "Frankford Hospital", "Central Oklahoma Cancer Center at INTEGRIS Southwest Medical Center", "Fort Smith", "Media", "St. Vincent Medical Center - Los Angeles", "Englewood Hospital and Medical Center", "Cancer Center at Paoli Memorial Hospital", "Omaha", "Saint Mary Regional Cancer Center", "St. Vincent's Medical Center", "Manhasset", "El Paso", "Lakeland Regional Cancer Center at Lakeland Regional Medical Center", "Kaiser Permanente", "Midstate Medical Center", "Community Medical Center", "Ozarks Medical Center", "Washington D.C.", "John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital", "Providence Alaska Medical Center", "Jonesboro", "Williamantic", "James P. Wilmot Cancer Center at University of Rochester Medical Center", "Leo W. Jenkins Cancer Center of University Health Systems of Eastern Carolina", "Ville Marie Breast Center", "Kaiser Permanente Center for Health Research", "Greenfield Park", "Kaiser Permanente Medical Center - Los Angeles", "Glens Falls", "Colorado Springs", "Queens Cancer Center of Queens Hospital", "Comprehensive Cancer Institute", "Beebe Medical Center", "Watson Clinic", "Kalispell", "Grand View Hospital", "Bellflower", "Oncology and Hematology Associates of Southwest Virginia, Inc.", "CCOP - Western Regional, Arizona", "Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha", "Shreveport", "Atlantis", "Kaiser Permanente Medical Center - Harbor City", "Genesee Surgical Associates", "Sioux Falls", "Providence Hospital", "St. Mary-Corwin Regional Medical Center", "Indiana Regional Cancer Center", "Bethesda", "CCOP - Sioux Community Cancer Consortium", "Mid-Illinois Hematology-Oncology Associates", "Mercy Community Hospital", "Hemet", "MBCCOP - San Juan", "New Hanover Regional Medical Center", "Stony Brook", "Toledo", "Darby", "Spokane", "Cornerstone Surgery", "Newark", "Mercy Hospital of Philadelphia", "Mid Delta Family Practice", "Cancer Care Specialists", "CCOP - Carle Cancer Center", "Ottumwa Regional Health Center", "Savannah", "Rhode Island Hospital", "Redding", "University of Connecticut Comprehensive Cancer Center at University of Connecticut Health Center", "San Francisco", "Bend", "Nashville", "Torrington", "Martha Jefferson Hospital", "Peoria", "Gaston Hematology and Oncology", "Battle Creek Health System", "CancerCare Manitoba", "Rush Copley Medical Center", "Mercy Memorial Hospital, Corporation", "Reading", "Altoona", "Hunterdon Regional Cancer Center", "Mercy Cancer Center at Mercy Medical Center - North Iowa", "Lakeland", "St. John's Hospital", "Comprehensive Cancer Center at Wake Forest University", "Sherbrooke", "Toronto", "Cleveland Clinic Cancer Center", "West Palm Beach", "Easton Hospital", "Santa Barbara", "Pennsylvania Oncology Hematology Associates", "Bismarck", "Comprehensive Cancer Centers of the Desert", "Berlin Corners", "MD Anderson Cancer Center Orlando", "Gynecologic Oncology Associates", "Southeastern Medical Oncology Center", "Davenport", "North York", "Sutter Breast Cancer Group", "Wilshire Oncology Medical Group, Incorporated - Pomona", "Scarborough", "Memphis", "St. Luke's Hospital", "Barbara Ann Karmanos Cancer Institute", "Central Baptist Hospital", "Saint Charles", "New Britain General Hospital", "Maine Center for Cancer Medicine and Blood Disorders - Scarborough", "St. Michael's Hospital - Toronto", "Woodbury", "Pomona", "Holland Community Hospital", "Detroit", "Southern New Hampshire Medical Center", "Booker Cancer Center at Riverview Medical Center", "Fremont", "Englewood", "Plymouth", "Everett", "Loma Linda", "Harvard Vanguard Medical Associates - Kenmore", "MBCCOP - LSU Health Sciences Center", "Palo Alto Medical Foundation", "Breast Associates", "Freeman Cancer Institute at Freeman Health System", "Lincoln", "USC/Norris Comprehensive Cancer Center and Hospital", "CCOP - Toledo Community Hospital", "Cleveland", "Riverside", "Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego", "Providence Memorial Hospital", "CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.", "Albert Einstein Clinical Cancer Center", "Bay City", "Harris Methodist Fort Worth", "Akron", "Memorial Medical Center", "Anchorage", "Ashland", "Texas Cancer Institute at St. Luke's Episcopal Hospital", "Genesis Regional Cancer Center at Genesis Medical Center", "Hendrick Cancer Center", "Providence Cancer Institute at Providence Hospital", "Abington Memorial Hospital", "City of Hope Comprehensive Cancer Center", "Naval Medical Center - San Diego", "Abramson Cancer Center at University of Pennsylvania Medical Center", "Hillman Cancer Center at University of Pittsburgh Cancer Institute", "Seattle", "Highland Park", "Mississauga", "Josephine Ford Cancer Center at Henry Ford Hospital", "Toronto General Hospital", "Lexington", "Hopital du Saint-Sacrement, Quebec", "CCOP - Northern New Jersey", "St. Vincent Mercy Medical Center", "CCOP - Michigan Cancer Research Consortium", "Fox Chase Cancer Center", "MBCCOP - Meharry Medical College - Nashville", "Dubuque", "Stuart", "Allentown", "Delaware County Memorial Hospital", "Trinity Medical Center - West", "Riddle Memorial Hospital", "Cleveland Clinic Health System STAR BCPT", "Laredo", "Greenville", "Kaiser Permanente Medical Center - Fontana", "Lafayette", "Wausau", "Baltimore", "Lahey Clinic Medical Center - Burlington", "Blumenthal Cancer Center at Carolinas Medical Center", "Joliet", "Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center", "Oklahoma City", "St. John Macomb Hospital", "Toronto Sunnybrook Regional Cancer Centre", "Toledo Hospital", "Puerto Rico", "North Idaho Cancer Center", "CCOP - Illinois Oncology Research Association", "St. Luke's Hospital Cancer Center", "Joplin", "San Antonio", "Toledo Clinic, Incorporated", "Fullerton", "Grand Island", "Midwest Hematology Oncology Group, Inc.", "Mayo Clinic Cancer Center", "Havertown", "Siteman Cancer Center", "Livingston", "Montana Cancer Institute - Benefis Healthcare", "Portland", "Elgin", "Hopital Charles Lemoyne", "West Florida Regional Medical Center", "Crosson Cancer Center at St. Jude Medical Center", "Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center", "Cancer Center at the Good Samaritan Health Systems", "Flemington", "Medical College of Wisconsin Cancer Center", "Lancaster General Hospital", "Berkshire Physicians and Surgeons, P.C.", "Kingston", "Centre Universitaire de Sante de L'Estrie", "Encinitas", "Ventura Hematology - Oncology Specialists - Oxnard", "Massachusetts General Hospital Cancer Center", "Cancer Care and Research Pavilion at St. Joseph's/Candler", "Coeur d'Alene", "NYU School of Medicine's Kaplan Comprehensive Cancer Center", "King's Daughters Medical Center", "Sellersville", "Winnipeg", "Bryn Mawr", "Saskatoon Cancer Centre", "Billings", "Orlando", "Greater Baltimore Medical Center and Cancer Center", "Southwest Cancer and Research Center at University Medical Center", "CCOP - Cancer Research for the Ozarks", "St. John Hospital and Medical Center", "Muncie", "Duluth", "Danville Hematology and Oncology, Incorporated", "Valencia", "Chesterfield", "Robert H. Lurie Comprehensive Cancer Center at Northwestern University", "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "Harrington Cancer Center", "Bay Diagnostic Center for Women", "St Louis", "MBCCOP - Massey Cancer Center", "Tulsa", "St. Barnabas Medical Center", "Evanston Northwestern Health Care - Highland Park Hospital", "Rapid City Regional Hospital", "Madison", "Harvey", "Latham", "Northwestern Memorial Hospital", "Pittsfield", "David Lee Cancer Center at Charleston Area Medical Center", "Comprehensive Cancer Center at Our Lady of Mercy Medical Center", "Bryn Mawr Hospital", "Jupiter", "Lutheran General Cancer Care Center", "Trenton", "Wynnewood", "Goldsboro", "Olympia Fields", "CCOP - Southern Nevada Cancer Research Foundation", "Harbor City", "Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas", "Keesler Air Force Base", "Forsyth Medical Center"], "intervention": ["Raloxifene"], "outcome": ["Effect of the study therapies on participants' quality of life.", "Effect of the study therapies on the incidence of fractures of the hip, spine, or Colles' fractures of the wrist.", "Effect of the study therapies on the incidence of endometrial cancer.", "Effect of the study therapies on the toxicity and side effects of each therapy.", "Effect of the study therapies on the incidence of intraductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).", "Incidence of invasive breast cancer; superiority of one of the therapies.", "Effect of the study therapies on the incidence of ischemic heart disease."]}, "NCT01942135": {"iv-cont-median": ["9.0", "1.9", "34.9", "3.8", "9.2", "10.4", "28.0", "1.0"], "iv-cont-count_of_participants": ["201", "3", "16", "1", "109", "10"], "iv-cont-number": ["85.5", "84.8"], "iv-bin-abs": ["21.0", "39.7", "66.3", "93.6", "98.8", "8.6"], "iv-cont-geometric_mean": ["295.1", "11.75", "70.70", "9.31", "302.5"], "iv-cont-mean": ["-0.3", "3.4", "1.8", "1.9", "-4.0", "-2.6", "-0.9", "3.3", "0.006", "-0.031", "3.8", "-1.8"], "age": ["18 Years"], "eligibility": ["Prior stem cell or bone marrow transplantation", "Any menopausal status", "Eastern Cooperative Oncology Group (ECOG) PS 0-1", "Major surgery or any anti-cancer therapy within 2 weeks of randomization", "Use of potent CYP3A4 inhibitors or inducers", "Adequate organ and marrow function, resolution of all toxic effects of prior therapy or surgical procedures", "Prior treatment with any CDK inhibitor, fulvestrant, everolimus, or agent that inhibits the PI3K-mTOR pathway", "Patients with extensive advanced/metastatic, symptomatic visceral disease, or known uncontrolled or symptomatic CNS metastases", "Progressed within 12 months from prior adjuvant or progressed within 1 month from prior advanced/metastatic endocrine breast cancer therapy", "Patient must agree to provide tumor tissue from metastatic tissue at baseline", "On an LHRH agonist for at least 28 days, if pre-/peri-menopausal, and willing to switch to goserelin (Zoladex \u00ae) at time of randomization.", "Measurable disease defined by RECIST version 1.1, or bone-only disease", "Women 18 years or older with metastatic or locally advanced disease, not amenable to curative therapy", "Confirmed diagnosis of HR+/HER2- breast cancer"], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Metastatic Breast Cancer"], "location": ["Belgium", "Pasadena", "Chiba", "SSD Oncologia Medica Addarii-Zamagni A.O.U. di Bologna Policlinico S. Orsola Malpighi", "Ufa", "Kennebunk", "Sheffield", "Prescott Valley", "Barwon Health, University Hospital Geelong", "Sutton", "Japan", "National Cancer Center", "Miami", "Dallas", "Aventura", "University of Pittsburgh Medical Center, William M. Cooper Pavilion, Hillman Cancer Center", "Northwest Georgia Oncology Centers, PC", "Inova Schar Cancer Institute", "Azienda U.L.S.S. n. 21 di Legnago, Presidio Ospedaliero Mater Salutis", "British Columbia Cancer Agency - Sindi Ahluwalia Hawkins Centre for the Southern Interior", "Osaka", "The Ottawa Hospital Cancer Centre, General Campus", "US Oncology lnvestigational Products Center (IPC)", "Fairfax", "Ukraine", "Portugal", "Stariy Oskol", "Bankstown", "Surrey", "Cardiff", "Oshawa", "Namur", "Orlando Health Cancer Institute", "Columbia St. Mary's", "The University of Arizona Cancer Center- North Campus", "Spitalul Municipal Ploiesti", "Virginia Cancer Specialists, PC", "The University of Arizona Cancer Center", "Royal Hallamshire Hospital", "Tournai", "Minneapolis", "Flagstaff", "Mercy Ministry Office", "Murdoch", "Institut Jules Bordet", "Texas Oncology- McAllen South Second Street", "Bankstown - Lidcombe Hospital", "Huntsman Cancer Hospital", "Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins", "Sunshine Hospital", "Philadelphia", "Peter MacCallum Cancer Centre Pharmacy", "Culver City", "Wilrijk", "Plantation", "Taipei", "Fort Worth", "Aichi Cancer Center Hospital", "Longview", "Sunshine Coast Hospital and Health Service", "Sheffield Teaching Hospitals NHS Foundation Trust, Weston Park Hospital", "Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates", "Westlake Village", "Fukuoka", "British Columbia Cancer Agency - Fraser Valley Centre", "Lisbon", "Ocoee", "Lviv", "ProHEALTHCARE Associates, LLP", "Brussels", "Holy Cross Hospital/Michael and Dianne Bienes Comprehensive Cancer Center", "Memorial Breast Cancer Center at Memorial Hospital West", "Royal Victoria Regional Health Centre", "Leids Universitair Medisch Centrum", "Chelyabinsk", "St. Catharines", "Cartersville", "City of Hope", "Charlottesville", "Calvary Mater Newcastle", "National Hospital Organization", "Samsung Medical Center", "Goodyear", "Gilbert", "Henderson", "UZ Antwerpen", "Saitama Cancer Center", "Mission Hospital, Inc.", "Mount Sinai Medical Center", "Arizona Oncology Associates, PC- HAL", "Romania", "FGBUZ Clinical Hospital 101 of the Federal Medical and Biological Agency\"", "Edina", "Policlinico di Modena Dipartimento ad attivita integrata di Oncologia,", "Torrance", "UCLA Hematology/Oncology - Santa Monica", "University of Miami Hospitals and Clinics (UHMC) Sylvester at Deerfield Beach", "GZA Ziekenhuizen - Campus St Augustinus", "La Jolla", "Chicago", "CareMount Medical", "Kharkiv", "McAllen", "S.C. Oncologia, A.O.S. Maria", "Zion", "Sylvester at Plantation", "Canada", "Swedish Medical Center", "University of Minnesota Medical Center, Fairview", "Bakersfield", "Rutgers Cancer Institute of New Jersey", "Pittsburgh", "Waratah", "Terni", "Birmingham", "Turkey (T\u00fcrkiye)", "Kagoshima", "Istituto Europeo di Oncologia", "Legnago (VR)", "Tucson", "Ballwin", "Leiden", "Taiwan", "Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital", "Haine-Saint-Paul", "Emily Couric Clinical Cancer Center", "IRST, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori", "Village Kuzmolovsky", "Memorial Cancer Institute at Memorial Hospital West", "Spitalul Clinic Judetean Mures", "Italy", "Libramont-Chevigny", "Irving", "Glendale", "Arizona Center for Cancer Care", "Peninsula and Southeast Oncology", "Fayetteville", "Maastricht", "Wellness Oncology & Hematology", "Komunalna ustanova \"Odeska oblasna klinichna likarnia\"", "M\u00fcnchen", "Ottignies", "OGBUZ Belgorod Oncology Dispensary", "Lake Success", "San Luis Obispo Oncology and Hematology Health Center/Pacific Central Coast Health Centers", "Podilskyi rehionalnyi tsentr onkolohii,", "ATTN - Research Pharmacist", "Ann Arbor", "Azienda Sanitaria Firenze, c/o Ospedale S. M. Annunziata Farmacia Interna", "UPMC Cancer Center, Monroeville", "Spitalul Clinic CF nr.2 Bucuresti", "Netherlands", "Farmacia Ospedaliera-Azienda U.L.S.S. n. 21 di Legnago", "Imelda Ziekenhuis", "CHU UCL Namur - Site Sainte-Elisabeth", "Shenandoah Oncology, P.C.", "United States", "The Jones Clinic, PC", "San Diego", "Montreal", "US Oncology Investigational Products Center (IPC)", "Catania", "Duarte", "UAB Hospital-Investigational Drug Service", "Atlanta", "Weslaco", "Southport", "Southern Cancer Center,PC", "Niagara Health System Walker Family Cancer Center", "Ottawa", "Fondazione IRCCS Istituto Nazionale dei Tumori", "Cabrini Brighton", "Mercy Hospital St.Louis- David C. Pratt Cancer Center", "Village Pesochny", "Geelong", "University of Miami Hospitals & Clinics", "Southern Cancer Center, PC", "Mobile", "Milan", "Mount Kisco", "Kita-adachi-gun", "National Hospital Organization Kyushu Cancer Center", "University of Alabama at Birmingham, The Kirklin Clinic", "Northern Westchester Hospital", "Comprehensive Cancer Centers of Nevada", "UCLA Hematology Oncology", "Monroeville", "Dnipro", "London", "Edegem", "Huntsman Cancer Institute", "University of Michigan Health System/Comprehensive Cancer Center", "Nambour", "Mount Sinai Comprehensive Cancer Center", "Norfolk", "Instituto Portugu\u00eas de Oncologia", "Velindre Cancer Centre", "Magee Womens Hospital of UPMC", "Piedmont Cancer Institute, PC", "Modena", "Maine Center for Cancer Medicine, dba: New England Cancer Specialists", "Nagoya", "Daphne", "UC San Diego Medical Center-Hillcrest", "Saint Petersburg GBUZ City Clinical Oncology Dispensary", "Texas Oncology- Dallas Presbyterian Hospital", "Brighton", "Hopital Erasme", "Rotterdam", "Klinikum der Universit\u00e4t M\u00fcnchen", "Santa Ana", "Memorial Cancer Institute at Memorial Regional Hospital", "Salt Lake City", "Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins, Green Spring Station", "Ege University Medical Faculty", "San Luis Obispo", "Aurora", "Grand Rapids", "National Hospital Organization Shikoku Cancer Center", "KNP Lvivskoi oblasnoi rady Lvivskyi onkolohichnyi", "Spitalul Judetean de Urgente \"Sf. Ioan cel Nou\"", "Porto", "Australia", "Mesa", "Chernivtsi", "Leesburg", "CHWaPi - Site IMC", "Princess Margaret Cancer Centre", "Tyler", "Goyang-si", "Central Coast Medical Oncology Corporation", "Global Research Management", "Rush University Medical Center", "IRCCS Istituto Nazionale per lo Studio e la Cura dei Tumori", "Izmir", "Brewster", "Cancer Care Centers of South Texas", "Los Angeles", "Stavropol", "Torrance Memorial Physician Network-Cancer Care", "Fiona Stanley Hospital - Cancer Centre", "GBUZ of Stavropol Territory \"Stavropol Regional Clinical Oncology Dispensary\"", "New Brunswick", "Auchenflower", "The Royal Marsden NHS Foundation Trust", "Swedish Medical Center First Hill IDS Pharmacy", "Milwaukee", "Lutherville", "Toronto East General Hospital", "Marietta", "Asheville", "Orlando Health", "Servizio di Farmacia - Istituto Europeo di Oncologia", "River City Pharmacy", "Kelowna", "Brunswick", "Virginia Oncology Associates", "Bucharest", "Seoul National University Hospital", "Thomas Jefferson University", "Malvern", "University of Colorado Hospital - Anschutz Cancer Pavilion (ACP)", "Miami Beach", "Las Vegas", "Tainan City", "Orange", "Virginia Beach", "Palo Verde Hematology Oncology", "Cliniques Universitaires Saint-Luc", "Austell", "Hospital of the University of Pennsylvania", "Matsuyama", "USC/Norris Comprehensive Cancer Center", "University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)", "Russia", "Seoul National University Bundang Hospital", "Pyatigorsk", "Odesa", "Farmacia - Fondazione Policlinico Universitario A. Gemelli", "Administrative Management Only: Translational Research Management", "West Hills", "LAC & USC Medical Center", "Seoul", "Portsmouth", "Germantown", "Cancer and Hematology Centers of Western Michigan", "Roma", "Chiba Cancer Center", "C.H. de l'Ardenne - site Libramont", "Breastlink Medical Group, Inc.", "Mequon", "Icon Cancer Care Southport", "Ploie\u015fti", "Cork", "Cancer Treatment Centers of America at Midwestern Regional Medical Center", "Zentrum fuer Radiologie und Nuklearmedizin am Johannisplatz", "Orbis Medisch Centrum", "Moscow", "Champalimaud Cancer Center/ Breast Unit", "Investigational Products Center (IPC)", "IRCCS Ospedale S. Raffaele", "St Albans", "National Cancer Center Hospital East", "Hollywood", "San Francisco", "Asan medical Center", "Pembroke Pines", "UCLA Hematology - Oncology Clinic - Westlake Village", "Ironwood Physicians P.C dba Ironwood Cancer & Research Centers", "UZ Leuven - Campus Gasthuisberg", "UC San Diego Medical Center-La Jolla", "Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust Portsmouth Haematology and Oncology Centre", "Leuven", "UC San Diego Moores Cancer Center", "Charleroi", "Grand H\u00f4pital de Charleroi - Site Notre Dame", "Toronto", "South Pasadena", "Mercy Hospital St. Louis", "Sedona", "Mercy Clinic St. Louis Cancer and Breast Institute", "National Cheng Kung University Hospital", "Haga Ziekenhuis", "UCLA Hematology/Oncology - Pasadena", "Farmacia IRCCS Ospedale San Raffaele", "Scarborough", "S.O.C. Oncologia Medica I, Azienda Sanitaria Firenze, c/o Ospedale S. M. Annunziata", "INDC Entit\u00e9 Jolimontoise - CH de Jolimont-Lobbes", "Tg. Mures", "GBUZ Leningrad regional oncological dispensary", "Deerfield Beach", "Inova Medical Group", "Western Regional Medical Center, Inc.", "Jewish General Hospital", "Germany", "Sittard-Geleen", "Monash Medical Centre", "Hope Women's Cancer Centers", "United Kingdom", "Sylvester Comprehensive Cancer Center Deerfield Beach", "Saint Petersburg", "Surprise", "Academisch Ziekenhuis Maastricht", "Keck Hospital of USC", "South Korea", "Santa Monica", "Seongnam-si", "Napoli", "Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital", "Texas Oncology- Weslaco", "Frankston", "Vinnytsia", "Fort Lauderdale", "Seattle", "Chandler", "Clinique Saint-Pierre", "Suceava", "University of California, San Francisco: Helen Diller Comprehensive Cancer Center", "Swedish Cancer Institute", "Cancer Centre of Southeastern Ontario @ Kingston Health Sciences Centre", "Hakuaikai Medical Corporation Sagara Hospital", "Universitaetsklinikum Leipzig AoeR", "The Hague", "Memorial Breast Cancer Center at Memorial Regional Hospital", "Arlington", "Baltimore", "Mount Sinai Medical Center- Aventura", "Bologna", "Barrie", "Lermontov", "GBUZ of Stavropol Territory \"Pyatigorsk Oncology Dispensary\"", "San Antonio", "TweeSteden Ziekenhuis", "Fullerton", "University of Alabama at Birmingham", "Bagno A Ripoli (FI)", "St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare", "FSBSI Russian Cancer Research Center n.a.NN Blokhin", "Kingston", "Winchester", "Ikazia Ziekenhuis", "Fondazione Policlinico Universitario A. Gemelli", "Leipzig", "Orlando", "Santa Maria", "University of Minnesota Physicians, Masonic Cancer Center", "Sunnybrook Research Institute", "GBUZ Republican Clinical Oncology Dispensary of Ministry of Health of the Republic of Bashkortostan", "Chesterfield", "Ireland", "Bon Secours Hospital", "Kashiwa", "Bonheiden", "Tilburg", "Cabrini Hospital", "GBUZ Chelyabinsk regional clinical center of oncology and nuclear medicine", "FGBU Russian Research Center for Radiology and Surgical Technologies", "Peter MacCallum Cancer Centre", "St Louis", "Melbourne", "Memorial Regional Hospital", "Texas Oncology- Longview Cancer Center", "Komunalnyi zaklad 'Miska klinichna likarnia No.4' Dniprovskoi miskoi rady,", "Meldola (FC)", "U.O. di Oncologia Medica P.O. Policlinico G. Rodolico\"", "Clayton", "Texas Oncology- Tyler", "Fairview Southdale Oncology Clinic", "Oblasne komunalne nekomertsiine pidpryiemstvo \"Bukovynskyi klinichnyi onkolohichnyi tsentr\"", "The Center for Cancer Prevention and Treatment at St. Joseph Hospital of Orange", "Saint Petersburg GBUZ \"City Clinical Oncology Dispensary\"", "Memorial Hospital West", "Hematology Oncology Medical Group of Orange County, Inc. (HOMG)", "Belgorod", "CBCC Global Research Inc. at Comprehensive Blood and Cancer Center", "Lakeridge Health Oshawa, R.S. McLaughlin Durham Regional Cancer Centre", "Avondale", "Sunshine Hospital Clinical Trials Pharmacy", "Komunalne nekomertsiyne pidpryiemstvo \"Oblasnyi", "National Taiwan University Hospital"], "intervention": ["Palbociclib + Fulvestrant", "Placebo + Fulvestrant", "Palbociclib"], "outcome": ["Observed Plasma Trough Concentration (Ctrough) for Palbociclib", "Time to Deterioration (TTD)", "Change From Baseline Between Treatment Comparison in EQ-5D Visual Analog Scale (VAS) Scores Scale", "Clinical Benefit Response (CBR)", "Change From Baseline Between Treatment Comparison in EORTC QLQ BR23 Symptom Scale Scores", "Overall Survival (OS)-Number of Participants Who Died", "Survival Probabilities at Year 1, Year 2, and Year 3", "Duration of Response (DR)", "Overall Survival (OS)", "Participants With Shifts From CTCAE Grade \u22642 at Baseline to CTCAE Grade 3 or 4 Postbaseline for Hematology Results", "Change From Baseline Between Treatment Comparison in European Organization for Research and Treatment of Cancer Breast Cancer Module (EORTC QLQ BR23) Functional Scale Scores", "Change From Baseline Between Treatment Comparison in EORTC QLQ-C30 Symptom Scale Scores", "Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities)", "Progression-Free Survival (PFS) as Assessed by the Investigator", "Ctrough for Fulvestrant", "Participants With Shifts From CTCAE Grade \u22642 at Baseline to CTCAE Grade 3 or 4 Postbaseline for Chemistry Results", "Change From Baseline Between Treatment Comparison in EuroQoL 5D (EQ-5D)- Health Index Scores", "Ctrough for Goserelin", "Objective Response (OR)", "Change From Baseline Between Treatment Comparison in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scale Scores"], "outcome-Measure": ["Observed Plasma Trough Concentration (Ctrough) for Palbociclib", "Time to Deterioration (TTD)", "Change From Baseline Between Treatment Comparison in EQ-5D Visual Analog Scale (VAS) Scores Scale", "Clinical Benefit Response (CBR)", "Change From Baseline Between Treatment Comparison in EORTC QLQ BR23 Symptom Scale Scores", "Overall Survival (OS)-Number of Participants Who Died", "Survival Probabilities at Year 1, Year 2, and Year 3", "Duration of Response (DR)", "Overall Survival (OS)", "Participants With Shifts From CTCAE Grade \u22642 at Baseline to CTCAE Grade 3 or 4 Postbaseline for Hematology Results", "Change From Baseline Between Treatment Comparison in European Organization for Research and Treatment of Cancer Breast Cancer Module (EORTC QLQ BR23) Functional Scale Scores", "Change From Baseline Between Treatment Comparison in EORTC QLQ-C30 Symptom Scale Scores", "Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities)", "Progression-Free Survival (PFS) as Assessed by the Investigator", "Ctrough for Fulvestrant", "Participants With Shifts From CTCAE Grade \u22642 at Baseline to CTCAE Grade 3 or 4 Postbaseline for Chemistry Results", "Change From Baseline Between Treatment Comparison in EuroQoL 5D (EQ-5D)- Health Index Scores", "Ctrough for Goserelin", "Objective Response (OR)", "Change From Baseline Between Treatment Comparison in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Functional Scale Scores"]}, "NCT00409071": {"age": ["18 Years"], "eligibility": ["Women with histologically proven non metastatic breast cancer", "ECOG performance status (PS) <= 2 (WHO scale)", "Follow-up impossible for social, geographical, familial or psychological reasons", "Treatment planning including 6 adjuvant CT courses with the first 3 being necessarily of the FAC50, FEC100 or TAC type", "Pregnant or lactating women", "Patients who cannot be contacted by phone", "Patient able to read and understand French", "Contraindication to corticosteroids or 5-HT3 receptor antagonists", "Written, voluntary, informed consent", "Age>= 18 years"], "condition": ["Breast Cancer"], "location": ["Centre Leon Berard", "France", "Lyon"], "intervention": ["Cocculine\u00ae"], "outcome": ["Rate of toxic effects (nausea and vomiting) recorded by investigators at the end of each of the 6 CT courses", "Patient autoevaluation (D1-D5) of nausea severity using a visual analogue scale and of the frequency of vomiting during the 1st, 2nd and 3rd adjuvant CT courses", "Score of \"vomiting\" and global score of \"nausea + vomiting\" calculated using the FLIE questionnaire at the time of the 1st, 2nd and 3rd adjuvant CT courses", "Score of \"nausea\" calculated using the FLIE questionnaire (Functional Living index for Emesis with 5-day recall)at the time of the 1rst adjuvant CT course", "Score of \"nausea\" calculated using the FLIE questionnaire at the time of the 2nd and 3rd adjuvant CT courses", "Evaluation of compliance: patient autoevaluation and counting of remaining tablets"]}, "NCT01435005": {"age": ["74 Years", "50 Years"], "eligibility": ["< 50 years of age", "Non-users of exogenous hormones or drugs related to estrogen metabolism, breast tissue growth", "Diabetes", "> 4 consecutive weeks absence during the intervention period", "Medical Exam,acceptable heart and lung function during a sub-maximal treadmill test", "Body mass index : 22 - 40", "Deemed too fit or too unfit on sub-maximal treadmill test", "Physically fit to undertake exercise program", "Non English Speaking", "Non-Smoker and non-excessive alcohol drinkers", "Pass the Physical Activity Readiness", "Age: 50- 74 years, postmenopausal women", "No previous cancer diagnosis", "Residents of Calgary and Edmonton able to attend fitness facility regularly."], "condition": ["Breast Neoplasms"], "location": ["Edmonton", "Canada", "Calgary", "Cross Cancer Centre", "Tom Baker Cancer Centre"], "intervention": ["Moderate Volume"], "outcome": ["Sex Hormone Levels", "Insulin resistance", "Body Fat", "Inflammation"]}, "NCT03046004": {"age": ["50 Years", "49 Years"], "eligibility": ["Women aged 49-50 who - in 2-4 months - will be invited to participate for the first time in the EDBCP of the Institut Hospital del Mar d'Investigacions M\u00e8diques (IMIM, Barcelona), ICO-Hospitalet (Hospitalet de Llobregat), Lleida Health Region, and the Canary Islands.", "Previous history of breast cancer", "Women with low health literacy will be included", "Cognitive impairment to understand or complete the materials based on the interviewer judgment", "Difficulty speaking Spanish or Catalan"], "condition": ["Breast Cancer Screening"], "location": ["Lleida Biomedical Research Institute (IRBLLEIDA)", "Lleida", "Spain"], "intervention": ["Decision aid for breast cancer screening"], "outcome": ["Confidence in the decision made", "Breast screening intention", "Anxiety about screening participation", "Breast screening attitudes", "Perceived risk of breast cancer", "Anticipated regret", "Time perspective", "Informed choice", "Decisional conflict", "Perceived importance of benefit/harms of screening", "Worry about breast cancer"]}, "NCT00311636": {"age": ["45 Years", "18 Years"], "eligibility": ["No evidence of metastases or localized or distant recurrence", "Investigation to exclude metastases required for any suspicious manifestation", "CMF (cyclophosphamide, methotrexate, and fluorouracil) every 28 days", "Histologically or cytologically confirmed breast cancer resected at time of original diagnosis", "E\u2192CMF (epirubicin hydrochloride followed by CMF every 28 days)", "FEC\u2192P (FEC every 21 days followed by paclitaxel every 21 days)", "Stage I-III disease", "FEC (fluorouracil, epirubicin hydrochloride, and cyclophosphamide) every 21 or 28 days", "No history of noncompliance to medical regimens or patients who are considered potentially unreliable", "EC\u2192P (epirubicin hydrochloride and cyclophosphamide every 21 days followed by paclitaxel every 21 days)", "Negative pregnancy test", "Female", "A\u2192CMF (doxorubicin hydrochloride followed by CMF)", "AC (doxorubicin hydrochloride and cyclophosphamide) every 21 days", "AC\u2192P (AC every 21 days followed by paclitaxel every 21 days)", "Not pregnant or nursing", "EC\u2192D (EC every 21 days followed by docetaxel every 21 days)"], "condition": ["Breast Cancer"], "location": ["Italy", "Sassari", "Como", "Naples", "Universita di Torino", "Sora", "Ospedale Silvestrini", "Ospedale Santa Croce", "Ospedale Treviglio Caravaggio", "Seconda Universita di Napoli", "Ospedale Civile", "Florence", "Carlo Poma Hospital", "Perugia", "Presidio Ospedaliero di Livorno", "Azienda Ospedaliera di Firenze", "Istituto G. Pascale", "Ospedale Sant Anna", "Livorno", "Mantova", "Treviglio", "Ospedale Santa Chiara Pisa", "Ospedale Civile ASL 1", "Trieste", "Cuneo", "Genoa", "Istituto Regina Elena", "Rome", "Ospedale SS Trinita", "Castelfranco - TV", "Federico II University Medical School", "Ospedale Maggiore dell' Universita", "Turin", "Istituto Nazionale per la Ricerca sul Cancro", "Pisa"], "intervention": ["cyclophosphamide"], "outcome": ["Toxicity as measured by Common Toxicity Criteria at each chemotherapy course", "Chemotherapy-induced early menopause as measured by follicle-stimulating hormone, 17 beta estradiol levels, and menstrual activity resumption at 1 year following the completion of chemotherapy"]}, "NCT00769080": {"eligibility": ["Upfront adjuvant hormonal therapy by an AI to which upfront adjuvant indication has not been granted by SFDA", "Provide signed and dated written Informed Consent", "Be capable of completing drug intake by herself", "Have been taking upfront AI adjuvant therapy in line with current SmPC", "Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)", "Be capable of understanding Chinese", "Upfront adjuvant AI medication which has exceeded over eight weeks"], "condition": ["Breast Cancer"], "location": ["Research Site", "Wuhan", "Chongqing", "Nanning", "Nanjing", "Guangzhou", "Harbin", "Beijing", "Tianjin", "Changsha", "China", "Qingdao", "Chengdu", "Shanghai", "Hangzhou"], "outcome": ["Morisky scale", "compare the 1-year adherence", "scores of Beliefs about Medicines Questionnaire (BMQ)", "Scores in Patient Centred Care Questionnaire (PCCQ)"]}, "NCT00983684": {"age": ["45 Years"], "eligibility": ["Operable invasive breast cancer (T1 and small T2, N0-1, M0) confirmed by cytological or histological examination", "Previously diagnosed and treated contralateral breast cancer may be entered but will be randomised to a separate stratum.", "Age 45 years or older", "Note: Individual centres may wish to restrict entry to a more exactly defined subset of patients, in which case, only patients with these characteristics may be entered by that particular centre. For example, centres may decide at outset to recruit only women over 50 or even over 65 years of age. Such policies must be pre-defined in writing and approved by the International Steering Committee.", "Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years is 90% or greater.", "Suitable for breast conserving surgery", "Bilateral breast cancer at the time of diagnosis.", "Patients presenting with gross nodal disease, considered to be clinically malignant or proven cytologically or by scanning. In general, 4 or more positive nodes or extranodal spread are not suitable for Targit alone and should receive EBRT as well. However, individual centres may decide that anything more than micrometastasis should receive EBRT.", "Patients known to have BRCA2 gene mutations, but testing for gene mutations is not required", "Any factor included as exclusion criterion in the local centre's Treatment Policy. This is particularly relevant to patients entered into the post pathology stratum.", "More than one obvious cancer in the same breast as diagnosed by clinical examination, mammography or ultrasonography.", "Lobular cancer or Extensive intraductal Component (EIC =>25% of the tumour is intraductal) on core biopsy or initial pathology (if performed)", "No more than 30 days can have elapsed between last breast cancer surgery (not axillary) and entry into the trial for patients in the post-pathology stratification.", "Patients with any severe concomitant disease that may limit their life expectancy.", "Ipsilateral breast had a previous cancer and/or irradiation.", "Available for regular follow-up for at least ten years."], "condition": ["Breast Cancer", "Invasive Breast Cancer"], "location": ["London", "Clinical Trials Group", "United Kingdom"], "intervention": ["EBRT", "Intrabeam", "IORT, targeted intra-operative radiotherapy, TARGIT", "Post-operative radiotherapy"], "outcome": ["Local relapse within the treated breast.", "Relapse-free survival and overall survival", "Site of relapse within the breast", "Local toxicity/morbidity"]}, "NCT00082433": {"iv-cont-median": ["15.64", "6.6", "4.40", "6.1", "16.39", "6.3", "6.24"], "iv-bin-abs": ["43.3", "28.8"], "iv-cont-number": ["42", "19"], "iv-cont-mean": ["0.0", "-0.5"], "age": ["18 Years"], "eligibility": ["Patients may not have had prior treatment with any epothilones and/or capecitabine (i.e. Xeloda)", "Patients may not have any history of brain and/or leptomeningeal metastases.", "Patients may not have Grade 2 or worse neuropathy at the time of study entry.", "Patients must have received prior treatment which included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel)."], "condition": ["Cancer", "Breast Cancer"], "location": ["London", "Gyeonggi-do", "Moscow", "Bethesda", "Prague", "Belgium", "V\u00f6cklabruck", "Canton", "Hartford", "East Melbourne", "Argentina", "Norfolk", "Jinan", "Arnhem", "Czechia", "Xi\u2019an", "Ramat Gan", "Local Institution", "Modena", "Genova", "Richmond", "Louisville", "Barrio Alto Verde", "Enschede", "Dallas", "Bela Vista", "Karlsruhe", "K\u00f8benhavn \u00d8", "Essen", "Reims", "Boston", "Chile", "Kinston", "Charleroi", "Boise", "Crete", "Jackson", "Zurich", "Wilton", "Terassa", "Baton Rouge", "Centro-Porto Alegre", "Thunder Bay", "Higienopolis", "Ja\u00e9n", "Potenza", "Voorhees Township", "Thun", "T\u00fcbingen", "Dilian", "Glasgow", "Canada", "Metz", "Memphis", "Durham", "Toowoomba", "Clermont-Ferrand", "Paris", "Bordeaux", "Jerusalem", "Iowa City", "Portugal", "Hickory", "Marburg", "Florence", "Birmingham", "Sydney", "Pretoria", "Turkey (T\u00fcrkiye)", "Beverly Hills", "Israel", "Hanover", "Germany", "Haifa", "Australia", "Pierre-B\u00e9nite", "South Africa", "Madrid", "Kortrijk", "United Kingdom", "Denmark", "Caen", "P\u00e1trai", "Saint Petersburg", "Tucson", "Graz", "Rio de Janeiro", "Barcelona", "South Korea", "Seville", "Johannesburg", "Santa Fe", "Taiwan", "Knoxville", "Coimbra", "Colmar", "Hradec Kr\u00e1lov\u00e9", "Greece", "Izmir", "Brazil", "Albuquerque", "South Brisbane", "Buenos Aires", "Switzerland", "Italy", "Kiel", "San Giovanni Rotondo", "Avellaneda", "Parkville", "The Hague", "New York", "China", "M\u00fcnchen", "Athens", "Nanjing", "The Bronx", "Adelaide", "Bari", "France", "Woodville", "Ghent", "Vienna", "Wilrijk", "Istanbul", "Plantation", "Tours", "Le Mans", "Taipei", "Netherlands", "Brisbane", "Panorama", "Thessaloniki", "Split", "Shrewsbury", "United States", "Evanston", "Montreal", "Saint-Gr\u00e9goire", "Elche (Alicante)", "Marshfield", "Saint-Brieuc", "Pontevedra", "Salamanca", "Beijing", "Wiesbaden", "Spain", "Ankara", "Berlin", "Ulm", "Zwolle", "S\u00e3o Paulo", "Torino", "Langhorne", "Bah\u00eda Blanca", "Saarbr\u00fccken", "Dalian", "Incheon", "Hasselt", "Kazan'", "Sora", "Zagreb", "Herlev", "Salta", "Lisbon", "San Miguel de Tucum\u00e1n", "Rozzano", "Rehling", "Reus", "Herston", "Russia", "Valencia", "Ireland", "Mineola", "Perugia", "Santiago", "Aalborg", "Guangzhou", "L'Hospitalet de Llobregat", "Belfast", "Brussels", "Dublin", "Saint-Herblain", "Ciudad Autonoma de Buenos Aires", "Erlangen", "Hangzhou", "Seoul", "Columbia", "Mendoza", "Westmead", "Villejuif", "Milan", "Brno", "Latham", "Zaragoza", "Perth", "Tel Aviv", "Bern", "Roma", "Shanghai", "Cadiz", "Charlottesville", "Resistencia", "C\u00f3rdoba", "Corona", "Bel\u00e9n de Escobar", "Croatia", "Singapore", "Columbus", "Goldsboro", "Austria", "Cork", "Santa Cruz de Tenerife", "Angers", "Galway", "Port Elizabeth"], "intervention": ["Capecitabine", "Epothilone", "Ixabepilone + Capecitabine", "IXEMPRA\u00ae"], "outcome": ["Duration of Response", "Response Rate (RR)", "Progression-Free Survival (PFS)", "Overall Survival (OS)", "Treatment-Related Safety Summary", "Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)", "Time to Response"], "outcome-Measure": ["Duration of Response", "Response Rate (RR)", "Progression-Free Survival (PFS)", "Overall Survival (OS)", "Treatment-Related Safety Summary", "Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)", "Time to Response"]}, "NCT03351075": {"iv-cont-mean": ["7.81", "3.70", "3.43", "5.53", "0.95", "4.22", "3.54", "14.99", "3.61", "10.05", "0.19", "1.76", "0.30", "19.77", "3.32", "2.37", "0.94", "-4.77", "7.26", "-0.01", "4.67", "50", "342", "0.51", "0.21", "-5.00", "9.49", "1.05"], "iv-cont-geometric_mean": ["0.812", "0.930", "0.760", "1.077", "0.987", "0.802", "0.896", "1.045"], "iv-cont-number": ["41", "30"], "eligibility": ["Cannot participate during the entire study period", "Active metastasis", "Axillary lymph node dissection and mastectomy/breast -conserving/reconstructive surgery OR Sentinel Node Biopsy and mastectomy/reconstructive surgery", "Patients with primary breast cancer"], "condition": ["Pain", "Breast Neoplasm"], "location": ["Leuven", "University Hospital Leuven", "Belgium"], "intervention": ["Intervention Group", "Control Group", "Standard physical therapy program"], "outcome": ["Self-reported Emotional Functioning: Stress", "Self-reported Change in Pain-related Disability", "Self-reported Emotional Functioning: Pain Catastrophizing", "Socio-economic Outcomes: Return to Work Rate", "Self-reported Pain-intensity", "Altered Somatosensory Functions (Nociception: Pinprick Sensation)", "Altered Somatosensory Functions (Nociception: Deep Pain Sensitivity)", "Self-reported Health-related Quality of Life", "Self-reported Emotional Functioning: Depression", "Self-reported Pain-related Disability", "Altered Somatosensory Functions (Touch)", "Endogenous Pain Inhibition Assessed by a Conditioned Pain Modulation Paradigm (0-10)", "Altered Somatosensory Functions (Temperature-warmth)", "General Physical Activity Level", "Altered Somatosensory Functions (Temperature-cold)", "Self-reported Upper Limb Function", "Self-reported Emotional Functioning: Anxiety", "Endogenous Pain Facilitation Assessed by a Temporal Summation Paradigm (0-10)", "Self-reported Central Sensitization Symptoms"], "outcome-Measure": ["Self-reported Emotional Functioning: Stress", "Self-reported Change in Pain-related Disability", "Self-reported Emotional Functioning: Pain Catastrophizing", "Socio-economic Outcomes: Return to Work Rate", "Self-reported Pain-intensity", "Altered Somatosensory Functions (Nociception: Pinprick Sensation)", "Altered Somatosensory Functions (Nociception: Deep Pain Sensitivity)", "Self-reported Health-related Quality of Life", "Self-reported Emotional Functioning: Depression", "Self-reported Pain-related Disability", "Altered Somatosensory Functions (Touch)", "Endogenous Pain Inhibition Assessed by a Conditioned Pain Modulation Paradigm (0-10)", "Altered Somatosensory Functions (Temperature-warmth)", "General Physical Activity Level", "Altered Somatosensory Functions (Temperature-cold)", "Self-reported Upper Limb Function", "Self-reported Emotional Functioning: Anxiety", "Endogenous Pain Facilitation Assessed by a Temporal Summation Paradigm (0-10)", "Self-reported Central Sensitization Symptoms"]}, "NCT02400567": {"age": ["18 Years"], "eligibility": ["Any surgery (not including minor procedures such as lymph node biopsy, primary tumor core biopsy, fine needle aspiration) within 4 weeks of start of study treatment; or not fully recovered from any side effects of previous procedures.", "QTc interval <=480 msec", "Serum Aspartate Transaminase (AST) and serum Alanine Aminotransferase Transaminase (ALT) <=2.5 x upper limit of normal (ULN)", "Assessment of nodal status available (Ultrasound guided FNA or biopsy if necessary)", "Total serum bilirubin <=1 x ULN", "Previous homolateral breast cancer (including in situ carcinoma), and/or contralateral breast cancer except if treated by surgery +/- radiation therapy alone without any systemic treatment", "ER-positive by IHC (Allred Score>=4)", "12 Lead electrocardiogram (ECG) with normal tracing or non clinically significant changes that do not require medical intervention.", "Previous use of SERMs such as raloxifene", "Non operable, bilateral, T4 or metastatic breast cancer", "No prior systemic therapy for the present tumor", "Alkaline phosphatase <=2.5 x ULN", "Either Luminal A AND proven nodal involvement (cytology or histology), or Luminal B through PAM50 ROR (Prosigna\u2122) centralized evaluation", "Absolute Neutrophil Count (ANC) >=1,500/mm3 or >=1.5 x 109/L", "Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drugs, such as the inability to take oral medication in tablet form and malabsorption syndrome", "Limited T2 breast cancer immediately accessible to conservative surgery", "Signed informed consent and health insurance coverage", "Stage II-IIIA", "HER2-negative by IHC (score 0 or 1+) and/or Fish/Cish", "Diagnosis of any previous malignancy within the last 5 years, except for adequately treated basal cell carcinoma, or squamous cell skin carcinoma, or in situ cervical carcinoma", "Patient with any psychological, familial, social or geographical condition which could potentially hamper compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.", "Platelets >=100,000/mm3 or >=100 x 109/L", "Aged >= 18 years, Post-menopausal women", "Newly diagnosed and operable unilateral invasive breast cancer, not candidate or uncertain for breast conservation - Note: Multicentric/multifocal tumors are allowed provided a maximum of 3 lesions are present, and all share the same characteristics: ER Allred 4, Her2- (PAM50 will be performed in the largest lesion)", "Previous hormone replacement therapy (HRT) stopped less than 2 weeks before beginning of treatment", "Non metastatic, M0", "Serum creatinine <=1.5 x ULN or estimated creatinine clearance >= 60 mL/min as calculated using the method standard for the institution", "Concurrent administration of herbal preparations as complementary medicine.", "Hemoglobin >=9 g/dL", "ECOG 0-1"], "condition": ["Neoadjuvant Operable Breast Cancer"], "location": ["Institut Curie", "Villejuif", "Paris", "Gustave Roussy", "France"], "intervention": ["Fluorouracile"], "outcome": ["Evaluation of the clinical response in each treatment arm as defined by clinical and ultrasound examination.", "Determination of the number and type of Adverse Events as a Measure of Safety and Tolerability", "Calculation of the rates of breast conservation therapy in the two arms with regard to the initially planned surgery.", "Correlation of the PAM50 risk of recurrence (ROR) score to its ability to predict RCB as defined in outcome 1", "Evaluation of the number of patients with a Residual Cancer Burden (RCB) 0-I index as a measure of efficacy"]}, "NCT02783222": {"age": ["65 Years"], "eligibility": ["Estimated life expectancy of >= 12 weeks", "No known active/symptomatic CNS metastases", "Measurable disease or non-measurable but evaluable disease according to RECIST 1.1 criteria", "Adequate organ function including ( Hemoglobin >= 9g/dL; Absolute neutrophil count >= 1.5 x 10^9/L; Platelets >= 100 x 10^9/L; Bilirubin <= 1.5 mg/dL; ALT and AST <= 3 x ULN (with or without known hepatic metastases); ALP <= 2.5 x ULN; Serum creatinine <= 1.5 ULN or calculated creatinine clearance (CrCl) >= 50mL/min according to the Cockcroft Gault formula", "ECOG performance status 0-2", "Presence of any psychological, familial, sociological or geographical condition that may potentially hamper compliance with the study protocol and follow-up schedule; these conditions should be discussed with the patient before trial registration", "Histologically or cytologically confirmed breast cancer, locally recurrent and/or metastatic; any estrogen/progesterone receptor status; HER2 receptor negative OR HER2 positive but with contraindication to anti-HER2 therapy (e.g. known congestive cardiac failure).", "Written informed consent (according to ICH/GCP and national/local regulations)", "Significant peripheral neuropathy (significant peripheral neuropathy is defined as >= grade 2 on CTCAE v4.0 criteria)", "Intake of any concomitant medications or therapies that may potentially interact with the trial agent. Any prohibited medication must be discontinued at least 14 days prior to trial entry"], "condition": ["Breast Cancer"], "location": ["A.O.U. Ospedali Riuniti", "Italy", "A.O.U. Federico Ii Di Napoli", "Brescia", "Istituto Oncologico Veneto", "Spedali Civili Brescia", "Padua", "Pavia", "Bergamo", "Ospedale Civile Maggiore", "Ospedale Ss. Trinita'", "Brindisi", "Lecce", "Udine", "Verona", "Milan", "Ospedale Antonio Perrino", "Azienda Ospedaliera Papa Giovanni Xxiii", "Ospedale Vito Fazzi", "Frosinone", "Istituto Europeo Oncologia", "Ausl 12 Viareggio", "Napoli", "Lucca", "Fondazione Maugeri", "Aviano", "Ancona", "Centro Di Riferimento Oncologico", "A.O.U. S. Maria Della Misericordia Di Udine"], "intervention": ["Abraxane", "Nab-paclitaxel"], "outcome": ["Event-free survival (EFS)", "Objective response rate (ORR)", "Progression free survival (PFS)", "Overall survival (OS)", "Clinical benefit rate (CBR)", "Incidence of adverse events"]}, "NCT00354302": {"age": ["45 Years", "120 Years"], "eligibility": ["More than 12 months since prior and no concurrent anticonvulsants", "No concurrent sodium fluoride at daily doses >= 5 mg/day", "No concurrent drugs (investigational or not), including bisphosphonates, for the prevention of osteoporosis (for patients with no osteopenia or osteoporosis [stratum I])", "Postmenopausal", "More than 6 months since prior and no concurrent corticosteroids at doses > 5 mg/day of prednisone (or equivalent) for > 2 weeks", "No long-term (i.e., > 6 months) use of coumarins", "More than 6 months since prior drugs (investigational or not), including bisphosphonates, for the prevention of osteoporosis (stratum I)", "No malabsorption syndrome", "No known cholecalciferol (vitamin D) deficiency, active hyper- or hypoparathyroidism, or Paget's disease", "No prior bisphosphonates (stratum II)", "Acceptable quality dual-energy x-ray absorptiometry (DEXA) of the L1-L4 postero-anterior spine and hip within 12 weeks prior to randomization on protocol CAN-NCIC-MA27", "Estrogen receptor- and/or progesterone receptor-positive tumor", "Female", "More than 12 months since prior and no concurrent anabolic steroids", "Enrolled in and meets eligibility requirements for protocol CAN-NCIC-MA27"], "condition": ["Breast Cancer", "Osteoporosis"], "location": ["The Moncton Hospital", "Regina", "Winnipeg", "Canada", "Cambridge", "Thunder Bay Regional Health Science Centre", "CHA-Hopital Du St-Sacrement", "Odette Cancer Centre", "Algoma District Cancer Program", "Cambridge Memorial Hospital", "St. Michael's Hospital", "CancerCare Manitoba", "Vancouver", "Qu\u00e9bec", "Greenfield Park", "Moncton", "Allan Blair Cancer Centre", "Hopital Charles LeMoyne", "Toronto", "Atlantic Health Sciences Corporation", "Thunder Bay", "Univ. Health Network-Princess Margaret Hospital", "Saint John", "BCCA - Vancouver Cancer Centre", "Sault Ste. Marie"], "intervention": ["calcium carbonate"], "outcome": ["Percentage of patients with osteopenia or osteoporosis (stratum II) who have \u2265 5% improvement of BMD at 2 years post randomization on protocol CAN-NCIC-MA27 and who have clinically apparent osteoporosis-related fracture of the long bones", "Percentage change in BMD at 5 years (from baseline)", "Mean percentage change in BMD at 1, 3, and 5 years (from baseline)", "Percentage change of bone mineral density (BMD) measured at 2 years (from baseline) in the L1-L4 region of the spine and the hip", "Proportion of patients without osteopenia or osteoporosis (stratum I) who develop BMD below the absolute threshold for osteopenia (< -2.0 standard deviation below the mean), suffer any osteoporotic fracture, or have an asymptomatic fracture revealed ...", "Clinical safety and tolerability of study medications", "Pattern of change in bone biomarkers from baseline"]}, "NCT00331097": {"age": ["65 Years", "80 Years"], "eligibility": ["GOT and-or GPT and/or bilirubin > 1.25 the upper normal limit", "Performance status >1", "Previous breast cancer treatment", "Concomitant conditions that contraindicate the use of the drugs in the protocol", "Distant metastasis", "Age > 65 and < 80 years", "Creatinine > 1.25 the upper normal limit", "Concomitant malignancy or malignancy within previous 5 years (except basal cell or spinocellular skin cancer and in situ cervical cancer if they have been adequately treated", "Intermediate-high risk of recurrence according to St. Gallen criteria: ER negative and PgR negative, or axillary lymph node metastasis, or tumor size > 2 cm, or tumor grade 2 or 3 (intermediate or high)", "Incapacity or refusal to provide informed consent", "Neutrophils < 2000/mm3 or platelets < 100000/mm3 or haemoglobin < 10 g/dl", "Histologically confirmed invasive unilateral breast cancer"], "condition": ["Breast Cancer"], "location": ["Italy", "Ospedale S. Luca ASL SA 3", "Treviglio", "Napoli", "Azienda Ospedaliera G. Rummo", "Monteforte Irpino", "Az. Osp. Treviglio - Caravaggio", "Azienda Sanitaria S. Giuseppe Moscati", "Policlinico Monteluce", "Vallo della Lucania", "Azienda Ospedaliera Cardarelli", "Universit\u00e0 Federico II, Cattedra di Oncologia Medica", "Benevento", "Istituto Nazionale dei Tumori, Divisione di Oncologia Medica C", "Sant'Andrea Delle Frate"], "intervention": ["docetaxel"], "outcome": ["toxicity", "overall survival", "quality of life", "disease free survival", "compliance"]}, "NCT00556374": {"iv-cont-median": ["NA"], "iv-cont-least_squares_mean": ["7.27", "-2.75", "3.41", "4.60", "-3.10", "-3.32"], "iv-cont-count_of_participants": ["31", "49", "27", "55"], "age": ["45 Years", "100 Years"], "eligibility": ["Serum creatinine >= 2 x ULN", "Current or prior intravenous (IV) bisphosphonate administration;", "Subjects who are currently on, or will initiate an approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting;", "A negative pregnancy test within 7 days prior to randomization. Subjects who have undergone a hysterectomy do not require a pregnancy test.", "Prior administration of denosumab;", "Greater than or equal to 3 years continuously,", "Subjects who ended treatment with investigational product (IP) prematurely in the double-blind phase; Treatment with commercial denosumab (Prolia or Xgeva) prior to participation in the OLP.", "Female subjects with non-metastatic disease who are estrogen receptor (ER) and/or progesterone receptor (PR) positive, and who have completed their treatment pathway;", "Recurrence of the primary malignancy (e.g., during the allowed interval of pretreatment with aromatase inhibitor);", "Aromatase inhibitor therapy for more than 24 months;", "Prior or concurrent treatment with SERMs (eg, tamoxifen);", "Diagnosis of any second non-breast malignancy within the last 5 years, except for adequately treated basal cell or squamous cell skin cancer, or for in situ carcinoma of the cervix uteri;", "Having undergone a bilateral oophorectomy;", "Any use during the 3-month period prior to participation in the OLP;", "Oral bisphosphonate treatment greater than or equal to 3 years continuously OR greater than 3 months but less than 3 years unless there was a washout period of at least 1 year prior to randomization OR any use during the 3-month period prior to randomization;", "Any sections of intestine removed.", "Randomized to placebo arm during the double-blind phase (as determined by unblinding procedures);", "Alanine transaminase >= 2.5 x ULN", "Known history of any of the following conditions either by subject self report or chart review", "Current or prior IV bisphosphonate administration;", "Major surgery, or significant traumatic injury occurring within 4 weeks prior to randomization", "Aspartate aminotransferase >= 2.5 x ULN", "Evidence of metastatic disease;", "Obtain signed and dated written informed consent prior to performing any study-specific procedure;", "Subjects currently taking an approved non-steroidal AIT (eg, anastrazole) or who have completed or discontinued AIT within 12 months prior to participation in the OLP;", "Known history of hypocalcemia", "Subjects who ended treatment with investigational product (IP) prematurely in the double-blind phase and OL phase", "Age >= 60 years;", "Greater than 3 months but less than 3 years unless subject has had a washout period of at least 1 year prior to participation in the OLP,", "Follicle-stimulating hormone (FSH) and estradiol in the postmenopausal range;", "Creatine clearance < 35ml/min Subjects that are pregnant or breastfeeding", "Obtain signed and dated written informed consent prior to performing any substudy-specific procedure", "Prior or concurrent treatment with Selective Estrogen Receptor Modulators (eg, tamoxifen);", "Known liver or renal deficiency;", "Parathyroid glands in neck surgically removed.", "All subjects with reproductive potential must have a negative pregnancy test within 7 days before randomization", "Known human immunodeficiency virus infection", "Subjects who are osteoporotic in baseline BMD", "Subjects that received OLP denosumab and completed OLP treatment", "More criteria may apply.", "Known sensitivity or intolerance to any of the products to be administered during the substudy (eg, ZA, calcium or vitamin D)", "Histologically or cytologically confirmed adenocarcinoma of the breast;", "Current or prior ZA administration.", "Active infection with hepatitis B or hepatitis C virus", "Any kind of disorder that compromises the ability to give written informed consent and/or comply with study procedures."], "ethinicity": ["Black/Afro-Caribbean", "Hispanic/Latino", "Missing", "White/Caucasian", "Asian"], "condition": ["Breast Cancer"], "location": ["Linz", "Gmunden", "Lienz", "Wolfsberg", "V\u00f6cklabruck", "Uppsala", "Salzburg", "Dornbirn", "G\u00e4vle", "G\u00fcssing", "Gothenburg", "Klagenfurt", "Baden", "Wels", "Weiz", "Braunau am Inn", "Oberpullendorf", "Vienna", "Villach", "Sch\u00e4rding", "Steyr", "Sweden", "Sankt P\u00f6lten", "Rottenmann", "Stockholm", "Graz", "Krems", "Research Site", "Sankt Veit an der Glan", "Feldkirch", "Leoben", "Ried", "Austria", "Hall in Tirol", "Kufstein", "Innsbruck", "Wiener Neustadt"], "intervention": ["Prolia\u00ae", "Placebo", "Denosumab", "Non-steroidal aromatase inhibitor therapy", "Administered as a subcutaneous injection"], "outcome": ["Bone Metastases-free Survival (BMFS)", "Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites", "Time to First Clinical Fracture", "Disease-free Survival (DFS)", "Overall Survival (OS)", "Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites", "Number of Participants With New Vertebral Fractures", "Number of Participants With New or Worsening Vertebral Fractures", "Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites"], "outcome-Measure": ["Bone Metastases-free Survival (BMFS)", "Percent Change From Baseline in Femoral Neck BMD at Month 36 at Pre-selected Sites", "Time to First Clinical Fracture", "Disease-free Survival (DFS)", "Overall Survival (OS)", "Percent Change From Baseline in Total Lumbar Spine Bone Mineral Density (BMD) at Month 36 at Pre-selected Sites", "Number of Participants With New Vertebral Fractures", "Number of Participants With New or Worsening Vertebral Fractures", "Percent Change From Baseline in Total Hip BMD at Month 36 at Pre-selected Sites"]}, "NCT02028221": {"iv-cont-mean": ["14.6", "-12.11", "-5.45", "0.178", "13.5", "-14.75", "-13.71", "0.170"], "age": ["54 Years", "21 Years"], "eligibility": ["No change in menstrual patterns for the past 6 months preceding the time of registration", "Elevated fasting glucose (>=100 mg/dL)", "Ability to understand and the willingness to sign a written informed consent document", "Have a history of lactic acidosis or risk factors for lactic acidosis", "Mammogram negative for breast cancer within the 12 months preceding the time of registration for women >= 50 years of age", "Have significant hepatic dysfunction (bilirubin >= 1.5 x ULN unless with Gilberts syndrome or AST/ALT >= 3 x ULN)", "Have a history of alcoholism or high alcohol consumption (average of > 3 standard drinks/day)", "Have electrically, magnetically, or mechanically activated implants including cardiac pacemaker, cochlear implants, magnetic surgical clips or prostheses", "Have a BMI of 25 kg/m2 or greater", "At least 55 years of age with prior hysterectomy with or without oophorectomy, or", "Waist circumference >= 35 inches or >= 31 inches for Asian Americans, individuals with polycystic ovary syndrome, or individuals with non-alcoholic fatty liver disease.", "Age 35 to 54 with a prior hysterectomy without oophorectomy OR with a status of ovaries unknown with documented follicle-stimulating hormone level demonstrating elevation in postmenopausal range", "On treatment with any drug for diabetes", "21-54 years of age", "Have a history of allergic reactions to metformin or similar drugs", "Have significant renal disease or dysfunction (creatinine >= 1.4 mg/dL)", "Have breast implants", "Postmenopausal women", "Premenopausal women", "Reduced HDL-C (< 50 mg/dL (1.3 mmol/L) or on drug treatment for reduced HDL-C", "Women who are pregnant, planning pregnancy within the next year, or breastfeeding", "Have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or any illness that would limit compliance with study requirements", "Amenorrhea for at least 12 months (preceding the time of registration), or", "History of hysterectomy and bilateral salpingo-oophorectomy, or", "Have a history of severe claustrophobia", "Elevated triglycerides (>= 150 mg/dL (1.7 mmol/L) or on drug treatment for elevated triglycerides", "Elevated blood pressure (>= 130 Hg systolic blood pressure or >=85 mm Hg diastolic blood pressure or on antihypertensive drug treatment in a patient with a history of hypertension"], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Breast Cancer Prevention"], "location": ["Tucson", "University of Arizona", "United States"], "intervention": ["Placebo", "Glumetza", "Fortamet", "Glucophage", "Metformin"], "outcome": ["Change From Baseline in Metabolomics Profile in Nipple Aspirate Fluid at 6 and 12 Months", "Change From Baseline in Plasma Metabolomics Profile at 6 and 12 Months", "Change From Baseline in Serum IGF-1 to IGFBP-3 Ratio at 6 and 12 Months", "Change From Baseline in Serum Testosterone Levels at 6 and 12 Months", "Change in Breast Density at 12 Months", "Change From Baseline in Waist Circumference at 6 and 12 Months", "Change From Baseline in Serum IGF-2 Levels at 6 and 12 Months", "Change in Breast Density at 6 Months", "Change From Baseline in Serum Insulin Levels at 6 and 12 Months", "Change From Baseline in Serum Leptin to Adiponectin Ratio at 6 and 12 Months", "Change From Baseline in Body Weight at 6 and 12 Months"], "outcome-Measure": ["Change From Baseline in Metabolomics Profile in Nipple Aspirate Fluid at 6 and 12 Months", "Change From Baseline in Plasma Metabolomics Profile at 6 and 12 Months", "Change From Baseline in Serum IGF-1 to IGFBP-3 Ratio at 6 and 12 Months", "Change From Baseline in Serum Testosterone Levels at 6 and 12 Months", "Change in Breast Density at 12 Months", "Change From Baseline in Waist Circumference at 6 and 12 Months", "Change From Baseline in Serum IGF-2 Levels at 6 and 12 Months", "Change in Breast Density at 6 Months", "Change From Baseline in Serum Insulin Levels at 6 and 12 Months", "Change From Baseline in Serum Leptin to Adiponectin Ratio at 6 and 12 Months", "Change From Baseline in Body Weight at 6 and 12 Months"]}, "NCT01516307": {"age": ["21 Years"], "eligibility": ["Platelets > 100,000/\u03bcL", "Anti-neoplastic agents", "Subjects with pleural effusions and/or ascites, due to malignancy, requiring paracentesis every 2 weeks or more frequently.", "Subjects with splenectomy.", "Ability to understand and the willingness to sign a written informed consent document according to institutional guidelines.", "Performance status: ECOG <= 1 and life expectancy >= 3 months.", "e.g. Type 1 juvenile onset diabetes mellitus, antibody positive for rheumatoid arthritis, Grave's disease, Hashimoto's thyroiditis, lupus, scleroderma, systemic vasculitis, hemolytic anemia, immune mediated thrombocytopenia, etc", "Subjects with any major autoimmune diseases or autoimmune disorders requiring systemic iv/oral steroids or immunosuppressive or immunomodulatory therapies.", "AST/ALT <= 3X ULN (upper limit of normal)", "Subjects with more than 2 events of disease progression after the development of metastatic breast cancer.", "AST/ALT <= 5X ULN [with underlying Liver Metastasis]", "No Symptomatic Congestive Heart Failure (Ejection Fraction EF >= 50%)", "Subjects who desire to enroll in this study and for whom anti-HER-2 therapy is not available or contraindicated, may be eligible to enroll in this trial.", "Subjects with HIV infection.", "ANC >= 1500 /\u03bcL", "Total Bilirubin <= 2.0 X ULN", "All positive or negative ER (estrogen receptor), PR (progesterone receptor), and HER-2 subjects are eligible for this study.", "Subjects are pregnant or breast-feeding at entry.", "Women of childbearing potential must be willing to implement adequate contraception during the study. An adequate method of contraception will be at the investigator's discretion.", "Female subjects >= 21 years of age with histological or cytological diagnosis of breast carcinoma.", "Subjects with bladder inflammation and urinary outflow obstruction.", "In countries where continuous anti-HER2 therapy is considered standard of care for HER-2 positive metastatic disease, HER-2 positive subjects are not eligible.", "Autoimmune disorders confined to the skin (e.g. psoriasis) are eligible, and topical steroids are allowed for the treatment of such skin disorders.", "During the study period, subjects using hormonal therapy and bisphosphonates should maintain a constant dose and should not change existing regimen.", "However, if a change in hormonal therapy is indicated, e.g. due to intolerable adverse effects, the regimen may be modified but change should be minimized thereafter.", "Immunosuppressants (e.g. Cyclosporin, Rapamycin, Tacrolimus, Rituximab, Alemtuzumab, Natalizumab, etc.).", "Subjects with any known severe allergies (e.g. anaphylaxis) to any active or inactive ingredients in the study drugs.", "Subjects with metastasis limited to the bone only are excluded. However, subjects with current metastasis limited to the bone only and with a history of distant metastasis are eligible. Subjects with current metastasis limited to the bone only and with current breast tissue lesion are eligible.", "However, subjects who are HER-2 positive and responsive to anti-HER-2 therapy (e.g. Herceptin), are encouraged to remain on anti-HER-2 therapy and not enroll in this trial.", "Subjects must have recovered from toxicities of prior therapies. (i.e. CTCAE <= grade 2).", "Serum Creatinine <= 1.5X ULN", "Subjects with any known uncontrolled inter-current illness including ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements."], "condition": ["Metastatic Breast Cancer"], "location": ["Dong-A University Hospital", "Daegu", "University of California, San Diego (UCSD)", "Korea University Anam Hospital", "Weill Cornell Medical College", "Shuang-Ho Hospital", "Inha University Hospital", "Chang Gung Memorial Hospital -Linkou", "Chungcheongbuk-Do", "Santa Maria", "San Luis Obispo", "New York", "Seoul St. Mary's Hospital", "China", "Hope Women's Cancer Center", "Mackay Memorial Hospital", "Taichung", "Koo Foundation Sun Yat-Sen Cancer Center", "University of California, Los Angeles (UCLA)", "Birmingham", "Yeungnam University Medical Center", "Taichung Veterans General Hospital", "Changhua", "Hollywood", "San Francisco", "University of California, San Francisco (UCSF)", "Houston", "Curie Manavata Cancer Centre", "Taipei Veterans General Hospital", "National Cancer Center", "Kaohsiung City", "Kyungpook National University Medical Center", "Seoul National University Hospital ,", "University of California, Irvine (UCI)", "Linkou District", "Seoul", "Memorial Regional Hospital", "Kaohsiung Medical University Hospital", "Kaohsiung Veterans General Hospital", "Bengaluru", "Chang Gung Memorial Hospital-KS", "India", "Asheville", "Chang Gung Memorial Hospital-Taipei", "Taipei", "University of Chicago Medical Center", "New Taipei City", "Coastal Integrative Cancer Care", "Busan", "Fullerton", "Pusan National University Hospital", "St. Jude Heritage Healthcare, Virginia K. Crosson Cancer Center", "South Korea", "Santa Monica", "The University of Alabama at Birmingham (UAB)", "United States", "Severance Hospital", "Taiwan", "La Jolla", "Central Coast Medical Oncology Corporation", "Changhua Christian Hospital", "Chi Mei Medical Center", "University of Texas MD Anderson Cancer Center", "China Medical University Hospital", "National Cheng Kung University Hospital", "UNIMED Medical Institute", "Chicago", "Mumbai", "Asan Medical Center", "Orange", "Tainan City", "Hong Kong", "Tri-Service General Hospital", "HCG, Bangalore Institute of Oncology", "National Taiwan University Hospital"], "intervention": ["OPT-822/OPT-821(30 \u03bcg/100 \u03bcg)"], "outcome": ["Progression Free Survival (PFS)", "Overall Survival (OS)"]}, "NCT01205503": {"iv-cont-geometric_mean": ["3.68", "102.63", "98.95", "73.54", "0.015", "3.55", "46.36", "49.24", "0.017", "108.82"], "age": ["18 Years"], "eligibility": ["doxorubicin 50 mg/m2, cyclophosphamide 750 mg/m2, vincristine 1.4 mg/m2 (capped at 2 mg dose), and prednisone 100 mg +/- rituximab 375 mg/m2", "total bilirubin <1.5 X normal institutional limits", "Age >18 years.Because these treatment regimens are rarely used in pediatric oncology, children are excluded from this study but will be eligible for future pediatric phase 2 trials.", "leukocytes >3,000/microliter (mcL) (unless due to cancer in marrow)", "creatinine clearance >60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal", "doxorubicin 50 mg/m2, cyclophosphamide 500 mg/m2, and docetaxel 75 mg/m2;", "creatinine within normal institutional limits OR", "left ventricular function >= 50 % ejection fraction", "Ability to understand and the willingness to sign a written informed consent document.", "Patients with known brain metastases should be excluded from this clinical trial because progressive neurologic dysfunction would confound the evaluation of neuro-cognitive outcomes.", "absolute neutrophil count >1,500/mcL (unless due to cancer in marrow)", "Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.", "Aspartate aminotransferase (AST) or serum glutamic oxaloacetic transaminase (SGOT)/Alanine aminotransferase (ALT) or serum glutamic pyruvic transaminase (SGPT) <2.5 X institutional upper limit of normal", "Patients requiring ongoing pharmacologic treatment of dementia are excluded.", "doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2;", "Zubrod performance score 2 or better.", "Life expectancy of greater than 6 months.", "platelets >100,000/mcL (unless due to cancer in marrow)"], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Non-Hodgkin's Lymphoma", "Breast Cancer"], "location": ["Lexington", "University of Kentucky Markey Cancer Center", "United States"], "intervention": ["Revimmune", "Mesnex", "Mesna", "Cyclophosphamide", "Placebo", "Endoxan", "Procytox", "Saline", "Cytoxan", "Cycloblastin", "Cycle 1 Mesna; Cycle 2 Saline", "Doxorubicin", "Cycle 1 Saline; Cycle 2 Mesna", "Adriamycin", "Neosar"], "outcome": ["TNF-alpha Levels in Patients Receiving Doxorubicin Containing Chemotherapy", "Protein Carbonyl Percent Changes From Baseline in Patients Receiving Doxorubicin Containing Chemotherapy", "Plasma HNE Percent Changes From Baseline in Patients Receiving Doxorubicin Containing Chemotherapy", "Troponin Levels in Patients Receiving Doxorubicin Containing Chemotherapy", "B-type Natriuretic Peptide (BNP) Blood Levels in Patients Receiving Doxorubicin Containing Chemotherapy"], "outcome-Measure": ["TNF-alpha Levels in Patients Receiving Doxorubicin Containing Chemotherapy", "Protein Carbonyl Percent Changes From Baseline in Patients Receiving Doxorubicin Containing Chemotherapy", "Plasma HNE Percent Changes From Baseline in Patients Receiving Doxorubicin Containing Chemotherapy", "Troponin Levels in Patients Receiving Doxorubicin Containing Chemotherapy", "B-type Natriuretic Peptide (BNP) Blood Levels in Patients Receiving Doxorubicin Containing Chemotherapy"]}, "NCT00721409": {"iv-cont-number": ["9", "7", "19", "31", "44", "32", "26", "39", "16", "41", "15", "2", "10", "12"], "iv-cont-median": ["20.9", "14.8", "20.3", "5.7", "18.8", "10.2", "33.3", "10.8", "20.2", "18.1", "35.1", "35.7", "7.92", "34.5", "11.1", "26.1", "37.5", "2.00", "1.04"], "iv-bin-abs": ["55.6", "38.8", "55.4", "2.2", "10.7", "81.0", "58.0", "41.9", "67.3", "33.3", "44.1", "6.5", "84.0", "5.4", "83.3", "25.0", "42.9", "42.0", "10.0", "34.8", "39.4", "43.8", "55.3", "7.9", "76.5"], "iv-cont-geometric_mean": ["1982", "94.95", "1933", "2583", "1739", "108.4", "NA", "1936", "104.0", "115.8", "63.08"], "iv-cont-mean": ["0.2", "28.81", "0.1", "0.6", "0.0", "1.1", "NA", "0.3", "1.2", "1.0"], "iv-bin-percent": ["2.76", "2.73"], "iv-cont-count_of_participants": ["33", "32", "13", "25", "83", "50", "66", "41", "46", "78", "20"], "age": ["18 Years"], "eligibility": ["Postmenopausal status.", "Acceptable bone marrow, liver and kidney function.", "Important cardiovascular events in the past 6 months.", "Inoperable estrogen receptor positive and HER2 negative breast cancer.", "Prior or concomitant treatment for advanced breast cancer.", "Tumor tissue (archived acceptable) available for biomarker studies. For Phase 2 Part 2 - CCND1 amplification and/or loss of p16 as determined by the central laboratory."], "condition": ["Breast Cancer"], "location": ["Moscow", "National Cancer Center, Center for Breast Cancer", "Henderson", "Pasadena", "Investigational Products Center (IPC)", "TORI Central Administration (Regulatory Managment Only)", "Orszagos Onkologiai Intezet, Kemoterapia B", "Ufa", "UCLA, Hematology/Oncology", "TORI Central Administration (Regulatory Management)", "M.O. di Oncologia - Azienda USL di Rimini - Ospedale \"Cervesi\"", "Donetsk", "Snellville", "Dallas", "Pyatigorsk Oncology Center", "Centre Paul Papin, CRLCC", "Redondo Beach", "Libertyville", "Municipal clinical treatment-and-propyilactic institution \"Donetsk regional oncology center',", "Lawrenceville", "Resurrection Medical Group", "Santa Barbara", "Mutterhaus der Borromaeerinnen, Innere Medizin I", "Chicago", "Budapest", "Mainz", "Skokie", "CHD Vendee", "Rimini", "Petz Aladar Megyei Oktato Korhaz, Onkoradiologia", "TRIO-US Central Administration", "Azienda Unita Sanitaria Locale di Rimini, U.O. di Oncologia ed Oncoematologia Ospedale degli Infermi", "Canada", "Fairfax", "Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe Universitaetsklinik Mainz", "Ukraine", "Drug Management Only: UCLA West Medical Pharmacy", "UCLA Hematology/Oncology", "Bakersfield", "UCLA Hematology Oncology-Santa Monica", "Pretoria", "Martin-Luther-Universitaet Halle-Wittenberg", "Universitaetsklinik und Poliklinik fuer Gynaekologie, Martin-Luther-Universitaet Halle-Wittenberg", "Department of Oncology and Medical Radiology, SI \"DMA of MOH, Ukraine, \"MI \"Dnipropetrovsk City", "Centro Oncologico de Galicia", "Germany", "Onkolog. Gemeinschaftspraxis", "Ny\u00edregyh\u00e1za", "Ico-Hospitalet", "Madrid", "Texas Oncology-Dallas Presbyterian Hospital", "South Africa", "Hospital Universitario 12 de Octubre", "Drug Management Only", "Ospedale Civile di Ravenna", "North Shore Oncology-Hematology Associates", "Kyiv", "Leesburg", "Bloemfontein", "Gy\u0151r", "Meldola", "Fovarosi Onkormanyzat Uzsoki Utcai Korhaz", "Dnipropetrovsk", "TORI -US Central Administration (Regulatory Management)", "Barcelona", "South Korea", "Santa Monica", "Seville", "Goyang-si", "Ronald Reagan UCLA Medical Center", "Central Coast Medical Oncology Corporation", "UCLA Hematology/Oncology - Alhambra", "Virginia Cancer Specialists, PC", "Divisione Oncologia Medica Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST", "Westwood Bowyer Clinic, Peter Morton Medical Building", "Highland Park", "Los Angeles", "Italy", "Szombathely", "St. Joseph Heritage Healthcare", "Kiel", "Municipal Treatment-and-Prophylactic Institution 'Donetsk City Oncological Dispensary' Radiology dep", "Gemeinschaftspraxis, Onkologischer Schwerpunkt am Oskar-Helene-Heim", "Gainesville", "Markusovszky Egyetemi Oktatokorhaz, Onkoradiologiai Osztaly", "Department of Oncotherapy, National Hospital", "Trier", "UCLA West Medical Pharmacy (Drug Management Only)", "Woodbridge", "North Shore Hematology Oncology", "M\u00fcnchen", "TORI -US Central Administration", "Arlington", "Lviv State Oncologic Regional Treatment and Diagnostic Centre", "State Budgetary Healthcare Institution \"Samara Regional Clinical Oncology Dispensary\"", "Regulatory Office: Comprehensive Cancer Centers of Nevada", "Hospital General Universitario Vall D'Hebron", "Halle", "Sansum Santa Barbara Medical Foundation Clinic", "Santa Monica-UCLA Medical Center and Orthopaedic Hospital", "France", "Federal State Budgetary Scientific Institution", "Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universitaet Muenchen", "Samara", "Borsod-Abauj-Zemplen Megyei Korhaz \u00e9s Egyetemi Oktato Korhaz, Onkologia", "Faenza, RA", "US Oncology Research and Clinical Pharmacy", "Mater Private Hospital", "La Roche-sur-Yon", "Vancouver", "Unita' Operativa di Oncologia, Ospedale Civile di Lugo", "Fort Worth", "Fullerton", "CSSS Champlain-Charles-Le Moyne Local HS-0054", "Gwinnett Hospital System Inc.-d/b/a-The Center for Cancer Care", "Frauenaerzte Pruener Gang Abts & Partner", "Crystal Lake", "United States", "Seoul National University Hospital", "Las Vegas", "Heidelberg", "Gemeinschaftspraxis Haematologie-Onkologie", "Alhambra", "Szent Margit Korhaz, Onkologia", "Spain", "Berlin", "St. Vincent's University Hospital", "Szabolcs-Szatmar-Bereg Megyei Korhazak es", "Cattolica", "Kyiv City Clinical Oncologic Center", "A Coru\u00f1a", "Torrance Health Association, DBA Torrance Memorial Physician Network/Cancer Care Associates", "Hungary", "BC Cancer Agency - Vancouver Centre", "Texas Oncology-Baylor Charles A. Sammons Cancer Center", "Miskolc", "Santa Maria", "Ospedale Civile di Faenza Centro Oncologico", "Lviv", "CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center", "UCLA West Medical Pharmacy", "Duluth", "Russia", "Valencia", "Central Hematology Oncology Medical group Inc.", "Dresden", "Ireland", "Pyatigorsk", "L'Hospitalet de Llobregat", "Bon Secours Hospital", "Mater Misericordiae University Hospital", "Ravenna", "Dublin", "Lugo, RA", "St. James's Hospital", "Nationales Centrum fuer Tumorerkrankungen", "Seoul", "Hospital Universitario Virgen Del Rocio", "Greenfield Park", "Roma", "Regulatory Managment", "Eastleigh Breast Care Centre", "Illinois Cancer Specialists", "UCLA Hematology/Oncology - Santa Clarita", "Frauenklinik vom Roten Kreuz", "Comprehensive Cancer Centers of Nevada", "Central Hematology Oncology Medical Group, Inc", "Ospedale Villa San Pietro", "Samsung Medical Center", "Cork", "Republican Clinical Oncology Dispensary of the Ministry of Health of Bashkortostan Republic", "Angers"], "intervention": ["Phase 2 (Letrozole)", "Phase 1 (Palbociclib + Letrozole)", "PD 0332991", "Phase 2 (Palbociclib + Letrozole)"], "outcome": ["Overall Survival (OS) at Phase 2", "Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment", "Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1", "Change From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2", "Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1", "Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment", "Duration of Response at Phase 2 - Investigator Assessment", "Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1", "Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1", "Number of Participants With CBR at Phase 2 - Investigator Assessment", "Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1", "Number of Participants With Dose Limiting Toxicities at Phase 1", "Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1", "Number of Participants With Treatment-Related Adverse Events at Phase 2", "Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1", "Summary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1", "Change From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2", "Number of Participants With TEAEs (All Causalities) at Phase 2", "Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1", "Percentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2", "Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1", "Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1", "Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1", "Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1", "Number of Participants With Treatment-Related Adverse Events at Phase 1"], "outcome-Measure": ["Overall Survival (OS) at Phase 2", "Progression-Free Survival (PFS) at Phase 2 - Investigator Assessment", "Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Tmax at Phase 1", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Clearance (CL/F) at Phase 1", "Change From Baseline in Modified Brief Pain Inventory in Pain Interference Scale (mBPI-sf) Questionnaire at Phase 2", "Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - p16/INK4A, CCND1", "Time to Tumor Progression (TTP) at Phase 2-Investigator Assessment", "Duration of Response at Phase 2 - Investigator Assessment", "Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Ki67", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Apparent Volume of Distribution (Vz/F) at Phase 1", "Percentage of Participants With Clinical Benefit Response (CBR) at Phase 1", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Time to Maximum Plasma Concentration (Tmax) at Phase 1", "Number of Participants With CBR at Phase 2 - Investigator Assessment", "Number of Participants With Increase From Baseline in Corrected QT (QTc) Interval at Phase 1", "Number of Participants With Dose Limiting Toxicities at Phase 1", "Presence or Absence of Tumor Tissue Biomarkers at Phase 2 - Tumor Retinoblastoma (RB) and CyclinD1", "Number of Participants With Treatment-Related Adverse Events at Phase 2", "Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: Cmax at Phase 1", "Summary of Copy Number for CCND1 (CCND1/CEP11) and p16/INK4A (p16/CEP9) at Phase 2", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Terminal Plasma Half-life (t1/2) at Phase 1", "Change From Baseline in Modified Brief Pain Inventory in Pain Severity Scale (mBPI-sf) Questionnaire at Phase 2", "Number of Participants With TEAEs (All Causalities) at Phase 2", "Objective Response Rate - Percentage of Participants With Confirmed Objective Response in Participants With Measurable Disease at Phase 2- Investigator Assessment", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC24) at Phase 1", "Percentage of Participants With Tumor Expression of CYP19A1 and CCND1 Genotypes at Phase 2", "Summary of Plasma Letrozole Pharmacokinetic Parameter Following Letrozole Alone and in Combination With Palbociclib: AUC24 at Phase 1", "Number of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities) at Phase 1", "Objective Response Rate - Percentage of Participants With Confirmed Objective Response at Phase 2- Investigator Assessment", "Summary of Plasma Palbociclib Steady-state Pharmacokinetic Parameter Following Palbociclib Alone and in Combination With Letrozole: Maximum Observed Plasma Concentration (Cmax) at Phase 1", "Objective Response Rate - Percentage of Participants With Confirmed Objective Tumor Response at Phase 1", "Number of Participants With Treatment-Related Adverse Events at Phase 1"]}, "NCT00356148": {"iv-cont-number": ["9", "25"], "iv-cont-mean": ["13", "30"], "age": ["18 Years"], "eligibility": ["History of receiving any antibiotics within prior 3 months,", "Receiving any neoadjuvant therapy,", "Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II.", "History of reaction to study antibiotics,", "Ductal carcinoma in situ (DCIS; stage 0 cancer),", "Having a remote infection,", "Advanced or distant metastatic stage,", "History of immunodeficiency,", "Denial of signing the consent form."], "condition": ["Breast Cancer"], "location": ["Marmara University Hospital", "Istanbul", "Turkey (T\u00fcrkiye)"], "control": ["No Prophylaxis Group"], "intervention": ["Prophylaxis Group", "Ampisid 1 gr", "Ampicillin/Sulbactam"], "outcome": ["Overall SSI-related Prophylaxis and Treatment Cost in Patients With BMI Over 25 Who Received Prophylaxis (Prophylaxis Group) and Not (No Prophylaxis Group).", "Number of Patients With Body Mass Index (BMI) Over 25 Who Developed Surgical Site Infection (SSI) in Groups Who Received Antibiotic Prophylaxis (Prophylaxis Group) and no Prophylaxis (No Prophylaxis Group)."], "outcome-Measure": ["Overall SSI-related Prophylaxis and Treatment Cost in Patients With BMI Over 25 Who Received Prophylaxis (Prophylaxis Group) and Not (No Prophylaxis Group).", "Number of Patients With Body Mass Index (BMI) Over 25 Who Developed Surgical Site Infection (SSI) in Groups Who Received Antibiotic Prophylaxis (Prophylaxis Group) and no Prophylaxis (No Prophylaxis Group)."]}, "NCT03253159": {"age": ["18 Years"], "eligibility": ["Minor Unilateral breast surgery indication (tumorectomy, lumpectomy, limited axillary node dissection, minor breast reconstruction\u2026)", "Patient with ASA\\score 1, 2, 3", "General anesthesia required", "Patient refusing hypnosis", "Psychic or mental Disorders", "Age < 18 years", "Major Surgery indication : mastectomy, bilateral surgery, full axillary dissection, major breast reconstruction", "French medical benefit", "Chronic pain", "Day case surgery (ambulatory surgery - living Day0-Day1)", "Patient with ASA score > 4;", "Under guardianship patient or guardianship", "Written informed consent", "Opiate therapeutic > 3 months", "Body mass index < 15 or 45kg/T;", "Female > 18 years", "Not ability to speak and read French language", "Deaf and dumb patient"], "condition": ["Breast Cancer"], "location": ["Institut r\u00e9ginal du Cancer de Montpellier", "Montpellier", "France"], "control": ["Control group"], "intervention": ["Hypnosis"], "outcome": ["Reduction of the pain using Visual Analogic Scale", "Assessment of pain scale"]}, "NCT01806259": {"iv-cont-count_of_participants": ["96", "80", "105", "93"], "age": ["85 Years", "18 Years"], "eligibility": ["Written informed Consent age : 18-85 years weight: 50-100 kg Neutrophils / Lymphocytes ratio >4 and/or \"triple negative\" histological status and/or Positive lymph nodes"], "condition": ["Inflammatory Positive/Negative Status", "Pre Surgical Incision Administration", "Curative Breast Cancer Surgery"], "location": ["Brussels", "Cliniques universitaires Saint-Luc", "Belgium"], "intervention": ["Ketorolac 30 mg IV", "ketorolac tromethamine", "Ketorolac 30 mg", "NaCl 0.9%", "NaCl 0.9% 3mL", "Placebos"], "outcome": ["Recurrence-free Survival", "Overall Survival"], "outcome-Measure": ["Recurrence-free Survival", "Overall Survival"]}, "NCT01511276": {"age": ["69 Years", "50 Years"], "eligibility": ["Willing to be randomly assigned to one of the three study arms", "Following, or the intention to follow, a structured weight loss programme elsewhere", "Any disorder that might impede participation in the exercise programme", "Sedentary (<2 hours per week of at least moderately intensive activities (>4 MET))", "Alcohol or drug abuse", "Presently using sex-hormones", "BMI 25-35 kg/m2", "Maintenance use of corticosteroids", "Suffering cancer (in medical history) except for non-melanoma skin cancers", "50-69 years of age", "Postmenopausal (>12 months after last menses)", "Female", "Informed consent to participate in all screening and study activities.", "Smoking"], "condition": ["Breast Cancer Risk"], "location": ["Medisch Spectrum Twente", "Utrecht", "Netherlands", "UMC Utrecht", "Enschede"], "control": ["Control, stable weight"], "intervention": ["Diet"], "outcome": ["anthropometrics and physical fitness.", "serum sex hormone levels"]}, "NCT01948128": {"age": ["18 Years"], "eligibility": ["Clinically palpable tumour(s) (greater than or equal to 2 cm)", "Hypercalciuria on initial baseline urine, defined as Ca/Creatinine Ratio> 1.0", "Written informed consent for study", "History of granulomatous disease such as tuberculosis or sarcoidosis.", "Intake of Vitamin D (cholecalciferol) supplement >= 2000 IU/day within the last 2 months", "Histologically confirmed female primary breast cancer patients whose surgery is planned for the next 2-8 weeks without neoadjuvant therapy as assessed by multidisciplinary team", "Current or previous history of urolithiasis or hyperparathyroidism", "Abnormal hepatic function according to Ottawa Hospital norms (Total Bilirubin >2x upper limit of normal, ALT/AST >3x upper limit of normal)and/or abnormal renal function (Creatinine > 150 \u00b5mol/L)", "Inability to comply with a study protocol in the opinion of the investigator (such as abuse of alcohol, drugs or psychotic states).", "Age >=18 years", "ECOG performance Status > 2", "Normal serum and urine calcium and serum PTH values at baseline (as defined by Ottawa Hospital)", "Patients with recurrent or metastatic breast cancer"], "condition": ["Breast Cancer"], "location": ["Canada", "The Ottawa Hospital Woman's Breast Health Centre", "Ottawa"], "intervention": ["Placebo", "Vitamin D3", "cholecalciferol", "Vitamin D"], "outcome": ["Pre and post vitamin D administration Ki67 levels and Caspase 3 levels (as assessed according to the apoptosis assay)", "Serum levels of 25-0HD and in vivo breast (cancer and non cancer) tissue levels of 1,25(OH)"]}, "NCT00080301": {"iv-cont-median": ["5.85", "11.7", "11.1", "5.6", "12.9", "12.0", "4.17", "6.4"], "iv-cont-mean": ["34.7", "-0.4", "14.3", "0.3"], "iv-cont-number": ["40", "33"], "age": ["18 Years"], "eligibility": ["Patients may not have CTC Grade 2 or greater neuropathy (motor or sensory).", "Patients must have received a minimum cumulative dose of anthracycline or must be resistant to an anthracycline.", "Patients may not have any history of brain and/or leptomeningeal metastases.", "Prior treatment must have included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).", "Patients must be resistant to taxane therapy.", "Patients may have not have had prior treatment with an epothilone and/or capecitabine (i.e., Xeloda)"], "condition": ["Breast Cancer", "Metastases"], "location": ["London", "Rosario", "Chelmsford", "Li\u00e8ge", "Edegem", "Brescia", "Belgium", "Hartford", "Jinan", "Argentina", "Xi\u2019an", "Gothenburg", "Sheffield", "Kuala Lumpur", "Local Institution", "San Francisco", "Nashville", "Besan\u00e7on", "Kampung Baharu Nilai", "Tacoma", "Leuven", "Jackson", "Bayonne", "Toronto", "Budapest", "Nantes", "Denver", "Burlington", "Chihuahua City", "Canada", "Toulouse", "Clermont-Ferrand", "Bordeaux", "Pittsburgh", "Sao Paulo - Sp", "Quezon City", "Newcastle upon Tyne", "Quezon", "Germany", "Mar del Plata", "Malaysia", "Madrid", "P\u00e9cs", "Oshawa", "United Kingdom", "Opole", "Forl\u00ec", "Bangkok", "Thailand", "Saint-Cloud", "Gy\u0151r", "Barcelona", "Fortaleza", "South Korea", "Quilmes", "Taiwan", "Santa Fe", "Knoxville", "Greece", "Bristol", "Brazil", "Albuquerque", "Guildford", "Italy", "Belo Horizonte", "Bobigny", "San Giovanni Rotondo", "Candiolo (To)", "Avignon", "New Brunswick", "New York", "China", "Athens", "Haedo", "Greenville", "Nanjing", "Baltimore", "Houston", "La Plata", "Oklahoma City", "France", "Ghent", "Santo Andr\u00e9", "Little Rock", "Manchester", "Vancouver", "Taipei", "Duisburg", "Stockholm", "Porto Alegre", "Thessaloniki", "M\u00e9rida", "Gdansk", "Acapulco de Ju\u00e1rez", "United States", "Kansas City", "Montreal", "Livingston", "Vallejo", "Saint-Brieuc", "Philippines", "Tainan City", "Beijing", "Austin", "Mexico", "Spain", "Berlin", "Lan\u00fas", "S\u00e3o Paulo", "Capital Federal", "Lyon", "Hungary", "Incheon", "Orlando", "Debrecen", "San Luis Potos\u00ed City", "Valencia", "Guangzhou", "Morgantown", "Strasbourg", "Omaha", "Saint-Herblain", "Erlangen", "Girona", "St Louis", "Peru", "Tulsa", "Seoul", "Washington D.C.", "Columbia", "Sweden", "Ogden", "Zaragoza", "Curitiba", "Ja\u00fa", "Shanghai", "Pilar", "C\u00f3rdoba", "Neuqu\u00e9n", "Distrito Federal", "Manila", "Lima", "Columbus", "Nice", "Poland", "Angers"], "intervention": ["Capecitabine", "IXEMPRA", "Ixabepilone + Capecitabine", "Epothilone", "BMS-247550"], "outcome": ["Overall Response Rate (ORR) Per IRRC", "Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC)", "Overall Survival (OS)", "Time to Response Per IRRC", "Treatment-related Safety Summary", "Duration of Response Per IRRC", "Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)"], "outcome-Measure": ["Overall Response Rate (ORR) Per IRRC", "Progression-free Survival (PFS) Per Independent Radiology Review Committee (IRRC)", "Overall Survival (OS)", "Time to Response Per IRRC", "Treatment-related Safety Summary", "Duration of Response Per IRRC", "Symptom Assessment Score Changes From Baseline for Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI)"]}, "NCT01048528": {"age": ["60 Years", "18 Years"], "eligibility": ["Working phone and address", "Use of immune modulating drugs (e.g. corticosteroids, antihistamines), nicotine, or > 3 drinks/ day alcohol", "Family history of breast cancer", "History of Hepatitis A or HA vaccination", "Plan to live in the area for one year", "History of autoimmune disease", "Fluent in English", "Reporting elevated levels of distress at screening.", "Prior cancer diagnosis (except non-melanoma skin cancer)", "Current major depressive episode", "History of Bipolar Disorder or Schizophrenia"], "condition": ["Breast Cancer"], "location": ["Fred Hutchinson Cancer Research Center", "Seattle", "United States"], "control": ["Wait-list"], "intervention": ["Cognitive Behavioral Stress Management (CBSM)", "Stress Management and Relaxation Training (SMART)"], "outcome": ["Linear mixed model regression with an exchangeable covariance structure will be used to investigate the effects of change in distress on immune response as a function of time. We will include time as a random effect.", "Linear mixed models regression with an exchangeable covariance structure will be used to determine the average change in IgM, IgG and proliferative response to HA vaccine antibody response to HA vaccine following the intervention, as a function of time."]}, "NCT02622711": {"age": ["18 Years"], "eligibility": ["patient is unable to find transportation to the study location over the study period, - or", "diagnosed with a first invasive non-metastatic breast carcinoma histologically confirmed,", "being able to participate in the intervention,", "contraindications to exercise due to history of heart condition, stroke, chest pain during activity or rest, severe hypertension", "BMI > 25,", "written informed consent.", "agree to be randomized to either group,", "severe medical condition or advanced age impeding the patient to adhere at the planned study follow-up period,", "orthopaedic disability that would prevent optimal participation in the physical activities prescribed,", "agree to wear the wrist-based activity monitor during the study period,", "within 6-month/one year of completion of main cancer treatment,", "plans to move away from Lombardy or to be out of town for more than 3 weeks during the study period."], "condition": ["Breast Cancer"], "location": ["Italy", "IEO Istituto Europeo di Oncologia", "Milan"], "intervention": ["PAI", "DI", "PADI", "Dietary Intervention", "LII", "Physical Activity Intervention", "Physical Activity and Dietary Intervention", "Less Intensive Intervention"], "outcome": ["Glucose level", "Quality of life", "Physical activity level", "Oestradiol level", "Pedometer Step Count", "Insulin level", "Mood", "Lipid Marker Change", "Long-term body weight control", "C-reactive protein level", "Body weight reduction", "Dietary intake"]}, "NCT01009918": {"iv-cont-count_of_participants": ["27", "43", "24", "5", "40", "46", "17", "15", "9", "45"], "iv-cont-mean": ["1", "2", "5"], "age": ["18 Years"], "eligibility": ["Sitting systolic blood pressure of > 90 mm Hg", "Patients with metastatic disease", "Known cardiac history: heart failure, myocardial infarction, radiation-induced cardiac dysfunction", "Left Ventricular Ejection Fraction (LVEF) >= 50% by MUGA scan or echocardiogram", "Hereditary or idiopathic angioedema", "Pulse >= 60 beats/minute", "Not pregnant or breastfeeding", "Males and Females >= 18 years old diagnosed with HER2 positive breast cancer", "Female patients of childbearing potential, who are sexually active, must have a negative pregnancy test before starting the study", "History of bronchial asthma or related bronchospastic conditions", "Current treatment with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), such as losartan, \u03b2-blockers or digoxin", "Both men and women must be willing to use effective contraception during the study. Teratogenicity is documented for both active study agents", "Known allergy to either ACE inhibitors or \u03b2-blockers", "Able to swallow capsules"], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Breast Cancer", "Cardiac Toxicity"], "location": ["Green Bay", "Norman", "Lakeland Regional Cancer Care Center - St. Joseph", "Canton", "Clemens Regional Medical Center", "River Forest", "Oak Lawn", "Medical Oncology and Hematology Associates at Mercy Cancer Center", "Danville", "Flint", "Findlay", "Southeast Cancer Center", "Hennepin County Medical Center - Minneapolis", "Southfield", "Kearney", "Cancer Care Associates - Mercy Campus", "Kalamazoo", "Covenant Cancer Treatment Center", "Saint Louis Park", "Rose Medical Center", "Littleton Adventist Hospital", "United States Air Force Medical Center - Wright-Patterson", "Waukesha", "Big Sky Oncology", "Lakeview Hospital", "St. Francis Cancer Center at St. Francis Medical Center", "Dayton", "Mercy and Unity Cancer Center at Unity Hospital", "Charles F. Kettering Memorial Hospital", "Good Samaritan Regional Health Center", "Lovelace Medical Center - Downtown", "Michiana Hematology Oncology PC - Plymouth", "Lacks Cancer Center at Saint Mary's Health Care", "Mercy General Health Partners", "Beaufort", "Singh and Arora Hematology Oncology, PC", "Pueblo", "Mercy Regional Cancer Center", "Martha Jefferson Hospital Cancer Care Center", "Illinois CancerCare - Canton", "West Suburban Center for Cancer Care", "CCOP - Dayton", "Cedar Rapids", "Traverse City", "Petoskey", "Fairview Ridges Hospital", "Shakopee", "Minneapolis", "Albuquerque", "Oncology Hematology Associates of Central Illinois, PC - Ottawa", "Ella Milbank Foshay Cancer Center at Jupiter Medical Center", "Wright-Patterson Air Force Base", "Suburban Hospital", "Oncology Center at St. Joseph Hospital", "CCOP - Northern Indiana CR Consortium", "Hope Cancer Care Center at Longmont United Hospital", "Macomb", "Pekin", "Porter Adventist Hospital", "Philadelphia", "Burnsville", "Greeley", "Maplewood", "Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare", "Michiana Hematology-Oncology, PC - Elkhart", "Saint Joseph Regional Medical Center", "Illinois CancerCare - Peru", "Waterloo", "Park Ridge Health", "Lapeer", "Boulder", "Hutchinson Area Health Care", "Natalie Warren Bryant Cancer Center at St. Francis Hospital", "Kokomo", "Fridley", "Illinois CancerCare - Monmouth", "Elkhart Clinic, LLC", "Janesville", "Sletten Cancer Institute at Benefis Healthcare", "Todd Cancer Institute at Long Beach Memorial Medical Center", "Kalispell Regional Medical Center", "Illinois CancerCare - Eureka", "Louis A. Weiss Memorial Hospital", "Michiana Hematology-Oncology, PC - South Bend", "Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center", "Willmar Cancer Center at Rice Memorial Hospital", "Charlottesville", "Mishawaka", "Henderson", "Illinois CancerCare - Pekin", "Wilkes-Barre", "La Grange", "Mercy Medical Center", "CCOP - Montana Cancer Consortium", "Northern Michigan Hospital", "Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center", "Bozeman Deaconess Cancer Center", "Regions Hospital Cancer Care Center", "Guthrie Cancer Center at Guthrie Clinic Sayre", "Galesburg", "Edina", "Goldschmidt Cancer Center", "Mercy and Unity Cancer Center at Mercy Hospital", "Havana", "Cooperstown", "Chicago", "Decatur", "Medical Oncology and Hematology Associates at John Stoddard Cancer Center", "Swedish Medical Center", "Mount Clemens", "Hutchinson", "Willmar", "Olive View - UCLA Medical Center Foundation", "New Orleans", "Medical Oncology and Hematology Associates - West Des Moines", "Virginia Piper Cancer Institute at Abbott - Northwestern Hospital", "Waconia", "Parker", "Lucille P. Markey Cancer Center at University of Kentucky", "Illinois CancerCare - Princeton", "Regional Cancer Center at Oconomowoc Memorial Hospital", "Nashua", "Advocate Christ Medical Center", "Cancer Center at Phoenixville Hospital", "McKee Medical Center", "St. Francis Hospital", "Munson Medical Center", "CCOP - Metro-Minnesota", "South Bend", "Great Falls", "Alvin and Lois Lapidus Cancer Institute at Sinai Hospital", "State College", "Humphrey Cancer Center at North Memorial Outpatient Center", "Greer", "Long Beach", "Missouri Baptist Cancer Center", "Vineland", "University of New Mexico Cancer Center", "Samaritan North Cancer Care Center", "CCOP - Colorado Cancer Research Program", "Joan Karnell Cancer Center at Pennsylvania Hospital", "Charles R. Wood Cancer Center at Glens Falls Hospital", "United States", "Penrose Cancer Center at Penrose Hospital", "Good Samaritan Cancer Center at Good Samaritan Hospital", "Aurora Presbyterian Hospital", "Elkhart General Hospital", "Coon Rapids", "Sylmar", "Elkhart", "Littleton", "Ottawa", "David L. Rike Cancer Center at Miami Valley Hospital", "Freeman Cancer Institute", "Kettering", "Geisinger Hazleton Cancer Center", "Long Branch", "Peru", "Bolivar", "La Grange Memorial Hospital", "Blanchard Valley Medical Associates", "Geisinger Cancer Institute at Geisinger Health", "UVMC Cancer Care Center at Upper Valley Medical Center", "UMDNJ University Hospital", "Great Lakes Cancer Institute - Lapeer Campus", "St. Anthony Central Hospital", "Reid Hospital & Health Care Services", "Augusta", "Phoenixville", "Waukesha Memorial Hospital Regional Cancer Center", "Galesburg Clinic, PC", "Oconomowoc", "Providence Cancer Institute at Providence Hospital - Southfield Campus", "Richmond", "HealthEast Cancer Care at St. John's Hospital", "Presbyterian - St. Luke's Medical Center", "St. Joseph Hospital", "CCOP - Mount Sinai Medical Center", "Geisinger Medical Group - Scenery Park", "Billings Clinic - Downtown", "Presbyterian Cancer Treatment Center at Presbyterian Kaseman Hospital", "Monmouth Medical Center", "Denver", "Cape Girardeau", "La Crosse", "Jordan Hospital Club Cancer Center", "Central Care Cancer Center", "Normal", "Nalitt Cancer Institute at Staten Island University Hospital", "Saint Luke's Hospital", "Aurora", "Illinois CancerCare - Community Cancer Center", "Grand Rapids", "Ruth G. McMillan Cancer Center at Greene Memorial Hospital", "Springfield", "West Michigan Cancer Center", "Dizzy Gillespie Cancer Institute at Englewood Hospital and Medical Center", "Illinois CancerCare - Carthage", "Saint Paul", "Wheat Ridge", "Bloomington Hospital Regional Cancer Institute", "Decatur Memorial Hospital Cancer Care Institute", "Hematology-Oncology Centers of the Northern Rockies - Billings", "Battle Creek", "St. Mary - Corwin Regional Medical Center", "Mecosta County Medical Center", "Mukwonago", "Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler", "Franklin", "Butterworth Hospital at Spectrum Health", "Stillwater", "Illinois CancerCare - Bloomington", "Indianapolis", "Resurrection Medical Center", "Lebanon", "Des Moines", "Rapid City", "Saint Joseph", "Loveland", "Miami Beach", "Fairview Southdale Hospital", "CCOP - Iowa Oncology Research Association", "Wayne Hospital", "Howard Community Hospital", "MBCCOP - Medical College of Georgia Cancer Center", "Princeton", "Sayre", "Gibbs Cancer Center - Pelham", "Lakeland Regional Cancer Center at Lakeland Regional Medical Center", "Regional Cancer Center at Memorial Medical Center", "Bozeman", "North Colorado Medical Center", "Glens Falls", "Colorado Springs", "Kalispell", "Hazleton", "Westville", "Lone Tree", "Missoula", "Middletown Regional Hospital", "Bethesda", "Michiana Hematology Oncology PC - La Porte", "Park Nicollet Cancer Center", "Minnesota Oncology - Woodbury", "Bassett Healthcare Regional Cancer Program at Mary Imogene Bassett Hospital", "Newark", "Foundation Medical Partners", "Mercy Hospital", "Savannah", "Big Rapids", "Cancer Care Associates - Norman", "Peoria", "McDowell Cancer Center at Akron General Medical Center", "Battle Creek Health System Cancer Care Center", "Lakeland", "Ridgeview Medical Center", "Mercy Hospital St. Louis", "Gundersen Lutheran Center for Cancer and Blood", "Bay Regional Medical Center", "Barbara Ann Karmanos Cancer Institute", "D.N. Greenwald Center", "La Porte", "Woodbury", "Detroit", "Lakeside Cancer Specialists, PLLC", "Staten Island", "Englewood", "Plymouth", "MBCCOP - LSU Health Sciences Center", "Memorial Hospital of South Bend", "Carthage", "Bay City", "Akron", "Montana Cancer Specialists at Montana Cancer Center", "Parker Adventist Hospital", "Illinois CancerCare - Macomb", "Green Bay Oncology, Limited at St. Mary's Hospital", "Boulder Community Hospital", "Lexington", "Eureka", "Center for Cancer Therapy at LaPorte Hospital and Health Services", "Greenville", "Keyserling Cancer Center at Beaufort Memorial Hospital", "Baltimore", "Bloomington", "Illinois CancerCare - Kewanee Clinic", "Monmouth", "Oklahoma City", "Troy", "St. Francis Hospital Cancer Care Services", "Kewanee", "CCOP - Illinois Oncology Research Association", "Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center", "Joplin", "Xenia", "Cedar Rapids Oncology Associates", "Exempla Lutheran Medical Center", "Portland", "Muskegon", "Billings", "Longmont", "Chesterfield", "Sky Ridge Medical Center", "St Louis", "Tulsa", "Jefferson City", "Illinois CancerCare - Havana", "Robbinsdale", "Aultman Cancer Center at Aultman Hospital", "Rapid City Regional Hospital", "United Hospital", "Clive", "Summa Center for Cancer Care at Akron City Hospital", "Jupiter", "Mount Vernon"], "intervention": ["Registered Trade names: Prinivil, Tensopril, Zestril, Hipril", "lisinopril", "Coreg CR\u00ae", "Arm III Placebo", "placebo", "carvedilol phosphate extended-release", "Arm I Lisinopril", "Arm II Coreg CR\u00ae"], "outcome": ["Number of Patients With Trastuzumab Course Interruption", "Number of Participants With Cardiotoxicity-free Survival at 750 Days From Baseline", "Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment", "Number of Participants With LVEF Decrease to <50%", "Quality-of-life Changes Between Baseline and 52-weeks"], "outcome-Measure": ["Number of Patients With Trastuzumab Course Interruption", "Number of Participants With Cardiotoxicity-free Survival at 750 Days From Baseline", "Number of Participants With Trastuzumab-Induced Cardiotoxicity After 52 Weeks of Treatment", "Number of Participants With LVEF Decrease to <50%", "Quality-of-life Changes Between Baseline and 52-weeks"]}, "NCT04174248": {"age": ["20 Years", "65 Years"], "eligibility": ["willing to participate in the study and provide informed consent.", "mental illness", "serious illness and life-threatening", "had an Android/iOS smartphone;", "first diagnosis of breast cancer with stage 0 to III in past year.", "aged 20 to 65 years", "able to read and write in Chinese;"], "condition": ["Breast Cancer", "Quality of Life"], "location": ["Taiwan", "National Yang-Ming University", "Taipei"], "control": ["Control group"], "intervention": ["BCSMS App"], "outcome": ["Change of EORTC QLQ-C30 at 3 month", "Baseline EORTC QLQ-BR23", "Baseline EORTC QLQ-C30", "Change of EORTC QLQ-C30 at 1.5 month", "Change of EORTC QLQ-BR23 at 3 month", "Change of EORTC QLQ-BR23 at 1.5 month"]}, "NCT01516736": {"iv-cont-mean": ["0.444", "1.36", "2.04", "1.19", "2.11", "0.490"], "iv-cont-count_of_participants": ["0", "13", "1", "17", "15", "14", "10", "12"], "age": ["18 Years"], "eligibility": ["previous therapy with any G-CSF (granulocyte-colony stimulating factor) product", "concurrent prophylactic antibiotics", "histologically proven breast cancer"], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Chemotherapy-induced Neutropenia", "Breast Cancer"], "location": ["Newport News", "Bashkortostan", "Moscow", "Tomsk", "Sandoz Investigational Site", "Rostov-on-Don", "Krasnoyarsk", "Gujarat", "Visakhapatnam", "Kazan'", "Argentina", "San Miguel de Tucum\u00e1n", "Omsk", "Mount Sterling", "Surat", "Arkhangelsk", "Russia", "Mangalore", "Valencia", "Detroit", "George Town", "Orenburg", "Vladimir", "Hot Springs", "Malaysia", "Madrid", "Puerto Rico", "Kampung Baharu Nilai", "Wichita", "Jonesboro", "India", "Hyderabad", "Santiago de Compostela", "Germantown", "Chile", "Kelantan", "Delhi", "San Juan", "Saint Petersburg", "Vellore", "Karamsad", "Barcelona", "Vadodara", "Oryol", "United States", "Lucknow", "Corona", "Eugene", "Pradesh", "Chennai", "Bismarck", "Mumbai", "Temuco", "Spain", "Bryansk", "Maharashtra"], "intervention": ["Neulasta", "LA-EP2006", "pegfilgrastim", "Neulasta\u00ae"], "outcome": ["Number of Patients With ANC Nadir Per Day in Cycle 1", "Depth of ANC Nadir in Cycle 1", "Incidence of Febrile Neutropenia (FN)", "Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy", "Number of Patients With at Least One Episode of Fever by Cycle and Across All Cycles", "Frequency of Infections by Cycle and Across All Cycles", "Time to ANC Recovery in Days in Cycle 1", "Mortality Due to Infection"], "outcome-Measure": ["Number of Patients With ANC Nadir Per Day in Cycle 1", "Depth of ANC Nadir in Cycle 1", "Incidence of Febrile Neutropenia (FN)", "Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy", "Number of Patients With at Least One Episode of Fever by Cycle and Across All Cycles", "Frequency of Infections by Cycle and Across All Cycles", "Time to ANC Recovery in Days in Cycle 1", "Mortality Due to Infection"]}, "NCT00448591": {"iv-bin-abs": ["72.44", "9.0", "53.14", "95.4"], "iv-cont-median": ["25.2", "9.7"], "age": ["18 Years"], "eligibility": ["HER-2 negative adenocarcinoma of the breast, with locally recurrent or metastatic disease; (HER-2 positive patients only if previously treated with Herceptin in the adjuvant setting;", "evidence of CNS metastases.", "concomitant Herceptin therapy for treatment of metastatic or locally recurrent HER-2 positive disease;", "concomitant hormonal therapy for metastatic or locally recurrent disease;", "patients, >=18 years of age;"], "condition": ["Breast Cancer"], "intervention": ["bevacizumab [Avastin]", "Bevacizumab"], "outcome": ["Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Related to Bevacizumab, Death, and AEs of Special Interest (AESIs)", "Percentage of Participants With Disease Progression", "Percentage of Participants With Recorded Death", "Time to Progression (TTP)", "Percentage of Participants by Best Overall Response to Treatment", "Overall Survival"], "outcome-Measure": ["Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs) Related to Bevacizumab, Death, and AEs of Special Interest (AESIs)", "Percentage of Participants With Disease Progression", "Percentage of Participants With Recorded Death", "Time to Progression (TTP)", "Percentage of Participants by Best Overall Response to Treatment", "Overall Survival"]}, "NCT00005957": {"iv-bin-abs": ["83", "82", "77"], "age": ["16 Years", "120 Years"], "eligibility": ["Patients with prior sentinel node dissection eligible if node negative, but still meet high-risk criteria", "Invasive carcinoma of the cervix, endometrium, colon, thyroid, or melanoma that was curatively treated at least 5 years prior to study participation", "ECOG 0-2", "Skarf-Bloom-Richardson grade 3", "If node positive, then a level I and II axillary dissection must be performed", "Histologically proven invasive carcinoma of the breast", "Female", "Node positive or high-risk node negative", "Primary tumor greater than 5 cm", "SGOT and/or SGPT no greater than 3 times upper limit of normal (ULN)\\*", "No psychiatric or addictive disorder that would preclude informed consent or study compliance", "Nonmelanomatous skin cancer", "Not pregnant or nursing", "Normally patients should have microscopically clear resection margins and those with positive margins should undergo reexcision", "Estrogen and progesterone receptor status known", "At least 5 years", "Lymphovascular invasion", "Alkaline phosphatase no greater than 3 times ULN\\NOTE: \\Patients with laboratory values greater than 3 times ULN may still be eligible if no metastatic disease by imaging examinations", "No serious nonmalignant pulmonary disease", "Carcinoma in situ of the cervix or endometrium", "Fertile patients must use effective contraception", "Pathologically positive axillary lymph nodes", "Estrogen receptor negative", "Premenopausal or postmenopausal", "No evidence of residual disease in axilla after dissection", "No evidence of T4, N2-3, or M1 disease prior to surgery", "No serious nonmalignant cardiovascular disease", "16 and over", "No serious nonmalignant renal disease", "Concurrent standard adjuvant hormonal therapy allowed"], "condition": ["Breast Cancer"], "location": ["Kitchener", "London", "London Regional Cancer Program", "CHUQ-Pavillon Hotel-Dieu de Quebec", "Regina", "Canada", "Winnipeg", "Calgary", "Juravinski Cancer Centre at Hamilton Health Sciences", "Saskatoon Cancer Centre", "BCCA - Vancouver Island Cancer Centre", "Centre hospitalier universitaire de Sherbrooke", "Tom Baker Cancer Centre", "Saskatoon", "Dr. H. Bliss Murphy Cancer Centre", "McGill University - Dept. Oncology", "Greater Sudbury", "Thunder Bay Regional Health Science Centre", "Grand River Regional Cancer Centre", "Ottawa", "CHA-Hopital Du St-Sacrement", "Odette Cancer Centre", "Victoria", "Surrey", "St. John's", "Edmonton", "CancerCare Manitoba", "Cross Cancer Institute", "Vancouver", "CHUM - Hopital Notre-Dame", "Northeast Cancer Center Health Sciences", "Qu\u00e9bec", "BCCA - Fraser Valley Cancer Centre", "Sherbrooke", "Moncton", "St. Catharines", "Allan Blair Cancer Centre", "Toronto", "Montreal", "Hamilton", "Atlantic Health Sciences Corporation", "Thunder Bay", "Univ. Health Network-Princess Margaret Hospital", "The Vitalite Health Network - Dr. Leon Richard", "Saint John", "Niagara Health System", "Halifax", "BCCA - Vancouver Cancer Centre", "Ottawa Health Research Institute - General Division", "QEII Health Sciences Center"], "intervention": ["Breast Radiation Plus Regional Radiation", "Standard Breast Irradiation"], "outcome": ["Disease-free Survival", "Overall Survival"], "outcome-Measure": ["Disease-free Survival", "Overall Survival"]}, "NCT02670603": {"eligibility": ["Patients having onycholysis before docetaxel treatment"], "condition": ["Breast Cancer", "Docetaxel Chemotherapy"], "location": ["Seoul", "Samsung Medical Center", "South Korea"], "intervention": ["Hydrating Nail Solution", "EVONAIL\u00ae solution"], "outcome": ["The incidence of onycholysis Gr 2 or more"]}, "NCT00607295": {"age": ["20 Years"], "eligibility": ["breast cancer patients", "who complain of vaginal dryness", "poor compliance", "who experience no menstruation after the previous therapy"], "condition": ["Breast Cancer", "Vaginal Atrophy"], "location": ["Seoul", "Seoul National University Hospital", "South Korea"], "intervention": ["clino-san vaginal lubricant"], "outcome": ["vaginal dryness score", "sexual dysfunction"]}, "NCT02087592": {"age": ["69 Years", "18 Years"], "eligibility": ["significant orthopedic disability which prevents from participating in the exercise training", "pregnancy", "insufficient knowledge of German language", "insufficient compliance", "life expectancy <3 years", "body mass index <15 kg/m2", "VO2max >150%", "women with proven pathogenic BRCA1/2 mutation", "Karnofsky index <60", "Maximal exercise capacity < 50 W", "vegan diet", "metastatic tumor disease", "no informed consent", "clinically limiting cardiovascular or respiratory disease", "severe concomitant disease which prevents from participating in the group interventions", "food allergies which prevent from mediterranean diet"], "condition": ["Hereditary Breast and Ovarian Cancer"], "location": ["University of Cologne", "Kiel", "University of Schleswig-Holstein Campus Kiel", "Cologne", "Germany", "Technische Universitaet Muenchen", "Munich"], "control": ["Control"], "intervention": ["Structured exercise training plus mediterranean diet"], "outcome": ["Physical activity (IPAQ questionnaire)", "Eating behaviour", "Total fat intake", "Body composition (body impedance analysis)", "Stress coping capacity (TICS)", "Grade of optimism (LOT)", "Laboratory parameters", "Aerobic exercise capacity during ergometry", "Quality of life (SF-36)", "Number of patients successfully completing the intervention program", "Body mass index as a marker of caloric balance", "maximum exercise capacity (VO2max) as a marker of physical fitness", "Anthropometric parameters (waist and hip circumference, skinfold measurements)"]}, "NCT03283553": {"iv-cont-count_of_participants": ["38", "42", "3", "7", "18", "0", "44", "39", "1", "8", "49", "52", "10", "30"], "iv-cont-mean": ["15.7", "15.4", "16.9", "90.3", "86.2", "88.0", "89.8"], "age": ["18 Years"], "eligibility": ["Medical oncology patient: Established patient of participating medical oncologist greater than 18 years of age, have a diagnosis of early stage or advanced breast cancer, are receiving active systemic therapy (in the form of IV adjuvant systemic therapy if early stage), are English speaking, able to provide informed consent themselves, and identify a family member who they would like to include in their care.", "Medical oncology provider: Practicing medical oncology provider at a participating clinic who provides care to patients with breast cancer.", "Care partner: Paid non-family member who accompanies patient to visits.", "Medical oncology patients: Younger than 18 years, pregnant, not being treated for breast cancer, do not attend medical oncology visits with family member or unpaid friend or unwilling for their family member or unpaid friend to be contacted."], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Active Breast Cancer Treatment"], "location": ["Lutherville", "Baltimore", "Johns Hopkins Kimmel Cancer Center - Medical Oncology", "Johns Hopkins Kimmel Cancer Center at Green Spring Station - Medical Oncology", "United States"], "intervention": ["Usual Care", "Checklist, MyChart, OpenNotes", "Multicomponent Intervention"], "outcome": ["Between-group Differences in Care Partner Satisfaction With Cancer Care at 9-months", "Between-group Differences in Patient Anxiety at 9-months", "Between-group Differences in Patient Complete Illness Understanding at 9-months", "Between-group Differences in Care Partner Anxiety at 9-months", "Between-group Differences in Patient Quality of Communication at 9-months", "Between-group Differences in Care Partner Quality of Communication at 9-months", "Between-group Differences in Care Partner Complete Illness Understanding at 9-months", "Between-group Differences in Mean Patient Satisfaction With Cancer Care at 9-months"], "outcome-Measure": ["Between-group Differences in Care Partner Exchange of Direct Messages in the Patient Portal at 9-months", "Between-group Differences in Care Partner Satisfaction With Cancer Care at 9-months", "Between-group Differences in Care Partner Views of Clinical Visit Notes in the Patient Portal at 9-months", "Between-group Differences in Patient Exchange of Direct Messages in the Patient Portal at 9-months", "Between-group Differences in Patient Anxiety at 9-months", "Between-group Differences in Patient Complete Illness Understanding at 9-months", "Between-group Differences in Care Partner Registration for Shared Access to the Patient Portal at 9-months", "Between-group Differences in Care Partner Anxiety at 9-months", "Between-group Differences in Patient Views of Clinical Visit Notes in the Patient Portal at 9-months", "Between-group Differences in Patient Quality of Communication at 9-months", "Between-group Differences in Care Partner Quality of Communication at 9-months", "Between-group Differences in Care Partner Complete Illness Understanding at 9-months", "Between-group Differences in Mean Patient Satisfaction With Cancer Care at 9-months"]}, "NCT01559194": {"age": ["30 Years"], "eligibility": ["All women must present a letter of medical clearance from their primary care physician.", "Pregnant women or women who plan to become pregnant during the study period will not be enrolled. Women who become pregnant during the intervention will be withdrawn from the study.", "Body mass index between 25-34 kg/m2", "Aged 30 and older", "Women who are already participating in a formal weight loss program (such as Weight Watchers)will not be eligible.", "Premenopausal (may be confirmed by FSH)", "Women must be expected to live in the Columbus area for the next 18 months.", "No previous diagnosis of cancer (except non-melanomatous skin cancer)", "All medical problems must be managed and controlled. Lipid profile, blood glucose, hemoglobin A1c, and blood pressure will be assessed at the screening visit. These results will be reviewed by the study physician. Women who have abnormal values that, at the discretion of the study physician, would benefit from medical management will be referred to a primary care physician prior to considering them for enrollment."], "condition": ["Breast Cancer", "Weight Loss"], "location": ["Ohio State University", "United States", "Columbus"], "intervention": ["Low Fat Diet plus exercise"], "outcome": ["Number of women that long-term weight loss impacted biomarkers (including Insulin-like growth factor (IGF)- 1 and IGFBP-3) associated with breast cancer risk", "Number of women who lose weight when following 1 of 2 different calorie-restricted diets"]}, "NCT02592070": {"age": ["60 Years", "30 Years"], "eligibility": ["pregnant", "outside of 30-60 years of age", "history of dementia or organic brain syndrome", "non-consent of physician", "women between 30 and 60 years of age", "reported trouble with memory/concentration", "fluent in English", "unable to walk unassisted", "physician's consent", "no longer undergoing treatment", "male", "not currently pregnant", "inability to communicate in English", "no diagnosis of breast cancer", "no health reasons that would prevent ability to exercise", "currently undergoing treatment for breast cancer", "no reported trouble with memory or concentration", "diagnosis of breast cancer", "able to walk unassisted", "no history of dementia or organic brain syndrome"], "condition": ["Breast Cancer", "Physical Activity", "Mild Cognitive Impairment"], "location": ["Urbana", "Freer Hall, University of Illinois", "United States"], "intervention": ["Walking"], "outcome": ["Physical activity guidelines in breast cancer survivors as assessed by graded exercise test.", "Change from baseline in cognitive function in breast cancer survivors immediately and one hour after an acute bout of exercise as assessed by a battery of cognitive functioning measures.", "Change in relationship between exercise and cognitive function in breast cancer survivors as assessed by psychosocial questionnaires.", "Change in relationship between exercise and cognitive function in breast cancer survivors as assessed by physical activity and fitness levels.", "Change from baseline in anxiety levels after one bout of exercise as assessed by HADS questionnaire."]}, "NCT01740427": {"iv-cont-median": ["16.3", "16.7", "53.9", "49.8", "51.2", "24.8", "20.1", "53.8", "14.5", "24.9"], "iv-bin-abs": ["71.2", "96.4", "38.3", "85.9", "46.4", "80.5", "49.1", "60.7", "99.1", "85.8"], "iv-cont-least_squares_mean": ["0.80", "2.95"], "iv-cont-geometric_mean": ["70.1"], "iv-cont-mean": ["0.219", "0.014", "-0.106", "-0.010"], "iv-cont-number": ["92.7", "94.9"], "iv-cont-count_of_participants": ["90", "328"], "age": ["18 Years"], "eligibility": ["Prior (neo)adjuvant treatment with letrozole or anastrozole with DFI <= 12-months from completion of treatment.", "Confirmed diagnosis of ER positive breast cancer", "Known uncontrolled or symptomatic CNS metastases", "No prior systemic anti-cancer therapy for advanced ER+ disease.", "Postmenopausal women", "Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or bone-only disease", "Patients with advanced, symptomatic, visceral spread that are at risk of life threatening complication in the short term", "Adequate organ and marrow function", "Patient must agree to provide tumor tissue", "Prior treatment with any CDK 4/6 inhibitor.", "Confirmed diagnosis of HER2 positive disease", "Adult women with locoregionally recurrent or metastatic disease not amenable to curative therapy.", "Eastern Cooperative Oncology Group [ECOG] 0-2"], "condition": ["Breast Neoplasms"], "location": ["Fiona Stanley Hospital", "Belgium", "Pasadena", "Newmarket", "Chiba", "Centre Antoine Lacassagne", "Ufa", "Cancer Specialists of North Florida-Southpoint", "Saint-Petersburg State Budget Healthcare Institution (SBHCI)", "Anger Cedex 02", "Danville", "Japan", "Virginia oncology Associates", "Affidea Diagnosztika Kft.", "Dallas", "Redondo Beach", "Municipal Non-profit Enterprise \"Regional Centre of Oncology\"", "Northwest Georgia Oncology Centers, PC", "Charing Cross Hospital", "Munich", "Osaka", "Saint Louis Park", "McGill University Health Centre (MUHC), Glen Site, Cedars Cancer Centre", "Municipal Medical Institution \"Makiivka City Hospital No.2 of Donetsk Region\"", "Hastings", "Halifax", "Maidstone", "Roanoke", "TRIO-US Central Administration", "Ukraine", "Mackay Memory Hospital", "Samsung Medical Center, Division of Hematology-Oncology, Department of Medicine", "Irvine", "Universitatsklinikum Erlangen, Frauenklinik", "Surrey", "Complejo Hospitalario de Jaen", "Whittingham Cancer Center @ Norwalk Hospital", "Emory University Hospital Midtown", "Diagnoscan Magyarorszag Kft.", "Birtinya", "Hospital Universitario Fundacion de Alcorcon", "The Emory Clinic", "Stony Brook University- Cancer Center", "Hospital Universitario Virgen del Rocio", "Ronald Reagan UCLA Medical Center", "British Columbia Cancer Agency-Vancouver Centre", "Makiivka", "Sapporo", "Rotkreuzklinikum Munchen, Frauenklinik,", "Southaven", "Centre Eugene Marquis", "Grand Junction", "Murdoch", "Institut Jules Bordet", "CHD Vend\u00e9e", "Gallatin", "Non-State Health Care agency \"Road Clinical Hospital of PLC\" Russian Railways", "Trier", "HOSPITAL Universitario 12 DE OCTUBRE", "State Budget Healthcate Institution \"Leningrad Region Oncology Dispensary\"", "B\u00f6blingen", "National Cancer Center Hospital", "Mercy Hospital St. Louis - David C. Pratt Cancer Center", "Drug Management Only: UCLA West Medical Pharmacy, Attn: Steven L Wong, Pharm.D.", "University Hospital Carl Gustav Carus - Department for Obstetrics and Gynecology.", "Wilrijk", "Tennessee Oncology PLLC", "Hospital Universitario de Canarias", "Plantation", "Vancouver", "Taipei", "Cancer Specialist of North Florida, Pharmacy", "Veterans General Hospital-Taipei", "Fort Worth", "Aichi Cancer Center Hospital", "Northwest Cancer Specialists P.C.", "Ryazan Regional Clinical Oncology Dispensary", "Hospital de Donostia", "Maroondah Hospital", "Waterford Regional Hospital", "Evanston", "Toulouse Cedex-9", "Dijon", "Zaporizhzhya", "Hamburg", "London Regional Cancer Program", "Westlake Village", "Urbana", "Fukuoka", "UCLA West Medical Pharmacy, Attn: Steven L. Wong", "Klinikverbund Sudwest - Kliniken Sidelfingen-Boblingen", "Seattle Cancer Care Alliance", "Stanford", "Tom Baker Cancer Centre", "Texas oncology-West Texas", "MI \"Zaporizhzhia Regional Clinical Oncology Dispensary\" Zaporizhzhia Regional Assembly,", "Lviv", "UCLA West Medical Pharmacy", "Brussels", "St. James Hospital", "Memorial Breast Cancer Center at Memorial Hospital West", "Erlangen", "Hospital Universitari Son Espases", "SBHI of Republic of Bashkortostan Emergency Hospital", "Oncology & Hematology Associates of Southwest Virginia, INC., D.B.A. Blue Rigde Cancer Care", "New Haven", "Regulatory Management Only: TRIO-US Central Administration", "Federal State Budget Institution", "Oncologie", "Azienda Ospedaliera San Giuseppe Moscati", "Hiroshima City Hiroshima Citizens Hospital", "Calvary Mater Newcastle", "University of Wisconsin", "Oncology and Radiotherapy Clinic", "MedStar Georgetown University Hospital", "Nice", "Poland", "Pisa", "Kumamoto", "Smyrna", "National Cancer Center, Center for Breast Cancer", "Ringwood East", "Henderson", "Saitama Cancer Center", "US Oncology Investigational Products Center", "Badajoz", "Louisville", "Universitaetsklinikum Hamburg-Eppendorf", "Edmonton", "City Oncology Centre of Central Municipal Clinical Hospital", "State institution \"Zaporizhzhia Medical Academy of Postgraduate Education MOH Ukraine\",", "Cross Cancer Institute", "Center Hospitalier Affilie Universitaire de Quebec, Universite Laval, Hopital du Saint Sacrement", "Centre Georges Fran\u00e7ois Leclerc", "Regulatory Office: Comprehensive Cancer Centers of Nevada Research Department", "Budapest", "Ja\u00e9n", "Northwest Cancer Specialists, P.C.", "Chicago", "GUZ Republic Clinical Oncology Dispensary of Ministry of Health of Republic of Tatarstan", "Hospital Universitario Arnau de Vilanova de Lleida", "San Luis Obispo Oncology and Hematology Health Center/ Pacific Central Coast Health Centers", "CareMount Medical", "Kharkiv", "Newport News", "Southlake Regional Health Centre- Stronach Regional Cancer Centre", "Canada", "Niigata", "Columbia University Medical Center", "Paris", "Sarah Cannon Research Institute", "UCLA Hematology/Oncology", "CHR East Belgium - Verviers", "TRIO-US Central Administration: Regulatory Management Only", "Waratah", "Centre Fran\u00e7ois Baclesse", "Kagoshima", "Szegedi Tudomanyegyetem Altalanos Orvosi Kar, Patologia Intezet", "Beatson Institute for Cancer Research", "University of California, San Francisco", "Translational Research Management", "Northwest Cancer Specialists, PC", "Institut Gustave Roussy", "Gy\u0151r", "Ryazan", "Ballwin", "Terrassa", "Avellino", "Centre Val d'Aurelle,", "Shepparton", "Taiwan", "Hospital Universitario Virgen Macarena", "Galway", "Sumy", "Northern Hospital", "Kursk", "Guys Hospital", "Memorial Cancer Institute at Memorial Hospital West", "Edinburgh Cancer Centre, Western General Hospital", "Jacksonville", "Italy", "Irving", "Kiel", "Glendale", "Regina", "Orszagos Onkologiai Intezet ,", "UCLA West Medical Pharmacy; Drug Management Only", "\u017bory", "Regional Budgetary Healthcare Institution Kursk Regional Clinical", "Los Angeles Hematology/Oncology Medical Group", "Kaiser Permanente Northwest Region", "Wellness Oncology & Hematology", "Hospital Clinic I Provincial", "M\u00fcnchen", "Houston", "Mattoon", "Adelaide", "France", "Universitatsklinikum Schleswig-Holstein, Campus Kiel, Klinik f\u00fcr Gynakologie und Geburtshilfe", "Josa Andras Teaching Hospital,", "Ann Arbor", "Saint Francis Medical Center", "Manchester", "Gdansk", "Emory University Hospital", "Allan Blair Cancer Centre", "United States", "San Diego", "Montreal", "Limerick", "State Institution Dnipropetrovsk Medical Academy at the Ministry of Health of Ukraine", "Spain", "Hospital Madrid Universitario Sanchinarro", "The University of Texas MD Anderson Cancer Center", "University of Maryland, Greenebaum Cancer Center", "Southern California Permanente Medical Group", "Atlanta", "Texas Oncology-Baylor Charles A. Sammons Cancer Center", "Oncology & Hematology Associates of Southwest Virginia, Inc. D.B.A Blue Ridge Cancer Care", "Low Moor", "Morgantown", "The University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology", "Wytheville", "Texas oncology-west Texas", "St. Mary's Hospital Regional Cancer Center", "Milan", "National Hospital Organization Hokkaido Cancer Center", "Mount Kisco", "Institut Curie, Departement d'Oncologie Medicale", "Kita-adachi-gun", "MI \"Dnipropetrovsk City Multidisciplinary Clinical Hospital No.4\" of the Dnipropetrovsk City Council", "National Hospital Organization Kyushu Cancer Center", "Northern Westchester Hospital", "Comprehensive Cancer Centers of Nevada", "Epworth Healthcare", "UCLA Hematology Oncology", "State Budget Medical Institution Republican Clinical Oncology", "Saint Augustine", "San Crist\u00f3bal de La Laguna", "Dnipro", "London", "Hospital del Mar", "Goulburn Valley Health", "Norfolk", "UCLA Hematology Oncology- Laguna Hills", "Oregon Health and Science University", "Icon Cancer Care", "Institut de Cancerologie de l'Ouest- Paul Papin", "St Vincent's Hospital Sydney", "Richmond", "UZ Brussel", "Hermitage", "Nagoya", "Post Falls", "Sylvester at Deerfield Beach", "WVU Medicine", "UCLA West Medical Pharmacy: Drug Management Only", "Breast Cancer, University of Munich, Grosshadern Hospital", "Institute of Postgraduate education and preuniversity preparing of Uzhgorod National Univ.", "Royal Adelaide Hospital", "Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet, Nuklearis Medicina Osztaly", "Epping", "Icon Cancer Care Corporate Office", "Carle Foundation Hospital DBA Carle Cancer Center", "Stanford Women's Cancer Center", "Mainz", "Memorial Cancer Institute at Memorial Regional Hospital", "Skokie", "Azienda Ospedaliero-Universitaria Pisana", "Niigata Cancer Center Hospital 2-15-3", "Lleida", "Saint Francis Medical Center, Saint Francis Cancer Treatment Center", "Winship Cancer Institute", "OHSU Center for Health and Healing", "Rennes", "Glasgow", "Tennessee Oncology, PLLC", "San Luis Obispo", "University of Michigan Health System", "Republican Clinical Hospital n.a. G.G. Kuvatov", "National Hospital Organization Shikoku Cancer Center", "Centro Oncologico de Galicia", "The Research And Development Office, The Christie NHS Foundation Trust", "Ny\u00edregyh\u00e1za", "Australia", "Port Macquarie", "Caen", "Seoul National University Hospital / Department of Internal Medicine", "Instituto Valenciano de Oncologia", "Saint-Cloud", "Qu\u00e9bec", "Department of Medical Oncology", "Hospital General Universitario Gregorio Mara\u00f1on", "Princess Margaret Cancer Centre", "Goyang-si", "Central Coast Medical Oncology Corporation", "Petz Aladar Megyei Oktato Korhaz, Onkoradiologiai Osztaly", "Hradec Kr\u00e1lov\u00e9", "Christie Hospital NHS Foundation Trust", "Dickson", "IRCCS - Istituto Europeo di Oncologia", "Brewster", "Hiroshima", "Los Angeles", "St. Joseph Heritage Healthcare", "Beaumont Hospital", "Grand Hopital de Charleroi / Service d'Hematologie et Oncologie", "Edinburgh", "New York", "Omsk", "Auchenflower", "Franklin", "Frauenklinik und Poliklinik Klinikum rechts der Isar, Technische Universitaet Muenchen", "Bendigo", "The Royal Marsden NHS Foundation Trust", "Marietta", "Hospital Clinico San Carlos", "Kumamoto City Hospital", "Waterford", "Lebanon", "Virginia Oncology Associates", "Shenandoah Oncology PC", "Gasthuis Zusters Antwerpen - Campus Sint- Augustinus", "Hopital Rene Huguenin/Institut Curie", "Las Vegas", "Blacksburg", "Princess Alexandra Hospital", "Virginia Beach", "Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi", "Moscow Area", "UCLA Santa Monica Medical Center and Orthopaedic Hospital", "A Coru\u00f1a", "Calgary", "Montpellier", "Matsuyama", "Park Nicollet Frauenshuh Cancer Center", "Irccs Irst", "Instituto Catalan de Oncologia L'Hospitalet", "Orlando Health, Inc.", "BC Cancer Agency-Fraser Valley Centre", "CHU Start Tilman", "Institut Claudius Regaud- Cancer Comprehensive Center- IUCT-O-Medical Oncology Department", "Russia", "Shelbyville", "James Graham Brown Cancer Center and University Hospital", "Seoul National University Bundang Hospital", "Alcorc\u00f3n", "Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet, Radiologiai Diagnosztikai Osztily", "Seodaemun-gu", "L'Hospitalet de Llobregat (Barcelona)", "El Paso", "West Hills", "St Vincents University Hospital", "Budget Institution of Healthcare", "Kuzmolovo", "Seoul", "Washington D.C.", "Badalona", "Germantown", "Roma", "Chiba Cancer Center", "Mid Western Regional Hospital", "The Mark M. Connolly Center for Cancer and Specialty Care", "Hospital Universitari Germans Trias i Pujol", "Bellflower", "Bendigo Health Care Group, The Bendigo Hospital Campus", "Cork", "Regional Municipal Establishment \"Sumy Regional Clinical Oncology Dispensary\", Thoracic Department", "Istituti Fisioterapici Ospitalieri", "Moscow", "Li\u00e8ge", "Bethesda", "QEII Health Sciences Centre, Victoria General Site", "Investigational Products Center (IPC)", "Salem", "Stony Brook", "The West Clinic, PC dba West Cancer Centre", "Czechia", "Darlinghurst", "National Cancer Center Hospital East", "Hollywood", "San Francisco", "Nashville", "Pembroke Pines", "Niepubliczny Zak\u0142ad Opieki Zdrowotnej \"Onko-Dent\" SP.P. G.L. S\u0142omian", "Numakunai", "Verviers", "State Budget Healthcare Institution Moscow City Oncology Hospital", "Torrance Health Association, DBa Torrance Memorial Physician Network", "Leuven", "Charleroi", "Hopital du Sacre-Coeur", "Walter Reed National Military Medical Center", "Toronto", "Fakultni nemocnice Hradec Kralove, Klinika onkologie a radiologie", "Consorci Sanitari de Terrassa", "Mercy Hospital St. Louis", "Mercy Clinic St. Louis Cancer and Breast Institute", "Grady Health System", "Szeged", "St. Michaels Hospital", "Chuo-Ku", "Smilow Cancer Hospital at Yale New Haven", "Laverty Pathology", "Memphis", "Corinth", "UCLA Hematology/Oncology- Westlake", "Woolloongabba", "Beverly Hills", "Deerfield Beach", "Effingham", "Germany", "Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg", "Madrid", "Texas Oncology-Dallas Presbyterian Hospital", "Administrative Address: UCLA Hematology/Oncology", "United Kingdom", "Kumamoto University Hospital", "National Hospital Organization Osaka National Hospital", "Saint Petersburg", "Laguna Hills", "Meldola", "Drug Management Only: TRIO-US Pharmacy UCLA Medical Plaza, Attn: Steven L Wong, Pharm.D.", "Severance Hospital, Yonsei University Health System", "Institut de Canc\u00e9rologie de l'Ouest-Rene Gauducheau", "Barcelona", "The University of Texas MD Anderson Cancer Center.", "UCLA Hematology/ Oncology- Irvine", "Santa Monica", "South Korea", "Palma de Mallorca", "Seville", "Seongnam-si", "The West Clinic, PC", "Murfreesboro", "Seattle", "South Brisbane", "Asan Medical Center, Division of Oncology, Department of Internal Medicine", "Donostia / San Sebastian", "Lviv State Oncologic Regional Treatment and Diagnostic Center, Chemotherapy Department", "Hakuaikai Medical Corporation Sagara Hospital", "Parkville", "James Graham Brown Cancer Center", "Memorial Breast Cancer Center at Memorial Regional Hospital", "Sora (FR)", "Kent Oncology Center", "Baltimore", "Bologna", "Iwate Medical University Hospital", "La Roche-sur-Yon", "OHSU Research Pharmacy Services", "Sylvester Comprehensive Cancer Center Plantation", "Sunshine Coast University Hospital", "Zaporizhzhia", "Fullerton", "Grand Island", "Orsz\u00e1gos Onkol\u00f3giai Int\u00e9zet \"B\" Belgyogyaszati osztaly", "Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont, Altalanos Orvostudomanyi Kar", "Magdeburg", "Hospital Universitario Infanta Cristina", "Portland", "Hospital Universitari Vall d'Hebron", "Katholisches Klinikum Mainz", "Coeur d'Alene", "Winchester", "Hungary", "Norwalk", "Orlando", "Kazan'", "Sunnybrook Research Institute", "Santa Maria", "UCLA Hematology/ Oncology- Pasadena", "Cancer Specialists of North Florida - St. Augustine", "Universitaetsklinikum Magdeburg AOR Universitaetsfrauenklinik", "Mid North Coast Diagnostic Imaging", "Valencia", "Dresden", "Ireland", "Bon Secours Hospital", "Mater Misericordiae University Hospital", "Kashiwa", "OHSU Center for Health and Healing 2", "Royal Melbourne Hospital", "Dublin", "Europejskie Centrum Zdrowia Otwock", "Saint-Herblain", "Uzhhorod", "St Louis", "Beverly Hills Cancer Center", "Memorial Regional Hospital", "Centro Oncologico MD Anderson Internacional Espa\u00f1a", "Szent Margit Korhaz", "Presence Infusion Care- Evanston", "Presence Infusion Care- Skokie", "Texas Oncology-west Texas", "Madison", "Villejuif", "Kootenai Clinic Cancer Services", "Memorial Hospital West", "Ospedale SS Trinita", "IOZ- Munchen, PGM- Studien GmbH", "Otwock", "Klinikum Mutterhaus", "University of California San Francisco - Helen Diller Family Comprehensive Cancer Center", "National Taiwan University Hospital"], "intervention": ["PD-0332991", "Palbociclib Plus Letrozole", "Placebo Plus Letrozole"], "outcome": ["Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs): All Causalities", "Duration of Response (DR)", "Disease Control (DC)/Clinical Benefit Response (CBR)", "Observed Plasma Trough Concentration (Ctrough) at Steady-State", "Overall Survival (OS): Final Analysis", "Objective Response: Participants With Measurable Disease at Baseline as Assessed by the Investigator", "Change From Baseline Between Treatment Comparison in Euro Quality of Life (EQ-5D) Index", "Change From Baseline Between Treatment Comparison in Functional Assessment of Cancer Therapy-Breast (FACT-B)", "Progression-Free Survival (PFS) as Assessed by the Investigator", "Survival Probability at 1 Year, 2 Year and 3 Year", "PFS by Tumor Tissue Biomarkers Status, Including Genes (eg, Copy Numbers of CCND1, CDKN2A), Proteins (eg, Ki67, pRb), and RNA Expression (eg, cdk4, cdk6)", "Percentage of Participants With Corrected QT Interval (QTc)", "Overall Survival (OS): Primary Analysis", "Number of Participants With Laboratory Abnormalities by Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade", "Objective Response as Assessed by the Investigator", "Corrected QT Interval (QTc) Time-Matched Change From Baseline on Cycle 1 Day 14"], "outcome-Measure": ["Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs): All Causalities", "Duration of Response (DR)", "Disease Control (DC)/Clinical Benefit Response (CBR)", "Observed Plasma Trough Concentration (Ctrough) at Steady-State", "Overall Survival (OS): Final Analysis", "Objective Response: Participants With Measurable Disease at Baseline as Assessed by the Investigator", "Change From Baseline Between Treatment Comparison in Euro Quality of Life (EQ-5D) Index", "Change From Baseline Between Treatment Comparison in Functional Assessment of Cancer Therapy-Breast (FACT-B)", "Progression-Free Survival (PFS) as Assessed by the Investigator", "Survival Probability at 1 Year, 2 Year and 3 Year", "PFS by Tumor Tissue Biomarkers Status, Including Genes (eg, Copy Numbers of CCND1, CDKN2A), Proteins (eg, Ki67, pRb), and RNA Expression (eg, cdk4, cdk6)", "Percentage of Participants With Corrected QT Interval (QTc)", "Overall Survival (OS): Primary Analysis", "Number of Participants With Laboratory Abnormalities by Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade", "Objective Response as Assessed by the Investigator", "Corrected QT Interval (QTc) Time-Matched Change From Baseline on Cycle 1 Day 14"]}, "NCT00418457": {"iv-cont-number": ["102", "111"], "iv-cont-count_of_participants": ["456", "87", "89", "442"], "iv-cont-mean": ["49.7", "49.8", "48.7", "48.1"], "age": ["85 Years", "18 Years"], "eligibility": ["Any contraindication to epidural or paravertebral anesthesia and analgesia (including coagulopathy, abnormal anatomy)", "Age < 18 or > 85 years old", "Primary breast cancer without known extension beyond the breast and axillary nodes (i.e. believed to be Tumor Stage 1-3, Nodes 0-2)", "Isolated \"lumpectomy\" with axillary node dissection (anticipated removal of at least five nodes)", "Any contraindication to midazolam, propofol, sevoflurane, fentanyl, or morphine", "ASA Physical Status >= 4", "Previous surgery for breast cancer (except diagnostic biopsies)", "Scheduled for unilateral or bilateral mastectomy with or without implant (isolated \"lumpectomy\" will not qualify)", "Written informed consent, including willingness to be randomized to morphine or regional analgesia", "Scheduled free flap reconstruction", "Inflammatory breast cancer", "Systemic disease believed by the attending surgeon to present >= 25% two-year mortality"], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Breast Neoplasms"], "location": ["Vienna", "Mater Misericordiae Hospital", "Peking Union Medical College Hospital", "Ireland", "Cleveland Clinic Foundation", "Medical University of Vienna", "Tan Tock Seng Hospital", "Austria", "Beijing", "Singapore", "Cleveland", "Germany", "Dublin", "University of D\u00fcsseldorf", "China", "D\u00fcsseldorf", "United States"], "intervention": ["Regional Analgesia and Propofol", "Regional analgesia and propofol", "General anesthesia and opioids", "General Anesthesia and Opioid", "General anesthesia", "Regional analgesia"], "outcome": ["Number of Participants That Experienced Neuropathic Pain After Surgery", "SF-12 MCS Score", "Number of Participants That Experienced Post-Surgical Pain", "Number of Participants Who Had Breast Cancer Recurrence After Breast Cancer Surgery", "SF-12 PCS Score"], "outcome-Measure": ["Number of Participants That Experienced Neuropathic Pain After Surgery", "SF-12 MCS Score", "Number of Participants That Experienced Post-Surgical Pain", "Number of Participants Who Had Breast Cancer Recurrence After Breast Cancer Surgery", "SF-12 PCS Score"]}, "NCT01216111": {"age": ["70 Years", "18 Years"], "eligibility": ["Adequate recovery from recent surgery (at least one week must have elapsed from the time of a minor surgery (excluding breast biopsy); at least three weeks for major surgery);", "Signed written informed consent.", "Adequate cardiac function, LEVF value > 50% by Muga scan or echocardiography;", "Clinically significant cardiovascular disease (e.g. unstable angina, congestive heart failure, uncontrolled hypertension (>150/90), myocardial infarction or cerebral vascular accidents) within 6 months prior to randomization;", "Patients accepting contraception intake during the overall length of treatment if of childbearing potential;", "Known prior severe hypersensitivity reactions to agents containing Cremophor EL;", "Individual deprived of liberty or placed under the authority of a tutor.", "Bilateral breast cancer or patient with controlateral DCIS;", "Initial clinical condition compatible with complete initial resection;", "Any clinically or radiologically suspect and non-explored damage to the controlateral breast;", "Adequate hepatic function: ASAT and ALAT <= 3 ULN alkaline phosphatases <= 2.5 ULN,total bilirubin <= 1,5 ULN;", "Women with a positive pregnancy test en enrollment or prior to study drug administration;", "WHO Performance status (ECOG) of 0 or 1;", "positive lymph node or negative lymph node with tumor size > 1.0cm", "Previous cancer (excepted cutaneous baso-cellular epithelioma or uterin peripheral ephitelioma) in the preceding 5 years, including invasive controlateral breast cancer;", "No peripheral neuropathy > 1;", "Women who are pregnant or breastfeeding. Adequate birth control measures should be taken during study treatment phase;", "Adequate renal function: serum creatinine <= 1 ULN;", "Triple negative \uff08ER-PR-Her-2-\uff09 Hormone receptor negativity is defined as ER<1%, PR<1% (IHC), HER2 negativity is defined as IHC 0-1+, or [IHC 2+ and FISH or CISH negative].", "LEVF < 50% (MUGA scan or echocardiography);", "Adequate hematological function (neutrophil count \u00b3 2x109/l, platelet count \u00b3 100x 109/l, Hemoglobin > 9 g/dl);", "Histologically proven invasive unilateral breast cancer (regardless of the type);", "Any metastatic impairment, including homolateral sub-clavicular node involvement,regardless of its type;", "No residual macro or microscopic tumor after surgical excision;", "Any T4 lesion (UICC1987) (cutaneous invasion, deep adherence, inflammatory breast cancer);", "Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and up to 8 weeks after treatment completion;", "No clinically or radiologically detectable metastases (M0);", "Women aged from 18 to 70 years;", "Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial;", "ER+ or PR+ or Her-2 overexpression"], "condition": ["Triple Negative Breast Cancer"], "intervention": ["Paclitaxel Cisplatin"], "outcome": ["disease-free survival gBRCA1 mutation carriers and homologous recombination repair (HRR)-related gene mutation carriers", "distant disease-free survival", "overall survival", "relapse-free survival", "disease-free survival"]}, "NCT01849133": {"age": ["75 Years", "48 Years"], "eligibility": ["Clinical mammographic/ultrasound diagnosis of unicentric carcinoma, with ultrasound diameter <=2.5 cm. Advisable, but not mandatory, the execution of mammoscintigraphy with MDP-99mTc (Methyl diphosphonate technetium-99m) : this procedure allows the bone staging and the mapping of eventual multi-focality/multi-centricity of the breast neoplasm.", "Tumor in the axillary tail.", "Personal anamnesis positive for malignancy (basocellular carcinoma, in situ carcinoma of the cervix, contralateral breast cancer free of disease after 15 years of follow-up excluded).", "Documented multi-centricity/multi-focality of the tumor.", "Tumor in close proximity to the skin.", "Age >= 48 and < 75", "Adequate information to the patient and informed consent.", "Histology different from carcinoma.", "Paget disease.", "Ductal or lobular non-infiltrating carcinoma.", "Patients with non-palpable lesions will undergo preoperative centering and stereotactic and/or ultrasound-guided cytology (the execution of this last procedure is not mandatory)."], "condition": ["Carcinoma Breast"], "location": ["Italy", "European Institute of Oncology", "Milan"], "intervention": ["external fractionated radiotherapy"], "outcome": ["Number of local relapses"]}, "NCT01422551": {"age": ["75 Years", "21 Years"], "eligibility": ["prior psychiatric treatment for a serious disorder (e.g., psychosis, suicidality),", "lack of fluency in English and had begun adjuvant therapy at time of first assessment", "prior cancer,", "-women diagnosed with breast cancer at stage III or below who had recently undergone lumpectomy or mastectomy"], "condition": ["Breast Cancer"], "location": ["Coral Gables", "Department of Psychology University of Miami", "United States"], "intervention": ["Cognitive Behavioral Stress Management"], "outcome": ["change from baseline to 12 months in physiological adaptation (decreased serum cortisol and increased Th1 cytokine production)", "change from baseline to 12 month follow-up in psychosocial adaptation (less negative affect and social disruption; more benefit finding and positive affect)"]}, "NCT02688998": {"age": ["19 Years"], "eligibility": ["Histologically confirmed primary breast cancer", "\u2022 Contraindication to central line placement.", ">=19 years of age", "Able to provide verbal consent"], "condition": ["Breast Cancer", "Cancer"], "location": ["The Ottawa Hospital Cancer Centre", "Canada", "Ottawa"], "control": ["No intervention"], "intervention": ["venous access PORT or PICC"], "outcome": ["Physician engagement", "Patient compliance", "Number of attempts at cannulation", "Rates of thrombotic events", "Accrual rates"]}, "NCT02910986": {"iv-cont-count_of_participants": ["101", "100", "110", "104", "88", "70", "114", "95", "99"], "age": ["40 Years", "74 Years"], "eligibility": ["Current diagnosis of breast cancer", "Speak English or Spanish", "Male", "Attending screening mammography at Mountain Park Health Center", "Female"], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Breast Cancer"], "location": ["Rochester", "Phoenix", "Scottsdale", "Mountain Park Health Center", "Mayo Clinic in Rochester", "Mayo Clinic in Arizona", "United States"], "control": ["Usual Care"], "intervention": ["Interpersonal", "Enhanced", "Written educational brochure"], "outcome": ["BC Risk Assessment - Survey", "Knowledge of Breast Density as a Masking Factor at First Follow-up", "Anxiety Short Term (Baseline T0 to First Follow-up T1)"], "outcome-Measure": ["BC Risk Assessment - Survey", "Knowledge of Breast Density as a Masking Factor at First Follow-up", "Anxiety Short Term (Baseline T0 to First Follow-up T1)"]}, "NCT02549430": {"age": ["18 Years"], "eligibility": ["Progression of advanced breast cancer on first or second line endocrine therapy for advanced breast cancer", "Current treatment with therapeutic doses of anticoagulant", "Current use or anticipated need for food or drugs that are known strong CYP3A4 inhibitors / inducers, drugs that are predominantly metabolized by CYP3A with narrow therapeutic indices, drugs with the potential of prolonging QT interval", "Measurable disease according to RECIST 1.1 (bone only disease is allowed only if measurable).", "Resolution of all acute toxic effects of prior therapy or surgical procedures to CTCAE grade >1", "Diagnosis of any secondary malignancy within the last 3 years", "ER positive tumor >= 10%", "Postmenopausal status", "Paraffin-embedded tumor available for centralized assessment of biomarkers", "Unstable brain metastases", "Adequate organ function", "Prior treatment with more than one line of CT or more than two lines of HT advanced breast cancer or any CDK inhibitor", "Histologically proven diagnosis of adenocarcinoma of the breast with evidence of metastatic disease", "Eastern Cooperative Oncology Group (ECOG) Performance status 0 -2", "HER2 negative breast cancer by FISH or IHC", "Active inflammatory bowel disease or chronic diarrhea", "Known human immunodeficiency virus infection; active hepatitis C, active hepatitis B"], "condition": ["Breast Cancer"], "location": ["Italy", "A.O.U. Federico Ii Di Napoli", "Napoli", "Pavia", "Milan", "Bergamo", "Fondazione Maugeri", "Ospedale Antonio Perrino", "Azienda Ospedaliera Papa Giovanni Xxiii", "A.O.U. S. Maria Della Misericordia Di Udine", "Brindisi", "Udine", "Istituto Europeo Oncologia"], "intervention": ["PD0332991", "Anastrozole", "Palbociclib"], "outcome": ["Duration of Response (DR)", "Incidence of complete response (CR), partial response (PR) or stable disease (SD) \u226524 weeks (clinical benefit)", "Overall Survival (OS)", "Time to Progression (TTP)", "Progression free survival (PFS)", "Objective Response (OR)", "Incidence of Treatment-Emergent Adverse Events"]}, "NCT00651456": {"age": ["75 Years", "18 Years"], "eligibility": ["At least 18 years of age, less than 76 years of age", "History of cerebral vascular accident (CVA) or transient ischemic attack", "Radiation therapy of thoracocentis tract (3 x 7Gy) performed before beginning medical study treatment, and the interval between thoracoscopic procedure and radiation will not exceed 28 days", "In case of pleural effusion, a talc pleurodesis, although not recommended, is allowed in accordance with current local practice, at the time of diagnostic thorascopy, with inclusion CT scan performed after pleurodesis.", "ECOG Performance status 0-2", "Malignant, histologically proved, non resectable pleural Mesothelioma", "Mesothelioma with only pleural effusion without uni- or bidimensionally measurable disease will be eligible (adapted RECIST criteria)", "Brain metastasis"], "condition": ["Mesothelioma"], "location": ["Thonon-les-Bains", "B\u00e9ziers", "Saint Quentin - CH", "Longjumeau", "HCL - Croix-Rousse", "Montpellier - CHRU", "Grenoble", "CHU (H\u00f4pital Calmette) - Pneumologie", "Le Mans - Clinique Victor Hugo", "Paray Le Monial - CH", "Centre Etienne Dolet", "Centre Hospitalier du Pays d'Aix", "Pau", "Auxerre - CH", "CH de Longjumeau", "Paray-le-Monial", "Thonon les bains - CH", "Besan\u00e7on", "Rouen - CHU", "Reims", "Strasbourg - NHC", "Pontoise - CH", "Elbeuf - CH", "Vesoul", "Reims - CHU", "Saint-Priest-en-Jarez", "Centre Georges Fran\u00e7ois Leclerc", "Suresnes - Hopital Foch", "Clinique de l'Europe", "Nantes", "Meaux", "Nevers", "B\u00e9ziers - CH", "Rennes", "Brest - CHU", "Mulhouse", "Le Havre - HPE", "Paris", "Brest", "H\u00f4pital Percy-Arm\u00e9es - Pneumologie", "Clermont-Ferrand", "Paray Le Monial - Clinique", "HCL - Lyon Sud (Pneumologie)", "Toulouse", "Lorient - CHBS", "Angers - CHU", "Le Havre", "Saint-Nazaire", "Chauny - CH", "Nevers - CH", "Chartres - CH", "Le Coudray", "Pierre-B\u00e9nite", "Flers - CH", "Colmar - CH", "Cr\u00e9teil", "Caen", "Institut Gustave Roussy", "Saint Brieuc - CHG", "Rouen", "Colmar", "Limoges - H\u00f4pital du Cluzeau", "Toulon - CHI", "Bobigny", "Tours - CHU", "Bobigny - H\u00f4pital Avicenne", "Cr\u00e9teil - CHI", "Centre L\u00e9on B\u00e9rard", "Valenciennes - Clinique", "Paris - Curie", "Mont-de-Marsan", "Mulhouse - CH", "Boulogne", "France", "Cherbourg", "Caen - Centre Fran\u00e7ois Baclesse", "Auxerre", "Meaux - CH", "Tours", "Le Mans", "Valence", "Suresnes", "Bois-Guillaume - CHU", "Toulon", "Denain", "APHM - H\u00f4pital Sainte Marguerite", "Nantes - Centre Ren\u00e9 Gauducheau", "Saint-Nazaire - CH", "Saint-Malo - CH", "Poitiers", "Valenciennes", "Roubaix - CH", "CH Valence", "APHP - Hopital Tenon - Pneumologie", "CHI de la Haute-Sa\u00f4ne - Pneumologie", "Saint-Brieuc", "Dijon", "Orl\u00e9ans - CH", "Evreux - CH", "Paris - Saint Louis", "Narbonne - Polyclinique Le Languedoc", "Cherbourg - CH", "Centre Hospitalier - Pneumologie", "Rennes - CHU", "Limoges", "Clamart", "Marseille", "Aix-en-Provence", "Boujan-sur-Libron", "Elbeuf", "Lyon", "Montpellier", "Brest - HIA", "Amiens", "Nice - CAC", "\u00c9vreux", "Mont de Marsan - CH", "H\u00f4pital Ambroise Par\u00e9 - Pneumologie", "CHU", "CHU Besancon - Pneumologie", "Strasbourg", "Lille", "CHU Toulouse - Pneumologie", "Nancy", "Denain - CH", "CHU H\u00f4pital du Bocage", "Orl\u00e9ans", "St-Malo", "Villefranche", "Villejuif", "Narbonne", "Flers", "CHU - Pneumologie", "Amiens - CHU", "Saint-Quentin", "Boujan sur Libron - Polyclinique Saint-Privat", "Institut de Canc\u00e9rologie de la Loire", "Pontoise", "CH de Villefranche - Pneumologie", "Annemasse - CH", "Lorient", "Pau - CH", "Ambilly", "CHU Grenoble - pneumologie", "Chauny", "Bois-Guillaume", "Nice", "Angers", "Roubaix"], "intervention": ["Standard Chemotherapy (Pemetrexed and Cisplatin)"], "outcome": ["Medico-economic assessments of drugs (direct/indirect costs)", "Number of participants with treatment-related adverse events as assessed by CTCAE v3.0", "Overall Survival", "% of patients with controled disease (responder and stable patients) at 6 months"]}, "NCT01958021": {"iv-cont-median": ["63.9", "22.6", "NA", "19.3", "51.4", "14.7"], "iv-bin-abs": ["79.6", "27.5", "40.7", "72.8"], "iv-cont-mean": ["4.9", "2.9"], "iv-cont-number": ["0"], "age": ["100 Years", "18 Years"], "eligibility": ["History of angina pectoris, symptomatic pericarditis, or myocardial infarction within 12 months prior to study entry.", "The patient had a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer by the local laboratory.", "Age >=60", "Medications known to be strong inducers or inhibitors of CYP3A4.", "Medications with a narrow therapeutic window and predominantly metabolized through CYP3A4.", "Any prior (neo) adjuvant anti-cancer therapy had to be stopped at least 5 half-lives or 7 days, whichever was longer, before randomization.", "Patients who had received (neo) adjuvant therapy for breast cancer were eligible. If the prior neo (adjuvant) therapy included letrozole or anastrozole, the disease-free interval had to be greater than 12 months from the completion of treatment until randomization.", "The patient had HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC was 2+, a negative in situ hybridization (FISH, CISH, or SISH) test was required by local laboratory testing.", "Prior bilateral oophorectomy", "History of any cardiac arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months.", "The patient had a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO).", "On screening, any of the following cardiac parameters: bradycardia (heart rate < 50 at rest), tachycardia (heart rate > 90 at rest), PR interval > 220 msec, QRS interval >109 msec, or QTcF >450 msec.", "Medications known to have a risk of prolonging the QT interval or inducing Torsades de Pointes.", "The patient had received any CDK4/6 inhibitor.", "History of documented congestive heart failure (New York Heart Association functional classification III-IV).", "The patient had a concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated, basal or squamous cell carcinoma, non-melanomatous skin cancer, or curatively resected cervical cancer.", "Patients who had received <= 14 days of letrozole or anastrozole for advanced disease prior to randomization were eligible.", "Documented cardiomyopathy.", "Herbal preparations/medications.", "Systolic blood pressure >160 or <90 mmHg.", "The patient had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.", "Women with advanced (locoregionally recurrent or metastatic) breast cancer that was not amenable to curative therapy.", "There was no prior systemic anti-cancer therapy for advanced disease."], "ethinicity": ["Black", "Native American", "Caucasian", "Pacific Islander", "Other", "Unknown", "Asian"], "condition": ["Advanced, Metastatic Breast Cancer"], "location": ["Gyeonggi-do", "Sioux Falls", "University of Chicago", "Gyula", "Brescia", "Belgium", "Salzburg", "Salem", "East Melbourne", "Argentina", "City of Hope National Medical Center", "Candiolo", "Frederick Memorial Hospital", "Czechia", "Georgia Cancer Specialists", "Gothenburg", "Alkmaar", "Lewis Hall Singletary Onc Ctr at John D. Archbold Mem Hosp.", "J\u00f6nk\u00f6ping", "Memorial Hospital", "Ramat Gan", "Foundation Medical Partners", "University of Texas Southwestern Medical Center", "Brno Bohunice", "Diyarbak\u0131r", "C R Wood Cancer Center at Glens Falls Hospital", "Genova", "Olomouc", "Hollywood", "Florida Cancer Specialists", "Oncology and Hematology Associates of Southwest Virginia Inc", "Nashville", "Groningen", "Kaohsiung City", "IU Simon Cancer Center", "Dana Farber Cancer Institute", "Besan\u00e7on", "Miami", "Glendale Adventist Medical Center", "Dallas", "Vanderbilt University Medical Ctr", "Mount Sinai School Of Medicine", "Goslar", "Tacoma", "Essen", "Boston", "Leuven", "Sidney Kimmel CCC At JH", "Jackson", "St. Petersburg", "Turku", "Velbert", "Toronto", "Vaxjo", "NYU Langone Med Center CV Research", "Mercy Medical Research Institute", "Ingalls Memorial Hospital", "Penn State Hershey Cancer Institute", "Budapest", "Univ of Colorado School of Medicine", "Sedona", "Chicago", "Bundang Gu", "Decatur", "Halifax", "T\u00fcbingen", "Honolulu", "Cancer Institute of New Jersey", "Rocky Mountain Cancer Centers", "Dean Health System", "Cincinnati", "McAllen", "Boynton Beach", "Kitchener", "Novartis Investigative Site", "Cooper Cancer Center", "Salt Lake City", "Canada", "Durham", "Fairfax", "Ctr For Cancer And Blood Disorders", "Bottrop", "Uppsala", "Bordeaux", "Sacred Heart Medical Oncology", "Sarah Cannon Research Institute", "Texas Oncology P A", "Texas Oncology Northeast Texas", "Truro", "Aurora", "Terni", "Camden", "Pretoria", "Ravensburg", "Turkey (T\u00fcrkiye)", "Newcastle upon Tyne", "Richardson", "Israel", "Comprehensive Cancer Center", "University of Illinois Cancer Center at Chicago", "Aarhus", "Germany", "La Rioja", "Aschaffenburg", "Australia", "Pierre-B\u00e9nite", "Burnaby", "Sittard-Geleen", "South Africa", "Everett", "Namur", "Offenbach", "Madrid", "Florida Cancer Specialists-North", "Providence Regional Cancer Partnership", "Denmark", "Naperville", "Davie", "Richardson Hematology Oncology Associates", "Cr\u00e9teil", "Bangkok", "Thailand", "United Kingdom", "Qu\u00e9bec", "Gy\u0151r", "Ryazan", "The Angeles Clinic and Research Institute", "Alta Bates Cancer Center", "Copenhagen", "Moanalua Medical Center Attn Oncology Dept", "Frederick", "Rouen", "Messina", "South Korea", "Barcelona", "Leiden", "Seville", "Taiwan", "Tyler", "Fort Myers", "Uni Of TX MD Anderson Cancer Cntr", "Ribeir\u00e3o Preto", "Napoli", "Pensacola", "Texas Oncology Houston Memorial City", "Izmir", "Bedford", "Minneapolis", "Hershey", "Brazil", "Nashua", "Reggio Calabria", "Chandler", "D\u00fcsseldorf", "St Lukes Hos Marion Bloch Neur Inst", "Los Angeles", "NEA Baptist Cancer Center", "Edward Hospital", "Ironwood Cancer and Research Centers", "Nedlands", "Sint-Niklaas", "Italy", "Glendale", "Bonn", "F\u00fcrth", "Beirut", "Avignon", "Odense C", "Fayetteville", "Maastricht", "Bergen", "Taoyuan District", "New Brunswick", "New York", "Chattanooga", "Allentown", "M\u00fcnchen", "El Achrafiy\u00e9", "Northwest Medical Specialties", "University Cancer Institute", "Baltimore", "Padua", "The Bronx", "Millennium Research Clin Develop", "Houston", "Florida Cancer Research Institute", "Oklahoma City", "France", "Highlands Oncology Group", "Norway", "Duke Univ Medical Center", "Vienna", "Wilrijk", "Istanbul", "Manchester", "Lecco", "Saida", "San Antonio", "Santiago de Compostela", "Le Mans", "Taipei", "Deventer", "Netherlands", "Fort Worth", "Indianapolis", "Avera Cancer", "Lebanon", "United States", "Evanston", "Liberec", "Kansas City", "Utah Cancer Specialists", "Montreal", "Helsinki", "Duarte", "NorthShore University Health System", "Edison", "Winthrop University Hospital", "Heidelberg", "Finland", "Spain", "Ankara", "Berlin", "Viterbo", "Ulm", "Zwolle", "S\u00e3o Paulo", "Thomasville", "Oncology Hematology Care Inc", "Berkeley", "Cedars Sinai Medical Center SC-5", "University Of Miami", "Lyon", "Hungary", "Orlando", "Hasselt", "Debrecen", "San Miguel de Tucum\u00e1n", "Texas Oncology", "Longmont", "Recklinghausen", "Arkhangelsk", "Russia", "Valencia", "Freiburg im Breisgau", "Ireland", "Mineola", "Perugia", "Zoetermeer", "L'Hospitalet de Llobregat", "Lund", "Ottawa", "Dublin", "Tilburg", "Vejle", "Saint-Herblain", "The Ohio State University Comprehensive Cancer Center", "Erlangen", "Hackensack Meridian Health", "Kurralta Park", "Oslo", "Seoul", "Arizona Oncology Associates PC HAL", "Nizhny Novgorod", "Petah Tikva", "Jonesboro", "Sweden", "Villejuif", "Milan", "Montefiore Medical Center", "Madison", "Harvey", "Brno", "Bielefeld", "New Taipei City", "Tel Aviv", "Roma", "M\u00e1laga", "Lehigh Valley Hospital", "Glens Falls", "Chattanooga Onc And Hem Assoc PC", "Sacramento", "Allina Hlth Cancer Inst Minneapolis", "Virginia Cancer Specialists", "C\u00f3rdoba", "Hamilton", "Jackson Oncology Associates", "Mercy Clinic Oklahoma Communities Mercy Oncology", "Singapore", "Columbus", "Austria", "Cork", "Aviano", "Eskilstuna", "Florida Retina Institute", "Nice", "Pisa", "Angers", "San Crist\u00f3bal de La Laguna"], "intervention": ["Ribociclib + Letrozole", "Ribociclib", "LEE011", "Placebo + Letrozole", "Letrozole"], "outcome": ["Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) by at Least One Category of the Score", "Clinical Benefit Rate (CBR) by Investigator Assessment", "Overall Response Rate (ORR) by Investigator Assessment", "Overall Survival (OS)", "Time to Definitive 10% Deterioration in the Global Health Status/Quality of Life (GHS/QoL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)", "Progression Free Survival (PFS) by Investigator Assessment", "Change From Baseline in the GHS/QoL Scale Score of the EORTC QLQ-C30"], "outcome-Measure": ["Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) by at Least One Category of the Score", "Clinical Benefit Rate (CBR) by Investigator Assessment", "Overall Response Rate (ORR) by Investigator Assessment", "All Collected Deaths", "Overall Survival (OS)", "Time to Definitive 10% Deterioration in the Global Health Status/Quality of Life (GHS/QoL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)", "Progression Free Survival (PFS) by Investigator Assessment", "Change From Baseline in the GHS/QoL Scale Score of the EORTC QLQ-C30"]}, "NCT01857232": {"iv-cont-count_of_participants": ["27", "33", "13", "21", "11", "37", "17", "20"], "age": ["18 Years"], "eligibility": ["Patients with a known prolactin-dependent tumour (e.g. pituitary gland prolactinoma or confirmed prolactin-dependent breast cancer) or phaeochromocytoma", "Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) < 5 x upper limit normal (ULN)", "Platelet count >= 100 x 109/L", "Patients receiving inhaled corticosteroids, unless started more than one month prior to the expected date of study entry", "Adequate cardiac, hepatic and renal function", "QTc interval < 500 ms", "Haemoglobin >= 8 g/dL", "Patients being treated with regular anti-emetic therapy including corticosteroids", "Patients with a pre-existing vestibular disorder", "Ability and willingness to give written informed consent", "Male or female patients >= 18 years of age", "White blood count >= 3.0 x 109/L", "For females of child-bearing potential: ability and willingness to use a highly effective form of contraception (e.g., abstinence from sexual intercourse, surgical sterilisation (of subject or partner) or a double-barrier method of contraception such as either an intra-uterine device (IUD) or an occlusive cap with spermicide, in conjunction with partner's use of a condom) during the study and for a period of at least 48 hours afterwards", "Creatinine < 3 x ULN", "Patients undergoing abdominal or pelvic irradiation within 48 hours prior to screening or scheduled to receive abdominal or pelvic irradiation between screening and 24 hours after cisplatin or AC administration", "Karnofsky performance score >= 60%", "Adequate haematological function", "Bilirubin < 5 x ULN"], "condition": ["CINV"], "location": ["Odense", "Denmark", "Odense University Hospital"], "intervention": ["APD403 20MG", "Placebo", "APD403 10MG", "ADP403 40MG", "Control ( Dexamethazon)", "Ondansetron"], "outcome": ["Number of Participants With CR in the Overall Phase.", "Number of Participants With Delayed Phase Complete Response(CR)"], "outcome-Measure": ["Number of Participants With CR in the Overall Phase.", "Number of Participants With Delayed Phase Complete Response(CR)"]}, "NCT00863655": {"iv-cont-median": ["2.83", "8.21", "4.40", "NA", "26.55", "6.93", "4.53", "30.98"], "iv-cont-number": ["0.87", "267", "0.96", "0.84", "1.00", "143"], "iv-bin-abs": ["18.0", "33.4", "9.5", "0.4"], "iv-cont-mean": ["0.63", "4.09", "16.04", "5.62", "0.43"], "age": ["18 Years"], "eligibility": ["Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer", "Disease refractory to non steroidal aromatase inhibitors (NSAI),", "Radiological or clinical evidence of recurrence or progression on or after the last systemic therapy prior to randomization.", "Postmenopausal women.", "Previous treatment with exemestane or mTOR inhibitors.", "Patients must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease as defined above.", "HER2-overexpressing patients", "Currently receiving hormone replacement therapy,", "Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin)."], "condition": ["Breast Cancer"], "location": ["Hidaka", "London", "Li\u00e8ge", "Frederick Memorial Hospital Dept. of FMH-IRB", "Cambridge", "Subiaco", "Belgium", "Prague", "Newmarket", "Nambour", "Salzburg", "Cherry Hill", "Palm Beach Cancer Institute", "Altunizade", "Czechia", "Menoufiya", "Alkmaar", "Sheffield", "University of Texas Southwestern Medical Center SimmonsComprehensiveCancerCtr.", "Medical Oncology & Hematology Associates of Northern VA Med. Onc&Hem Assoc. of No.VA", "Warsaw", "Genova", "Louisville", "Hematology Oncology Clinic Hematology Oncology Clinic (2)", "Olomouc", "Hollywood", "San Francisco", "Grass Valley", "Southampton", "Japan", "Nashville", "Nagoya", "Cairo", "Dallas", "Charleston", "Wichita", "Amsterdam", "Bunkyo-ku", "Edina", "Leuven", "Salvador", "Nottingham", "Reston", "Sherbrooke", "University of New Mexico Cancer Research Center Dept of UNM Cancer & Research", "Osaka", "Baton Rouge", "Toronto", "West Palm Beach", "La Jolla", "Anne Arundel Health System Research Institute Wayson Pavilion", "Budapest", "Chicago", "Lawton", "ProHealth Care", "Decatur", "Halifax", "Regional Cancer Care Associates Dept. of the CCHD", "Hong Kong", "Szeged", "Medical University of South Carolina -Hollings Cancer Center Dept. MUSC/HollingsCancerCtr", "Lleida", "Burlington", "Cancer Centers of Southwest Oklahoma Cancer Research Dept.of Southwest Oklahoma", "Novartis Investigative Site", "Chiang Mai", "Salt Lake City", "Canada", "Crescent City Research Consortium, LLC Dept of Hem&Onc Specialist - 2", "Cancer Care Associates Dept.ofCancerCareAssoc. (2)", "Paris", "Uppsala", "Kitakyushu", "Fairview Southdale Medical Oncology Clinic", "Provo", "Truro", "Bakersfield", "Terni", "Bedford Park", "Saint-Nazaire", "Turkey (T\u00fcrkiye)", "Richardson", "Wels", "Grass Valley Hematology Oncology Medical Group Dept. of Grass Valley Hem/Onc", "Kagoshima", "Premiere Oncology/Pinnacle Oncology Hematology Dept.ofPremiereOncologyAZ", "Germany", "University of California San Francisco UCSF Medical Center", "Metairie", "Australia", "Rush University Medical Center Study Coordinator", "Sittard-Geleen", "Madrid", "Cardiff", "University of Wisconsin Hospital & Clinics UW ComprehensiveCancerCtr(2)", "United Kingdom", "Thailand", "Southeast Nebraska Oncology Cancer Center", "Davie", "Nyack", "Lincoln", "University of Utah / Huntsman Cancer Institute Dept.ofHuntsmanCancerInst.(2)", "Bangkok", "Varese", "Qu\u00e9bec", "Silver Spring", "Rio de Janeiro", "The Angeles Clinic and Research Institute", "Hematology Oncology Association of Rockland", "Frederick", "Moncton", "Rouen", "Barcelona", "South Korea", "Santa Monica", "Redcliffe", "Seville", "Palma de Mallorca", "Zephyrhills", "Fort Myers", "Terrassa", "Sharp Memorial Hospital SharpClinicalOncologyResearch", "Lahey Clinic Dept of Lahey Clinic (2)", "University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(2)", "Central Utah Clinic CRAD001Y2301", "Mannheim", "Isehara", "Macerata", "University of Louisville / James Graham Brown Cancer Center SC", "Sapporo", "Rzesz\u00f3w", "Izmir", "Hershey", "Brazil", "USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3", "Albuquerque", "Kitaadachi-gun", "Weinberg Cancer Institute at Franklin Square Hospital", "Uberl\u00e2ndia", "Cancer Center of Kansas Dept.ofCancerCtr.ofKansas", "Chandler", "D\u00fcsseldorf", "Los Angeles", "Utah Cancer Specialists Dept.of Utah Cancer Spec. (2)", "Sint-Niklaas", "Ironwood Cancer and Research Centers", "Linz", "Italy", "Oncology Specialists, SC Dept.of Oncology Specialists", "Koto", "New Zealand", "Hope Oncology HOPE Richardson", "Parkville", "Florida Cancer Specialists DeptofFloridaCancerSpecialists", "Fayetteville", "St Joseph Heritage Healthcare Dept. of RRMG (4)", "Trier", "Maebashi", "New York", "Antella - Bagno A Ripoli", "The Hague", "Saint-Herblain C\u00e9dex", "M\u00fcnchen", "Florida Medical Clinic PA Dept.ofFloridaMedicalClinic", "Egypt", "Lafayette", "L\u00f8renskog", "Baltimore", "Lake Success", "Houston", "Florida Cancer Research Institute", "Hematology Oncology of Indiana", "Maryland Hematology/Oncology Associates, P.A.", "France", "Anaheim", "Cancer Care Associates SC", "Dordrecht", "Norway", "Vienna", "Wilrijk", "Washington", "La Roche-sur-Yon", "Suita", "Highlands Oncology Group DeptofHighlandsOncologyGrp(2)", "Le Mans", "Santiago de Compostela", "Netherlands", "Fort Worth", "Stockholm", "Porto Alegre", "Indianapolis", "Penn State University / Milton S. Hershey Medical Center Division of Oncology (2)", "Hwasun-gun", "United States", "San Diego", "Park Ridge", "Montreal", "Catania", "Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C", "Kyoto", "Comprehensive Cancer Center - Boca Raton Deerfield Beach", "St. Louis Cancer & Breast Institute Dept.ofSt.LouisCancer&Breast", "MD Anderson Cancer Center - Orlando Dept.ofMDACC-Orlando(2)", "Hong Kong SAR", "Berlin", "Spain", "Ankara", "Marseille", "Northern Utah Cancer Associates SC", "Innsbruck", "Boca Raton", "S\u00e3o Paulo", "Torino", "A Coru\u00f1a", "Elizabeth", "Scripps Clinic SC", "Calgary", "Lyon", "Hungary", "Comprehensive Blood and Cancer Center Dept. of CBCC (3)", "Clinical Research Alliance Dept.ofArenaOncologyAssoc(2)", "Matsuyama", "Orlando", "Fukuoka", "Trinitas Comprehensive Cancer Center Dept. of Trinitas", "Perugia", "Holy Cross Hospital Holy Cross", "Eindhoven", "Kashiwa", "Christchurch", "Krakow", "Beth Israel Medical Center Dept.ofBeth Israel Med. Ctr(2)", "Fresno", "Brussels", "M\u00fcnster", "Brindisi", "Szolnok", "Saronno", "St Louis", "Tulsa", "Seoul", "The Center for Cancer and Blood Disorders Dept. of The Ctr for C & BD(2)", "Chuo-ku", "Mallorca", "Sweden", "Ogden", "Madison", "Brno", "Weill Cornell Medical College Weill Cornell Med. Ctr.", "Memorial Hospital Memorial Cancer Institute", "Frankfurt", "Broomfield", "Greenfield Park", "M\u00e1laga", "Santa Rosa", "Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(5)", "Georgia Cancer Specialists. Drug Ship", "St. Catharines", "Weston", "Alexandria", "Horizon Oncology Center", "Austria", "Mercy Medical Center Medical Oncology & Hematology", "Annapolis", "Poland", "Marion L. Shepard Cancer Center", "Songkhla", "Kumamoto"], "intervention": ["Placebo + Exemestane", "Everolimus + Exemestane", "Everolimus", "Exemestane", "RAD001"], "outcome": ["Exemestane Concentrations at Week 4", "Clinical Benefit Rate (CBR)", "Proportion of Patients With no Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Using Kaplan-Meier", "Patient-reported Outcomes (PROs): Time to Deterioration of PRO Scores Using Kaplan Meier - EORTC QLQ-C30", "Proportion of Patients With Having no Overall Response Based on Investigator Assessment", "Overall Survival (OS) by Number of Deaths", "Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments.", "Overall Response Rate (ORR)", "Duration of Response (Among Participants With Best Overall Response of CR or PR) Estimated Per Kaplan-Meier", "Estradiol Plasma Concentrations", "Everolimus Concentrations at Week 4", "Overall Survival (OS) by Median"], "outcome-Measure": ["Exemestane Concentrations at Week 4", "Clinical Benefit Rate (CBR)", "Proportion of Patients With no Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) Using Kaplan-Meier", "Patient-reported Outcomes (PROs): Time to Deterioration of PRO Scores Using Kaplan Meier - EORTC QLQ-C30", "Proportion of Patients With Having no Overall Response Based on Investigator Assessment", "Overall Survival (OS) by Number of Deaths", "Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments.", "Overall Response Rate (ORR)", "Duration of Response (Among Participants With Best Overall Response of CR or PR) Estimated Per Kaplan-Meier", "Estradiol Plasma Concentrations", "Everolimus Concentrations at Week 4", "Overall Survival (OS) by Median"]}, "NCT00459771": {"age": ["79 Years", "18 Years"], "eligibility": ["Patients with New York Heart Association (NYHA) class II/III/IV congestive heart failure", "WHO: <= 2", "Strongly HER2-positive breast cancer, defined as an immunohistochemistry score of 3+ using the HercepTestTM, or gene amplification by fluorescence in situ hybridization, or chromogenic in situ hybridization (CISH).", "Written informed consent to participate in the study", "Women aged >=18 years", "Uncontrolled serious concurrent illness", "Pregnancy or breast feeding", "LVEF \u00b3 50% assessed by multigated angiography (MUGA) or cardiac ultrasound", "Trastuzumab treatment according to standard medical care", "Thyroid stimulating hormone between 0.5-3.9 MU/l", "Myocardial infarction < 6 months before randomization", "History of hypersensitivity to the study medication", "Blood pressure systolic >= 140 mmHg and diastolic >= 90 mmHg is acceptable at randomization. However prior to the first administration of trastuzumab blood pressure should be regulated and should be systolic >= 100 mmHg and <= 180 mmHg and diastolic >= 60 mmHg and <= 100 mmHg. (blood pressure should be regulated according to the guidelines of appendix 5)", "Serum creatinine <140 umol/l or creatinine clearance > 50 ml/min (by Cockcroft-Gault formula)"], "condition": ["Breast Cancer"], "location": ["UMC St. Radboud", "Jeroen Bosch Hospital", "Medisch Spectrum Twente", "'s-Hertogenbosch", "Wilhelmina Ziekenhuis", "Medisch Centrum Alkmaar", "Alkmaar", "Heerenveen", "Deventer Ziekenhuis", "Isala Klinieken", "VieCuri Medisch Centrum voor Noord-Limburg", "Canisius-Wilhelmina Hospital", "Onze Lieve Vrouwe Gasthuis", "University Medical Center Groningen", "Almere Stad", "Flevoziekenhuis", "Slotervaart Hospital", "Enschede", "Leeuwarden", "Winterswijk", "Amsterdam", "Nieuwegein", "Deventer", "Venlo", "Netherlands", "The Netherlands Cancer Institute", "Ziekenhuis de Tjongerschans", "Medisch Centrum Leeuwarden", "Assen", "Martini Ziekenhuis", "Nijmegen", "Streekziekenhuis Koningin Beatrix", "Antonius Ziekenhuis", "Groningen", "Zwolle"], "intervention": ["AT1 blocker candesartan"], "outcome": ["The occurrence of cardiotoxicity, defined as a decline in LVEF (MUGA) of more than 15% or a decrease of less than 15% to an absolute value below 45%."]}, "NCT03029286": {"iv-cont-count_of_participants": ["16", "1", "3"], "iv-cont-mean": ["0.61", "0.72"], "age": ["40 Years", "69 Years"], "eligibility": ["Do not want to be contacted for research", "History of LCIS", "Women must also have a valid email address.", "Not able to speak and read English", "Either (a) an intermediate 5-year risk (>1.67%-2.49%) and extremely dense breasts or (b) a high 5-year risk (>=2.50%) and either heterogeneously dense or extremely dense breasts utilizing the Breast Cancer Surveillance Consortium Risk Calculator (http://tools.bcsc-scc.org/BC5yearRisk/)", "Dis-enrolled from health plan between mammogram and start of recruitment.", "Women, aged 40-69", "Prior cancer diagnosis (including DCIS)", "Have previously participated in intervention development activities", "Enrolled at Group Health", "Have had a negative mammogram as part of their routine care", "Known BRCA1/2 family mutation, or previous receipt of cancer genetic counseling"], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Breast Cancer Female", "Breast Density"], "location": ["Kaiser Permanente Washington Health Research Institute", "Seattle", "United States"], "intervention": ["Personalized Web Intervention Arm", "Usual Care Arm"], "outcome": ["Number of Participants Receiving Breast MRI", "Distress Related to Cancer Risk", "Number of Participants Taking Chemoprevention at 12 Months"], "outcome-Measure": ["Number of Participants Receiving Breast MRI", "Distress Related to Cancer Risk", "Number of Participants Taking Chemoprevention at 12 Months"]}, "NCT01246427": {"age": ["18 Years"], "eligibility": ["Patient able to understand, read and write French", "Lapp lactase deficiency, isomaltase invertase deficiency", "Mandatory affiliation with a health insurance system", "Women with histologically proven non metastatic breast cancer", "galactose, fructose intolerance", "Signed, written informed consent", "Patient suspected of poor compliance with protocol or treatment", "Patient receiving adjuvant hormonal therapy for at least 1 month (aromatase inhibitor or Tamoxifen \u00b1 ovarian function suppression (Luteinizing Hormone Releasing Hormone agonist (LH-RH agonist), ovariectomy...))", "Follow up impossible because of social, familial, geographical or psychological reasons", "ECOG PS <= 1", "Female patient aged >= 18 years", "Patient complaining of hot flashes with moderate to severe intensity, affecting quality of life, for at least 1 month before inclusion", "Patient with a condition known to induce hot flashes such as hyperthyroidism, diabetes, adrenal tumor, enteric carcinoid tumor, mastocytosis...", "known hypersensitivity to one of the components of the study drug", "Glucose or galactose malabsorption syndrome", "Patient with severe renal failure, severe hepatic failure, or cardiovascular disease"], "condition": ["Breast Cancer"], "location": ["Lyon", "Clermont-Ferrand", "Centre Hospitalier d'Annecy", "Roanne", "Centre Hospitalier de Montelimar", "Mont\u00e9limar", "Centre Hospitalier de Valence", "Clinique Armoricaine de radiologie", "Centre Leon Berard", "France", "Centre Hospitalier de Chambery", "Chamb\u00e9ry", "Centre Hospitalier de Roanne", "Valence", "Saint-Priest-en-Jarez", "Centre Jean Perrin", "Saint-Brieuc", "Institut de Canc\u00e9rologie Lucien Neuwirth", "Pringy"], "intervention": ["BRN01"], "outcome": ["Evaluation of patient compliance", "Evaluation of treatment tolerance", "Evaluation of quality of life in both arms", "Evaluation of the mean daily intensity of hot flashes during the run-in period and on the 4th and 8th weeks of treatment in both arms.", "Evaluation of the mean daily frequency of hot flashes during the run-in period and on the 4th and 8th weeks of treatment in both arms.", "Evaluation of patient satisfaction with the treatment and with the management of hot flashes.", "Evaluation of BRN01 efficacy in reducing the hot flash score after 8 weeks of treatment", "Evaluation of BRN01 efficacy in reducing hot flash score after 4 weeks of treatment"]}, "NCT02149524": {"iv-bin-abs": ["51.7", "99.5", "100.0", "92.7", "96.3", "91.2", "35.8", "42.0", "93.8", "45.8"], "age": ["65 Years", "18 Years"], "eligibility": ["History of any prior invasive breast carcinoma, except for subjects with a past history of ductal carcinoma in situ (DCIS) and/or lobular carcinoma in situ (LCIS) treated with surgery only", "Known hypersensitivity to murine proteins", "Known hypersensitivity to the investigational product (IPs), non-IPs or any of the ingredients or excipients of the IPs or non-IPs", "Female aged 18-65 years", "Known hormone receptor (oestrogen receptor and progesterone receptor) status", "angina pectoris requiring anti-anginal medication", "clinically significant valvular heart disease", "uncontrolled hypertension (systolic > 180 mmHg and/or diastolic > 100 mmHg)", "LVEF < 55% by echocardiography or MUGA scan", "high risk uncontrolled arrhythmias", "Subjects unwilling to follow the study requirements", "tumour size >= 2 cm", "histologically confirmed primary invasive carcinoma of the breast", "history of documented congestive heart failure (CHF) (New York Heart Association, NYHA, class II or greater heart disease)", "Baseline left ventricular ejection fraction (LVEF) >= 55% measured by echocardiography or multiple gated acquisition (MUGA) scan", "evidence of transmural infarction on electrocardiogram (ECG)", "Known history of dihydropyrimidine dehydrogenase (DPD) deficiency", "Pregnant or lactating women. A pregnancy test result is required for all women of childbearing potential including women who had menopause onset within 2 years prior to Randomisation. Women of childbearing potential must agree to use contraceptive methods (see section 7.4.2) during the study and 6 months after the last dose of IP", "Subjects must be able to provide informed consent, which must be obtained prior to any study related procedures", "Concurrent hormonal therapy including birth control pills, ovarian hormone replacement for menopause, selective oestrogen receptor modulator (SERM) either for osteoporosis or breast cancer prevention", "HER2-positivity confirmed by a central laboratory or an accredited local laboratory and defined as immunohistochemistry (IHC) 3+ or fluorescence in situ hybridisation (FISH)+", "Past or current history of malignant neoplasms within 5 years prior to Randomisation, except for curatively treated carcinoma in situ of uterine cervix, basal cell carcinoma of the skin or squamous cell carcinoma of the skin (malignant neoplasms occurring more than 5 years prior to Randomisation are permitted if curatively treated with surgery only)", "Metastatic (stage IV) or bilateral or multifocal/multicentric breast cancer", "Serious pulmonary illness enough to cause dyspnoea at rest or requiring supplementary oxygen therapy", "Pre-existing peripheral sensory or motor neuropathy >= grade 2, defined by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.0", "Eastern Cooperative Oncology Group (ECOG) performance status of 0-1", "Known history of hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection"], "condition": ["HER2 Positive Early or Locally Advanced Breast Cancer"], "location": ["Investigational Site", "Prague", "Czechia"], "intervention": ["SB3 (proposed trastuzumab biosimilar)", "Herceptin (Trastuzumab)", "Herceptin", "Herceptin (trastuzuamb)", "SB3 (Proposed Trastuzumab Biosimilar)"], "outcome": ["The Pathologic Complete Response (pCR) Rate of the Primary Breast Tumour", "Total Pathological Complete Response (tpCR) Rate", "Event-free Survival (EFS)", "Overall Survival (OS)", "Overall Clinical Response Rate (ORR)"], "outcome-Measure": ["The Pathologic Complete Response (pCR) Rate of the Primary Breast Tumour", "Total Pathological Complete Response (tpCR) Rate", "Event-free Survival (EFS)", "Overall Survival (OS)", "Overall Clinical Response Rate (ORR)"]}, "NCT02341235": {"iv-cont-mean": [".26", "1.32", "71.74", "-.05", ".62", "-1.76", ".6", "-.96", ".29", "-.27", ".32", ".72", ".53", "-44.35", "-.74", "-.14", ".68", "-1.39", ".30", "20.87", "15.82", "-.57", ".01", "-.04", ".11", "-0.03", "-1.53", "-1.11"], "iv-bin-percent": [".33", "1.04", ".4", ".39"], "age": ["45 Years", "75 Years"], "eligibility": ["Age between 45 and 75 years old", "Surgery in the past six months", "Report a heart condition, chest pain during periods of activity or rest, loss of consciousness, etc. on the Physical Activity Readiness Questionnaire (PAR-Q), unless cleared by their physician", "Willing to be randomized to either group", "Cessation of menses for 12 months or more", "Participant is active (90 minutes of moderate-vigorous intensity activity per week or more)", "Able to read words in standard applications on a mobile device 3-4\" large", "Able to read and understand English", "Able to find transportation to the study location", "Currently participating in a physical activity or weight loss program", "Participant already uses an electronic activity monitor (we will ask them to stop)", "Report a history of severe orthopedic complications that would prevent optimal participation in the physical activities prescribed (e.g., severe arthritis, leg amputations, etc.)", "Currently pregnant or nursing", "Current smoker", "Plans to move away from the Galveston-Houston area or to be out of town for more than 1 week during the study period", "Report a breast cancer diagnosis no more than 10 years prior to enrollment", "Lost more than 5% body weight in the previous 6 months", "Stroke, hip fracture, hip or knee replacement, or spinal surgery in the past 6 months", "Participant reports hospitalization within the past year due to psychiatric problem(s)", "Evidence of disease recurrence", "Report current symptoms of alcohol or substance dependence", "Able to walk for exercise", "Willing to use a mobile device provided by the study to participate (or to use one of their own)", "BMI is under 25 kg/m2 or over 35 kg/m2", "Clinical judgment concerning safety"], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Obesity", "Breast Cancer"], "location": ["The University of Texas Medical Branch", "Galveston", "United States"], "intervention": ["Game intervention", "Game Intervention", "Standard Intervention"], "outcome": ["Change in Physical Function From Baseline to 6 Months as Measured by the Senior Fitness Test's 8 Foot Up and Go Test", "Change in Physical Function From Baseline to 6 Months as Measured by the Senior Fitness Test's Back Scratch Measure", "Change in Quality of Life From 6 Months to 1 Year", "Change in Breast Cancer-Specific Quality of Life From Baseline to 6 Months as Measured by Functional Assessment of Cancer Therapy - Breast Measure's Breast Cancer Subscale", "Change in Weight From 6 Months to 1 Year", "Change in Physical Function From Baseline to 6 Months as Measured by the Senior Fitness Test's Arm Curl Measure", "Character Identification (Measured in Narrative Group Only), Measured Using the Player Identification Scale", "Change in Motivation From 6 Months to 1 Year, Measured by Autonomous Motivation Specific to Physical Activity", "Change in Social/Family Quality of Life From Baseline to 6 Months as Measured by Functional Assessment of Cancer Therapy - Breast Measure's Social/Family Well-Being Subscale", "Change in Anxiety From Baseline to 6 Months", "Maintenance of Physical Fitness From 6 Months to 1 Year, Measured by a 6 Minute Walk Test", "Change in Integrated Regulation From Baseline to 6 Months, Measured by Integrated Regulation Specific to Physical Activity", "Change in Intrinsic Motivation From Baseline to 6 Months, Measured by Intrinsic Motivation Specific to Physical Activity", "Acceptability, Measured Using Self-report Measures of Usability and Liking of the Apps", "Change in Emotional Quality of Life From Baseline to 6 Months as Measured by Functional Assessment of Cancer Therapy - Breast Measure's Emotional Well-Being Subscale", "Narrative Engagement (Measured in Narrative Group Only), Measured Using the Narrative Engagement Scale", "Maintenance of Physical Function From 6 Months to 1 Year, Measured by the Senior Fitness Test", "Change in Physical Function From Baseline to 6 Months as Measured by the Senior Fitness Test's Chair Stand Measure", "Change in Sleep From 6 Months to 1 Year", "Change in Fatigue From Baseline to 6 Months", "Change in Exercise Identity From Baseline to 6 Months", "Change in Physical Function From Baseline to 6 Months as Measured by the Senior Fitness Test's Sit and Reach Measure", "Change in Minutes Per Day of Physical Activity", "Change in Weight From Baseline to 6 Months", "Change in Depression From 6 Months to 1 Year", "Number of Participants Who Report Adverse Events", "Change in Sleep From Baseline to 6 Months", "Adherence, Measured by Objective Measures to Investigate Adherence to Study Protocols", "Change in Physical Fitness From Baseline to 6 Months, as Measured by 6 Minute Walk Test", "Play Experience, Measured Using the Play Experience Questionnaire", "Maintenance of Physical Activity From 6 Months to 1 Year", "Change in Functional Quality of Life From Baseline to 6 Months as Measured by Functional Assessment of Cancer Therapy - Breast Measure's Functional Well-Being Subscale", "Change in Fatigue From 6 Months to 1 Year", "Change in Physical Quality of Life From Baseline to 6 Months as Measured by Functional Assessment of Cancer Therapy - Breast Measure", "Change in Identified Regulation From Baseline to 6 Months, Measured by Identified Regulation Specific to Physical Activity", "Change in Depression From Baseline to 6 Months"], "outcome-Measure": ["Change in Physical Function From Baseline to 6 Months as Measured by the Senior Fitness Test's 8 Foot Up and Go Test", "Change in Physical Function From Baseline to 6 Months as Measured by the Senior Fitness Test's Back Scratch Measure", "Change in Quality of Life From 6 Months to 1 Year", "Change in Breast Cancer-Specific Quality of Life From Baseline to 6 Months as Measured by Functional Assessment of Cancer Therapy - Breast Measure's Breast Cancer Subscale", "Change in Weight From 6 Months to 1 Year", "Change in Physical Function From Baseline to 6 Months as Measured by the Senior Fitness Test's Arm Curl Measure", "Character Identification (Measured in Narrative Group Only), Measured Using the Player Identification Scale", "Change in Motivation From 6 Months to 1 Year, Measured by Autonomous Motivation Specific to Physical Activity", "Change in Social/Family Quality of Life From Baseline to 6 Months as Measured by Functional Assessment of Cancer Therapy - Breast Measure's Social/Family Well-Being Subscale", "Change in Anxiety From Baseline to 6 Months", "Maintenance of Physical Fitness From 6 Months to 1 Year, Measured by a 6 Minute Walk Test", "Change in Integrated Regulation From Baseline to 6 Months, Measured by Integrated Regulation Specific to Physical Activity", "Change in Intrinsic Motivation From Baseline to 6 Months, Measured by Intrinsic Motivation Specific to Physical Activity", "Acceptability, Measured Using Self-report Measures of Usability and Liking of the Apps", "Change in Emotional Quality of Life From Baseline to 6 Months as Measured by Functional Assessment of Cancer Therapy - Breast Measure's Emotional Well-Being Subscale", "Narrative Engagement (Measured in Narrative Group Only), Measured Using the Narrative Engagement Scale", "Maintenance of Physical Function From 6 Months to 1 Year, Measured by the Senior Fitness Test", "Change in Physical Function From Baseline to 6 Months as Measured by the Senior Fitness Test's Chair Stand Measure", "Change in Sleep From 6 Months to 1 Year", "Change in Fatigue From Baseline to 6 Months", "Change in Exercise Identity From Baseline to 6 Months", "Change in Physical Function From Baseline to 6 Months as Measured by the Senior Fitness Test's Sit and Reach Measure", "Change in Minutes Per Day of Physical Activity", "Change in Weight From Baseline to 6 Months", "Change in Depression From 6 Months to 1 Year", "Number of Participants Who Report Adverse Events", "Change in Sleep From Baseline to 6 Months", "Adherence, Measured by Objective Measures to Investigate Adherence to Study Protocols", "Change in Physical Fitness From Baseline to 6 Months, as Measured by 6 Minute Walk Test", "Play Experience, Measured Using the Play Experience Questionnaire", "Maintenance of Physical Activity From 6 Months to 1 Year", "Change in Functional Quality of Life From Baseline to 6 Months as Measured by Functional Assessment of Cancer Therapy - Breast Measure's Functional Well-Being Subscale", "Change in Fatigue From 6 Months to 1 Year", "Change in Physical Quality of Life From Baseline to 6 Months as Measured by Functional Assessment of Cancer Therapy - Breast Measure", "Change in Identified Regulation From Baseline to 6 Months, Measured by Identified Regulation Specific to Physical Activity", "Change in Depression From Baseline to 6 Months"]}, "NCT02632435": {"age": ["19 Years"], "eligibility": [">=19 years of age", "Able to provide verbal consent", "Histologically confirmed primary breast cancer", "Planned to start trastuzumab based neo/adjuvant therapy: FEC-DH or AC-DH, or; dose-dense AC-TH, or docetaxel/cyclophosphamide/trastuzumab or docetaxel/carboplatin/trastuzumab, or weekly paclitaxel with trastuzumab.", "\u2022 Contraindication to central line placement."], "condition": ["Breast Cancer", "Cancer"], "location": ["The Ottawa Hospital Cancer Centre", "Canada", "Ottawa"], "intervention": ["PICC"], "outcome": ["Rates of events", "Patient compliance", "Physician engagement", "Accrual rates"]}, "NCT00869206": {"iv-bin-abs": [".5", "67.6", "2.0", "67.9", "1.2", "1.0"], "iv-cont-mean": ["2.06", ".4", "0.82", "0.84", "2.09"], "iv-cont-count_of_participants": ["101", "119", "19", "15", "107", "83", "75", "35", "34", "49", "113", "30"], "age": ["18 Years"], "eligibility": ["Prior radiation therapy to bone is allowed, provided that at least one site of bone metastasis has not been irradiated and radiation is completed prior to registration; there should be no plan for radiation therapy to non-irradiated sites of bone metastases", "No prior treatment with radiopharmaceuticals; prior treatment with radioactive iodine is allowed; prostate cancer patients treated with brachytherapy are eligible", "Not pregnant and not nursing", "Histologic documentation of one of the following: breast adenocarcinoma, prostate adenocarcinoma or multiple myeloma", "Patients with known brain metastases are not eligible; patients who develop brain metastases during the study will be allowed to continue treatment as assigned", "At least one site of bone metastasis or bone involvement by radiologic imaging including plain radiograph, computed tomography (CT), positron emission tomography (PET) scan, PET/CT scan, magnetic resonance imaging, bone scan, or skeletal survey; indeterminate lesions should be confirmed by a second imaging method", "No prior treatment with denosumab", "No current treatment with investigational agent(s)", "Calculated creatinine clearance >= 30 mL/min", "No prior treatment with IV bisphosphonates is allowed; prior treatment with oral bisphosphonates is allowed, but they must be discontinued prior to the initiation of protocol therapy", "ECOG performance status 0-2", "Corrected serum calcium >= 8.0 mg/dL (2.00 mmol/L) and < 11.6 mg/dL (2.90 mmol/L) \\Corrected serum calcium should be calculated using standard institutional practices"], "condition": ["DS Stage I Plasma Cell Myeloma", "Urinary Complications", "Pain", "Metastatic Malignant Neoplasm to the Bone", "DS Stage II Plasma Cell Myeloma", "Musculoskeletal Complication", "Breast Adenocarcinoma"], "location": ["Alta Bates Summit Medical Center - Summit Campus", "Scottsdale", "Northridge", "Castro Valley", "Paradise", "Rebecca and John Moores UCSD Cancer Center", "Contra Costa Regional Medical Center", "Camino Medical Group - Treatment Center", "Highland General Hospital", "Modesto", "Fairfield", "North Bay Cancer Center", "Martinez", "Mountain View", "Oakland", "Fremont", "Mayo Clinic Scottsdale", "Feather River Hospital Cancer Center", "Fairbanks", "Bay Area Breast Surgeons, Incorporated", "CCOP - Bay Area Tumor Institute", "Leavey Cancer Center at Northridge Hospital Medical Center", "Palo Alto Medical Foundation", "Palo Alto", "Tom K Lee, Incorporated", "Larry G Strieff MD Medical Corporation", "Valley Medical Oncology", "El Camino Hospital Cancer Center", "Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital", "United States", "La Jolla", "East Bay Radiation Oncology Center", "Memorial Medical Center", "Valley Medical Oncology Consultants - Castro Valley"], "intervention": ["Arm II (Zoledronic Acid Every 12 Weeks)", "Arm I (Zoledronic Acid Every 4 Weeks)", "zoledronic acid"], "outcome": ["Skeletal Morbidity Rate", "Incidence of Osteonecrosis of the Jaw", "Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Prostate Cancer)", "Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Breast Cancer)", "Average Pain Intensity Score as Assessed by the Brief Pain Inventory (BPI) Questionnaire", "Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Breast Cancer", "Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Prostate Cancer", "Average ECOG Performance Status", "Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Multiple Myeloma)", "Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization", "Incidence of Renal Dysfunction", "Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Multiple Myeloma"], "outcome-Measure": ["Skeletal Morbidity Rate", "Incidence of Osteonecrosis of the Jaw", "Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Prostate Cancer)", "Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Breast Cancer)", "Average Pain Intensity Score as Assessed by the Brief Pain Inventory (BPI) Questionnaire", "Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Breast Cancer", "Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Prostate Cancer", "Average ECOG Performance Status", "Bone Turnover Assessed by Serum C-telopeptide (CTX) Levels (Multiple Myeloma)", "Percentage of Participants With at Least One Skeletal-related Event (SRE) Within 2 Years After Randomization", "Incidence of Renal Dysfunction", "Proportion of Patients Having at Least One SRE Within 24 Months After Randomization for the Subgroups of Patients With Multiple Myeloma"]}, "NCT02691195": {"age": ["60 Years", "18 Years"], "eligibility": ["Patients with chronic ethanol", "Patients of American Society of Anesthesiologists' (ASA) Physical Status class I-II scheduled for first modified radical mastectomy were included.", "unable to cooperate with this research due to cognitive impairment, psychopathy or not willing for the hospital follow-up;", "contraindications for serratus plane block including coagulopathy, infection at the puncture site;", "long-term use of psychotropic drugs (e.g. sedative drugs and antidepressant);"], "condition": ["Anesthesia"], "location": ["China", "Fuzhou", "Fujian Provincial Hospital"], "intervention": ["Ropivacaine", "0.9% Nacl", "Normal saline", "local anesthetic"], "outcome": ["The quality of recovery", "Postoperative pain intensity"]}, "NCT02005770": {"age": ["85 Years", "18 Years"], "eligibility": ["ASA I-III", "Concomitant regional anesthesia", "Chronic opioids medication", "Breast feeding", "Primary breast cancer (TNM stage = T1-3, N0-2, M0)", "Primary surgery", "Non German-speaking patients", "Pregnancy", "Known hypersensitivity or suspected allergy to propofol, soya or egg proteins", "Written informed consent", "Age 18 to 85", "Any systemic immunosuppressive therapy", "Known hypersensitivity to volatile anesthetics (malignant hyperthermia)", "Metastatic breast cancer"], "condition": ["Female Breast Carcinoma"], "location": ["Zurich", "Institute of Physicians for Anesthesia and Intensive Care Klinik Hirslanden", "University Hospital Zurich, Institute of Anesthesiology", "Switzerland"], "intervention": ["Sevoflurane"], "outcome": ["Number of CTC before and after administration of anesthetics"]}, "NCT00156052": {"eligibility": ["Status for adjuvant systemic therapy not determined.", "More than one primary invasive tumour in the same breast.", "The presence of invasive or intraductal (noninvasive) breast cancer involving the surgical margins.", "Breast deemed too large to permit satisfactory radiation (ie. separation > 25 cm).", "Psychiatric or addictive disorders which preclude obtaining informed consent or adherence to the protocol.", "Currently pregnant or lactating.", "Previous concomitant malignancies of any type except squamous, or basal cell carcinomas of the skin, or carcinoma \\\\fIin situ\\\\fR of the cervix which have been effectively treated.", "Has had a lumpectomy (including segmental resection and partial mastectomy), that is, surgical excision of the tumour with a rim of normal tissue.", "Clinical evidence prior to surgery of infiltration of the skin of the involved breast such as edema, ulceration, or fixation of the tumour to underlying muscle, or inflammatory breast cancer.", "Tumour greater than 5 cm in greatest diameter on pathological examination.", "Pathological status of axilla is unknown.", "Serious nonmalignant disease (eg. cardiovascular, renal, etc.) which would preclude surgical or radiation treatment.", "The female patient has a histological diagnosis of invasive carcinoma of the breast, and no evidence of metastatic disease.", "Geographic inaccessibility for follow-up.", "Patient has not had an axillary dissection, OR for patients who have had an axillary dissection, all nodes are negative for metastatic disease.", "Previous surgery for breast cancer.", "Bilateral malignancy of the breast (synchronous or metachronous)."], "condition": ["Breast Cancer"], "location": ["London", "Canada", "Regional Cancer Program of the Sudbury Regional Hospital", "Regional Cancer Care - Thunder Bay HSC", "Greater Sudbury", "Windsor", "Ottawa", "Ottawa Hospital-Integrated Cancer Program", "Toronto Sunnybrook Regional Cancer Centre", "The Princess Margaret Hospital", "Montreal General Hospital", "Windsor Regional Cancer Centre", "St. Catharines", "Toronto", "Montreal", "Hamilton", "Thunder Bay", "Juravinski Cancer Centre", "Niagara Health System", "Cancer Centre of Southeastern Ontario at Kingston General Hospital", "Kingston", "London Regional Cancer Centre"], "intervention": ["Conventional whole breast radiation schedule"], "outcome": ["Local breast recurrence", "Cost effectiveness", "Morbidity"]}, "NCT01535066": {"age": ["18 Years"], "eligibility": ["Patients must not have had prior acupuncture treatment within the past 12 months or for AI-induced joint symptoms at any time", "Patients must not have a history of bone fracture or surgery of the afflicted knees and/or hands within 6 months prior to registration", "Patients must not have received oral corticosteroids, intramuscular corticosteroids, or intra-articular steroids within 28 days prior to registration", "Patients must be women with histologically confirmed primary invasive carcinoma of the breast (Stage I, II, or III) with no evidence of metastatic disease (M0); patients must have undergone modified radical mastectomy or breast-sparing surgery; patients must have recovered from all side-effects of the surgery", "Patients must have completed the S1200 Brief Pain Inventory-Short Form (BPI-SF) within 14 days prior to registration; patients must have a worst pain score of at least 3 on the Brief Pain Inventory (item #2) that has started or increased since starting AI therapy", "Patients must not have a history of illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk to the patient", "Patients must be positive for estrogen receptor (ER) and/or progesterone receptor (PgR) as determined by institutional standard", "Patients must not be on narcotics within 14 days of registration", "Patients must not have concurrent medical/arthritic disease that could confound or interfere with evaluation of pain or efficacy including: inflammatory arthritis (e.g., rheumatoid arthritis, systemic lupus, spondyloarthropathy, psoriatic arthritis, polymyalgia rheumatica), gout, episodes of acute monoarticular arthritis clinically consistent with pseudogout, Paget disease affecting the study joint (knees/hands), a history of septic arthritis or avascular necrosis or intra-articular fracture of the study joint, Wilson disease, hemochromatosis, alkaptonuria, or primary osteochondromatosis", "Prior bilateral oophorectomy", "Patients must be willing to submit blood and urine samples for serum hormones (estradiol, FSH, LH), inflammatory biomarkers (serum TNF\u03b1, IL-6, IL-12, CRP and urine CTX-II), urine AI metabolites, and DNA analysis (CYP19A1), and must be given the option to consent to use of remaining specimens for future translational medicine studies; baseline samples must be obtained prior to beginning intervention", "Patients must be able to complete study questionnaires in English or Spanish", "Patients must currently be taking a third-generation aromatase inhibitor (AI) - anastrozole, letrozole, or exemestane for at least the previous 90 days prior to registration with plans to continue for at least an additional 1 year after registration; patients may have switched AIs provided that they have been on a stable dose for at least 90 days; concurrent trastuzumab (Herceptin) is allowed", "Patients must not have a severe bleeding disorder", "Previous hysterectomy with one or both ovaries left in place (or previous hysterectomy in which documentation of bilateral oophorectomy is unavailable) AND follicle-stimulating hormone (FSH) values consistent with the institutional normal values for the postmenopausal state; if patient is under the age of 55, FSH levels must be obtained within 28 days prior to registration", "Patients must have a Zubrod performance status of 0 to 1", "Current use of a gonadotropin-releasing hormone (GnRH) agonist", ">= 12 months since the last menstrual period"], "condition": ["Breast Cancer", "Pain"], "location": ["Kaiser Permanente-Roseville", "Gresham", "San Jose", "Kaiser Permanente-Richmond", "Walnut Creek", "Legacy Meridian Park Hospital", "Kaiser Permanente-Redwood City", "South San Francisco", "Huntsman Cancer Institute/University of Utah", "Kaiser Permanente-Stockton", "Richmond", "Spectrum Health Reed City Hospital", "Oakland", "Legacy Good Samaritan Hospital and Medical Center", "San Francisco", "Big Rapids", "Kaiser Permanente - Sacramento", "Legacy Salmon Creek Hospital", "Lahey Hospital and Medical Center", "Kaiser Permanente-San Francisco", "Boise", "Greenville Health System Cancer Institute-Eastside", "USC / Norris Comprehensive Cancer Center", "Burlington", "Mercy Health Saint Mary's", "Saint Luke's Mountain States Tumor Institute", "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", "Spartanburg", "Salt Lake City", "Columbia University Medical Center", "Tualatin", "Grand Rapids", "Kaiser Permanente, Fremont", "Kaiser Permanente Medical Center - Santa Clara", "Fremont", "Mercy Health Mercy Campus", "Roseville", "San Rafael", "Spectrum Health Big Rapids Hospital", "Kaiser Permanente-San Rafael", "Kaiser Permanente Medical Center-Vacaville", "Traverse City", "San Leandro", "Greenville Health System Cancer Institute-Greer", "Seattle", "Los Angeles", "Battle Creek", "Saint Luke's Mountain States Tumor Institute - Meridian", "Greenville Health System Cancer Institute-Seneca", "Antioch", "Bronson Battle Creek", "New York", "Grand Rapids Clinical Oncology Program", "Munson Medical Center", "Vacaville", "Greenville", "Greenville Memorial Hospital", "Greenville Health System Cancer Institute-Faris", "Kaiser Permanente-Santa Rosa", "Kaiser Permanente San Leandro", "Redwood City", "Kaiser Permanente-Vallejo", "Greer", "Vancouver", "Spectrum Health at Butterworth Campus", "Kaiser Permanente-Deer Valley Medical Center", "Kaiser Permanente-Walnut Creek", "Kaiser Permanente-Oakland", "United States", "Portland", "Vallejo", "Muskegon", "Legacy Mount Hood Medical Center", "Greenville Health System Cancer Institute-Spartanburg", "Kaiser Permanente-South Sacramento", "Seattle Cancer Care Alliance", "Santa Clara", "Kaiser Permanente-Santa Teresa-San Jose", "Greenville Health System Cancer Institute-Butternut", "Seneca", "Meridian", "Reed City", "Greenville Health System Cancer Institute-Andrews", "Kaiser Permanente-South San Francisco", "Stockton", "Santa Rosa", "Sacramento"], "control": ["Arm III"], "intervention": ["acupuncture therapy"], "outcome": ["Analgesic and opioid use", "Safety and tolerability of acupuncture", "AI adherence", "Decrease of joint pain associated with the use of AIs as measured by BPI-SF", "Benefit of acupuncture maintenance as assessed by BPI-SF, WOMAC, M-SACRAH, PROMIS PI-SF, FACT-ES, and TGUG", "Long-term effects of acupuncture as assessed by BPI-SF, WOMAC, M-SACRAH, PROMIS PI-SF, FACT-ES, and TGUG", "Durability of response as assessed by BPI-SF, WOMAC, M-SACRAH, PROMIS PI-SF, FACT-ES, and TGUG"]}, "NCT00194363": {"age": ["18 Years"], "eligibility": ["No medical conditions or medications that would prohibit participation in an exercise program or would negatively impact our ability to test our primary aims", "6-40% girth volume difference between the affected and non- affected limb for a dominant arm inter-limb discrepancy in volume or circumference at the point of greatest visible difference OR swelling or obscuration of anatomic architecture upon close inspection OR pitting edema.", "Women without lymphedema must be 1-5 years post breast cancer diagnosis", "0-40>10% girth volume difference between the affected and non- affected limb for a non-dominant arm", "No more than one lymphedema related infection requiring antibiotics within the past 3 months.", "Not pregnant or lactating or planning to become pregnant during the study", "Participation in all Activities of Daily Living (ADLs) without lymphedema exacerbation for the past 3 months.", "Not planning to move away from the area over the next year", "For ALL participants (with and without lymphedema)", "No plans for additional (e.g. reconstructive) surgery during the study period", "Among women who have given birth: at least 6 months post pregnancy and at least 3 months post lactation", "Women with lymphedema must be 1-15 years post breast cancer diagnosis", "A prior clinical diagnosis of lymphedema and having had any prior intensive lymphedema therapy on the affected arm", "No bilateral breast cancers (because this prohibits our ability to assess the primary outcome of interest)", "Not morbidly obese (body mass index >50 kg/m2)", "2 cm circumference difference", "No recorded arm girth change of 15% or greater within the three months."], "condition": ["Lymphedema"], "location": ["Philadelphia", "Penn State Cancer Institute", "United States"], "intervention": ["Strength training"], "outcome": ["Secondary aim 3: To assess self-reported changes in health related quality of life, sleep, fatigue, self-esteem, optimism, life satisfaction, sexual function, body image, social support, and general quality of life.", "Secondary aim 4: To assess changes in psychosocial mediators of exercise behavior, as well as achievement of outcome expectancies that may occur from participation in strength training.", "Specific aim 1: To determine whether there are any changes in lymphedema in breast cancer survivors who participate in a one-year randomized exercise intervention of twice-weekly strength training, as compared to a non-exercising group.", "Secondary aim 1: To assess changes in physical functioning of the arms, as measured by tests of range of motion, coordination, pain, and strength that may result from strength training.", "Secondary aim 2: To assess changes in body composition that may occur from strength training.", "Secondary aim 5: To assess changes in biomarkers related to breast cancer, among the participants who start the study with a BMI over 25."]}, "NCT01830933": {"iv-cont-mean": ["48.9", "56.4"], "iv-bin-abs": ["69.9", "65.9", "51.6", "61.5", "41", "15"], "age": ["40 Years", "74 Years"], "eligibility": ["Physician component: Primary care physicians currently practicing at the GIM clinics at SFGH and UCSF", "Self-identify as Asian American, Spanish- and English-speaking Latinas, African American, or White", "Have no history of breast cancer are eligible to participate.", "Between the ages of 40 and 74", "Women who visit the General Internal Medicine (GIM) practices at SFGH and UCSF during the study period", "Patient component: Women whose physicians object to their participation in the study"], "condition": ["Breast Cancer"], "location": ["San Francisco General Hospital (SFGH)", "University of California, San Francisco Mt. Zion campus", "United States", "San Francisco"], "control": ["BreastCARE Comparison"], "intervention": ["Usual Care", "BreastCARE Intervention", "BreastCARE"], "outcome": ["Percentage of Participants Who Reported Discussion of Mammography Screening", "Percentage of Participants With Correct Perception of Risk", "Percentage of Participants Who Had a Discussion of Breast Cancer Risk", "Knowledge of Breast Cancer Risk Factors"], "outcome-Measure": ["Percentage of Participants Who Reported Discussion of Mammography Screening", "Percentage of Participants With Correct Perception of Risk", "Percentage of Participants Who Had a Discussion of Breast Cancer Risk", "Knowledge of Breast Cancer Risk Factors"]}, "NCT01106820": {"age": ["18 Years"], "eligibility": ["BMI at least 18", "breast cancer patient after lumpectomy or mastectomy, stage I-III", "contraindication for exercise"], "condition": ["Breast Cancer", "Cancer-related Fatigue"], "location": ["Germany", "German Cancer Research Center", "Heidelberg"], "intervention": ["Supervised progressive resistance training"], "outcome": ["Depression measured by \"Allgemeine Depressionsskala\" (ADS, the German version of the Center for Epidemiological Studies Depression Scale (CES-D))", "Muscle strength measured at the IsoMed2000\u00ae", "Quality of Life measured by the European Organisation for Research and Treatment of Cancer questionnaire (EORTC-QLQ30/BR23)", "Biomarker in blood, urine, and saliva", "Fatigue measured by Fatigue Assessment Questionnaire (FAQ)", "Number of patients with adverse events potentially related to the resistance training", "Cardiorespiratory fitness measured by ergospirometry"]}, "NCT03492047": {"age": ["85 Years", "18 Years"], "eligibility": ["Hypersensitivity to NAC.", "Diabetes mellitus.", "Adequate bone marrow function (white blood count >=4,000/mm3, platelet count >=100,000/mm3), liver function (serum total bilirubin <1.5 mg/dl), renal function (creatinine <1.5 mg/dl).", "Adult patients (>18 years old).", "Patients receiving antidepressants, opioids, adjuvant analgesic agents (eg, anticonvulsants, clonazepam, or mexiletine), topical analgesics, and amifostine.", "Clinical neuropathy.", "ECOG performance status 0-2", "Breast cancer patients who will receive adjuvant weekly paclitaxel for 12 cycles."], "condition": ["Peripheral Neuropathy Due to Chemotherapy"], "location": ["Cairo", "AinShams University Hospitals", "Egypt"], "intervention": ["low dose N-acetylcysteine"], "outcome": ["severity of chemotherapy induced-peripheral neuropathy", "Adverse effects", "the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity(FACT-GOG-NTX) subscale", "Incidence of chemotherapy induced-peripheral neuropathy", "serum malionaldehyde", "serum nerve growth factor"]}, "NCT01116713": {"age": ["79 Years", "18 Years"], "eligibility": ["American Society of Anesthesiologists classes I-II female patients with breast cancer scheduled for surgical treatment; mastectomy plus axillary node dissection.", "Patients with any history of motion sickness and or previous postoperative nausea and vomiting after any surgical procedure.", "American Society of Anesthesiologists classes III and IV.", "Age more than 80 years; pregnancy; active menstruation; treatment with steroids; severe diabetes mellitus (serum HbA1c > 8%); use of opioids, sedatives or any kind of analgesics less than one week before mastectomy, or a history of alcohol or drug abuse."], "condition": ["Postoperative Pain", "Postoperative Vomiting", "Postoperative Nausea"], "location": ["Breast Clinic. Oncologic Institute of Jalisco", "Research Unit in Clinical Epidemiology, Specialties Hospital. Mexican Institute of Sociaql Security", "Mexico", "Guadalajara"], "intervention": ["intravenous dexamethasone", "Homologated placebo.", "no other intervention"], "outcome": ["The incidence of nausea and vomiting was recorded immediately on return to the recovery room and at 6, 12 and 24 h after the operation, using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 = vomiting).", "Pain was assessed immediately on return to the recovery room and at 6, 12 and 24 h after the operation using a visual analogue scale (VAS; 0 = no pain to 10 = most severe pain).", "Morbidity and mortality after mastectomy", "Total dose of backup analgesic and antiemetic medication administrated to each patient"]}, "NCT01519700": {"iv-cont-mean": ["0.776", "1.17", "0.744", "0.808", "1.2"], "iv-cont-number": ["42", "54", "104", "206", "168", "39", "51", "50", "46", "41", "204", "49", "55", "102"], "iv-cont-median": ["2.0"], "age": ["18 Years"], "eligibility": ["Estimated life expectancy of more than six months", "Women >= 18 years of age"], "condition": ["Breast Cancer", "Chemotherapy Associated Neutropenia"], "location": ["State Medical-Prophylactic Institution SMPI Reginal Clinical Oncological Dispensary", "Szombathely", "Moscow", "Kuzmolovsky", "Hungary", "Ukraine", "Nitra", "Debrecen", "Czechia", "Lviv", "State Healthcare Institution (SHI) \"Clinical Oncological Dispensary \u21161\" of Healthcare Department of Krasnodar Territory", "Russia", "Vinnytsya Regional Clinical Oncological Center, Chemotherapy Department", "Pyatigorsk", "Krasnodar", "Saint-Petersburg State Healthcare Institution (SPb SHI) \"City Clinical Oncological Dispensary\"", "State Healthcare Institution (SHI)\"Voronezh Regional Clinical Oncological Dispensary\"", "Voronezh", "Insitut Onkologie a Rehabilitaca na Plesi", "Odesa", "Medical center of Limited Liability Company \"Inter\"", "Fovarosi Onkormanyzat Uzsoki utcai Korhaz, Onkoradiologia", "Obninsk", "Ny\u00edregyh\u00e1za", "Sz\u00e9kesfeh\u00e9rv\u00e1r", "Affiliate No1 of State Healthcare Institution (SHI) \"Nizhny Novgorod Regional Oncological Dispensary\"", "Fakultna nemocnica Nitra, Oddelenie radioterapie a klinickej onkologie", "DE OEC, Onkologiai Tanszek", "Non-State Healthcare Institution NSHI", "Nizhny Novgorod", "Daugavpils", "Institution of the Russian Academy of Medical Sciences Medical Radiology Research Center RAMS", "Saint Petersburg", "Luhansk", "Latvia", "Communal Institution \"Odesa regional clinical hospital\", Mammology Center", "Dnipropetrovsk", "Chelyabinsk", "Semmelweis Egyetem, III. Belgyogyaszati Klinika", "Slovakia", "Institution of the Russian Academy of Medical Sciences Russian Oncology Research Center n.a. N.N.Blochin of RAMS\", Surgery Department of the Female Reproductive System Tumors", "Communal Institution \"Krivorizhskiy oncology dispensary\" of Dnipropetrovsk regional Council, Chemotherapy Department", "Lviv state oncological regional treatment-and-diagnostics center, Chemotherapy Department", "State Healthcare Institution (SHI) \"Leningrad Regional Oncological Dispensary\" at the Surgery Department 2", "Kryvyi Rih", "Vinnitsya", "Ves Pod Plesi 110", "Budapest", "Josa Andras Oktato Korhaz Nonprofit Kft", "State Healthcare Institution SHI Pyatigorsk Oncological Dispensary", "Vas Megyei Markusovszky Korhaz, Onkoradiologiai Osztaly", "Fejer Megyei Szent Gyorgy Korhaz, Onkologiai Osztaly", "Daugavpils Regional Hospital", "Communal Institution \"Dnipropetrovsk \u0421ity multiple-discipline Clinical Hospital 4\" of Dnipropetrovsk Regional Council"], "intervention": ["EP2006", "EP2006 + Neupogen", "Neupogen", "Neupogen + EP2006", "Filgrastim"], "outcome": ["Depth of Absolute Neutrophil Count Nadir", "Time to Absolute Neutrophil Count Recovery", "Incidence of Hospitalizations Due to Febrile Neutropenia", "Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy", "Frequency of Infections", "Incidence of Febrile Neutropenia", "Number of Days of Fever"], "outcome-Measure": ["Depth of Absolute Neutrophil Count Nadir", "Time to Absolute Neutrophil Count Recovery", "Incidence of Hospitalizations Due to Febrile Neutropenia", "Mean Duration of Grade 4 Neutropenia During Cycle 1 of Chemotherapy", "Frequency of Infections", "Incidence of Febrile Neutropenia", "Number of Days of Fever"]}, "NCT01140282": {"age": ["18 Years"], "eligibility": ["Body mass index (BMI) > 25 kg/m^2 or body fat > 30% (determined by Dr. Dieli-Conwright at baseline visit)", "Willing to travel to the exercise facility and USC", "Newly diagnosed (I-III) with a first primary invasive breast cancer", "Weight reduction >= 10% within past 6 months", "Nonsmokers (i.e., not smoking during previous 12 months)", "Metastatic disease", "Planned reconstructive surgery with flap repair during trial and follow-up period", "Able to provide physician clearance to participate in exercise program", "Cardiovascular, respiratory or musculoskeletal disease or joint problems that preclude moderate physical activity", "History of chronic disease including diabetes, uncontrolled hypertension or thyroid disease", "Currently participate in less than 60 minutes of physical activity per week May use adjuvant endocrine therapy if use will be continued for duration of study period", "Women of all racial and ethnic backgrounds will be included in the study enrollment process", "Have undergone a lumpectomy or mastectomy"], "condition": ["Stage IIIB Breast Cancer", "Stage IIIA Breast Cancer", "Stage IIIC Breast Cancer", "Stage II Breast Cancer", "Stage I Breast Cancer"], "location": ["Los Angeles", "USC Norris Comprehensive Cancer Center", "United States"], "intervention": ["questionnaire administration"], "outcome": ["Maintain positive benefits of an exercise intervention", "Improvement of physical fitness, cardiorespiratory fitness, and muscle strength", "Feasibility of a supervised exercise program for cancer survivors", "Changes in body composition, waist circumference, blood pressure, and serum levels of insulin, glucose, lipids, C-reactive protein, and HbA1c"]}, "NCT02165605": {"iv-cont-count_of_participants": ["3", "7", "13", "5", "2", "4"], "age": ["99 Years", "18 Years"], "eligibility": ["Ability to give Informed Consent", "Diagnosis of breast cancer", "Female, age 18 or older", "Ability to understand and comply with the requirements of this study", "Women who are pregnant or lactating", "For sexually active females, patient agrees to use acceptable method of birth control", "Collagen vascular disease such as Lupus, or scleroderma", "Allergic history, including anaphylaxis or severe allergies to products in study serum or placebo", "Planned relocation which would make follow-up visits impossible during the course of the study", "Severe renal failure creatinine > 3.0 within 6 months of study registration", "Use of concomitant skin care preparations at any of the treated or control portal areas to be observed", "Intact breast (not surgically absent)"], "condition": ["Breast Cancer"], "location": ["University of Texas Southwestern Medical Center", "United States", "Dallas"], "intervention": ["HylaCare", "Hylacare-Experimental"], "outcome": ["Acute Skin Toxicity Per Investigator Grading Scale", "Acute Skin Toxicity, as Measured by Number of Participants With Skin Reactions", "Acute Skin Toxicity Per NCI-CTC v4.0"], "outcome-Measure": ["Acute Skin Toxicity Per Investigator Grading Scale", "Acute Skin Toxicity, as Measured by Number of Participants With Skin Reactions", "Acute Skin Toxicity Per NCI-CTC v4.0"]}, "NCT00320710": {"iv-bin-abs": ["23.2", "22"], "iv-cont-median": ["NA"], "iv-cont-mean": ["14.697", "0.5", "0.797", "0.31", "10.612", "4.514", "0.24"], "iv-bin-percent": ["0.46", "0.50"], "age": ["18 Years"], "eligibility": ["Abnormal kidney function determined by serum creatinine levels. Current active dental problems including: ongoing infection of the teeth or jawbone; current exposed bone in the mouth; and current or prior diagnosis of osteonecrosis of the jaw.", "Female patients >= 18 years of age. Confirmed breast cancer with bone metastasis. Pretreated with Zometa\u00ae, or Aredia (pamidronate) or all sequential regimens of both, for a minimum of 9 doses;", "Recent (within 8 weeks) or planned dental or jaw surgery (e.g., extraction, implants)."], "condition": ["Breast Cancer"], "location": ["Memorial Sloan Kettering Cancer Center", "Bethesda", "The Harry and Jeanette Weinberg Cancer Institute at Franklin", "Cancer and Blood of the Desert", "Baptist Cancer Center", "Canton", "Ohio Cancer Specialists", "Ventura County Hematology and Oncology", "Cherry Hill", "Frederick Memorial Hospital", "West Worthington", "Methuen", "Guthrie Cancer Center", "Spokane", "New Albany", "Wayne State University", "Mainline Oncology Hematology Assoc.", "Arena Oncology Associates, PC", "Kentucky Lung Clinic & Kentucky Sleep Clinic", "Cancer Center of Kansas", "Barberton Citizens Hospital", "U of Pittsburgh Cancer Institute Magee-Womens Hospital", "Rochester", "The Center for Cancer Care and Research", "Corvallis", "The Corvallis Clinic, P.C.", "St. Agnes Hospital", "Providence Alaska Medical Center Cancer Research", "Bay Area Cancer Research", "University of Michigan Clinical Trials Office", "Jackson", "Eastern Connecticut Hematology & Oncology Associates", "Suburban Hematology-Oncology", "Siouxland Hematology-Oncology Associates LLP", "Advanced Oncology Associates", "Saint Barnabas Medical Center", "Oxnard", "Georgetown University/Lombardi Cancer Center", "Lawrenceville", "Lancaster", "Gabrail Cancer Center", "Chicago", "Associated Physicians & Surgeons Clinic", "Denver", "Skokie", "Alamance Regional Medical Cancer Center", "Great Neck", "Milton S Hershey Medical Center", "Burlington", "Armonk", "Springdale", "Pacific Cancer Medical Center, Inc.", "Nevada Cancer Centers 2851 North Tenaya Way", "Trilogy Cancer Care", "Access Clinical Research", "Iowa City", "Pittsburgh", "Medical College of Wisconsin", "Caritas Holy Family Hospital", "Sioux City", "Norwich", "Pomona", "Detroit", "Somerset Hematology Oncology Associates", "Wilshire Oncology Medical Group", "Everett", "Naperville", "Lincoln", "Henry Ford Hospital Oncology", "Center for Cancer & Blood Disorders", "Wooster", "Frederick", "Cabrini Center for Cancer Care", "Terre Haute", "Anchorage", "Mansfield", "Pasco Hernando Oncology", "Minneapolis", "Hershey", "Seattle", "Nebraska Hematology-Oncology PC", "Jacksonville", "La Verne", "Southwest Oncology Associates Ltd.", "Los Angeles", "North Valley Hematology/Oncology Providence Holy Cross Medical", "The Office of Dr. Elizabeth Tan-Chiu, MD PA", "South Bay Oncology Hematology Partners", "Lexington", "Hematology/Oncology Consultants Inc.", "New York", "Lexington Oncology Associates", "Concord", "Dubuque", "Cancer Care Center", "Lafayette", "Baltimore", "Sumter", "Houston", "Cancer Centers of South Texas", "The Center for Chest Care", "Witchita", "Anaheim", "University of California at Los Angeles", "Medical Associates Clinic, PC", "Hot Springs", "Ann Arbor", "Lancaster Cancer Center", "Milwaukee", "Greenbaum Cancer Center", "San Antonio", "Topeka", "New Port Richey", "Fairview Clinical Trial Services", "Beth Israel Medical Center", "University of California Davis Cancer Center", "Indianapolis", "United States", "Evanston", "Medical Oncology Care Associates", "Univ. of Minnesota Cancer Center 420 Delaware St.", "Hubert H. Humphrey Cancer Center", "Capitol Comprehensive Cancer Care Clinic", "Livingston", "Seattle Cancer Care Alliance Seattle Cancer Care Alliance", "Saint Joseph", "Las Vegas", "Columbia Presbyterian Medical Center", "Orange", "Washington Hospital Center", "Jmaes P. Wilmot Cancer Center", "Pacific Coast Hem/Onc", "Kingston", "Fountain Valley", "Campbell", "University of Iowa Health Care", "Cotton O'Neil Oncology Clinic", "Rockwood Clinic Rockwood Clinic, PS", "Midwest Cancer Research Group", "Northridge", "Investigative Clinical Research", "Northeast Oncology Associates Suite 250", "Sylmar", "Duluth", "Sayre", "M. Francisco Gonzalez, MD., FACP", "Santee Hematology/Oncology", "Kenmar Research Institute", "Evanston Northwestern Healthcare Medical Group", "Oncology Care Associates, PLLC", "Denver Health Medical Center CACZ885M2301", "St Louis", "Hazard", "Washington D.C.", "The Office of Dr. Swarna Chanduri, MD", "Columbia", "NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr", "Robbinsdale", "Jefferson City", "Barberton", "Edward Cancer Center", "Heritage Physicians Group Oncology", "Sacramento", "St. Luke's Hospital and Health Network", "MD Anderson Cancer Center/University of Texas 1155 Herman Pressler Street", "Alexandria", "Wynnewood", "Rancho Mirage", "Jackson Oncology Associates", "Benedictine Hospital", "Bay Area Hospital - Pharmacy", "Somerset", "Coos Bay", "Center for Cancer and Hematologic Disease", "Providence Everett Medical Clinic", "Planatation"], "intervention": ["Zoledronic Acid Every (q) 4 Weeks", "Placebo / Zoledronic Acid", "Placebo", "Zoledronate", "Zometa", "Zoledronic Acid q 12 Weeks", "Zoledronic acid", "ZOL446"], "outcome": ["Skeletal Morbidity Rate", "Change From Baseline in Mean Analgesic Score", "Time to First Individual Type of SRE", "Change From Baseline in Urinary N-telopeptide / Creatinine Ratio", "Change From Baseline in Serum Bone Specific Alkaline Phosphatase", "Time to First SRE", "Change From Baseline in Mean Composite Brief Pain Inventory (BPI) Score", "Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE)"], "outcome-Measure": ["Skeletal Morbidity Rate", "Change From Baseline in Mean Analgesic Score", "Time to First Individual Type of SRE", "Change From Baseline in Urinary N-telopeptide / Creatinine Ratio", "Change From Baseline in Serum Bone Specific Alkaline Phosphatase", "Time to First SRE", "Change From Baseline in Mean Composite Brief Pain Inventory (BPI) Score", "Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE)"]}, "NCT00990977": {"age": ["75 Years", "18 Years"], "eligibility": ["active treatment for psychiatric disease including alcohol abuse", "diseases or disabilities hindering MBSR-participation", "women 18-75 years", "speak and read danish", "operated for breast cancer stage I-III at either Herlev hospital (F-118) or Ringsted sygehus (Mammakirurgisk Klinik) after september 2006"], "condition": ["Breast Cancer"], "location": ["Danish Cancer Sociaty Research Center, Suvivorship", "Denmark", "Copenhagen"], "control": ["controls"], "intervention": ["MBSR (Kabat-Zinn)", "mindfulness based stress reduction (MBSR)"], "outcome": ["standardized validated psychometric scales", "clinical databases, containing information on BC (stage, treatment protocol) and comorbidity (other acute or chronic physical or psychiatric diseases)", "SCL-90r Depression and anxiety subscales"]}, "NCT00045032": {"iv-bin-abs": ["7.29", "83.5", "18.4", "2.2", "16.1", "19.4", "29.7", "90.5", "21.9", "1.07", "86.1", "35.8", "76.4", "75.2", "90.7", "69.3", "4.40", "23.2", "79.8", "23.9", "28.8", "25.8", "22.2", "70.7", "92.7", "87.50", "26.6", "82.8", "33.6", "89.0", "66.0", "72.4", "14.7", "69.2", "27.7", "64.7", "92.4", "81.3", "87.7", "96.5", "1.02", "73.60", "15.5", "16.3", "85.80", "0.86", "30.5", "76.5", "63.5", "83.4", "1.8", "86.0", "85.9", "25.3", "89.9", "94.39", "15.1", "27.8", "70.0", "94.4", "23.4", "90.9", "12.9", "78.18", "68.5", "7.5", "20.6", "86.7", "2.4", "75.9", "71.0", "1.4", "65.8", "94.98", "22.6", "72.5", "18.8", "62.5", "71.2", "19.5", "95.88", "14.9", "89.4", "87.3", "82.7", "78.6", "29.8", "90.8", "88.1", "84.4", "97.4", "0.11", "97.28", "7.6", "19.7", "70.3", "13.0", "64.8"], "age": ["18 Years"], "eligibility": ["Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>=) 55 percent (%)", "Prior invasive breast carcinoma", "Prior mediastinal irradiation except for internal mammary node irradiation for the present breast cancer", "Women of childbearing potential or less than 1 year post-menopause unwilling to use adequate contraceptive measures", "Clinical T4 tumors", "Known hormone receptor status", "Pregnancy or lactation", "Cumulative doxorubicin exposure greater than (>) 360 milligrams per meter-squared (mg/m^2) or epirubicin >720 mg/m^2 or any prior anthracyclines unrelated to the present breast cancer", "Non-irradiated internal mammary nodes or supraclavicular lymph node involvement", "Peripheral stem cell or bone marrow stem cell support", "Poor hematologic, hepatic, or renal function", "Non-metastatic primary invasive breast cancer overexpressing HER2 (determined by immunohistochemistry 3+ or positive fluorescence in situ hybridization test) that has been histologically confirmed, adequately excised, axillary node positive or negative, and tumor size at least T1c according to Tumor/Node/Metastasis (TNM) staging"], "condition": ["Breast Cancer"], "location": ["Faculdade De Medicina Do ABC", "Maternidade Byssaia Barreto", "Hospital General Universitario Valencia", "West Yorkshire", "Belgium", "V\u00f6cklabruck", "Martin Luther Universitaet", "Hospital Universitario San Cecilio de Granada", "Sheffield", "Centre Regional Francois Baclesse", "Sonderborg Sygehus", "Japan", "Centre Hospitalier Universitaire Vaudois", "Hospital Universidad Virgen Del Rocio", "I.R.C.C.S. Policlinico San Matteo", "Huddersfield Royal Infirmary", "Gliwice", "St. Vincentius-Kliniken", "Ospedale Civile ASL 1", "Moscow Oncology Hospital", "Huddersfield, West Yorks", "Munich", "Broomfield Hospital", "Turin", "Hong Kong", "Cork University Hospital", "Hospital Aleman de Buenos Aires", "Metz", "Universitaetsklinik fuer Innere Medizin I", "Portugal", "Florence", "Diakonessenhuis Utrecht", "British Columbia Cancer Agency - Centre for the Southern Interior", "Alzira", "Ospedali Riuniti di Bergamo", "Surrey", "South Africa", "Namur", "Kortrijk", "Thailand", "Pretoria - East Hospital", "Trento", "Granada", "Kanagawa", "Hopital Universitaire Erasme", "Groote Schuur Hospital", "Complejo Hospitalario Santa Maria", "Centralsygehuset I Naestved", "Greece", "Institut Jules Bordet", "Leeds", "Middlesbrough", "Universitaetsspital-Basel", "Hospital de Gran Canaria Dr. Negrin", "Pavia", "Halle", "Mount Sinai Hospital - Toronto", "Uppsala University Hospital", "Centro Medico", "Clinical Hospital Center Split", "Bradford", "Vienna", "Vancouver", "Sieff Hospital", "Hospitais da Universidade de Coimbra (HUC)", "Innsbruck Universitaetsklinik", "Lausanne", "Wiesbaden", "Limoges", "Mendrisio", "Chulalongkorn University Hospital", "Hospital Militar", "Firenze (Florence)", "Ospedale Oncologico A. Businco", "Instituto Nacional Del Cancer", "Hospital Cuidad de Jaen", "Lisbon", "Windsor", "Perugia", "Durban", "Epping Essex", "Brussels", "Primario U.O. di Oncologia Medica", "Trillium Health Centre - Mississauga Site", "Rostock", "St. Catharines", "Diana Princess of Wales Hospital", "Imperial College of Medicine", "Hospital Juan Ramon Jimenez", "Tom Baker Cancer Centre - Calgary", "Ospedale degli Infermi - ASL 12", "Croatia", "Singapore", "Faro", "Poland", "Hospital Universitario Nuestra Senora de la Candelaria", "Complexo Hospitalario Xeral de Vigo", "Basel", "Universita di Torino", "Feldkirch-Tisis", "Saskatoon", "Lynnwood", "University Hospital of Linkoping", "Warsaw", "Ospedale Valduce", "Villach", "Centre Hospitalier Peltzer-La Tourelle", "Zurich", "James Cook University Hospital", "Budapest", "Ja\u00e9n", "Como", "Ospedale Bellaria", "Canada", "Saskatoon Cancer Centre at the University of Saskatchewan", "Toowoomba", "Baudour", "Ospedale Santa Croce", "St. Vincent's Hospital", "Wuhan", "Ospedale Presenti Fenaroli", "Israel", "Hanover", "Ospedale San Lazzaro", "Instituto Portugues de Oncologia, Centro Regional de Coimbra", "European Institute of Oncology", "Hospital Dr. Sotero Del Rio", "Istituto Clinico Humanitas", "University Hospital of Santa Maria", "Rome", "Brazil", "Italy", "Sassari", "Kiel", "Regina", "Medical University", "Porto Alegre Hospital", "Azienda Ospedaliera Di Parma", "Evangelisches Bethesda Krankenhaus GmbH", "Ziekenhuis Netwerk Antwerpen Middelheim", "Maastricht", "Hospital General Universitario De Guadalajara", "China", "Hospital Insular de Gran Canaria", "France", "Ospedale Sant' Eugenio", "Guatemala", "Universitaet Ulm", "Victoria", "Instituto Nacional De Cancerologia", "Hospital Universitario Miguel Servet", "Instituto Nacional de Cancer", "Biella", "Allan Blair Cancer Centre at Pasqua Hospital", "Netherlands", "Porto Alegre", "Gdansk", "Fundacion Arturo Lopez Perez", "Heraklion", "Pontevedra", "Heidelberg", "Alba", "Spain", "Berlin", "Innsbruck", "UniversitaetsSpital Zuerich", "Ospedale Ostetrico Ginecologica Sant Anna", "Landeskrankenhaus Feldkirch", "Hospital Santa Rita", "Hillerod Hospital", "Hospital Serruys Ziekenhuis", "Bogot\u00e1", "Malmo", "Klinikum Rechts Der Isar - Technische Universitaet Muenchen", "Northern Centre for Cancer Treatment at Newcastle General Hospital", "Geelong", "Milan", "National Institute of Oncology", "Cuneo", "Hamilton", "Maasland Hospital", "Austria", "Santa Cruz de Tenerife", "Dr. Horst-Schmidt-Kliniken", "Centro Oncologico De Galicia Jose Antonio Quirogay Pineyro", "Herning", "San Crist\u00f3bal de La Laguna", "Vigo Pontevedra", "London", "Las Palmas de Gran Canaria", "Andrew Love Cancer Centre", "Brescia", "Tokai University School Of Medicine", "Cazk Groeninghe - Campus St-Niklaas", "Argentina", "Tokyo", "Modena", "Frauenklinik Vom Roten Kreuz", "Hospital De La Ribera", "Presidio Ospedaliero", "Landeskrankenhaus Klagenfurt", "Karlsruhe", "Ospedale Niguarda Ca'Granda", "University of Modena Hospital and Reggio Emilia School of Medicine", "Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A.", "Southend NHS Trust Hospital", "Alzano Lombardo", "Grimsby", "Genoa", "Landeskrankenanstalten - Salzburg", "Fovarosi Onkormanyzat Szent Margit Korhaz, Okologia", "Spitaeler Chur AG", "Aarau", "Clinique Sainte Elisabeth", "Queen Mary Hospital", "Uppsala", "Chelmsford, Essex", "Guadalajara", "Parma", "Hotel Dieu Health Sciences Hospital - Niagara", "Hospital Distrital De Faro", "Shatin, New Territories", "Reseau Hospitalier De Medecine Sociale", "Newcastle upon Tyne", "Herning Central Hospital", "Bergamo", "Australia", "Royal Victoria Hospital of Barrie", "Hull", "Clinique Saint-Joseph", "Denmark", "Caen", "Universita Degli Studi Di Florence", "Bangkok", "Kantonspital Aarau", "Medical University of Gdansk", "Qu\u00e9bec", "Rio de Janeiro", "Centre Hospitalier Universitaire de Tivoli", "Coimbra", "Centralsygehus I Esbjerg", "Carpi", "Toowoomba Hospital", "Sault Ste. Marie", "Bradford Hospitals NHS Trust", "Fraser Valley Cancer Centre at British Columbia Cancer Agency", "Ostend", "British Columbia Cancer Agency - Vancouver Cancer Centre", "Cagliari", "Las Palmas", "Morgagni-Pierantoni Ospedale", "Centre Hospital Regional Universitaire de Limoges", "Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology", "Hospital Roosevelt", "Guatemala City", "Link\u00f6ping", "British Columbia Cancer Agency - Vancouver Island Cancer Centre", "Linz Donau", "Evaggelismos Hospital", "Safed", "Poznan", "Santo Andr\u00e9", "Toronto East General Hospital", "University Hospital of Malmoe", "Colombia", "Stockholm", "Airedale General Hospital", "Kelowna", "Seoul National University Hospital", "Inselspital Bern", "Ospedale A. Manzoni", "Esbjerg", "Ospedale San Filippo Neri", "Ulm", "Wiener Neustadt", "A Coru\u00f1a", "La Louvi\u00e8re", "Calgary", "Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg", "Johns Hopkins Singapore International Medical Centre", "Rozzano", "Prince Edward Island Cancer Centre at Queen Elizabeth Hospital", "Russia", "Freiburg im Breisgau", "Carlo Poma Hospital", "Santiago", "Tongji Medical University", "Ourense", "Leonberg", "University of Crete School of Medicine", "Livorno", "Seoul", "Kantonsspital - St. Gallen", "Sweden", "Azienda Ospedaliero Careggi", "Zaragoza", "Perth", "Hospital Universitario Canarias", "Hiller\u00f8d", "Cork", "Aviano", "Policlinico Monteluce", "Ospedale B. Ramazzini", "Sahlgrenska University Hospital - Molndal at Gothenburg University", "Semmelweis University", "Oncologic Center", "Li\u00e8ge", "Universitaetsklinikum Freiburg", "Moscow", "Reggio Emilia", "Saint Margaret's Hospital", "Windsor Regional Cancer Centre at Windsor Regional Hospital", "Salzburg", "Toledo", "Westcliff-on-Sea", "Charite - Campus Charite Mitte", "Cape Town", "A. oe. Krankenhaus Wiener Neustadt", "N\u00e6stved", "LKH Voecklabruck", "CancerCare Manitoba", "Verviers", "Essen", "Ume\u00e5", "Cancer Research Centre at Weston Park Hospital", "Chile", "Leuven", "CHU Liege - Domaine Universitaire du Sart Tilman", "Charleroi", "M\u00f6lndal", "Toronto", "Algoma Regional Cancer Program at Sault Area Hospital", "Cookridge Hospital at Leeds Teaching Hospital NHS Trust", "Centre Hospitalier Notre Dame - Reine Fabiola", "Mount Hospital", "Hospital Clinico San Borja Arriaran", "Henriettenstiftung Krankenhaus", "Germany", "Madrid", "Centro di Riferimento Oncologico - Aviano", "United Kingdom", "Forl\u00ec", "Princess Royal Hospital", "Hospital Sao Lucas da PUCRS", "Umea Universitet", "Academisch Ziekenhuis Maastricht", "Margaret and Charles Juravinski Cancer Centre", "Barcelona", "South Korea", "Seville", "Johannesburg", "P.A. Hertzen Research Oncology Institute", "Yonsei Cancer Center at Yonsei University Medical Center", "S\u00f8nderborg", "Kreiskrankenhaus Leonberg - Frauenklinik", "Hopital Clinique Claude Bernard", "Istituto Nazionale per la Ricerca sul Cancro", "Hospital Del Mar", "Buenos Aires", "Switzerland", "Mississauga", "Tuen Mun Hospital", "Academisch Ziekenhuis der Vrije Universiteit Brussel", "Wilhelminenspital der Stadt Wien", "Hopital du Saint-Sacrement, Quebec", "Athens", "Ramathibodi Hospital", "Princess Margaret Hospital", "Utrecht", "Chur", "Frauenklinik - Universitaetsklinikum Rostock am Klinikum Sudstadt", "Bologna", "Barrie", "Parklands Hospital", "Lecco", "Mantova", "Sankt P\u00f6lten", "Tokyo Metropolitan - Komagome Hospital", "Sankt Gallen", "Split", "Consorci Hospitalari del Parc Tauli", "Magdeburg", "Charlottetown", "Azienda Ospedaliera", "University Hospital Schleswig-Holstein - Kiel Campus", "Winnipeg", "Prince of Wales Hospital", "Spedali Civili di Brescia", "Hospital Virgen Del La Salud", "Hungary", "Ospedale Beata Vergine", "Sittard", "Klagenfurt", "Valencia", "Ireland", "Antwerp", "Medical Oncology Centre of Rosebank", "Sandton Oncology Centre", "Sabadell", "Complejo Hospitalario de Pontevedra", "Saint John of God Hospital", "Landeskrankenhaus St. Poelten", "Bern", "Universitaets-Hautklinik Heidelberg", "U.Z. Gasthuisberg", "LKH Villach", "Huelva", "Hospital de la Princesa", "Karolinska University Hospital - Huddinge"], "control": ["Observation Arm"], "intervention": ["Trastuzumab", "Herceptin 1-Year Arm", "Herceptin 2-Year Arm", "Herceptin"], "outcome": ["Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "OS Rate According to Kaplan-Meier Analysis Compared to Observation: 11-Year Median Follow-Up", "Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up", "Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up", "DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up", "Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up", "Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up", "DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "DTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up", "Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up", "DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "DDFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "DTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "TR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up", "DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "TR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "DDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "OS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up", "OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up", "OS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up", "RDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "RFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up", "Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up", "DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "DFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up", "DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up", "DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up", "RFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up", "Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up", "Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up"], "outcome-Measure": ["Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "OS Rate According to Kaplan-Meier Analysis Compared to Observation: 11-Year Median Follow-Up", "Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up", "Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up", "DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up", "Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up", "Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up", "DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "DTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up", "Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up", "DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "DDFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "DTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "TR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up", "DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "TR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "DDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "OS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up", "OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up", "OS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up", "RDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "RFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up", "Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up", "Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up", "DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up", "DFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up", "DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up", "DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up", "RFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up", "Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up", "Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up", "Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up"]}, "NCT00967824": {"eligibility": ["Believed to be at increased risk of breast cancer (risk of >= 1.66% over 5 years) according to electronic-based medical data"], "condition": ["Breast Cancer"], "intervention": ["informational intervention"], "outcome": ["Development and testing of a decision aid that describes the risks and benefits of taking tamoxifen citrate to prevent primary breast cancer"]}, "NCT02104895": {"iv-bin-abs": ["95.1", "1.5", "89.6", "37.7", "2", "1.4"], "age": ["40 Years"], "eligibility": ["Clips placed in tumor bed", "Recurrent breast cancer", "Wide excision or quadrantectomy with clear margins (>5 mm)", "Tumor size <25 mm", "Multifocal cancer", "Cardiac dysfunction", "Forced expiratory volume in 1 second (FEV1) <1 L/m", "Extensive intraductal carcinoma", "Full informed consent from patient", "Psychiatric problems", "Age at presentation >40 y"], "condition": ["Breast Cancer"], "intervention": ["Whole Breast Irradiation (WBI)", "Accelerated partial breast irradiation (APBI)", "Partial Breast Irradiation (APBI)"], "outcome": ["Ipsilateral Breast Tumor Recurrence", "Acute Skin Toxicity", "Excellent Cosmesis"], "outcome-Measure": ["Ipsilateral Breast Tumor Recurrence", "Acute Skin Toxicity", "Excellent Cosmesis"]}, "NCT02240199": {"age": ["75 Years", "18 Years"], "eligibility": ["undergoing a unilateral or bilateral mastectomy or partial-mastectomy (breast conserving surgery), for prophylactic (e.g. family history or BRCA gene mutation) or belief of isolated (non-metastatic) cancerous lesions", "patient has chronic pain or a chronic pain syndrome for which they have taken 4 or more daily medications (i.e. opioids, anti-convulsants, anti-spasmodic, anti-depressants, anti-inflammatories) or routine pain intervention (i.e. nerve blocks) during the past 3 months", "renal insufficiency with creatinine > 120 \u00b5mol/L", "undergoing a DIEP (Deep Inferior Epigastric Perforator) flap procedure", "pregnant", "language difficulties that would impede valid completion of questionnaires", "receiving a general anesthetic", "previous breast surgery within six months of index surgery", "history of ventricular tachycardia, ventricular fibrillation, or atrioventricular block >= type II", "history of congestive heart failure", "known or previously documented cirrhosis", "female patients 18-75 years of age", "unlikely to comply with follow-up (e.g. no fixed address, plans to move out of town)", "documented hypersensitivity or allergy to pregabalin, gabapentin, or lidocaine", "patient requires gabapentin or pregabalin for a medical condition or has been taking gabapentin or pregabalin daily during the past 1 week", "unable to swallow study medications", "patient's surgeon believes patient is inappropriate for inclusion in trial"], "condition": ["Chronic Post-surgical Pain", "Post-mastectomy Pain Syndrome"], "location": ["Juravinski Hospital", "Toronto", "Sunnybrook Health Sciences Centre", "Hamilton", "Canada"], "intervention": ["Lyrica", "Perioperative Pregabalin", "Xylocaine", "Intraoperative Intravenous Lidocaine Infusion", "Perioperative Pregabalin Placebo"], "outcome": ["Length of hospital stay", "Acute postoperative pain", "Feasibility", "Somatic Pre-occupation and Coping Scale", "Post-mastectomy pain syndrome", "Quality of Life"]}, "NCT00282035": {"age": ["40 Years"], "eligibility": ["7\\. Previous irradiation to the ipsilateral breast that would preclude whole breast irradiation.", "Patients with a prior diagnosis of invasive or non-invasive breast cancer in either breast are excluded regardless of disease free interval. Patients with concurrent invasive or non-invasive contralateral breast cancer are also excluded.", "3\\. Tumour size > 3 cm in greatest diameter on pathological examination (including both the invasive and non-invasive component).", "3\\. Negative axillary node involvement including micrometastasis <= 0.2mm or positive cells only identified by IHC as determined either by: (i) sentinel node biopsy (ii) axillary node dissection or (iii) clinical exam for patients with DCIS only", "6\\. More than one primary tumour in different quadrants of the same breast.", "1a. Female patient with a new histological diagnosis of DCIS only. OR", "15\\. Geographic inaccessibility for follow-up.", "17\\. Inability to adequately plan the patient for the experimental technique.", "16\\. Inability to localize surgical cavity on CT (i.e., no evidence of surgical clips or seroma).", "10\\. Estrogen receptor status (ER) not known.", "2\\. Treated by BCS with microscopically clear resection margins for invasive and non-invasive disease (or no residual disease on re- excision).", "1\\. Age < 40 years.", "Patients with prior or concurrent basal cell or squamous cell skin cancers are eligible for the trial.", "9\\. Serious non-malignant disease (e.g. cardiovascular, pulmonary, systemic lupus erythematosus (SLE), scleroderma) which would preclude definitive radiation treatment.", "14\\. Psychiatric or addictive disorders which would preclude obtaining informed consent or adherence to protocol.", "2\\. A known deleterious mutation in BRCA 1 and/or BRCA 2.", "8\\. Presence of an ipsilateral breast implant or pacemaker.", "4\\. Tumour histology limited to lobular carcinoma only.", "1b. Female patient with a new histological diagnosis of invasive carcinoma of the breast and no evidence of metastatic disease.", "13\\. Currently pregnant or lactating."], "condition": ["Breast Cancer"], "location": ["Kitchener", "London", "Mississauga", "New Zealand", "BC Cancer Agency - Abbotsford Centre", "Canada", "Winnipeg", "Calgary", "QE II HSC - Nova Scotia Cancer Centre", "Durham Regional Cancer Centre - Lakeridge Health Corporation", "Auckland City Hospital", "British Columbia Cancer Agency - Fraser Valley Centre", "East Melbourne", "Tom Baker Cancer Centre", "Abbotsford", "Brantford", "British Columbia Cancer Agency - Vancouver Centre", "Cancer Care Manitoba", "Greater Sudbury", "Windsor", "British Columbia Cancer Agency - Centre for the Southern Interior", "Grand River Regional Cancer Centre", "Ottawa", "McGill University - Jewish General Hospital", "Peter MacCallum Cancer Centre - Monash Medical Centre Moorabbin", "Brantford General Hospital", "Windsor Regional Cancer centre", "Bendigo", "Surrey", "McGill University - Montreal General Hospital", "Australia", "Peter MacCallum Cancer Centre", "British Columbia Cancer Agency - Vancouver Island Centre", "Princess Margaret Hospital - University Health Network", "Melbourne", "Oshawa", "Edmonton", "Irving Greenberg Family Cancer Centre", "Hopital Maisonneuve-Rosemont", "Cross Cancer Institute", "Vancouver", "Fleurimont", "CHUQ, L'Hotel Dieu de Quebec", "Credit Valley Hospital - Carlo Fidani Peel Regional Cancer Center", "Qu\u00e9bec", "The Ottawa Hospital Cancer Centre", "CHUS - Hopital Fleurimont", "Box Hill", "Kelowna", "St. Catharines", "CHUM - Hospital Notre Dame", "Toronto", "Montreal", "Hamilton", "Atlantic Health Sciences Corporation", "Juravinski Cancer Centre", "Saint John", "Niagara Health System", "Halifax", "Auckland", "Northeastern Regional Cancer Centre", "London Regional Cancer Centre"], "intervention": ["APBI utilizing 3D-CRT radiation"], "outcome": ["cost effectiveness", "overall survival", "quality of life based on questionnaire responses", "ipsilateral breast tumour recurrence defined as recurrent invasive or in situ cancer in the ipsilateral breast including the axillary tail.", "radiation toxicity", "disease free survival", "adverse cosmetic outcome", "event free survival"]}, "NCT02003599": {"age": ["70 Years", "30 Years"], "eligibility": ["Patients who underwent breast-conserving surgery or mastectomy without breast reconstruction", "At full volume : \" Hot Spot \" ( ICRU ) <= 110 %", "In the central court : \" Hot Spot \" ( ICRU ) <= 107 %", "Patient with indication for treatment in supraclavicular fossa", "Patients without histological diagnosis of breast cancer", "Age at least 18 years, female gender only.", "Patients suffering from collagen", "Patients undergoing mastectomy with immediate breast reconstruction"], "condition": ["Radiotherapy; Adverse Effect, Dermatitis or Eczema", "Breast Neoplasms"], "location": ["Barretos", "Brazil", "Hospital do Cancer de Barretos"], "intervention": ["Low-Level Laser Therapy", "Laser therapy", "Placebo", "Placebo Treatment", "LLLT", "Low Level Laser Therapy"], "outcome": ["Evaluate the effects of Laser InGaAIP 660Nm in decreased pain secondary to radiodermatitis", "Evaluate the effects of Laser InGaAIP 660Nm in preventing radiodermatitis in women submitted to adjuvant radiotherapy."]}, "NCT01712009": {"iv-bin-abs": ["46.6", "4.5", "3.1", "34.4", "34.7", "34.3", "40.3", "4.7", "42.5"], "iv-cont-least_squares_mean": ["3.0", "1.8", "3.3", "9.3", "1.7", "3.9", "7.0", "2.2", "7.7"], "iv-cont-number": ["194", "188", "192"], "age": ["100 Years", "18 Years"], "eligibility": ["Adequately treated cervical carcinoma in situ without evidence of disease", "Age 18 years or over", "Eastern cooperative oncology group (ECOG) performance status 0-2", "History of clinically significant bleeding disorders, thromboembolism within 6 months prior to randomization", "Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease", "Currently enrolled in, or less than 30 days since ending, any pain intervention study", "Female subjects who are pregnant or lactating or of reproductive potential not willing to employ an effective method of birth control during treatment and for 17 days after discontinuing study treatment", "\\- Chronic oral aspirin use for cardiovascular-related indications", "Subject has provided informed consent", "Creatinine <= 1.5 X upper limit of normal (ULN)", "Prior use of granulocyte colony stimulating factor (G-CSF)", "History of clinically significant gastrointestinal (GI) bleeding, history of GI ulcers or active GI bleeding within 6 months prior to randomization"], "condition": ["Bone Pain in Stage I - III Breast Cancer"], "location": ["Augusta", "Paducah", "Spokane", "Louisville", "Bend", "Bethlehem", "Lowell", "Torrance", "Lakeland", "Jackson", "Daytona Beach", "Denver", "Mount Vernon", "Skokie", "Whittier", "Boynton Beach", "Pinehurst", "Johnson City", "Hutchinson", "Mount Sterling", "Hickory", "Florence", "Sioux City", "Norwich", "Gastonia", "East Syracuse", "Watertown", "Bristol", "Huntington", "Nashua", "Fort Lauderdale", "Battle Creek", "Lexington", "Elmhurst", "Chattanooga", "Stuart", "Denville", "Westminster", "Lafayette", "South Bend", "Anaheim", "Plantation", "New Port Richey", "Wauwatosa", "Indianapolis", "Fullerton", "Waterloo", "United States", "Kansas City", "Muscle Shoals", "Stamford", "Saint Joseph", "Marrero", "Plano", "Racine", "Rockville", "Thomasville", "Randallstown", "Langhorne", "Urbana", "Billings", "Cumberland", "Corpus Christi", "Santa Maria", "Janesville", "Duluth", "Golden", "Littleton", "Omaha", "Zanesville", "St Louis", "Jefferson City", "Ogden", "Chesapeake", "Madison", "Massillon", "Santa Rosa", "Research Site", "Weston", "Alexandria", "Saint Cloud", "Gurnee", "Shreveport"], "intervention": ["No Prophylaxis", "Loratadine 10 mg QD", "Naproxen 500 mg BID", "Naproxen"], "outcome": ["Percentage of Participants With Bone Pain (All Grades) by Cycle (2-4) and Across Cycles", "Percentage of Participants With Severe Bone Pain by Cycle and Across Cycles", "Mean Patient-reported Bone Pain by Cycle and Across Cycles", "Percentage of Participants With Bone Pain (All Grades) in Cycle 1", "Area Under the Curve (AUC) for Patient-reported Bone Pain", "Number of Participants With Adverse Events (AEs)", "Maximum Patient-reported Bone Pain by Cycle and Across Cycles"], "outcome-Measure": ["Percentage of Participants With Bone Pain (All Grades) by Cycle (2-4) and Across Cycles", "Percentage of Participants With Severe Bone Pain by Cycle and Across Cycles", "Mean Patient-reported Bone Pain by Cycle and Across Cycles", "Percentage of Participants With Bone Pain (All Grades) in Cycle 1", "Area Under the Curve (AUC) for Patient-reported Bone Pain", "Number of Participants With Adverse Events (AEs)", "Maximum Patient-reported Bone Pain by Cycle and Across Cycles"]}, "NCT01645839": {"age": ["18 Years"], "eligibility": ["Histologically proven invasive breast cancer", "Patient affiliated to the French Social Security", "Contra-indication to MRI (including claustrophobia)", "Eastern Cooperative Oncology Group (ECOG) performance status <= 2.", "Adequate bone marrow, renal, and hepatic function with the following range: bilirubin <= 3 x upper limit of normal (ULN), ASAT <= 2.5 x ULN or <= 5 x ULN in presence of liver metastases", "Expected survival of at least 2 months. Patients with rapidly progressive systemic disease are not eligible for this trial", "Hypersensitivity to cytarabine or DepoCyte", "Patients unable to walk due to a palsy but able to use a wheelchair are considered as ambulatory patients", "Able to understand the requirements of the study, date and sign written informed consent", "Active infection (systemic or CNS)", "Prior systemic cytarabine treatment or prior systemic high-dose methotrexate treatment", "Impossibility to adhere to the requirements of the study for geographic, social or psychological reasons", "Ventriculo-peritoneal shunt", "New diagnosis of leptomeningeal metastasis confirmed by CSF cytology, or by the combination of typical clinical symptoms or signs with typical MRI abnormalities", "Contra-indication to lumbar puncture and to implantation of a ventricular device", "Adequate contraception (CPMP/ICH/286/95) for patients of reproductive potential (e.g., barrier method, vasectomy of partner, abstinence) (hormonal contraception not permitted)", "Breast feeding woman or pregnancy. Nursing is not permitted for 6 months after the study", "MRI criteria: CSF flow obstruction (hydrocephalus on brain MRI or obstacle on spinal MRI)", "Concomitant systemic high-dose methotrexate treatment", "Co-existing asymptomatic brain metastases are permitted"], "condition": ["Leptomeningeal Metastases", "Breast Cancer"], "location": ["Centre Val d'Aurelle", "Centre Oscar Lambret", "Montpellier", "Paris", "Amiens", "Centre Antoine Lacassagne", "Grenoble", "Centre Hospitalier Bretagne Sud", "Centre Hospitalier Universitaire Groupe Sud", "Lille", "Centre G.F. Leclerc", "France", "Centre Hospitalier Universitaire Lyon", "Bron", "CHU de Grenoble", "H\u00f4pital Salp\u00e9tri\u00e8re", "Lorient", "Centre Hospitalier Universitaire de Nice", "Dijon", "Nice"], "control": ["Systemic treatment without Depocyte"], "intervention": ["Aracytine", "Depocyte", "Liposomal Cytarabine"], "outcome": ["Quality of life (questionnaire QLQ C30, BN20 and C15)", "Q-TWiST", "Overall survival", "Autonomy in daily life (questionnaire Instrumental Activities in Daily Living)", "Identification and quantification of tumor cells in the CSF by the Veridex technique for the diagnosis and the follow-up of breast cancer leptomeningeal metastases", "Tolerance to DepoCyte\u00ae according to NCI CTCAE V4.0", "Leptomeningeal disease-related neurological progression-free survival (LM-PFS)", "Progression free survival (PFS)", "Emotional state of the patient assessed by the psychological distress score", "Leptomeningeal response according to RANO criteria combining clinical, CSF cytological and imaging response", "Response of leptomeningeal metastases"]}, "NCT00673335": {"age": ["40 Years", "69 Years"], "eligibility": ["ALT and AST < 2.5 times upper limit of normal", "Age > 60 years", "Hemoglobin > 10 g/dL", "absolute neutrophil count (ANC) > 2,000/mm^3", "Prior cardiac ischemia", "No osteoporosis by bone density scan (DEXA) within the past 2 years or prior osteoporotic fracture (femur, lumbar spine T score > -2 DS)", "Renal or hepatocellular insufficiency, cholestasis, or cytolysis", "Carrier of the BRCA1/BRCA2 deleterious mutation (nonsense mutation or stop)", "No prior bilateral breast cancer", "Bilateral oophorectomy", "Invasive cancer diagnosed in the past 5 years, except for basal cell or squamous cell skin cancer or carcinoma in situ of the cervix", "No prior hormonal therapy in the past year", "Platelet count > 100,000/mm^3", "No prior bilateral mastectomy", "Refused preventive mastectomy", "With or without invasive unilateral breast cancer more than 5 years ago, with no recurrence", "Geographical, social, or psychological reasons that preclude medical monitoring in this study", "Adequate cardiovascular function (e.g., no history of myocardial infarction, angina pectoris, or heart failure)", "No evidence of breast cancer by mammography or MRI within the past year", "Age <= 60 years with no hysterectomy or amenorrhea within the past 12 months", "Deprived of liberty or guardianship", "Eastern Cooperative Oncology Group (ECOG) or WHO performance status 0-1", "Bilirubin normal", "Creatinine clearance >= 60 mL/min", "At least 3 months since prior and no concurrent hormone replacement therapy (e.g., thyroid-stimulating hormone)", "Age <= 60 years with prior hysterectomy or FSH > 20 IU/L", "Hypersensitivity to letrozole or its excipients, especially titanium oxide", "Prior cerebrovascular accident"], "condition": ["brca2 Mutation Carrier", "Breast Cancer", "Hereditary Breast/Ovarian Cancer (brca1, brca2)", "brca1 Mutation Carrier"], "location": ["Rennes", "Institut Curie Hopital", "Vand\u0153uvre-l\u00e8s-Nancy", "Centre Oscar Lambret", "Lyon", "Avignon", "Clermont-Ferrand", "Montpellier", "Paris", "Polyclinique De Courlancy", "Toulouse", "Niort", "Centre Antoine Lacassagne", "Centre Hospitalier General de Niort", "Centre Rene Huguenin", "CHU Sainte-Etienne - Hopital Nord", "Saint-Etienne", "Centre Regional Francois Baclesse", "Strasbourg", "Lille", "Centre Leon Berard", "France", "Hopital Saint Michel", "Hopital Arnaud de Villeneuve", "CHU Poitiers", "Centre Catherine de Sienne", "Centre Henri Becquerel", "Institut Claudius Regaud", "Hotel Dieu de Paris", "Caen", "Reims", "Villejuif", "Saint-Cloud", "Institut Gustave Roussy", "Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes", "Centre Alexis Vautrin", "Institut Sainte Catherine", "Poitiers", "Rouen", "Centre Jean Perrin", "Nantes", "Centre Paul Strauss", "Nice", "Marseille", "Centre Eugene Marquis"], "intervention": ["Placebo", "Femara", "letrozole"], "outcome": ["Survival without contralateral or unilateral invasive breast cancer at 5 years (prior breast cancer)", "Toxicity according to CTCAE version 3.0", "Survival without invasive breast cancer at 5 years", "Breast cancer in situ-free survival at 5 and 10 years", "Lipid tolerance or cardiovascular or bone event", "Overall survival at 5 and 10 years", "Event- free (local relapse or metastatic, contralateral, or second cancer) survival at 5 and 10 years", "Relapse-free (local or metastatic disease) survival in patients with history of breast cancer at 5 and 10 years", "Second cancer-free survival at 5 and 10 years", "Quality of life according to MRS and SF36 questionnaires", "Invasive cancer-free survival at 10 years"]}, "NCT00309556": {"age": ["19 Years", "80 Years"], "eligibility": ["No prior or current neoplasm except for curatively treated non-melanoma skin cancer, in situ carcinoma of the cervix", "No distant disease / secondary carcinoma judged clinically and at least by chest X-ray, liver sonography, and bone scan upon randomization", "Stage T4d / inflammatory breast cancer", "Concurrent treatment with corticosteroids except as use for the prophylactic regimen, inhalational use, treatment of acute hypersensitivity reactions, treatment of nausea/vomiting or chronic treatment (initiated > 6 months prior to study entry) at low dose (<= 20 mg methylprednisolone or equivalent)", "WHO performance status <= 2", "Concurrent psychiatric illness according to ICD (alcohol addiction) at the time of study entry", "Signed and dated informed consent before the start of specific protocol procedures", "Pre-existing motor or sensory neurotoxicity of a severity >= WHO grade 2", "Age 18-70 years", "active uncontrolled infection", "Previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrythmias", "history of significant neurologic or psychiatric disorders, including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent", "Prior or concomitant systemic antitumor therapy", "hematology: neutrophils >= 4.0 x 109/l, platelets >= 150 x 109/l, haemoglobin >= 13 g/dl", "histology, grading, hormone receptor status, HER-2/neu status", "hepatic function: total bilirubin < 1 x ULN, ASAT (SGOT) and ALAT (SGPT) < 1x ULN, alkaline phosphatase < 1 x ULN. In case of abnormal values, liver function tests have to be repeated within 3 days before study treatment.", "Pregnant or lactating patients; patients of childbearing potential must implement adequate contraceptive measures during study participation", "Treatment with an investigational drug within 30 days prior to study entry", "Known dihydropyrimidine-dehydrogenase (DPD) deficit", "laboratory requirements: within 2 weeks before enrolment", "renal function: creatinine <= 1 x ULN,", "congestive heart failure or unstable angina pectoris, even if medically controlled.", "chest wall CT, abdomen CT, bilateral mammography: within 4 weeks before enrolment;", "Negative pregnancy test in the presence of childbearing potential", "Known hypersensitivity against taxanes and/or epirubicin and/or fluorouracil/capecitabine", "Female patients with histologically proven, core-biopsied, invasive breast cancer of any clinical and/or radiological T-stage (except for T4d)"], "condition": ["Breast Cancer"], "location": ["State Hospital Klagenfurt", "Linz", "Wolfsberg", "Innsbruck", "Kirchdorf", "Hospital Krems", "Salzburg", "State Hospital Wolfsberg", "G\u00fcssing", "Hospital BHB St. Veit/Glan, Surgery", "Medical University Vienna, General Hospital", "Rankweil", "State Hospital Steyr", "Klagenfurt", "Baden", "Wels", "District Hospital Kufstein", "Gynaegological Medical University Graz", "Hospital Guessing", "General Hospital Linz", "Ordination Dr. Wette", "Klinikum Wels-Grieskirchen", "Oberpullendorf", "Villach", "Saint Veit A. D. Glan", "Paracelsus Medical University Salzburg - Oncology", "Hospital BHS Linz", "State Hospital Leoben", "Medical University of Innsbruck", "Vienna", "Medical University of Graz, Oncology", "Steyr", "Graz", "State Hospital Kirchdorf", "State Hospital Vienna-Hietzing", "State Hospital Feldkirch/Rankweil", "Hanusch Hospital", "Krems", "Hospital Baden", "State Hospital Villach", "Hospital Oberpullendorf", "Hospital Oberwart", "Leoben", "Austria", "Oberwart", "Kufstein", "Hospital of Wiener Neustadt", "Wiener Neustadt"], "intervention": ["Epirubicin"], "outcome": ["Rate of pathological complete remissions", "Rates of axillary lymph node involvement and breast-conserving procedures"]}, "NCT02437318": {"iv-cont-median": ["10.9", "9.23", "5.7", "7.23", "10.97", "11.0", "NA", "7.39", "7.4", "34.30", "18.14", "9.0", "31.4", "40.44", "19.98", "5.65", "37.29", "7.43", "34.07", "39.3", "3.7"], "iv-bin-abs": ["20.9", "13.4", "61.5", "26.6", "53.9", "12.9", "49.1", "44.8"], "iv-cont-least_squares_mean": ["-2.477", "-0.369", "1.524", "2.698"], "iv-cont-geometric_mean": ["424", "10.8", "10.3"], "iv-cont-number": ["0"], "age": ["100 Years", "18 Years"], "eligibility": ["The patient had Eastern Cooperative Oncology Group (ECOG) performance status 2 or more.", "If female, the patient was postmenopausal.", "The patient had symptomatic visceral disease or any disease burden that made the patient ineligible for endocrine therapy per the investigator's best judgment.", "The patient had a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive breast cancer by a local laboratory and had HER2 negative breast cancer.", "The patient had inflammatory breast cancer at screening.", "The patient had a history of acute pancreatitis within 1 year of screening or a past medical history of chronic pancreatitis.", "The patient had recurrence or progression of the disease during or after AI therapy (i.e., letrozole, anastrozole, exemestane).", "The patient had CNS involvement unless he/she was at least 4 weeks from prior therapy completion to starting the study treatment and had a stable CNS tumor at the time of screening and was not receiving steroids and/or enzyme-inducing antiepileptic medications for brain metastases.", "Patients had an established diagnosis of diabetes mellitus type I or uncontrolled type II.", "Newly diagnosed with advanced breast cancer, then relapsed with documented evidence of progression while on or after only one line of endocrine therapy.", "Relapsed with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy and then subsequently progressed with documented evidence of progression while on or after only one line of endocrine therapy for metastatic disease.", "Relapsed with documented evidence of progression while on (neo)adjuvant endocrine therapy or within 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for metastatic disease.", "The patient had either measurable disease per RECIST 1.1 criteria or at least one predominantly lytic bone lesion present.", "The patient had adequate bone marrow function.", "The patient had identified PIK3CA status.", "The patient relapsed with documented evidence of progression more than 12 months from completion of (neo)adjuvant endocrine therapy with no treatment for metastatic disease.", "The patient had participated in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever was longer.", "Patients had Child pugh score B or C."], "ethinicity": ["Black or African American", "Other", "American Indian or Alaska", "Unknown", "Asian", "White"], "condition": ["Breast Cancer"], "location": ["London", "Gyeonggi-do", "Sioux Falls", "Edegem", "Prague", "Cambridge", "Belgium", "Mercy Medical Center", "Vi\u00f1a del Mar", "Massachusetts General Hospital", "Argentina", "City of Hope National Medical Center", "Wahroonga", "G\u00e4vle", "Czechia", "Minato Ku", "Ramat Gan", "Badajoz", "Palermo", "Prisma Health Upstate", "San Francisco", "Florida Cancer Specialists", "Fort Wayne Medical Oncology Hematology Inc", "Japan", "Nashville", "Rio Negro", "Lyon 08", "Nagoya", "Romania", "Dallas", "Corvallis", "Verviers", "Berazategui", "Boston", "Chile", "Detroit Clinical Research Center", "Good Samaritan Regional Medical Center", "St. Petersburg", "Velbert", "Osaka", "Toronto", "La Jolla", "Budapest", "Lancaster", "Chicago", "Monterrey", "Bundang Gu", "Rionero in Vulture", "Mainz", "St Francis Health Comprehensive Cancer Center", "Hong Kong", "Plovdiv", "El Paso Texas Oncology", "Burlington", "Novartis Investigative Site", "Canada", "Szeksz\u00e1rd", "Toulouse", "Fairfax", "Clermont-Ferrand", "Terneuzen", "Kaiser Permanent Southern Californi", "Texas Oncology Northeast Texas", "Rutgers Cancer Institute of New Jersey", "St Lukes Cancer Institute", "Beverly Hills", "Israel", "Hanover", "Kagoshima", "University Hospitals of Cleveland Seidman Cancer Center", "Germany", "La Rioja", "Ny\u00edregyh\u00e1za", "Aschaffenburg", "Australia", "Haifa", "N\u00eemes", "Madrid", "Plymouth", "Florida Cancer Specialists-North", "Cr\u00e9teil", "Thailand", "Naperville", "Caen", "Bangkok", "United Kingdom", "Saint Petersburg", "Sofia", "C\u00e1ceres", "Cleveland", "Qu\u00e9bec", "L\u00fcbeck", "Meldola", "Ryazan", "Jerez de la Frontera", "Elizabeth Vale", "Pontedera", "Barcelona", "Rouen", "South Korea", "Wenatchee", "Potsdam", "Seville", "Palma de Mallorca", "Tyler", "Fort Myers", "Taiwan", "Rush University Medical Center", "Venray", "Isehara", "Hradec Kr\u00e1lov\u00e9", "Sapporo", "Greece", "Brazil", "Kitaadachi-gun", "Chandler", "Akashi", "Italy", "Sint-Niklaas", "Chuo Ku", "Ironwood Cancer and Research Centers", "Linz", "Kiel", "Sassari", "Beirut", "Scripps Green Hospital", "Avignon", "Fayetteville", "Vijayawada", "New Brunswick", "Mayo Clinic Arizona", "Savona", "Maebashi", "Athens", "El Achrafiy\u00e9", "Ottignies", "San Borja", "Greenville", "S\u00e3o Jos\u00e9 do Rio Preto", "Varna", "Baltimore", "Padua", "Le Chesnay", "France", "Highlands Oncology Group", "Ia\u0219i", "Homburg", "Levallois-Perret", "Pozuelo de Alarc\u00f3n", "Vienna", "Surquillo", "La Roche-sur-Yon", "Saida", "San Antonio", "Santiago de Compostela", "Taipei", "Topeka", "Netherlands", "Thessaloniki", "V\u00e4ster\u00e5s", "Texas Oncology PA Dallas Presbyterian Hospital", "Avera Cancer", "Lebanon", "United States", "Evanston", "St Vincent Frontier Cancer Center", "San Diego", "Kansas City", "SCRI Oncology Partners", "Duarte", "NorthShore University Health System", "Lahey Clinic", "Wooloongabba", "CABA", "Mumbai", "Craiova", "Flore\u015fti", "Owosso", "Ancona", "Temuco", "Lancaster General Hospital", "Wenatchee Valley Medical Center", "Mexico", "Spain", "Marseille", "Ulm", "Beersheba", "S\u00e3o Paulo", "Torino", "Zl\u00edn", "Bulgaria", "Scottsdale", "Calgary", "Montpellier", "Billings", "Leipzig", "Hungary", "Negrar", "Matsuyama", "Yokohama", "El Palmar", "UCSF", "San Luis Potos\u00ed City", "Recklinghausen", "Arkhangelsk", "Russia", "Valencia", "Libramont", "Santiago", "Ottawa", "Friedrichshafen", "Brussels", "El Paso", "Saint-Herblain", "Nagpur", "Peru", "Melbourne", "Seoul", "Beverly Hills Cancer Center", "Castellon", "Petah Tikva", "Chieti", "Badalona", "India", "Sweden", "Villejuif", "Milan", "Edward Cancer Center", "Frankfurt", "\u00d6rebro", "Tel Aviv", "Rostock", "Roma", "Virginia Cancer Specialists", "Pokfulam", "Leicester", "Natal", "Mays Cancer Ctr Uthsa Mdacc", "Lima", "Austria", "Aviano", "Alicante", "Lajeado", "Fort Wayne", "Angers", "San Crist\u00f3bal de La Laguna", "Kumamoto"], "intervention": ["Fulvestrant", "Alpelisib + Fulvestrant", "Placebo + Fulvestrant"], "outcome": ["Trough Plasma Concentration of Alpelisib", "Time to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score From Baseline", "Overall Survival (OS) in the PIK3CA Mutant Cohort", "PFS Per Investigator Assessment in the PIK3CA Non-mutant Cohort", "Clinical Benefit Rate (CBR) Per Investigator Assessment", "Trough Plasma Concentration of Fulvestrant", "Updated PFS Per Investigator Assessment in the PIK3CA Mutant Cohort (Longer Follow-up)", "OS in the PIK3CA Non-mutant Cohort", "Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort", "Overall Response Rate (ORR) Per Investigator Assessment", "Time to 10% Deterioration in the Global Health Status (GHS) /Quality of Life (QOL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)", "PFS Per Investigator Criteria in Subjects With PIK3CA Mutation Status Measured in ctDNA at Baseline", "Change From Baseline in the GHS/QOL Scale Score of the EORTC QLQ-C30"], "outcome-Measure": ["Trough Plasma Concentration of Alpelisib", "Time to Definitive Deterioration of Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score From Baseline", "Overall Survival (OS) in the PIK3CA Mutant Cohort", "PFS Per Investigator Assessment in the PIK3CA Non-mutant Cohort", "Clinical Benefit Rate (CBR) Per Investigator Assessment", "Trough Plasma Concentration of Fulvestrant", "Updated PFS Per Investigator Assessment in the PIK3CA Mutant Cohort (Longer Follow-up)", "OS in the PIK3CA Non-mutant Cohort", "Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort", "All Collected Deaths", "Overall Response Rate (ORR) Per Investigator Assessment", "Time to 10% Deterioration in the Global Health Status (GHS) /Quality of Life (QOL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)", "PFS Per Investigator Criteria in Subjects With PIK3CA Mutation Status Measured in ctDNA at Baseline", "Change From Baseline in the GHS/QOL Scale Score of the EORTC QLQ-C30"]}, "NCT02278120": {"iv-cont-median": ["21.2", "21.3", "40.9", "NA", "23.8", "13.0", "17.5"], "iv-bin-abs": ["29.7", "79.1", "69.7", "40.9"], "iv-cont-mean": ["5.0", "4.6"], "iv-cont-number": ["6", "5"], "age": ["59 Years", "18 Years"], "eligibility": ["Patients who had received (neo) adjuvant therapy for breast cancer were eligible", "Patients had HER2-negative breast cancer", "Patients who had received any prior hormonal anti-cancer therapy for advanced breast cancer, except for <= 14 days of tamoxifen or NSAI \u00b1 goserelin for advanced breast cancer prior to randomization.", "Patients with CNS metastases.", "Patients had active cardiac disease or a history of cardiac dysfunction", "Patients must have either had measurable disease or If no measurable disease was present, then at least one predominantly lytic bone lesion", "Patients were postmenopausal", "Patients who currently had inflammatory breast cancer at screening.", "Patients were pregnant or nursing or physiologically capable of becoming pregnant and not using highly effective contraception.", "Patients had a histologically and/or cytologically confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer", "Patients had adequate bone marrow and organ function", "Patients were premenopausal or perimenopausal at the time of study entry", "Patients had advanced (locoregionally recurrent or metastatic) breast cancer not amenable to curative therapy", "Patients had a concurrent malignancy or malignancy within 3 years of randomization, with the exception of adequately treated basal cell skin carcinoma, squamous cell skin carcinoma, non-melanomatous skin cancer or curatively resected cervical cancer.", "Patients who had received a prior CDK4/6 inhibitor", "Patients had an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1"], "condition": ["Advanced Metastatic Breast Cancer"], "location": ["Metepec", "Penn State University Milton S Hershey Medical Center", "Gyeonggi-do", "Mays Cancer Ctr Uthsa Mdacc SC-4", "Heraklion Crete", "Belgium", "United Arab Emirates", "Argentina", "Candiolo", "Comprehensive Cancer Center at Saint Joseph Hospital SC", "Kuala Lumpur", "Le\u00f3n", "Diyarbak\u0131r", "Genova", "Louisville", "University of New Mexico Hospital SC-2", "Hollywood", "Iju\u00ed", "Nashville", "University of Michigan Comprehensive Cancer Center Onc Dept", "Benevento", "Kaohsiung City", "Massachusetts General Hospital Onc Dept", "Miami", "Edmonton", "Geneva", "Tacoma", "Essen", "Boston", "Wan Chai", "Adana", "Kadlec Clinic Hematology and Onco Kadlec Clinic Hematology & Onc", "Leuven", "Duke Univ Medical Center Duke (SC)", "L\u2019Aquila", "Toronto", "University Of California Los Angeles Dept of Onc", "Budapest", "Chicago", "Northern Utah Cancer Associates", "Szeged", "Denver", "Bundang Gu", "Hong Kong", "Prato", "Honolulu", "Monter\u00eda", "Washington Uni School of Med SC", "Esslingen am Neckar", "Novartis Investigative Site", "Canada", "Durham", "Paris", "Toulouse", "Kennewick", "Bakersfield", "Midlothian", "Waratah", "Terni", "Portugal", "Turkey (T\u00fcrkiye)", "Ravensburg", "Barakaldo", "Changhua", "Elche", "Germany", "La Rioja", "Londrina", "Australia", "Kolkata", "Malaysia", "Porto", "Madrid", "Everett", "Namur", "Offenbach", "Providence Regional Cancer Partnership", "Thailand", "Caen", "Bangkok", "Saint Petersburg", "Sofia", "Qu\u00e9bec", "Meldola", "Barcelona", "Rouen", "South Korea", "Taiwan", "Fort Myers", "Florida Cancer Specialists Onc Dept", "Nashik", "Napoli", "Macerata", "Uni of TX MD Anderson Cancer Cntr SC-5", "Greece", "Izmir", "Hershey", "Brazil", "Albuquerque", "Switzerland", "Murdoch", "Los Angeles", "Italy", "Beirut", "Nedlands", "Florida Cancer Specialists SC-2", "Kiel", "Almer\u00eda", "Bonn", "Donostia / San Sebastian", "Edirne", "Barretos", "Taoyuan District", "El Chouf", "Chattanooga", "M\u00fcnchen", "University of Wisconsin / Paul P. Carbone Comp Cancer Center Univ Wisc 3", "El Achrafiy\u00e9", "Clinical Research Alliance .", "Greenville", "Varna", "Moanalua Medical Center. Attn: Oncology Dept SC", "Baltimore", "Pavia", "Lake Success", "Houston", "France", "University of Chicago SC-3", "Passo Fundo", "Bologna", "Lecce", "Udine", "Ann Arbor", "Northwest Medical Specialties Dept of Onc", "Wilrijk", "Istanbul", "Saida", "San Antonio", "Vancouver", "Marietta", "Riyadh", "Santiago de Compostela", "Taipei", "Saudi Arabia", "Fort Worth", "Colombia", "Thessaloniki", "Memorial Cancer Institute SC", "Gdansk", "Box Hill", "NorthWest Georgia Oncology Centers IRB", "Lebanon", "United States", "Montreal", "Catania", "Bangalore", "Heidelberg", "Lucca", "The Center for Cancer and Blood Disorders SC", "Mumbai", "Danbury Hospital SC", "Bon Secours Cancer Center SC", "Mexico", "Spain", "Ankara", "Ulm", "S\u00e3o Paulo", "Methodist Hospita Methodist Can Cen Dept of Oncology", "Bulgaria", "Lyon", "Montpellier", "Leipzig", "Kowloon", "Hungary", "Debrecen", "Lisbon", "Arkhangelsk", "Russia", "University Of Miami Univ Miami 2", "Valencia", "Dresden", "Bogot\u00e1", "Perugia", "Alcorc\u00f3n", "Strasbourg", "Ottawa", "Lille", "Johor Bahru", "Meridian Health Systems SC", "Brussels", "Sidney Kimmel CCC At JH Dept of Onc.", "San Salvador de Jujuy", "Comprehensive Blood and Cancer SC-2", "Erlangen", "Brooke Army Medical Center SC", "Szolnok", "Cona", "Sant Joan Desp\u00ed", "St Louis", "Monterrey Nuevo Leon", "Konin", "Seoul", "Danbury", "SCRI Oncology Partners Tennessee Oncology (3)", "Mallorca", "Badalona", "India", "Ogden", "Sabadell", "Milan", "Madison", "New Taipei City", "M\u00fchlhausen", "Roma", "M\u00e1laga", "Norton Cancer Institute SC", "Erlanger Medical Center SC", "Bon Secours Virginia Health System", "C\u00f3rdoba", "Cremona", "Singapore", "Al Ain Abu Dhabi", "Poland", "Neptune City"], "intervention": ["Tamoxifen", "Placebo + NSAI/Tamoxifen+ Goserelin", "Ribociclib", "Ribociclib + NSAI/Tamoxifen + Goserelin", "LEE011"], "outcome": ["Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) by at Least One Category of the Score", "Clinical Benefit Rate (CBR) by Investigator Assessment", "Overall Response Rate (ORR) by Investigator Assessment", "Overall Survival (OS)", "Time to Response (TTR) by Investigator Assessment", "Time to Definitive 10% Deterioration in the Global Health Status/Quality of Life (GHS/QoL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)", "Duration of Response (DOR) by Investigator Assessment", "Progression Free Survival (PFS) by Investigator Assessment", "Change From Baseline in the GHS/QoL Scale Score of the EORTC QLQ-C30"], "outcome-Measure": ["Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) by at Least One Category of the Score", "Clinical Benefit Rate (CBR) by Investigator Assessment", "Overall Response Rate (ORR) by Investigator Assessment", "All Collected Deaths", "Overall Survival (OS)", "Time to Response (TTR) by Investigator Assessment", "Time to Definitive 10% Deterioration in the Global Health Status/Quality of Life (GHS/QoL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)", "Duration of Response (DOR) by Investigator Assessment", "Progression Free Survival (PFS) by Investigator Assessment", "Change From Baseline in the GHS/QoL Scale Score of the EORTC QLQ-C30"]}, "NCT01735175": {"iv-cont-mean": ["1.72", "1.58", "0.83", "0.75", "0.921", "1.102"], "iv-cont-count_of_participants": ["7", "0", "5", "11", "6", "9", "4", "14", "2"], "age": ["18 Years"], "eligibility": ["previous therapy with any G-CSF (granulocyte-colony stimulating factor) product", "concurrent prophylactic antibiotics", "histologically proven breast cancer"], "ethinicity": ["Unknown or Not Reported", "Not Hispanic or Latino", "Hispanic or Latino"], "condition": ["Chemotherapy-induced Neutropenia", "Neutropenic Complications", "Chemotherapeutic Toxicity", "Breast Neoplasms"], "location": ["Bashkortostan", "Ivanovo", "Moscow", "Sandoz Investigational Site", "Juchit\u00e1n", "Ukraine", "Kabardino", "Kazan'", "Veliky Novgorod", "Aguascalientes", "Russia", "Krasnodar", "Berdsk", "Iju\u00ed", "Cherkasy", "Rajasthan", "Ia\u0219i", "Romania", "Santo Andr\u00e9", "Chernivtsi", "India", "Madurai", "Vinnytsia", "Saint Petersburg", "Luhansk", "Delhi", "Barnaul", "Ryazan", "Oktyabrskaya", "Andhra Pradesh", "Dnipropetrovsk", "Zaporizhzhia", "Tula", "Bucharest", "Mariupol", "Kryvyi Rih", "Mumbai", "Kursk", "Mexico", "Brazil", "Lajeado", "Kharkiv", "Maharashtra", "Suceava"], "intervention": ["LA-EP2006", "pegfilgrastim", "Neulasta\u00ae"], "outcome": ["Number of Patients With ANC Nadir Per Day in Cycle 1", "Depth of ANC Nadir in Cycle 1", "Incidence of Febrile Neutropenia (FN)", "Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy", "Number of Patients With at Least One Episode of Fever by Cycle and Across All Cycles", "Frequency of Infections by Cycle and Across All Cycles", "Time to ANC Recovery in Days in Cycle 1", "Mortality Due to Infection"], "outcome-Measure": ["Number of Patients With ANC Nadir Per Day in Cycle 1", "Depth of ANC Nadir in Cycle 1", "Incidence of Febrile Neutropenia (FN)", "Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy", "Number of Patients With at Least One Episode of Fever by Cycle and Across All Cycles", "Frequency of Infections by Cycle and Across All Cycles", "Time to ANC Recovery in Days in Cycle 1", "Mortality Due to Infection"]}, "NCT00343460": {"iv-cont-number": ["164", "163", "152", "128", "170", "156", "37", "34", "183", "102", "23", "25", "127", "141", "148", "178", "192", "35", "66", "135", "142", "98", "56", "113", "110", "195", "125", "0.781", "0.763", "41", "78", "147", "158", "85", "0.738", "42", "112", "101", "184", "146", "0.811", "0.803", "0.755", "121", "159", "154", "105", "160", "52", "120"], "iv-bin-percent": ["2.3", "3.4", "3.1", "2.4", "2.5", "2.1"], "age": ["120 Years", "18 Years"], "eligibility": ["Must be able to receive standardized doses of dexamethasone for the prevention of emesis during study treatment", "No greater than mild nausea or any vomiting within 24 hours before beginning study treatment", "No head and neck cancer or upper gastrointestinal cancer", "No psychological problem that, in the opinion of the investigator, is severe enough to preclude study participation", "Histologically or cytologically confirmed malignant disease", "No recent history (i.e., <= 1 year) of alcohol or drug abuse", "More than 7 days since prior antinausea medications", "Negative pregnancy test", "No concurrent use of APF530, palonosetron hydrochloride, or aprepitant as rescue medications", "Fertile patients must use effective contraception", "More than 30 days since prior treatment on an investigational trial", "Duration of each course <= 28 days", "Not pregnant or nursing", "Causing nausea and vomiting in 30-100% of patients if untreated according to Hesketh algorithm", "ECOG performance status 0-2", "QTc interval <= 500 ms", "No concurrent condition that, in the opinion of the investigator, could affect assessment of study medication or interfere with the nausea/vomiting response (e.g., severe renal or hepatic impairment)", "No cardiac abnormality predisposing the patient to arrhythmia"], "condition": ["Unspecified Adult Solid Tumor, Protocol Specific", "Nausea and Vomiting"], "location": ["Providence Hospital", "Bethesda", "Pottsville", "Cancer Outreach Associates - Abingdon", "Kentuckiana Cancer Institute, PLLC", "Mercy Medical Center", "Canton", "Compassionate Cancer Care Medical Group Incorporated - Fountain Valley", "Buffalo", "New Albany", "Elmira", "Northern Michigan Hospital", "Louisville", "Hudson Valley Hematology-Oncology Associates - Poughkeepsie", "Medical Oncology Care Associates - Orange", "MedCentral - Mansfield Hospital", "Arkansas Cancer Research Center at University of Arkansas for Medical Sciences", "Charleston", "Hendersonville", "Innovative Medical Research of South Florida, Incorporated", "McDowell Cancer Center at Akron General Medical Center", "MultiCare Regional Cancer Center at Tacoma General Hospital", "Falck Cancer Center at Arnot Ogden Medical Center", "Tacoma", "Abingdon", "Eastern North Carolina Medical Group, PLLC", "Charleston Hematology Oncology Associates, PA", "Rocky Mount", "Anniston", "Skokie", "Cancer Treatment Centers of America at Southwestern Regional Medical Center", "Gabrail Cancer Center - Dover Office", "Julie and Ben Rogers Cancer Institute at Memorial Hermann Baptist Beaumont Hospital", "North Miami Beach", "Comprehensive Cancer Center at Pardee Hospital", "Texas Cancer Clinic", "Medical Center Vincennes", "Norwich", "Middletown", "Center for Cancer and Blood Disorders at Suburban Hospital", "Pascagoula", "Investigative Clinical Research, LLC", "Pottsville Cancer Clinic", "Tucson", "Compassionate Cancer Care Medical Group Incorporated - Corona", "Akron", "Petoskey", "Mary Babb Randolph Cancer Center at West Virginia University Hospitals", "Columbus Clinic, PC", "Hagerstown", "Mansfield", "Family Medicine of Vincennes Clinical Trial Center", "Los Angeles", "Phillipsburg", "Beaumont", "Glendale", "Hematology-Medical Oncology Associates at Central Maine Comprehensive Cancer Center", "Richlands", "Signal Point Hematology Oncology Incorporated", "Pacific Cancer Medical Center, Incorporated", "Baltimore", "Cancer Center of Indiana", "Anaheim", "Advanced Research Management Services, Incorporated", "Regional Cancer Center at Singing River Hospital", "Little Rock", "San Antonio", "Poughkeepsie", "New Port Richey", "Indianapolis", "Lewiston", "United States", "Palo Verde Hematology Oncology - Glendale", "Kansas City", "Virginia Oncology Care, PC", "Kansas City Cancer Centers - South", "Western Washington Oncology, Incorporated, PS at Western Washington Cancer Center", "Kentucky Cancer Clinic - Hazard", "Dover", "Arizona Clinical Research Center, Incorporated", "Orange", "Fountain Valley", "Campbell", "Vincennes", "Anniston Oncology, PC", "Pasco Pinellas Cancer Center - New Port Richey", "Lacey", "Clintell, Incorporated", "Kenmar Research Institute", "Veterans Affairs Medical Center - Buffalo", "Morgantown", "Star Hematology & Oncology", "Center for Clinical Research at Washington County Hospital", "Hazard", "Gabrail Cancer Center - Canton Office", "Tulsa", "Washington D.C.", "Eastern Connecticut Hematology and Oncology Associates", "Boice Willis Clinic, PA", "Corona", "Southbay Oncology / Hematology Medical Group", "Columbus"], "intervention": ["Cycle 1 Aloxi 0.25 mg - Moderately", "APF530", "Cycle 1 APF530 10 mg - Moderately", "Cycle 1 APF530 5 mg - Moderately", "Cycle 1 Aloxi 0.25 Highly", "Cycle 1 APF530 10 mg - Highly", "Cycle 1 APF530 5 mg - Highly"], "outcome": ["Quality of Life and the Impact of Nausea and Vomiting on Day 5", "Number of Emetic Episodes", "Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1", "Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses", "First and Overall Use of Rescue Medication", "Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1", "Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)", "Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1", "Time to First Treatment Failure", "Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1", "Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1"], "outcome-Measure": ["Quality of Life and the Impact of Nausea and Vomiting on Day 5", "Number of Emetic Episodes", "Proportion of Patients With CR During Delayed-onset Phase (24-120 Hours) After Administration of Chemotherapy Course 1", "Sustainability of Antiemetic Effect of APF530 Over Multiple Chemotherapy Courses", "First and Overall Use of Rescue Medication", "Patient's Global Satisfaction With Antiemetic Therapy During Acute Phase and Chemotherapy Course 1", "Severity of Nausea Daily and During Chemotherapy Course 1 (0-120 Hours)", "Proportion of Patients With Complete Control During the Acute Phase (0-24 Hours), Delayed-onset Phase (24-120 Hours), and During Chemotherapy Course 1", "Time to First Treatment Failure", "Proportion of Patients With Total Response During the Acute Phase, Delayed-onset Phase, and During Chemotherapy Course 1", "Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1"]}, "NCT02422615": {"iv-cont-median": ["10.9", "40.0", "NA", "20.5", "12.8", "19.4"], "iv-bin-abs": ["21.5", "70.2", "62.8", "32.4"], "iv-cont-mean": ["4.5", "2.7"], "iv-cont-geometric_mean": ["627", "75.6"], "iv-cont-count_of_participants": ["0"], "age": ["18 Years"], "eligibility": ["Newly diagnosed with advanced/metastatic breast cancer at diagnosis and progressed after receiving one line of endocrine therapy (antiestrogen or aromatase inhibitor), with documented evidence of progression.", "Relapsed with documented evidence of relapse on or within 12 months from completing (neo)adjuvant endocrine therapy, without any prior treatment for advanced/metastatic disease.", "Patients had a confirmed diagnosis of estrogen-receptor positive and/or progesterone receptor positive breast cancer, determined through histological and/or cytological examination by a local laboratory. Patients also had HER2-negative breast cancer.", "5\\. Patients with clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality.", "3\\. Patients with inflammatory breast cancer at the screening stage. Patients with central nervous system (CNS) involvement, unless they were at least 4 weeks from completing prior therapy before initiating the study treatment and had a stable CNS tumor at the time of screening. They were also required not to be receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases.", "Relapsed with documented evidence of relapse more than 12 months after completing adjuvant endocrine therapy and subsequently progressed after receiving one line of endocrine therapy (antiestrogen or aromatase inhibitor) for advanced/metastatic disease.", "Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.", "Patients had either measurable disease as per RECIST 1.1 criteria or at least one predominantly lytic bone lesion.", "Known strong inducers or inhibitors of CYP3A4/5.", "Herbal preparations/medications, dietary supplements.", "Relapsed with documented evidence of relapse more than 12 months after completing (neo)adjuvant endocrine therapy, without any prior treatment for advanced/metastatic disease.", "Patients with symptomatic visceral disease or disease burden that rendered them ineligible for endocrine therapy, based on the investigator's judgment.", "Substances with a narrow therapeutic window and predominantly metabolized through CYP3A4/5.", "Patients had adequate bone marrow and organ function.", "Substances with a known risk of prolonging the QT interval or inducing Torsades de Pointes.", "Patients were adults, both male and female, aged >= 18 years at the time of providing informed consent. Female patients were required to be postmenopausal. Informed consent was obtained prior to any trial-related activities, following local guidelines.", "Newly diagnosed with advanced/metastatic breast cancer and treatment-na\u00efve."], "condition": ["Advanced Breast Cancer"], "location": ["Li\u00e8ge", "UF Health Cancer Center at Orlando Health", "Basel", "Prague", "Brescia", "Millennium Research Clin Develop SC", "Belgium", "Newmarket", "East Melbourne", "Breda", "Czechia", "Fort Collins", "Warsaw", "Brno Bohunice", "Oncology Specialists, SC Advocate Medical Group-Niles", "Besan\u00e7on", "Enschede", "Amsterdam", "Northern Utah Cancer Associates CFTY720DUS01", "Reims", "Brampton", "Leuven", "Charleroi", "Jackson", "Sherbrooke", "Georgsmarienh\u00fctte", "L\u2019Aquila", "Zurich", "Velbert", "Vaxjo", "Budapest", "Halifax", "T\u00fcbingen", "Poudre Valley Hospital", "Honolulu", "Monter\u00eda", "Aarau", "Novartis Investigative Site", "Canada", "Paris", "Brest", "Porto", "Bordeaux", "St Leonards", "Portugal", "Turkey (T\u00fcrkiye)", "Ravensburg", "Newcastle upon Tyne", "Oaxaca City", "Highlands Oncology Group .", "Hanover", "Aarhus", "Surrey", "Germany", "Malaysia", "St Joseph Heritage Healthcare", "Australia", "Pierre-B\u00e9nite", "Augsburg", "Florida Hospital Cancer Institute SC", "NYU Langone Med Center CV Research NYU Langone Medical Center", "Everett", "Namur", "Sittard-Geleen", "Cr\u00e9teil", "Nieuwegein", "Denmark", "Tambov", "Southern Cancer Center PC SC-2", "Davie", "Bangkok", "Oldenburg", "Thailand", "Sofia", "Saint-Cloud", "L\u00fcbeck", "United Kingdom", "Central Coast Medical Oncology Corporation SC", "Copenhagen", "Pontedera", "Moncton", "Hoofddorp", "Granada", "South Korea", "Barcelona", "Seville", "Napoli", "Madrid", "Izmir", "Hershey", "Albuquerque", "Seattle", "Chandler", "Switzerland", "Los Angeles", "Italy", "Beirut", "Nedlands", "Kuching", "Bonn", "F\u00fcrth", "Plymouth", "Odense C", "Cologne", "Rimouski", "Fayetteville", "Troisdorf", "Maastricht", "The Hague", "New York", "Toulon La Seyne Sur Mer", "M\u00fcnchen", "El Achrafiy\u00e9", "Clinical Research Alliance .", "University of New Mexico Cancer Center SC", "Moanalua Medical Center. Attn: Oncology Dept SC", "Meridian Health Systems Regulatory", "Amman", "Lake Success", "Houston", "France", "Victoria", "Lecce", "Norway", "Vienna", "Istanbul", "San Sebasti\u00e1n de los Reyes", "Vancouver", "Le Mans", "Deventer", "Netherlands", "Colombia", "Lebanon", "United States", "Penn State University Milton S Hershey Medical Center SC", "Montreal", "Park Ridge", "Providence Regional Cancer System SC", "Liberec", "Catania", "Roermond", "Salamanca", "Heidelberg", "Mexico", "Limoges", "Spain", "Berlin", "Kingston", "Trois-Rivi\u00e8res", "Innsbruck", "Hamburg", "Thomasville", "A Coru\u00f1a", "Providence Regional Cancer Partnership .", "Virginia Mason Medical Center-Oncology SC", "Saarbr\u00fccken", "Aalst", "Bulgaria", "Hungary", "Orlando", "Hasselt", "Herlev", "Santa Maria", "Debrecen", "Lisbon", "UCLA Medical Center .", "Rozzano", "Arkhangelsk", "Herston", "Russia", "Dresden", "Lacey", "Bogot\u00e1", "Alcorc\u00f3n", "Aalborg", "Strasbourg", "Ironwood Cancer and Research Centers SC-2", "Lille", "Johor Bahru", "Genesis Cancer Services SC", "Tilburg", "Vejle", "Zanesville", "Erlangen", "Sant Joan Desp\u00ed", "Langen", "Szolnok", "Weiden", "Konin", "Oslo", "Seoul", "Jordan", "Mobile", "Ogden", "Sweden", "Milan", "Brno", "Bielefeld", "M\u00fchlhausen", "Jackson Oncology Associates SC", "M\u00e1laga", "Santa Rosa", "Glens Falls", "John D Archbold Memorial Hospital Main", "Sundsvall", "Singapore", "Austria", "Eskilstuna", "Poland", "Groningen", "Neptune City", "CR Wood Cancer Center SC", "Florida Cancer Research Institute Dept of Oncology"], "intervention": ["Placebo + Fulvestrant", "Fulvestrant", "Ribociclib", "Ribociclib + Fulvestrant", "LEE011"], "outcome": ["LEQ803 Plasma Concentrations", "Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) in One Score Category", "Clinical Benefit Rate (CBR) Per Investigator Assessment", "Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC)", "Ribociclib Plasma Concentrations", "Overall Survival (OS)", "Time to Response (TTR) Per Investigator Assessment", "Progression Free Survival (PFS) Per Investigator Assessment", "Overall Response Rate (ORR) Per Investigator Assessment", "Time to Definitive 10% Deterioration in the Global Health Status/Quality of Life (GHS/QoL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)", "Duration of Response (DOR) Per Investigator Assessment", "Change From Baseline in the GHS/QoL Scale Score of the EORTC QLQ-C30"], "outcome-Measure": ["LEQ803 Plasma Concentrations", "Time to Definitive Deterioration of Eastern Cooperative Oncology Group Performance Status (ECOG PS) in One Score Category", "Clinical Benefit Rate (CBR) Per Investigator Assessment", "Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC)", "Ribociclib Plasma Concentrations", "All Collected Deaths", "Overall Survival (OS)", "Time to Response (TTR) Per Investigator Assessment", "Progression Free Survival (PFS) Per Investigator Assessment", "Overall Response Rate (ORR) Per Investigator Assessment", "Time to Definitive 10% Deterioration in the Global Health Status/Quality of Life (GHS/QoL) Scale Score of the European Organization for Research and Treatment of Cancer's Core Quality of Life Questionnaire (EORTC QLQ-C30)", "Duration of Response (DOR) Per Investigator Assessment", "Change From Baseline in the GHS/QoL Scale Score of the EORTC QLQ-C30"]}, "NCT00066703": {"iv-bin-abs": ["93.3", "88.8", "93.4", "91.1", "87.3", "92.8", "93.8", "92.0"], "age": ["65 Years", "18 Years"], "eligibility": ["Bone density is at least 1.5 standard deviations below the young adult normal mean", "Enlarged internal mammary nodes (unless pathologically negative)", "Tumor confined to the breast and axillary nodes", "Stage I papillary thyroid cancer", "Supraclavicular node involvement", "Sex", "No systemic renal disease that would preclude prolonged follow-up", "Inflammatory breast cancer", "Fertile patients must use effective nonhormonal contraception", "Female", "Positive sentinel nodes must have either axillary dissection or radiation of axillary nodes", "Endocrine therapy", "Surgery", "Menopausal status", "Prior or concurrent neoadjuvant or adjuvant trastuzumab allowed", "Participation in a randomized clinical study testing bisphosphonates in the adjuvant breast cancer setting", "Not pregnant or nursing", "No systemic pulmonary disease that would preclude prolonged follow-up", "No distant metastases", "Renal", "No history of noncompliance to medical regimens", "Hematopoietic", "Stage IA carcinoma of the cervix", "Has not used any form of hormonal treatment (including hormonal contraception) within the past 6 months", "Completely resected disease", "No prior bilateral oophorectomy", "No clinically detectable residual loco-regional axillary disease", "Hepatic", "Biologic therapy", "Borderline or stage I ovarian cancer", "Premenopausal", "Tumor detected in internal mammary chain nodes by sentinel node procedure and is not enlarged is allowed", "Cardiovascular", "Axillary lymph node dissection or a negative axillary sentinel node biopsy required", "No concurrent oral or transdermal hormonal therapy", "No systemic hepatic disease that would preclude prolonged follow-up", "Patients with negative or microscopically positive axillary sentinel nodes are eligible", "Histologically confirmed breast cancer", "Pulmonary", "At least 10% of the tumor cells positive by immunohistochemistry", "No prior neoadjuvant or adjuvant endocrine therapy since diagnosis of breast cancer", "Estrogen and/or progesterone receptor positive", "Menstruating regularly for the past 6 months", "Age", "No prior ipsilateral or contralateral invasive breast cancer", "Performance status", "Stage IA or B endometrioid endometrial cancer", "If > 1 breast tumor, each tumor must be hormone receptor positive", "Life expectancy", "No systemic cardiovascular disease that would preclude prolonged follow-up", "No prior thrombosis (e.g., deep vein thrombosis) and/or embolism unless patient is medically suitable"], "condition": ["Breast Cancer"], "location": ["St. Joseph Medical Center", "Lakeland Regional Cancer Care Center - St. Joseph", "Belgium", "Greenebaum Cancer Center at University of Maryland Medical Center", "Canton", "Fitzroy", "Frauenklinik des Universitaetsklinikum Erlangen", "Fort Collins", "Danville", "Centre Hospitalier Universitaire Vaudois", "Peabody", "Hennepin County Medical Center - Minneapolis", "Pratt", "Kinston", "Cancer Therapy Centre at Campbelltown Hospital", "Greensboro", "Rosenheim", "Saint Louis Park", "Roswell Park Cancer Institute", "Oncology Institute of Southern Switzerland", "Waukesha", "Kantonsspital Graubuenden", "Prato", "Front Range Cancer Specialists", "Independence", "Aurora Advanced Healthcare East Mequon Clinic", "Cancer Center of Kansas, PA - Pratt", "Mercy and Unity Cancer Center at Unity Hospital", "CCOP - Wichita", "Klinikum Obergoeltzsch Rodewisch", "Ospedali Riuniti di Bergamo", "Roseville", "South Africa", "Burbank", "Taree", "Moncton", "Shawnee Mission Medical Center", "Cancer Center of Kansas, PA - Newton", "UNMC Eppley Cancer Center at the University of Nebraska Medical Center", "Fairview Ridges Hospital", "Lowell General Hospital", "Minneapolis", "Shawnee Mission", "Institut Jules Bordet", "Pardee Memorial Hospital", "Suburban Hospital", "University of Colorado Cancer Center at UC Health Sciences Center", "Mercy General Hospital", "CCOP - Northern Indiana CR Consortium", "Liverpool", "Oncocare Sonnenhof-Klinik Engeriedspital", "Gainesville", "Universitaets-Frauenklinik Goettingen", "Concord", "Royal Oak", "Baden-Baden", "Universitaetsspital-Basel", "Burnsville", "Sk\u00f6vde", "Pavia", "Fox Chase Virtua Health Cancer Program at Virtua Memorial Hospital Marlton", "North Kansas City Hospital", "Maplewood", "Mountainview Medical", "Franklin & Edith Scarpa Regional Cancer Center at South Jersey Healthcare", "William Beaumont Hospital - Royal Oak Campus", "Our Lady of Mercy Medical Center Comprehensive Cancer Center", "Udine", "Saint Joseph Regional Medical Center", "South Tyneside District Hospital", "Kingman", "Bellinzona", "Edwards", "Sanford Cancer Center at Sanford USD Medical Center", "Maroondah Hospital", "Evanston", "Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center", "Mumbai", "Lausanne", "Mendrisio", "Kokomo", "Urbana", "Research Medical Center", "Fridley", "St. Vincentius - Kliniken", "Elkhart Clinic, LLC", "University of Chicago Cancer Research Center", "Midland", "Windsor", "Brussels", "Erlangen", "Trillium Health Centre - Mississauga Site", "Cancer Center of Kansas, PA - Wellington", "Royal Hobart Hospital", "Lawrence Memorial Hospital", "Michiana Hematology-Oncology, PC - South Bend", "Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center", "Sacramento", "Tom Baker Cancer Centre - Calgary", "G\u00f6ttingen", "Mishawaka", "Lima", "Cancer Center of Kansas, PA - Kingman", "Royal Brisbane and Women's Hospital", "Tamworth", "Basel", "Ringwood East", "Mayo Clinic - Jacksonville", "Wilkes-Barre", "Cambridge", "Mercy Medical Center", "Moses Cone Regional Cancer Center at Wesley Long Community Hospital", "Massachusetts General Hospital", "Buffalo", "Saskatoon", "University Hospital of Linkoping", "Gothenburg", "Caritas - Krankenhaus Saint Josef", "Cancer Center of Kansas, PA - Parsons", "Bethke Cancer Center at Emerson Hospital", "Erlanger Cancer Center at Erlanger Hospital - Baroness", "Lowell", "Tamworth Base Hospital", "Truman Medical Center - Hospital Hill", "Edmonton", "Wichita", "Regions Hospital Cancer Care Center", "Ljubljana", "Edina", "Manning Base Hospital", "Centre Hospitalier Peltzer-La Tourelle", "Mercy and Unity Cancer Center at Mercy Hospital", "Zurich", "La Jolla", "Budapest", "Flinders Medical Centre", "Farmington", "Klinikum Schwaebisch Gmuend Stauferklinik", "Chicago", "Waikato Hospital", "Decatur", "Thun", "Whittier", "Ospedale di Circolo e Fondazione Macchi", "Regionalspital", "Canada", "Azienda Sanitaria di Bolzano", "Medical X-Ray Center, PC", "Saskatoon Cancer Centre at the University of Saskatchewan", "Cancer Therapy Centre at Liverpool Hospital", "Waratah", "Chanute", "Slovenia", "Virginia Piper Cancer Institute at Abbott - Northwestern Hospital", "Mission Hills", "Cancer Center of Kansas, PA - Wichita", "Waconia", "European Institute of Oncology", "Wellington", "Istituto Clinico Humanitas", "Kootenai Cancer Center - Coeur d'Alene", "Brazil", "Doctor's Hospital of Laredo", "Jacksonville", "Regensburg", "Newton", "Italy", "Evanston Hospital", "Palm Springs", "Glendale", "Regina", "Brustzentrum Klinikum Mittelbaden", "Egypt", "NSMC Cancer Center - Peabody", "South Bend", "CCOP - Metro-Minnesota", "Box Hill Hospital", "The Bronx", "Oncology Alliance - Franklin", "Mountain States Tumor Institute at St. Luke's Regional Medical Center", "Aurora Memorial Hospital of Burlington", "Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center", "Beth Israel Deaconess Medical Center", "Winfield", "Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis", "State College", "Allan Blair Cancer Centre at Pasqua Hospital", "Fort Wayne Medical Oncology and Hematology", "Vineland", "Skaraborgs Hospital", "Brisbane", "Associates in Womens Health, PA - North Review", "Porto Alegre", "Fondazione Salvatore Maugeri", "Deggendorf", "United States", "Heidelberg", "UniversitaetsSpital Zuerich", "Elkhart General Hospital", "Coon Rapids", "Cancer Center of Kansas, PA - Medical Arts Tower", "Rebecca and John Moores UCSD Cancer Center", "Klinikum Deggendorf", "Universitaetsklinikum Schleswig-Holstein - Campus Luebeck", "Elkhart", "Morgantown", "Addenbrooke's Hospital", "Austin Hospital", "Geisinger Hazleton Cancer Center", "Oncology Alliance, SC - Milwaukee - East", "Peru", "Addison Gilbert Hospital", "Breast Unit Mercy Private", "India", "Milan", "National Institute of Oncology", "Royal Perth Hospital", "Campbelltown", "Frankfurt", "Geisinger Cancer Institute at Geisinger Health", "South Shields", "Hamilton", "Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute", "Alfred Hospital", "Oncology Alliance - Kenosha South", "Klinikum Landkreis Tuttlingen", "Newcastle Mater Misericordiae Hospital", "Brescia", "Cancer Center of Kansas, PA - Salina", "Cancer Center of Kansas-Independence", "Lismore", "Randolph Hospital", "HealthEast Cancer Care at St. John's Hospital", "St. Vincent's Hospital - Melbourne", "Frederick Memorial Hospital Regional Cancer Therapy Center", "Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center", "National Cancer Institute of Egypt", "Mission Hospitals - Memorial Campus", "MidMichigan Medical Center - Midland", "Hendersonville", "Rochester", "Karlsruhe", "CCOP - Kansas City", "Tacoma", "Boston", "Geisinger Medical Group - Scenery Park", "Ospedale \"la Carita\", Locarno", "Boise", "Jackson", "Columbia Saint Mary's Water Tower Medical Commons Milwaukee", "Ruby L. Golleher Cancer Program at Presbyterian Intercommunity Hospital", "Mainz", "Poudre Valley Hospital", "Parsons", "Rimini", "Burlington", "Sibley Memorial Hospital", "Cancer Center of Kansas, PA - Winfield", "Sahlgrenska University Hospital", "Asheboro", "Aurora", "Bedford Park", "Sioux City", "Annie Penn Cancer Center", "Rodewisch", "Bergamo", "Roy and Patricia Disney Family Cancer Center at Providence Saint Joseph Medical Center", "Desert Regional Medical Center Comprehensive Cancer Center", "Universitaetsfrauenklinik Mannheim", "Tata Memorial Hospital", "Australia", "Siouxland Hematology-Oncology Associates, LLP", "Lawrence", "Peterborough", "Saint Luke's Cancer Institute at Saint Luke's Hospital", "Saint Paul", "Frederick", "Mary Babb Randolph Cancer Center at West Virginia University Hospitals", "Carpi", "Locarno", "Decatur Memorial Hospital Cancer Care Institute", "Marlton", "Saint Louis University Cancer Center", "New York", "Chattanooga", "Link\u00f6ping", "Doctor Leon Richard Oncology Centre", "Franklin", "Institute of Oncology - Ljubljana", "Langlade Memorial Hospital", "Sutter Cancer Center", "Milwaukee", "Asheville", "Peterborough Hospitals Trust", "Topeka", "Wauwatosa", "Box Hill", "Resurrection Medical Center", "Inselspital Bern", "Kansas City", "Gloucester", "Saint Joseph", "Tweed Heads Hospital", "West Tennessee Cancer Center at Jackson-Madison County General Hospital", "Fairview Southdale Hospital", "Hobart", "Howard Community Hospital", "Calgary", "Launceston", "Rozzano", "Omaha", "Aurora Health Center - Waukesha", "Kantonsspital - St. Gallen", "Washington D.C.", "Huy", "Sweden", "Shaw Regional Cancer Center", "Instituto Nacional de Enfermedades Neoplasicas", "South Bend Clinic", "Perth", "Greenfield Park", "Mutlangen", "Cancer Center of Kansas, PA - Dodge City", "Mequon", "El Dorado", "Aviano", "Cancer Center of Kansas, PA - El Dorado", "MetroHealth Cancer Care Center at MetroHealth Medical Center", "Hazleton", "Fort Wayne", "Aurora Health Center - Racine", "Sioux Falls", "Li\u00e8ge", "Bethesda", "Nuremberg", "Windsor Regional Cancer Centre at Windsor Regional Hospital", "Park Nicollet Cancer Center", "Universitatsklinik Mainz", "East Melbourne", "Coffs Harbour Health Campus", "Lugano", "CCOP - Carle Cancer Center", "Northeast Georgia Medical Center", "San Francisco", "Coffs Harbour", "Cairo", "Verviers", "Misericordia e Dolce Hospital", "Providence Holy Cross Cancer Center", "Leuven", "CHU Liege - Domaine Universitaire du Sart Tilman", "Toronto", "UCSF Helen Diller Family Comprehensive Cancer Center", "Ridgeview Medical Center", "Kinston Medical Specialists", "Voorhees Township", "Berlin Corners", "Antigo", "Bolzano", "La Porte", "Oncology Alliance, SC - Milwaukee - West", "Centre Hospitalier Hutois", "Lakeside Cancer Specialists, PLLC", "Walter Reed Army Medical Center", "Germany", "University of Wisconcin Cancer Center at Aspirus Wausau Hospital", "Fox Chase Virtua Health Cancer Program at Virtua West Jersey", "Cross Cancer Institute at University of Alberta", "Centro di Riferimento Oncologico - Aviano", "United Kingdom", "Launceston General Hospital", "Memorial Hospital of South Bend", "Cairo Oncology Center", "Tuttlingen", "Varese", "Cleveland", "L\u00fcbeck", "Margaret and Charles Juravinski Cancer Centre", "Johannesburg", "Mannheim", "Salina", "Switzerland", "CCOP - Greenville", "New Zealand", "Center for Cancer Therapy at LaPorte Hospital and Health Services", "Lismore Base Hospital", "Laredo", "Klinikum Rosenheim", "Onkologie-Praxis ZeTup Chur", "Greenville", "Wausau", "Baltimore", "Policlinico Universitario Udine", "Hope A Women's Cancer Center", "Chur", "Ospedale Civile Ramazzini", "NYU Cancer Institute at New York University Medical Center", "Ospedale Civico", "Sankt Gallen", "Madigan Army Medical Center - Tacoma", "Grand Island", "Mayo Clinic Cancer Center", "Hopital Charles Lemoyne", "Via Christi Cancer Center at Via Christi Regional Medical Center", "Oncology Alliance, SC - Milwaukee - South", "Sutter Cancer Center at Roseville Medical Center", "Racine", "Universitaetsfrauenklinik Frankfurt", "Ospedale Civile Rimini", "Coeur d'Alene", "Spedali Civili di Brescia", "Ospedale Beata Vergine", "Hungary", "Tweed Heads", "Heartland Regional Medical Center", "Kenosha", "Peter MacCallum Cancer Centre", "St Louis", "Melbourne", "Sandton Oncology Centre", "Reidsville", "Aultman Cancer Center at Aultman Hospital", "Tufts Medical Center Cancer Center", "Dodge City", "Robbinsdale", "Bern", "United Hospital", "U.Z. Gasthuisberg", "Overland Park", "Columbia-Saint Mary's Hospital-Ozaukee", "Fletcher Allen Health Care - University Health Center Campus", "Cancer Center of Kansas, PA - Chanute", "Cotton-O'Neil Cancer Center", "Klinikum Nuernberg - Klinikum Nord", "Menorah Medical Center", "Hospital de Clinicas de Porto Alegre"], "intervention": ["tamoxifen", "Decapeptyl Depot", "triptorelin", "Aromasin", "Nolvadex", "exemestane", "T+OFS", "GnRH analogue", "E+OFS", "Trelstar Depot"], "outcome": ["Distant Recurrence-free Interval", "Breast Cancer-free Interval", "Overall Survival", "Disease-free Survival"], "outcome-Measure": ["Distant Recurrence-free Interval", "Breast Cancer-free Interval", "Overall Survival", "Disease-free Survival"]}, "NCT00314977": {"age": ["70 Years", "18 Years"], "eligibility": ["Patients must be accessible for treatment and follow-up", "Estrogen and/or progesterone receptor analysis performed on the primary tumour in the biopsy material", "Adequate bone marrow function (within 14 days prior to registration): WBC >=3.0 x 109/l, neutrophils >=1.5 x 109/l, platelets >=100 x 109/l", "Her2/neu receptor analysis performed on the primary tumour in the biopsy material", "Age >=18 years and age <=70 years", "Patients with a history of breast cancer", "Adequate liver function (within 4 weeks prior to start treatment): bilirubin <=1.5 x upper limit of normal (UNL) range, ALAT and/or ASAT <=2.5 x UNL, Alkaline Phosphatase <=5 x UNL", "Karnofsky Performance score >=70%", "Measurable disease (breast and/or lymph nodes)", "Evidence of distant metastases (M1)", "Adequate renal function (within 4 weeks prior to start treatment): the calculated creatinine clearance should be >=50 mL/min", "Women presenting with large resectable or locally advanced breast cancer (T2 >=3 cm, T3, or T4, and/or LN positive)", "Written informed consent according to the local Ethics Committee requirements", "Patients with advanced pulmonary disease of any cause (oxygen dependent)- Peripheral neuropathy > grade 2 whatever the cause"], "condition": ["Breast Cancer"], "location": ["Radboud University Medical Centre", "Zaandam", "Mesos Medisch Centrum", "Zaans Medical Centre", "Heerlen", "Spaarne Ziekenhuis", "'s-Hertogenbosch", "Waterland Hospital", "Maastricht", "The Hague", "Sittard", "Jeroen Bosch Ziekenhuis", "Maxima Medisch Centrum", "Arnhem", "Catharina Ziekenhuis", "Rijnstate Ziekenhuis", "Deventer Ziekenhuis", "Atrium Medisch Centrum", "Harderwijk", "Leids Universitair Medisch Centrum (LUMC)", "Eindhoven", "Utrecht", "Onze Lieve Vrouwe Gasthuis", "Tilburg", "Elkerliek Ziekenhuis", "UMC Utrecht", "St. Antonius Hospital", "Purmerend", "St. Elisabeth Ziekenhuis", "Amsterdam", "Canisius Wilhelmina Ziekenhuis", "Nieuwegein", "Doetinchem", "Deventer", "Netherlands", "Slingeland Hospital", "HAGA Ziekenhuis", "Helmond", "Hoofddorp", "Leiden", "St. Jansdal Ziekenhuis", "Veldhoven", "Academical Hospital Maastricht (AZM)", "Nijmegen", "Maasland Hospital", "Geldrop", "St. Anna Hospital"], "intervention": ["Revimmune", "Cytoxan", "Taxotere", "Doxorubicin", "adriamycin", "Docetaxel", "Cyclophosphamide", "Neosar", "hydroxyldaunorubicin"], "outcome": ["The delivered chemotherapy dose and dose-intensity of both chemotherapy regimens", "The tolerability (grade 3/4 CTC toxicities) of both chemotherapy regimens.", "The value of breast MRI in evaluating response to neoadjuvant chemotherapy as compared to clinical palpation, ultrasound techniques and histo-pathological outcome.", "The false-negative rate of the sentinel node biopsy after neoadjuvant chemotherapy.", "The prognostic and predictive value of tumour- and molecular markers, including ER, PgR, c-erbB2, microarray and other tumour characteristic analyses.", "The relation between pCR and DFS/OS.", "The pathologic complete response rate to neoadjuvant chemotherapy.", "The feasibility of the criteria for reporting pathological tumour response in surgical breast and axillary node resection specimens.", "The clinical responses of neoadjuvant chemotherapy correlated to pathological responses after neoadjuvant chemotherapy.", "The disease-free and overall survival after 3 and 5 years follow-up."]}, "NCT00462891": {"age": ["18 Years"], "eligibility": ["Age 42 to 69 years (randomized portion of study)", "No patient who the Massachusetts General Hospital system lists as having a primary care provider who is not in one of the MGPC-PBRN networks (linking patients with a provider or practice)", "No mammogram within the past 2 years (randomized portion of study)", "No prior bilateral mastectomy (randomized portion of study)", "Billing, scheduling, and clinical electronic data sources required", "No patient who is not linked to specific provider or practice (randomized portion of study)", "Any outpatient at a participating Massachusetts General Primary Care Practice-Based Research Network (MGPC-PBRN) practice within the past 3 years", "Female"], "condition": ["Breast Cancer"], "location": ["Massachusetts General Hospital", "Boston", "United States"], "control": ["Usual Care"], "intervention": ["IT System"], "outcome": ["Difference in percentage of patients overdue at baseline receiving mammogram during the study period in intervention and control practices at 6 months", "Comparison of time to mammography completion in intervention vs control groups", "Clinical and nonclinical outcomes recorded by Mammography FastTrack tool", "Proportion of overdue patients completing mammography screening in intervention and control groups"]}, "NCT01684215": {"iv-cont-count_of_participants": ["42", "0", "5", "1", "6", "40"], "iv-bin-abs": ["0", "47.6", "75.6", "85.7"], "iv-cont-geometric_mean": ["1595", "1322", "51.74", "2838", "3514", "41.37", "59.75", "1730", "1276", "547.5", "124.7", "35.51", "1979", "971.7", "2483", "50.29", "684.5", "2396", "96.43", "72.76", "1039", "1296", "104.1", "1215", "63.21"], "iv-cont-median": ["5.02", "1.105", "41.4", "4.90", "NA", "4.00", "1.855", "2.060", "1.130"], "iv-cont-mean": ["106.46", "25.72", "80.22", "23.93", "71.52"], "iv-cont-number": ["1590", "1509", "19", "41"], "age": ["20 Years"], "eligibility": ["Prior neoadjuvant or adjuvant treatment with a non steroidal aromatase inhibitor (ie, anastrozole or letrozole) with disease recurrence while on or within 12 months of completing treatment.", "HER2 positive tumor based on local laboratory results utilizing one of the sponsor approved assays.", "Documentation of histologically or cytologically confirmed diagnosis of ER(+) breast cancer based on local laboratory results.", "Resolved acute effects of any prior therapy to baseline severity or Grade <=1", "Phase 2", "Uncontrolled infection, unstable or sever intercurrent medical condition, or current drug or alcohol abuse", "Adequate blood cell counts, kidney function and liver function and and Eastern Cooperative Oncology Group [ECOG] score of 0 to 2.", "Adequate blood cell counts, kidney function and liver function and and Eastern Cooperative Oncology Group [ECOG] score of 0 or 1.", "Known active uncontrolled or symptomatic CNS metastases, carcinomatous meningitis, or leptomeningeal disease.", "Phase 1", "Active or unstable cardiac disease or history of heart attack within 6 months", "In Part 1, advanced solid tumor (except SCLC or retinoblastoma) proven histologically or cytologically at original diagnosis, that is refractory to standard therapy or for whom no standard of care therapy is available.", "Active uncontrolled or symptomatic CNS metastases."], "condition": ["Neoplasms", "Breast Neoplasms"], "location": ["Kumamoto", "Hakuaikai Medical Corporation Sagara Hospital", "Fukuoka", "Saitama Cancer Center", "Chiba", "Kyoto University Hospital", "Kumamoto Shinto General Hospital", "National Cancer Center Hospital", "National Cancer Center Hospital East", "Kashiwa", "National Hospital Organization Shikoku Cancer Center", "Kagoshima", "Japan", "Nagoya", "Iwate Medical University Hospital", "Numakunai", "Kumamoto University Hospital", "National Hospital Organization Osaka National Hospital", "National Hospital Organization Hokkaido Cancer Center", "Kita-adachi-gun", "Kumamoto City Hospital", "Aichi Cancer Center Hospital", "National Hospital Organization Kyushu Cancer Center", "Chiba Cancer Center", "Osaka", "Hiroshima City Hiroshima Citizens Hospital", "Ehime", "Kyoto", "Sapporo", "Hiroshima", "Chuo-Ku"], "intervention": ["PD-0332991 125 mg+ Letrozole 2.5 mg: MTD Cohort", "PD-0332991 125 mg+ Letrozole 2.5 mg: Expanded Cohort", "PD-0332991 125 mg: Dose Escalation Cohort", "PD-0332991 100 mg: Dose Escalation Cohort", "PD-0332991"], "outcome": ["Pre-dose Plasma Concentration (Ctrough) of PD-0332991: Phase 2", "Duration of Response (DOR): Phase 2", "AUC24 Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1", "Volume of Distribution (Vz/F) of PD-0332991 Following Single Dose: Part 1 Phase 1", "Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991: Part 1 Phase 1", "Cmax Dose Normalized to 125 mg of PD-0332991: Part 1 Phase 1", "Terminal Half-Life (t1/2) of PD-0332991: Part 1 Phase 1", "Percentage of Participants With Disease Control (DC): Phase 2", "Maximum Observed Plasma Concentration (Cmax) Of PD-0332991: Phase 2", "Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991: Phase 2", "Area Under the Plasma Concentration Time Curve Over Dosing Interval (AUCtau) of PD-0332991: Phase 2", "Change From Baseline in Trial Outcome Index (TOI): Phase 2 at Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and End of Treatment", "Accumulation Ratio (Rac) of PD-0332991 Following Multiple Dose: Part 1 Phase 1", "Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1", "Number of Participants With Treatment-Emergent Adverse Events (AEs) By Severity: Phase 1 (Part 1) and Phase 2", "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of PD-0332991 Following Single Dose: Part 1 Phase 1", "Apparent Oral Clearance of PD-0332991: Part 1 Phase 1", "Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs): Phase 1 (Part 1) and Phase 2", "Percentage of Participants With Objective Response: Phase 2", "AUCtau Dose Normalized to 125 Milligram (mg) of PD-0332991 Following Multiple Dose: Part 1 Phase 1", "Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 2 Phase 1", "Presence of Tumor Tissue Biomarker- Ki67: Phase 2", "AUCinf Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1", "Maximum Observed Plasma Concentration (Cmax) Of PD-0332991: Part 1 Phase 1", "Apparent Oral Clearance of PD-0332991: Phase 2", "Number of Participants With Clinically Significant Laboratory Abnormalities", "Area Under the Plasma Concentration Time Curve Over Dosing Interval (AUCtau) of PD-0332991 Following Multiple Dose: Part 1 Phase 1", "Area Under the Plasma Concentration-Time Curve From 0 to Time 24 Hours (AUC24) of PD-0332991 Following Single Dose: Part 1 Phase 1", "Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G): Phase 2 at Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and End of Treatment", "AUClast Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1", "Percentage of Participants With Objective Response: Phase 1", "Area Under the Plasma Concentration-Time Curve From 0 to Time of Last Measurable Concentration (AUClast) of PD-0332991 Following Single Dose: Part 1 Phase 1", "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) By Severity: Part 2 Phase 1", "Linearity (Rss) of PD-0332991 Following Multiple Dose: Part 1 Phase 1", "Duration of Response (DOR): Part 2 Phase 1", "Presence of Tumor Tissue Biomarkers- Estrogen Receptor (ER) H-Score, Retinoblastoma (Rb) H-Score, B-cell Lymphoma-1 (BCL-1) H-Score, P16 H-Score: Phase 2", "Percentage of Participants With 1 Year Progression Free Survival (PFS): Phase 2", "Progression Free Survival (PFS): Part 2 Phase 1", "Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B): Phase 2 at Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and End of Treatment", "Overall Survival (OS): Phase 2", "Pre-dose Plasma Concentration (Ctrough) of PD-0332991 Following Multiple Dose: Part 1 Phase 1"], "outcome-Measure": ["Pre-dose Plasma Concentration (Ctrough) of PD-0332991: Phase 2", "Duration of Response (DOR): Phase 2", "AUC24 Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1", "Volume of Distribution (Vz/F) of PD-0332991 Following Single Dose: Part 1 Phase 1", "Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991: Part 1 Phase 1", "Cmax Dose Normalized to 125 mg of PD-0332991: Part 1 Phase 1", "Terminal Half-Life (t1/2) of PD-0332991: Part 1 Phase 1", "Percentage of Participants With Disease Control (DC): Phase 2", "Maximum Observed Plasma Concentration (Cmax) Of PD-0332991: Phase 2", "Time to Reach Maximum Observed Plasma Concentration (Tmax) of PD-0332991: Phase 2", "Area Under the Plasma Concentration Time Curve Over Dosing Interval (AUCtau) of PD-0332991: Phase 2", "Change From Baseline in Trial Outcome Index (TOI): Phase 2 at Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and End of Treatment", "Accumulation Ratio (Rac) of PD-0332991 Following Multiple Dose: Part 1 Phase 1", "Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1", "Number of Participants With Treatment-Emergent Adverse Events (AEs) By Severity: Phase 1 (Part 1) and Phase 2", "Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of PD-0332991 Following Single Dose: Part 1 Phase 1", "Apparent Oral Clearance of PD-0332991: Part 1 Phase 1", "Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs): Phase 1 (Part 1) and Phase 2", "Percentage of Participants With Objective Response: Phase 2", "AUCtau Dose Normalized to 125 Milligram (mg) of PD-0332991 Following Multiple Dose: Part 1 Phase 1", "Number of Participants With Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 2 Phase 1", "Presence of Tumor Tissue Biomarker- Ki67: Phase 2", "AUCinf Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1", "Maximum Observed Plasma Concentration (Cmax) Of PD-0332991: Part 1 Phase 1", "Apparent Oral Clearance of PD-0332991: Phase 2", "Number of Participants With Clinically Significant Laboratory Abnormalities", "Area Under the Plasma Concentration Time Curve Over Dosing Interval (AUCtau) of PD-0332991 Following Multiple Dose: Part 1 Phase 1", "Area Under the Plasma Concentration-Time Curve From 0 to Time 24 Hours (AUC24) of PD-0332991 Following Single Dose: Part 1 Phase 1", "Change From Baseline in Functional Assessment of Cancer Therapy-General (FACT-G): Phase 2 at Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and End of Treatment", "AUClast Dose Normalized to 125 mg of PD-0332991 Following Single Dose: Part 1 Phase 1", "Percentage of Participants With Objective Response: Phase 1", "Area Under the Plasma Concentration-Time Curve From 0 to Time of Last Measurable Concentration (AUClast) of PD-0332991 Following Single Dose: Part 1 Phase 1", "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) By Severity: Part 2 Phase 1", "Linearity (Rss) of PD-0332991 Following Multiple Dose: Part 1 Phase 1", "Duration of Response (DOR): Part 2 Phase 1", "Presence of Tumor Tissue Biomarkers- Estrogen Receptor (ER) H-Score, Retinoblastoma (Rb) H-Score, B-cell Lymphoma-1 (BCL-1) H-Score, P16 H-Score: Phase 2", "Percentage of Participants With 1 Year Progression Free Survival (PFS): Phase 2", "Progression Free Survival (PFS): Part 2 Phase 1", "Change From Baseline in Functional Assessment of Cancer Therapy-Breast Cancer (FACT-B): Phase 2 at Day 1 of Cycle 2, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and End of Treatment", "Overall Survival (OS): Phase 2", "Pre-dose Plasma Concentration (Ctrough) of PD-0332991 Following Multiple Dose: Part 1 Phase 1"]}, "NCT01724450": {"age": ["18 Years"], "eligibility": ["Patients with HER 2 expression"], "condition": ["Heart Failure", "Breast Cancer", "Cardiotoxicity"], "location": ["S\u00e3o Paulo", "Heart Institute University of Sao Paulo", "Brazil"], "intervention": ["Carvedilol"], "outcome": ["Prevention of myocardial injury measured by the levels of biomarkers (ultrasensitive troponin, BNP and miRNA-208) Effect of carvedilol in the prevention of diastolic dysfunction.", "Prevention of systolic dysfunction in patients undergoing chemotherapy with anthracycline. Systolic dysfunction is characterized by a 10% drop in ejection fraction of left ventricle."]}, "NCT01670448": {"age": ["85 Years", "18 Years"], "eligibility": ["patients with chronic pain before the surgery", "patients ASA status I-IV", "allergy to a drug used in the protocol (local anesthetic)", "refusal of the PECBLOCK", "women aged 18-85 yrs old"], "condition": ["Cancer", "Pain"], "location": ["University Hospital, Limoges", "Montreal", "Canada", "France", "Limoges", "CHUM"], "intervention": ["PECBLOCK under echoguidance"], "outcome": ["Pain score at rest in the recovery room", "Total morphine consumption in the recovery room", "Assess any complication from PECBLOCK", "Total sufentanil consumption during surgery"]}, "NCT02840890": {"age": ["99 Years", "18 Years"], "eligibility": ["Operated for a breast cancer stage 1 to 3, in complete resection", "Distance home CGFL 0 to 50 km, 50 to 100 km, 100 to 200 kms.", "Inability to receive one of the basic elements antibiotic treatment", "Failure to submit to medical testing for geographical reasons (distance home - CGFL more than 200 km), social or psychic", "Refusal to participate to the trial", "Wife", "non-affiliation to a social security scheme or to the State Medical Aid (AME) or the universal medical coverage (CMU)", "Digestive disorders known or known digestive disease", "planned antiemetic treatment which should include EMEND 125, 80, 80 at J1, J2, J3, ZOPHREN 8 mg IV 1 bulb at J1, Solumedrol 80 mg IV on day 1, Primperan 10 mg 3 tablets a day, from day 1 to day 3, XANAX 0,25 mg 1 tablet morning 1tablet evening from D1 to D3.", "Breast cancer surgery with incomplete excision", "Persons deprived of liberty or under guardianship", "Pregnant woman or likely to be", "Having considered the information note", "Man", "written, dated and signed Informed consent", "Age over 18 years", "Metastatic breast cancer"], "condition": ["Breast Cancer"], "location": ["CGFL", "France", "Dijon"], "intervention": ["osteopathic technique"], "outcome": ["Quality of life questionnaire(QLQ-C30)", "episode of nausea and / or vomiting", "episode of constipation"]}, "NCT03647930": {"age": ["18 Years"], "eligibility": ["Undergoing simple mastectomy with or without sentinel lymph nodes biopsy OR modified radical mastectomy for the treatment of breast cancer", "Systemic anticoagulation", "Age greater than or equal to 18 years", "Choosing not to participate in the study", "Sentinel lymph node biopsy requiring conversion to axillary lymph node dissection", "Undergoing partial mastectomy", "Immediate reconstructive surgery"], "condition": ["Seroma"], "location": ["Savannah", "Memorial Health University Medical Center", "United States"], "control": ["Control"], "intervention": ["Microporous Polysaccharide Hemospheres (MPH)"], "outcome": ["Total Drain Output", "Total Drain Days"]}, "NCT02428114": {"age": ["19 Years"], "eligibility": ["Histologically confirmed primary breast cancer", "Contraindication to Filgrastim", ">=19 years of age", "Able to provide verbal consent"], "condition": ["Early Stage Breast Cancer"], "location": ["The Ottawa Hospital Research Institute", "Canada", "Ottawa", "Cancer Centre of Southeastern Ontario at Kingston General Hospital", "Kingston"], "outcome": ["ANC results at the end of each cycle of chemotherapy.", "percentage of patients who require chemotherapy dose decrease", "hospital admissions", "Feasibility of performing this study will be measured with composite endpoints: physician engagement, time for local or provincial research ethics approval, accrual rates, and patient/physician compliance.", "percentage of patients who require chemotherapy dose delays", "Rates of documented febrile neutropenia (laboratory confirmation)"]}, "NCT00000611": {"age": ["50 Years", "79 Years"], "eligibility": ["Postmenopausal women ages 50 to 79."], "condition": ["Colonic Neoplasms", "Coronary Disease", "Bone Diseases", "Breast Neoplasms", "Cardiovascular Diseases", "Osteoporosis", "Myocardial Ischemia", "Heart Diseases", "Postmenopause"], "intervention": ["hormone replacement therapy"]}, "NCT03248427": {"age": ["18 Years"], "eligibility": ["Uncontrolled hypertension (Systolic blood pressure >160 mmHg or <90 mmHg and/or diastolic >100 mmHg).", "Herbal preparations/medications, dietary supplements.", "Breast cancer eligible for primary surgery.", "Patient with a Child-Pugh score B or C.", "Strong inducers or inhibitors of CYP3A4/5, including grapefruit, grapefruit hybrids, pummelos, star-fruit and Seville oranges.", "Adequate hematological, renal and hepatic function.", "ER-positive and/or PgR-positive and HER2-negative tumor by ASCO/CAP guidelines assessed locally.", "In the case of a multifocal tumor (defined as the presence of two or more foci of cancer within the same breast quadrant), the largest lesion must be >= 2 cm and designated the \"target\" lesion for all subsequent tumor evaluations and HR+/HER2-negative status must be documented in all the tumor foci.", "Inability or unwillingness to swallow pills.", "Available pre-treatment FFPE core (Tru-cut) biopsy evaluable for PAM50 or possibility to obtain one. Minimal sample requirements are to have at least 2 tumor cylinders with a minimal tissue surface of 10 mm2 tissue, containing at least 10% tumor cells and having enough tissue to do at least 2 cuts of 10 micrometers each.", "ECOG performance status of 0 or 1.", "Inoperable locally advanced or inflammatory (i.e., inoperable Stage III) breast cancer.", "Significant traumatic injury within 3 weeks prior to initiation of study treatment.", "Long QT Syndrome or family history of idiopathic sudden death or congenital long QT syndrome.", "Hormone replacement therapy stopped less than 2 weeks before treatment start.", "Post-menopausal status and age >=18 years.", "No evidence of distant metastasis (M0)", "Ability and willingness to comply with study visits, treatment, testing and to comply with the protocol.", "Primary tumor >= 2cm in largest diameter as measured by breast MRI", "Symptomatic hypercalcemia despite adequate management.", "Any prior treatment for primary invasive breast cancer.", "History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty or stenting) or symptomatic pericarditis within 12 months prior to screening.", "Multicentric breast cancer, defined as the presence of two or more foci of cancer in different quadrants of the same breast.", "On screening 12-lead ECG, any of the following cardiac parameters (defined as the mean of triplicate ECGs: bradycardia (resting heart rate < 50), tachycardia (resting heart rate > 90), PR interval > 220 msec, QRS interval >109 msec, or QTcF interval >=450 msec (using Fridericia's correction).", "Patients who have undergone sentinel lymph node biopsy prior to study treatment.", "Clinical significant cardiac arrhythmias (e.g. ventricular tachycardia), complete left bundle branch block, high-grade AV block (e.g. bifascicular block, Mobitz type II and third-degree AV block)", "Patient has a Left Ventricular Ejection Fraction (LVEF) < 50% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO).", "Participation in a prior investigational study within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.", "Known human immunodeficiency virus (HIV) infection.", "History of documented congestive heart failure (New York Heart Association functional classification III-IV).", "Luminal B subtype as per PAM50 analysis of pre-treatment sample.", "Medications that have a known risk to prolong the QT interval or cause Torsades de Pointe.", "Documented cardiomyopathy.", "Bilateral invasive breast cancer.", "Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.", "Signed Informed Consent Form prior to any study-specific procedure.", "Major surgical procedure (not including minor procedures such as lymph node biopsy, tumor core biopsy, fine needle aspiration) within 4 weeks prior to initiation of study treatment or not fully recovered from any side effects of previous procedures.", "Stage I to stage IIIA breast cancer", "Medications with a narrow therapeutic window and predominantly metabolized through CYP3A4/5.", "Female patients.", "Currently receiving or has received systemic corticosteroids until 2 weeks before treatment start or who have not fully recovered from side effects of such treatment. Following corticosteroid uses are permitted: single doses, topical applications (e.g. for rash), inhaled sprays (e.g. for obstructive airways diseases), eye drops or local injections (e.g. intra-articular)", "Metastatic (Stage IV) breast cancer.", "Any prohibited medication as per letrozole, doxorubicin, cyclophosphamide, or paclitaxel label.", "Known hypersensitivity to any of the excipients of ribociclib, letrozole, doxorubicin, cyclophosphamide or paclitaxel.", "Active infection requiring intravenous (IV) antibiotics."], "condition": ["Breast Cancer"], "location": ["Consorcio Hospitalario Provincial de Castell\u00f3n", "Granollers", "Castell\u00f3", "Fundaci\u00f3 Privada Hospital Asil de Granollers", "Hospital Universitario Fundaci\u00f3n de Alcorc\u00f3n", "Centro Oncol\u00f3gico MD Anderson International Espa\u00f1a", "Hospital Clinic de Barcelona", "Valencia", "Complexo Hospitalario Universitario de Santiago", "Hospital General de Catalunya", "Centro Integral Oncologico Clara Campal", "Hospital Universitari Son Espases", "Madrid", "Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz", "Hospital Universitari Arnau de Vilanova de Val\u00e8ncia", "Hospital Rey Juan Carlos", "Santiago de Compostela", "C\u00e1ceres", "Hospital San Pedro de Alc\u00e1ntara", "Barcelona", "Fundaci\u00f3n Instituto Valenciano de Oncolog\u00eda", "Seville", "Institut Catal\u00e0 d'Oncologia l'Hospitalet", "Hospital Universitario 12 de octubre", "Hospital Quir\u00f3n Madrid", "Hospital Cl\u00ednico Universitario de Valencia", "Hospital Virgen del Roc\u00edo", "Hospital Universitari Vall d' Hebron", "Palma", "Spain", "Hospital Virgen Macarena"], "intervention": ["Letrozole 2.5mg", "LEE011", "Ribociclib"], "outcome": ["PEPI Score", "Decrease in Ki67 in both treatment arms.", "Rate of breast conserving surgery (BCS)", "Rate of ROR-low according to the Prosigna test.", "Incidence, duration and severity of Adverse Events (AEs)", "Residual Cancer Burden (RCB)", "pCR in the breast and axillary lymph nodes", "Tumor Overall response rate (ORR)"]}, "NCT00121160": {"age": ["60 Years", "18 Years"], "eligibility": ["Current infectious disease", "Use of immune modulating drugs", "Working phone", "Female, age 18-60 years", "Family history of breast cancer", "History of Hepatitis A or HA vaccination", "Plan to live in the area for one year", "History of autoimmune disease", "Working address", "Fluent in English", "Current major depressive episode", "Prior cancer diagnosis (except non-melanoma skin cancer)", "History of Bipolar Disorder or Schizophrenia"], "condition": ["Psychological Stress"], "location": ["Fred Hutchinson Cancer Research Center", "Seattle", "United States"], "intervention": ["Cognitive Behavioral Stress Management (CBSM) group intervention"], "outcome": ["Multiple regression analyzes will be used to test changes in cortisol and changes in perceived risk of breast cancer; coping or social support mediate the effects of the intervention on antibody response to vaccine and distress", "Independent sample t-test will be used to compare 1) antibody change scores from before to after the first and second dose of vaccine, and 2) distress change scores from before to after the intervention"]}, "NCT02263651": {"age": ["85 Years", "18 Years"], "eligibility": ["Women with indication of bilateral mastectomy or immediate reconstruction.", "Degenerative neuromuscular disease with thoracic muscular damage", "Any physical or psychiatric condition that could impair with patient's ability to cooperate with postoperative data collection.", "Women with operable breast cancer (invasive carcinoma and/or carcinoma in situ) for whom mastectomy is recommended or preferred by the patient either alone or in association with sentinel lymph node biopsy or standard level I/II axillary node dissection", "Women >= 18 years and <= 85 years", "Planned ambulatory surgery", "French social security affiliation", "Women that give her informed written consent"], "condition": ["Breast Cancer"], "location": ["Tours", "Conception Hospital", "Nantes", "CHU de Poitiers", "Saint-Cyr-sur-Loire", "Institut de Canc\u00e9rologie de l'Ouest", "France", "CHRU de Tours", "Institut POALI-CALMETTES", "Marseille", "Alliance Clinic", "Poitiers"], "intervention": ["Quilting suture", "Conventional closure", "Quilting suture without drainage", "Conventional closure with drainage"], "outcome": ["Pain", "Health related quality of life : EQ-5D-5L", "Cost-effectiveness assessment", "Cosmesis results", "Homolateral shoulder movement", "Other wound complications", "Wound seroma whatever their type (requiring or not intervention)", "Wound seroma requiring aspiration or surgical intervention", "Surgical morbidity"]}, "NCT00301457": {"age": ["45 Years", "99 Years"], "eligibility": ["Previous hormonal therapy as adjuvant breast cancer treatment besides tamoxifen.", "postmenopausal patients with hormone receptor positive breast cancer who have already received 2 to 3 years of adjuvant tamoxifen, and who never had signs of loco-regional recurrences or distant metastasis"], "condition": ["Breast Cancer"], "location": ["Zaandam", "Geleen", "Heerlen", "Zevenaar", "Roosendaal", "Almelo", "'s-Hertogenbosch", "Winschoten", "Maastricht", "Stadskanaal", "The Hague", "Terneuzen", "Hoogeveen", "Arnhem", "Breda", "Gorinchem", "Zutphen", "Flushing", "Leidschendam", "Alkmaar", "Haarlem", "Heerenveen", "Zoetermeer", "Bergen op Zoom", "Eindhoven", "Amersfoort", "Utrecht", "Apeldoorn", "Hardenberg", "Almere Stad", "Drachten", "Tilburg", "Dordrecht", "Woerden", "Enschede", "Hilversum", "Purmerend", "Leeuwarden", "Tiel", "Winterswijk", "Amsterdam", "Hengelo", "Nieuwegein", "Doetinchem", "Capelle aan den IJssel", "Deventer", "Dirksland", "Netherlands", "Spijkenisse", "Venlo", "Hoofddorp", "Gouda", "Leiden", "Goes", "Research Site", "Ede", "Roermond", "Rotterdam", "Amstelveen", "Veldhoven", "Nijmegen", "Uden", "Emmen", "Sneek", "Hoorn", "Geldrop", "Beugen", "Schiedam", "Zwolle"], "intervention": ["ARIMIDEX", "Anastrozole", "ZD1033"], "outcome": ["To compare the incidence of contralateral breast cancer after 6 years versus 3 years adjuvant anastrozole, subsequent to 2 to 3 years of tamoxifen", "To compare toxicity of 6 years versus 3 years of adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2 to 3 years of tamoxifen", "To compare the cost effectiveness of 3 years versus 6 years adjuvant anastrozole therapy, after subsequent 2 to 3 years of adjuvant tamoxifen treatment.", "To relate the number of osteoporotic fractures during and following treatment with adjuvant anastrozole with the compliance to osteoporotic guidelines.", "To compare the overall survival after 6 years versus 3 years adjuvant anastrozole, subsequent to 2 to 3 years of tamoxifen", "To determine regional differences in the initial treatment of breast cancer retrospectively by collecting baseline information on initial therapies.", "To assess the disease free survival (DFS) with 6 years of adjuvant anastrozole compared with 3 years of adjuvant anastrozole in postmenopausal hormone sensitive breast cancer patients, subsequent to 2 to 3 years of adjuvant tamoxifen", "To assess patterns of care in The Netherlands in prevention, detection and treatment of osteoporosis in postmenopausal women with breast cancer treated with adjuvant anastrozole.", "To analyse occurrence of distant (bone) metastases in relation to occurrence of osteopenia and osteoporosis, and in relation to use of supplements and therapy for reduced BMD."]}, "NCT01144468": {"iv-cont-mean": ["-6.1", "-1.8"], "age": ["18 Years"], "eligibility": ["Women who have ever been on strontium for more than 1 month;", "Women who have ever been on a bisphosphonate for more than 6 months;", "Women participating in the MAP.3 clinical trial at centres with access to HR-pQCT", "Women who are on chronic oral steroids (the equivalent of 5mg of prednisone a day or higher for more than 2 weeks within the past 6 months and will likely require ongoing therapy);", "Women with decompensated diseases of the liver, bowel, kidney, pancreas, lung, or heart.", "Women who have been on any bone drug, such as hormone replacement therapy, selective estrogen receptor modulators, bisphosphonates, teriparatide, parathyroid hormone, sodium fluoride, strontium, calcitonin and high dose vitamin D (more than 2000iu of vitamin D3 daily),in the past 3 months;", "Women with a fragility fracture after age 40;", "Women with T-score of -2.0 or below at the lumbar spine (L1-L4), total hip or femoral neck;", "Women with osteoporosis;"], "condition": ["Osteoporosis", "Breast Cancer"], "location": ["Sacramento", "Mayo Clinic", "Rochester", "Toronto", "Canada", "University of California Davis", "Women's College Hospital", "University Health Network, TGH", "United States"], "intervention": ["Placebo", "Exemestane 25 mg Daily"], "outcome": ["Mean Percent Change in Total Volumetric Bone Mineral Density (BMD) Measured by High Resolution Peripheral Quantitative Computer Tomography (HR-PQCT) From Baseline to 24 Months"], "outcome-Measure": ["Mean Percent Change in Total Volumetric Bone Mineral Density (BMD) Measured by High Resolution Peripheral Quantitative Computer Tomography (HR-PQCT) From Baseline to 24 Months"]}, "NCT00711529": {"iv-cont-median": ["58", "3", "25.5", "7.5", "21.5", "1.5", "4.5", "26", "5", "22", "1", "45.5", "6.5", "4", "10"], "age": ["18 Years"], "eligibility": ["History or active secondary cancer within the last 5 years (except for superficial basal cell skin cancers).", "Women with non-invasive or pre-invasive lesions of the breast, including but not limited to ductal carcinoma in situ (DCIS), atypical ductal hyperplasia (ADH) or lobular carcinoma in situ (LCIS) are eligible for participation.", "Women with a history of breast cancer must have undergone treatment with curative intent.", "Allergy to gabapentin.", "Karnofsky performance status > 70%.", "Able to provide voluntary informed consent.", "Women with histologic confirmation of a diagnosis of infiltrating carcinoma of the breast are eligible for participation.", "adequate hematopoietic function (ANC >= 1500/mm3; Platelets >= 100,000/mm3; Hemoglobin >= 8 g/dL)", "Any woman age 60 years or more who cannot take estrogen therapy because of a real or perceived risk of developing breast cancer are eligible.", "Subjective report of at least one daily hot flash.", "Women with a known breast cancer susceptibility gene (eg, BRCA) mutation or strong family history of breast cancer are eligible.", "Patients must have access to a compact disk player.", "Women under the age of 60 with a Gail model score of 1.6% or more are eligible.", "History of seizure disorder.", "Unable to give informed consent or unable to adhere to protocol.", "adequate renal and hepatic function [Bilirubin <= 1.5 times upper limit of normal (ULN), serum glutamic-oxaloacetic transaminase (SGOT) <= 2.5x ULN, Alkaline phosphatase <= 2.5x ULN, and Creatinine <= 2x ULN].", "Any history of alcohol or drug abuse.", "No clinical evidence of disease (complete remission).", ">= 18 years-old. There will be no upper limit for age inclusion.", "Any serious medical or psychiatric illness likely to interfere with participation in this clinical study, concurrent uncontrolled illness, or ongoing or active infection will be excluded."], "condition": ["Hot Flashes", "Breast Cancer"], "location": ["Providence", "Breast Health Center, Program in Women's Oncology, Women & Infants' Hospital of Rhode Island", "United States"], "intervention": ["gabapentin", "Gabapentin", "mind-body therapy", "Neurontin", "hypnosis", "gabarone", "Hypnotherapy"], "outcome": ["Hot Flash Related Daily Interference Score (HFRDIS)", "Hot Flash Severity Score", "Number of Daily Hot Flashes"], "outcome-Measure": ["Hot Flash Related Daily Interference Score (HFRDIS)", "Hot Flash Severity Score", "Number of Daily Hot Flashes"]}, "NCT00337103": {"iv-cont-median": ["198", "484", "125.0", "119.0", "440", "330", "129", "126"], "iv-cont-mean": ["0.1", "0.7", "-3.7", "1.7", "415.8", "4.8", "0.4"], "iv-bin-abs": ["0.644", "0.580", "11.5", "11.0"], "iv-cont-count_of_participants": ["512", "362", "494", "224", "496", "196", "483", "222"], "age": ["18 Years"], "eligibility": ["Adequate liver function as evidenced by bilirubin <= 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine transaminase (ALT), and aspartate transaminase (AST) <= 3 x ULN (in the case of liver metastases <= 5 x ULN), or in case of bone metastases, liver specific alkaline phosphatase <= 3 x ULN.", "Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception (considered to be two methods of contraception, one of which must be a barrier method, e.g. condom, diaphragm or cervical cap). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.", "Patients with pre-existing neuropathy > Grade 2.", "Female patients with histologically or cytologically confirmed carcinoma of the breast. Every effort should be made to ensure that paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen are available for confirmation of diagnosis.", "Patients who participated in a prior E7389 clinical trial.", "Patients with known positive human immunodeficiency virus (HIV) status.", "Patients willing and able to complete the EORTC (European Organization for Research on the Treatment of Cancer) quality of life questionnaire (QLQ-C30 with breast cancer module QLQ-BR23) and to record their pain level on the Visual Analog Scale (VAS).", "Prior treatment with mitomycin C or nitrosourea.", "Life expectancy of >= 3 months.", "Age >= 18 years.", "Patients willing and able to comply with the study protocol for the duration of the study.", "Significant cardiovascular impairment (history of congestive heart failure > New York Heart Association [NYHA] Grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).", "Patients with known estrogen and/or progesterone receptor-expressing tumors may have additionally been treated with hormonal therapy.", "Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.", "Patients who have received capecitabine as a prior therapy for their disease.", "Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.", "Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >= 1.5 x 10^9/L, hemoglobin >= 10.0 g/dL (a hemoglobin < 10.0 g/dL acceptable if it is corrected by growth factor or transfusion), and platelet count >= 100 x 10^9/L.", "Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin) and a taxane (e.g., paclitaxel, docetaxel), either in combination or in separate regimens.", "Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment with study treatment. Any symptoms attributed to brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing a contrast-enhanced Computed Tomography Scan (CT) or Magnetic Resonance Imaging (MRI) brain scan performed during screening to a prior scan performed at least 4 weeks earlier.", "Radiation therapy encompassing > 30% of marrow.", "Patients with meningeal carcinomatosis.", "Severe/uncontrolled intercurrent illness/infection.", "Patients with organ allografts requiring immunosuppression.", "Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative.", "Patients with known human epidermal growth factor 2 (HER2/neu) over-expressing tumors may additionally have been treated with trastuzumab in centers where this treatment is available.", "Adequate renal function as evidenced by serum creatinine <1.5 mg/dL or calculated creatinine clearance > 50 mL/minute (min) per the Cockcroft and Gault formula.", "Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice."], "condition": ["Metastatic Breast Cancer"], "intervention": ["Capecitabine 2.5 g/m^2/Day", "Eribulin Mesylate 1.4 mg/m^2", "Eribulin Mesylate"], "outcome": ["Change From Baseline in European Organization for the Treatment of Cancer Quality of Life Core Questionnaire Scores Based on Breast Cancer Specific 23 Items (EORTC-QLQ- BR 23) at Week 6", "Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for the Treatment of Cancer Quality of Life Core Questionnaire Scores Based on Core 30 Items (EORTC-QLQ-C30) at Week 6", "Plasma Concentrations of Eribulin Mesylate", "Duration of Response (DOR): Independent Review", "Overall Survival (OS)", "Overall Survival Rate", "Change From Baseline in Pain Intensity by Visual Analog Scale (VAS) Until 30 Days After the Last Dose of Study Drug", "Number of Participants With Consumption of Analgesics During the Study", "Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)", "Objective Response Rate (ORR): Independent Review", "Number of Participants Who Took at Least One Concomitant Medication", "Duration of Eribulin Mesylate Exposure", "Progression Free Survival (PFS)", "Number of Participants With Treatment-emergent Markedly Abnormal Laboratory Parameter Values"], "outcome-Measure": ["Change From Baseline in European Organization for the Treatment of Cancer Quality of Life Core Questionnaire Scores Based on Breast Cancer Specific 23 Items (EORTC-QLQ- BR 23) at Week 6", "Change From Baseline in Global Health Status/Quality of Life (QoL) Measured by European Organization for the Treatment of Cancer Quality of Life Core Questionnaire Scores Based on Core 30 Items (EORTC-QLQ-C30) at Week 6", "Plasma Concentrations of Eribulin Mesylate", "Duration of Response (DOR): Independent Review", "Overall Survival (OS)", "Overall Survival Rate", "Change From Baseline in Pain Intensity by Visual Analog Scale (VAS) Until 30 Days After the Last Dose of Study Drug", "Number of Participants With Consumption of Analgesics During the Study", "Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)", "Objective Response Rate (ORR): Independent Review", "Number of Participants Who Took at Least One Concomitant Medication", "Duration of Eribulin Mesylate Exposure", "Progression Free Survival (PFS)", "Number of Participants With Treatment-emergent Markedly Abnormal Laboratory Parameter Values"]}, "NCT00878709": {"iv-bin-abs": ["8.9", "1.16", "0.8", "0.92", "94.2", "91.3", "91.9", "1.82", "1.1", "11.5", "94.0", "8.2", "8.0", "1.3", "95.5", "99.64", "90.2", "5.4", "99.43", "12.3", "3.8", "5.3", "7.0", "4.7", "6.8", "87.7", "95.3", "7.5", "8.5", "9.2", "3.7"], "age": ["18 Years"], "eligibility": ["Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry.", "Been treated for early breast cancer with standard of care duration of trastuzumab.", "Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease.", "History of gastrointestinal disease with diarrhea as the major symptom.", "History of heart disease.", "Could have been treated neoadjuvantly but have not reached pathologic complete response.", "Corrected QT (QTc) interval >0.45 seconds"], "condition": ["Breast Cancer"], "location": ["Green Bay", "Gyeonggi-do", "Phoenix", "Medical Oncology & Hematology Mercy Medical Center", "Hospital De Basurto", "Rhyl", "Belgium", "Newmarket", "Chiba", "Cherry Hill", "The Hospital Affiliated Academy Military Medical Science, Chinese People's", "Klinikum Kempten - Oberallgaeu", "Grenoble", "Sheffield", "Arizona Cancer Center", "Kuala Lumpur", "Gelre ZH", "Fondazione per la Ricerca e la Cura dei Tumori Tommaso Campanella", "VZW Jesseziekenhuis - Campus Virga Jesse", "Centre Hospitalier de Montlu\u00e7on", "Bethlehem", "Japan", "Jersey Shore University Medical Center", "Kaohsiung City", "Praxis Gynaekologie Arabella Muenchen", "Fort Gordon", "Dr. Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi", "Dallas", "Charleston", "Burton-on-Trent", "Mid-Florida Hematology & Oncology Centers, PA", "Gilroy", "Hospital Provincial de Zamora", "Aventura", "Inova Schar Cancer Institute", "ICO de Girona - Hospital Universitario de Girona Dr. Josep Trueta", "Saint-Priest-en-Jarez", "Gettysburg", "Baton Rouge", "CHU de Li\u00e8ge - Domaine Universitaire du Sart Tilman", "Osaka", "Saint Louis Park", "Mercy Medical Research Institute", "Oxnard", "Charleston Hematology Oncology Associates, PA", "Oncologos del Occidente", "The Center for Cancer and Hematologic Disease", "Poliklinika ADUS", "Glendale Adventist Medical Center Cancer Services", "Hong Kong", "Albert Einstein Cancer Center", "Medicus Alliance Clinical Research Org., Inc.", "Honolulu", "Aichi Cancer Center", "Bydgoszcz", "Cincinnati", "Hamelin", "Port Saint Lucie", "Munster", "Centre Hospitalier Affilie Universitaire de Quebec Hopital du St-Sacrement", "Sozialstiftung Bamberg Klinik fuer Haematologie und Internistische Onkologie", "Institutul Oncologic \"Prof. Dr. Ion Chiricuta\"", "Kirkland", "Durham", "Fairfax", "Oncomedica S.A. IMAT", "Bordeaux", "Westerstede", "Marienhospital Witten", "Sir Paul Boffa Hospital", "Unita' Operativa Complessa Oncologia Medica, A.O.R.N. \"Cardarelli\"", "Helen Diller Family University of California San Francisco Comprehensive Cancer Center", "Trinitas Comprehensive Cancer Center", "Florence", "Sydney", "Innovative Medical Research of South Florida, Inc.", "Norwich", "Hospital de Barbastro", "Gorukle/Bursa", "Olten", "Queen Mary Hospital, Department of Medicine", "Fudan University Shanghai Cancer Center", "Complejo Hospitalario de Jaen", "Centre Henri Becquerel", "Oshawa", "Kortrijk", "Kurume Daiichi Social Insurance Hospital", "Oldenburg", "Sofia", "Pawtuket Memorial Hospital", "Hospital Universitario Fundacion de Alcorcon", "Ieper", "Kanagawa", "Rouen", "Viagrande (CT)", "Betsi Cadwaladr University Health Board", "Vechta", "Petoskey", "Amphia Ziekenhuis - Interne Geneeskunde", "Hospital Universitario Virgen del Rocio", "AZ Nikolaas", "Virginia Cancer Specialists, PC", "C.H.U. Ambroise Par\u00e9", "Medical University of South Carolina Hollings Cancer Center", "C.H.U. De Bordeaux Saint Andre", "Klinicki bolnicki centar \"Sestre Milosrdnice\"", "Minneapolis", "Greece", "University Health Network, Princess Margaret Hospital", "Institute of Oncology and Radiology of Serbia", "Paramus", "D\u00fcsseldorf", "Sint-Niklaas", "Ospedale Treviglio e Caravaggio, UO Oncologia Medica", "Jelenia G\u00f3ra", "UNIMED Medical Institute, Comprehensive Centre for Breast Diseases", "Tokai University Hospital", "Bekes M. Kepviselotest. Pandy Kalman Korhaz, Megyei Onkol. Kp., Klin. Onkol. es Sugartherapias Oszt.", "Gainesville", "Hanover Medical Specialists, PA", "Centre Oscar Lambret", "Klinikum der Johannes-Gutenberg-Universitaet", "Bratislava", "Roskilde", "Leeds", "Minnesota Oncology Hematology, PA", "Concord", "Universitaetsfrauenklinik Tuebingen", "Cancer Specialists of South Texas, P.A.", "Universitaetsklinikum Magdeburg A.oe.R.", "Hospital San Pedro de Alcantara", "Philadelphia", "Masarykuv Onkologicky ustav", "Sumter", "CSSS Alphonse-Desjardins", "Ospedale Belcolle Viterbo", "Florida Cancer Specialists, P.L.", "Wilmington", "Staedtische Kliniken Frankfurt am Main-Hoechst Frauenklinik", "Florida Medical Clinic, P.A.", "NorthEast Oncology Associates Carolinas Medical Center NorthEast", "AZ Zusters van Barmhartigheid", "Auckland", "Willamette Valley Cancer Institute and Research Center", "Pocatello", "Cliniques Universitaires de Bruxelles", "Istanbul", "Hospital Universitario de Canarias", "Alexandroupoli", "Plantation", "Mid Dakota Clinic, PC", "Vancouver", "Fort Worth", "Regionshospital Viborg", "CHU Paul Brousse", "Slovakia", "Osaka Medical Center for Cancer and Cardiovascular Diseases", "Sugar Land", "Multiscan s. r. o.", "Medical Arts Associates, Ltd", "Dijon", "University Malaya Medical Centre", "Austin", "Southington", "Wiesbaden", "Mexico", "Community Hospital", "Frauenarzt-Zentrum-Zehlendorf", "Tarn\u00f3w", "Gaziantep Universitesi", "Queens Hospital", "Wheeling Hospital", "Denton", "Universitaetsfrauenklinikum Schleswig-Holstein", "The Methodist Hospital Breast Center", "London Regional Cancer Program", "Osijek", "Interdistrict Dispensary for Oncology Diseases", "Fukuoka", "Roskilde University Hospital", "Azienda Ospedaliera San Luigi Gonzaga", "Hasselt", "Northeast Arkansas Clinic", "Zagreb", "Miskolc", "Fakultni Nemocnice v Motole", "Osaka University Hospital", "Eindhoven", "Guangzhou", "Malta", "Strasbourg", "University General Hospital of Alexandroupoli, Department of Medical Oncology", "Krakow", "Hospital Universitario Ramon y Cajal", "Southern Medical University Nanfang Hospital", "Brussels", "Hospital Madrid Norte Sanchinarro. Centro Integral Oncologico Clara Campal", "Brindisi", "Girona", "BC Cancer Agency", "Kurralta Park", "Lithuania", "Hangzhou", "Hospital Universitari Son Espases", "St. Bartholomew's Hospital", "Columbia", "Massachusetts General Hospital - Gillette Center", "Cl\u00ednica Vista Alegre / Unidad de Investigacion", "Santa Rosa", "Cadiz", "Azienda Ospedaliera San Giuseppe Moscati", "Oncology and Hematology Specialist", "Weston", "Erfurt", "Hospital Clinico Universitario de Valencia", "North Shore Cancer Research Associates", "Croatia", "Singapore", "Samsung Medical Center", "Hospital Universitario Vall D\u00b4Hebron", "Garland", "The Valley Hospital, Luckow Pavilion", "Singleton Hospital", "Poland", "Pisa", "Kumamoto", "MTV Abts & Partner Kiel", "Bialostockie Centrum Onkologii im. M. Sklodowskiej- Curie w Bialymstoku", "Hematology Oncology Associates", "The Bahamas", "Perelman Center for Advanced Medicine", "National Cancer Center, Center for Breast Cancer", "Providence Cancer Center Oncology and Hematology Care - Westside", "Skopje", "Centre Hospitalier Regional de La Citadelle", "Saitama Cancer Center", "Raleigh", "Massachusetts General Hospital", "Fondazione Giovanni Pascale", "Worcester", "Ronse", "Majadahonda", "Dwight David Eisenhower Army Medical Center", "Cancer Care & Hematology Specialists of Chicagoland", "Soroka University MC, Department of Oncology", "Sweden", "Spital STS AG", "Warsaw", "Baden", "Cerrahpasa/Istanbul", "Swansea", "Texas Oncology - Memorial City", "Hopital Maisonneuve Rosemont", "Texas Oncology P.A.", "Central Maine Healthcare Corp", "Romania", "Azienda Ospedaliera San Gerardo", "District Dispensary for Oncology Diseases Internal Unit- Plovdiv EOOD, Second", "Edmonton", "Specialised Hospital of Active Treatment in Oncology", "Onkologische Gemeinschaftspraxis Frankfurt", "Cross Cancer Institute", "Odense Universitetshospital", "Peking Union Medical College Hospital of Chinese Academy of Medical Sciences", "Ospedale San Pietro Fatebenefratelli", "Catanzaro", "Hospital Clinic i Provincial de Barcelona", "Institute de Cancerologie de la Loire", "Highland", "Nottingham", "The Western Hospital", "Vanderbilt-Ingram Cancer Center", "Hospital General Universitario de Elche", "Greenbrae", "Hippokratio General Hospital of Athens", "Eastchester Center for Cancer Care", "General Hospital Varazdin", "Hospital Universitario Reina Sofia", "Budapest", "Ja\u00e9n", "Torrevieja", "Chicago", "North Mississippi Hematology and Oncology Associates, Ltd.", "Decatur", "Thun", "General Hospital of Chania Ag. Georgios", "Gettysburg Cancer Center", "Pinnacle Health Cancer Center Community Campus", "Zion", "Medical Specialty Associates", "Bornova/Izmir", "Canada", "Florida Cancer Specialists and Research Institute", "Niigata", "Paris", "Capa/Istanbul", "Signal Point Hematology/Oncology, Inc.", "Terni", "Norfolk & Norwich University Hospitals", "Fachpraxis fuer Innere Medizin", "Birmingham", "Saint-Nazaire", "Centre Fran\u00e7ois Baclesse", "Turkey (T\u00fcrkiye)", "Dokuz Eylul Universitesi Tip Fakultesi", "Israel", "Vejle Sygehus", "University Hematology/Oncology Associates PLLC", "Hanover", "Kagoshima", "Cedars-Sinai Medical Group", "Borsod-Abauj-Zemplen M. Korhaz es Egyetemi Okt. K., Klin. Onk., Sugarterapias es Kozp. Szuro Centrum", "CHU Bretonneau Centre Henry Kaplan", "York Hospital Oncology Treatment Center", "Haifa", "Mercy Physicians of Oklahoma", "Mons", "Sydvestjysk Sygehus", "Augsburg", "Offenbach", "Mission Hills", "Centrum Medyczne Ostrobramska Niepubliczny Zaklad Opieki Zdrowotnej \"Magodent\"", "C\u00e1ceres", "East Texas Medical Center Cancer Institute", "Institut Gustave Roussy", "Tucson", "Frankfurt am Main", "Advocate Medical Group", "Summit Medical Group", "Veszpr\u00e9m", "Rigshospitalet", "ICO de Barcelona - Hospital Duran i Reynals, Hospitalet de Llobregat Consorci Sanitari de Terrassa", "Wenatchee", "Avellino", "Terrassa", "Taiwan", "Ehime", "Cluj-Napoca", "Park Nicollet Institute", "Raleigh Hematology Oncology Associates Cancer Centers of North Carolina", "Amstelveen", "Inciralti/Izmir", "Brazil", "Queen Mary Hospital, Department of Clinical Oncology, Professorial Block", "Szpital Morski im. PCK Gdynskie Centrum Onkologii Oddzial Chemioterapii", "Italy", "The Cancer Prevention and Treatment Center", "Purchase Cancer Group", "Kiel", "Glendale", "Oddelenie radioterapie a onkologie", "Center for Oncology Research", "Hematology-Oncology Clinic", "Cookeville Regional Cancer Center", "The Cancer Institute Hospital of Japanese Foundation for Cancer Research", "The Hospital of Lithuanian University of Health Sciences Kauno klinikos Oncology and Haematology Clinic", "Christie Hospital", "Azienda Ospedaliera Universitaria \"Policlinico Vittorio Emanuele\"", "Hospital Universitario Puerta del Mar", "Beaver Medical Group, L.P.", "Centrum Onkologii im. prof. Franciszka \u0141ukaszczyka", "China", "M\u00fcnchen", "Kaiser Permanente Northwest Region Oncology Hematology", "Consorcio Hospitalario Provincial de Castellon", "Southwestern Vermont Regional Cancer Center", "McLeod Oncology and Hematology Associates", "The Bronx", "Le Chesnay", "Lake Success", "Houston", "Adelaide", "Florida Cancer Research Institute", "Hematology Oncology of Indiana", "France", "North Platte", "Crescent City Research Consortium, LLC", "Southeast Nebraska Hematology & Oncology Consultants, PC", "ProHealth Care Associates", "North Adelaide Oncology Calvary Hospital North Adelaide", "Hospital Universitario Miguel Servet", "Simmons Cancer Institute", "Manchester", "Long Beach", "Jihlava", "Clinical centre Nis", "Korea University Anam Hospital, Department of Oncology/Hematology", "NYU Clinical Cancer Center", "Netherlands", "Porto Alegre", "Istanbul Universitesi Istanbul Tip Fakultesi", "Oncologianova GmbH", "Gdansk", "United States", "The Jones Clinic, PC", "AZ Groeninge ampus Maria's Voorzienigheid (MV) Oncologisch Centrum", "Montreal", "Stamford", "Phoebe Cancer Center", "Orange City", "Lethbridge", "The Queen Elizabeth Hospital", "Heraklion", "Kaposi Mor Oktato Korhaz, Onkologiai Centrum", "Marrero", "Catania", "Hospital Virgen de la Salud", "Pardubice", "Heidelberg", "Beijing", "Hyogo Cancer Center", "Kyoto", "Craiova", "Spain", "Demetevler/Ankara", "Wenatchee Valley Medical Center", "Berlin", "Hospital Mutua de Terrassa", "Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hp", "Beersheba", "Surco", "St. Joseph's Oncology", "P\u00e9rigueux", "Guy's Hospital", "Elizabeth", "R.S. McLaughlin Durham Regional Cancer Centre", "Jack Ady Cancer Centre", "Hillerod Hospital", "Jan Yperman Ziekenhuis", "Queen Mary Hospital, Department of Medicine, Blk K", "Atlanta", "Corpus Christi", "Herlev", "Az. St. Jan", "York Village", "Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi", "Texas Oncology", "Sun Yat-Sen University Cancer Center", "Recklinghausen", "Orszagos Onkologiai Intezet \"B\" Belgyogyaszati osztaly", "Bogot\u00e1", "Zaklad Opieki Zdrowotnej MSWiA z Warminsko - Mazurskim Centrum Onkologii w", "Center for Integrative Cancer Medicine, PA", "Aalborg", "Universitaetsklinikum Duesseldorf, Frauenklinik", "Morgantown", "Vejle", "Facharzt fuer Frauenheilkunde und Geburtshilfe", "Peru", "National Hospital Organization Hokkaido Cancer Center", "Viborg", "Ashland-Bellefonte Cancer Center", "Department of Clinical Oncology, Tuen Mun Hospital", "National Hospital Organization Kyushu Cancer Center", "Shanghai", "South Texas Institute of Cancer", "Abington Hematology Oncology Associates, Inc", "Stronach Regional Cancer Centre at Southlake", "Central Indiana Cancer Centers", "Rancho Mirage", "Rutland", "Santa Cruz de Tenerife", "Birmingham Hematology and Oncology Associates, LLC", "San Crist\u00f3bal de La Laguna", "Neptune City", "Aarhus University Hospital", "Klinik und Poliklinik fuer", "London", "Las Palmas de Gran Canaria", "Ko\u0161ice", "Gyula", "Saint Barnabas Health Care System", "Augusta", "Paducah", "Norfolk", "Centre Georges Francois Leclerc", "Breda", "Chang Gung Medical Foundation, Linkou Branch", "Aachen", "Nottingham City Hospital", "Rio Patras", "Morristown", "Oregon Health and Science University", "Tokyo", "Pereira", "Broward General Medical Center", "Kumamoto Municipal Hospital", "OLVZ Medische Oncologie", "Seoul National University Hospital, Department of Internal Medicine", "Willow Grove", "Cancer Centers of Florida", "Kwei-Shan, Taoyuan", "Serbia", "Southend University Hospital", "Luisenkrankenhaus", "Treviglio, BG", "Euromedica General Clinic", "Wheaton Franciscan Cancer Care-All Saints", "Moline", "Hippokration Hospital Athens", "MetroHealth Medical Center", "Tacoma", "Boston", "Oncology Institute of Vilnius University", "Rutland Regional Medical Center", "Uludag Universitesi Tip Fakultesi", "Guthrie Clinic, Limited", "Jabboury Foundation for Cancer Research, Inc.", "Northern Michigan Hematology/Oncology", "University of Cincinnati", "Larissa", "St. Petersburg", "Duke University Medical Center Medical Oncology", "Hopital du Sacre-Coeur de Montreal", "Springfield Clinic, LLP", "Tupelo", "Shizuoka", "Vlietland Ziekenhuis", "Hilton Head Island", "Thompson Cancer Survival Center", "Tianjin Cancer Hospital", "Temple University Hospital", "Skokie", "Tianjin", "Institut Curie, D\u00e9partement d'Oncologie M\u00e9dicale", "Plovdiv", "Klinikum St. Georg/Franziskus, Abteilung fuer Senologie", "Mainz", "Azienda Ospedaliero-Universitaria Pisana", "Niigata Cancer Center Hospital 2-15-3", "Kanagawa Cancer Center", "Lleida", "Boynton Beach", "Aarau", "Affinity Research Limited", "Salt Lake City", "Sihhiye/Ankara", "Samaritan Hematology & Oncology Consultants", "Clermont-Ferrand", "Hiroshima City Hospital", "Kreiskrankenhaus Hameln, Onkologische Ambulanz", "Kyoto University Hospital", "Weston Park Hospital", "Zhejiang Cancer Hospital", "Guadalajara", "Ziekenhuis Amstelland", "Bialystok", "University Hospital of Patras", "Augusta Oncology Associates (ACORN), P.C.", "Kantonsspital Olten-Medizinische Onkologie", "Shizuoka Cancer Center", "Grand Rapids", "Hematology Oncology, PC", "North Broward Medical Center", "Springfield", "Aalborg Sygehus", "National Hospital Organization Shikoku Cancer Center", "Azienda Ospedaliera Bianchi Melacrino Morelli", "Centro Oncologico de Galicia", "Middletown", "Elche", "Aarhus C", "Ny\u00edregyh\u00e1za", "Midwest Center for Hematology/Oncology", "Australia", "Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w", "Cascade Cancer Center", "Albany", "Turnhout", "Facharzt fuer Frauenheilkunde", "Chania", "Cancer Hospital, Chinese Academy of Medical Sciences", "Denmark", "Caen", "Qu\u00e9bec", "Fakultni nemocnice Brno", "Service d'Oncologie et de Radiotherapie, Polyclinique Francheville, 38", "Saitama", "Klinik f\u00fcr Gynaekologie und gyn. Onkologie", "Copenhagen", "Clinique Sainte Anne Centre de Radioth\u00e9rapie", "Klinikum Oldenburg GmbH", "Monongahela", "Pawtucket", "Hospital General Universitario Gregorio Mara\u00f1on", "Tyler", "West Virginia University Mary Babb Randolph Cancer Center", "Knoxville", "El Paso Cancer Treatment Center - West", "Vilnius", "Rush University Medical Center", "Tel Litwinsky", "Harrisburg", "Nucleo de Especialidades Oncol\u00f3gicas", "Auckland Hospital", "Besevler/Ankara", "Reggio Calabria", "Hiroshima", "Cancer Care Centers of South Texas", "Francisco Gonzalez MD PA", "Hospital Universitario de Guadalajara", "Connecticut Oncology and Hematology", "Ostend", "Kantonsspital Baden", "Sheba Medical Center, Oncology Institute Tel Hashomer", "St. Marienhospital Vechta", "New York", "University Hospitals, Cleveland Medical Center", "Chattanooga", "University Hospital Center Zagreb", "Hopital La Pitie-Salpetriere", "University Cancer Institute, LLC", "Westminster", "Cancer Center of Central Connecticut", "Bruges", "Varna", "Padua", "Niles", "Istanbul Universitesi Cerrahpasa Tip Fakultesi, Ic Hastaliklari Anabilim Dali", "Orchard Healthcare Research, Inc.", "Redwood Regional Medical Group", "Bennington", "Hospital Universitario Nuestra Se\u00f1ora de Candelaria", "Tours", "Hospital Clinico San Carlos", "Arizona Oncology Associates", "San Francisco Oncology Associates", "Colombia", "Indianapolis", "Ronald Yanagihara, M.D.", "Lewiston", "Bucharest", "Breastlink Medical Group", "Virginia Oncology Associates", "Hirslanden Medical Center Tumor Center", "Rehovot", "Quincy Medical Group, Cancer Center at Blessing Hospital", "Thomas Jefferson University", "Capitol Comprehensive Cancer Care Clinic", "Veszprem Megyei Csolnoky Ferenc Korhaz Nonprofit Zrt.", "Kaunas", "Saint Joseph", "Bilbao", "Aurora BayCare Medical Center", "Esbjerg", "M.D. Anderson Cancer Center Orlando", "Istituto Oncologico del Mediterraneo", "Asan Medical Center", "Praxis f\u00fcr interdisziplinaere Onkologie & Haematologie GbR", "Administradora Country S.A-Clinica del Country", "Viterbo", "Ventura County Hematology-Oncology Specialists", "Josa Andras Oktatokorhaz Egeszsegugyi Szolgaltato Nonprofit Kft. / Onkoradiologiai Osztaly", "A Coru\u00f1a", "Montana Cancer Specialists", "University General Hospital of Larissa", "Sayre", "Washington University School of Medicine Siteman Cancer Center", "Freiburg im Breisgau", "Vara\u017edin", "Alcorc\u00f3n", "Fovarosi Onkormanyzat Szent Imre Korhaz", "Ege Universitesi Tip Fakultesi", "District Dispensary for Oncology Diseases Internal Unit- Plovdiv EOOD, Ist", "Cancer Care Northwest-North", "Onkologische Schwerpunktpraxis", "El Paso", "Interna onkologicka klinika", "Loxahatchee Groves", "Anniston Oncology", "South Texas Oncology & Hematology", "National Cancer Centre Singapore", "Hospital Universitari Arnau de Vilanova de Lleida", "N\u00e6stved Sygehus", "Witten", "Seoul", "North Adelaide", "Arizona Oncology Associates, PC - HAL", "Washington D.C.", "Gemeinschaftspraxis fuer Haematologie und Onkologie", "Castellon", "Jonesboro", "Badalona", "Ogden", "AZ Damiaan - Site Sint-Jozef", "Germantown", "Nemocnice Jihlava", "Cancer and Hematology Centers of Western Michigan", "Brno", "Barbastro", "Straub Clinic & Hospital", "Oncology and Hematology of West Broward", "Zaragoza", "Roma", "Sint-Elisabethziekenhuis", "Pole Hospitalier Mutualiste", "Chiba Cancer Center", "Semmelweis Egyetem Radiologiai \u00e9s Onkoterapias Klinika", "Hokkaido", "Sygehus Sonderjylland", "C\u00f3rdoba", "Hospital Universitari Germans Trias i Pujol", "Hiller\u00f8d", "Oncologia Medica A, Istituti Fisioterapici Ospitalieri", "Hopital Saint Louis", "IRCCS Istituto Oncologico Veneto di Padova", "Missoula", "Cookeville", "Great Plains Regional Medical Center", "Schiedam", "Orbis Medisch Centrum", "Uniwersyteckie Centrum Kliniczne w Gdansku", "Nov\u00e1 Ves pod Ple\u0161\u00ed", "Sioux Falls", "Li\u00e8ge", "Ocala", "Rambam Health care campus, Oncology institute", "Prague", "Cooper University Hospital", "Floriana", "Charing Cross Hospital, Department Of Medical Oncology", "Toledo", "Maxima Medisch Centrum", "Northwest Medical Specialties PLLC", "Washington Cancer Institute at Washington Hospital Center", "Tamarac", "Czechia", "Spokane", "Herlev Hospital", "Olsztynski Osrodek Onkologiczny Kopernik Sp. z o.o.", "Westcliff-on-Sea", "District Dispensary for Oncology Diseases Internal Unit- Sofia EOOD", "National Cancer Center Hospital East", "Hospital de Torrevieja", "San Francisco", "Bend", "Long Beach Memorial Medical Center", "University Hospital Centre Osijek, Department of Radiotherapy and Oncology", "Institut Onkologie a Reahabilitace na Plesi", "Nashville", "Torrington", "Hospital Universitario Insular de Gran Canaria", "University Hospital of Heraklion", "N\u00e6stved", "Orbassano (TO)", "CancerCare Manitoba", "Corvallis", "Lakeland", "Hospital Clinico Universitario Virgen de La Victoria", "Georgsmarienh\u00fctte", "Toronto", "Presidio Ospedaliero di Summa - Antonio Perrino", "Hematology Oncology Associates of Treasure Coast", "Consorci Sanitari de Terrassa", "Sedona", "Anniston", "Voorhees Township", "Bismarck", "Hy\u014dgo", "North Macedonia", "T\u00fcbingen", "Haga Ziekenhuis", "Onkologiska Kliniken", "Facey Medical Group", "Pius-Hospital Oldenburg", "Gynecologic Oncology Associates", "Monter\u00eda", "Ni\u0161", "CHU Strasbourg", "Kaohsiung Medical University Chung-Ho memorial Hospital", "Texas Oncology Cancer Care and Research Center", "Hospital Sao Lucas da Pontificia Universidade Catolica do Rio Grande do Sul", "Barbara Ann Karmanos Cancer Institute", "Desert Hematology Oncology Medical Group, Inc", "Monza", "Sweeney-Melenyser Pavillion", "Wheeling", "Sydney West Cancer Trials Centre", "Nashville Breast Center", "Waco", "Frauenklinik der J.W. Goethe-Universitaet", "Beverly Hills", "Deerfield Beach", "Detroit", "Olsztyn", "Jichi Medical University Hospital", "Bacs-Kiskun Megyei Korhaz Onkoradiologiai Kozpont", "Aichi", "Germany", "Coastal Bend Cancer Center", "Szpital Wojewodzki im. Sw. Lukasza Samodzielny Publiczny Zaklad Opieki", "Malaysia", "Sittard-Geleen", "Madrid", "Kaposv\u00e1r", "SC Oncolab S.R.L.", "Kaplan Medical Center, Department of Oncology", "United Kingdom", "Lincoln", "National Hospital Organization Osaka National Hospital", "Zamora", "Newport Beach", "Orchard Research, LLC", "Cleveland", "L\u00fcbeck", "Barcelona", "South Korea", "Palma de Mallorca", "Seville", "Zephyrhills", "Iron Cancer Care South Brisbane", "Napoli", "Columbia University Medical Center, Herbert Irving Comprehensive Cancer Center", "Ashland", "Northwest Cancer Specialist, P.C.", "Piedmont Cancer Institute", "S\u00f8nderborg", "Bedford", "Poprad", "Fort Lauderdale", "South Brisbane", "Switzerland", "Harry and Jeanette Weinberg Cancer Center", "Nedlands", "Kecskem\u00e9t", "New Zealand", "Hakuaikai Medical Corporation Sagara Hospital", "Gazi Universitesi Tip Fakultesi", "Odense C", "Klinik fuer Gynaekologie und Geburtshilfe", "Bend Memorial Clinic", "The Hague", "Praxisklinik Krebsheilkunde fuer Frauen", "Skanes Onkologiska Kliniken", "Athens", "South Carolina Cancer Specialists", "Alliance Hematology Oncology, PA Carroll County Cancer Center", "Sora (FR)", "Hopital de Versailles", "Hacettepe Universitesi Tip Fakultesi", "Baltimore", "Hospital Puerta de Hierro-Majadahonda", "Nassau", "Joliet", "Oklahoma City", "Portneuf Medical Center", "Gdynia", "Sehitkamil/Gaziantep", "Texas Oncology - Baylor Charles A. Sammons Cancer Center", "San Antonio", "St James's University Hospital", "Universitaetsklinikum Duesseldorf", "Mountain Lakes", "Thessaloniki", "University Hospitals of Leicester", "Magdeburg", "Cancer Care Specialists of Illinois, Decatur Memorial Hospital Clinical Research", "Utah Cancer Specialists", "Portland", "Livingston", "The Christ Hospital Cancer Center", "Marienhospital", "Onkologische Praxis", "Santee Hematology Oncology", "Universita Campus Bio-Medico", "Centre Rene Gauducheau", "Lakeland Regional Cancer Center", "Arizona Oncology Associates, PC - NAHOA", "Racine", "Spitalul Universitar de Urgenta Bucuresti", "Winnipeg", "Aalst", "Bulgaria", "Azienda Ospedaliera S. Maria", "Hungary", "University Clinic for Radiotherapy and Oncology", "Orlando", "Midwestern Regional Medical Center", "Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Wojewodzki Oddzial", "Florida Cancer Affiliates - Ocala", "Mercy Hospital Oncology/Hematology Center", "Hollywood Private Hospital", "Kempten", "Valencia", "L'Hospitalet de Llobregat", "Lund", "Texas Oncology, P.A.", "Lille", "University of Texas Southwestern Medical Center Simmons Cancer Center", "Bamberg", "Apeldoorn", "Royal Melbourne Hospital", "Soquel", "Saint-Herblain", "C.H.U.M. - Hopital Notre-Dame, Departement d'Oncologie", "Chinese People's Liberation Army General Hospital", "St Louis", "Melbourne", "Nationales Centrum fuer Tumorerkrankungen", "North Utah Associates", "Fundacion Instituto Valenciano de Oncologia", "California Cancer Care", "Tochigi", "Jefferson City", "Avera Medical Oncology and Hematology - Avera Cancer Institute", "Villejuif", "Taipei TOC", "Oncologie department, Hopital albert Michalon", "M\u00e1laga", "Ashford Cancer Centre Research", "Humber River Regional Hospital - Church Street Site", "Belgrade", "Leicester", "Quincy", "Ospedale SS Trinita", "Oncology-Hematology of Lehigh Valley, PC", "University of Massachusetts Memorial Medical Center", "National Taiwan University Hospital"], "intervention": ["Placebo", "neratinib", "placebo", "Neratinib", "HKI-272", "Nerlynx"], "outcome": ["Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 5", "Distant Disease-free Survival (DDFS) in Neratinib Arm Compared to Placebo Arm at Year 2", "Percentage of Participants With Time to Distant Recurrence (TTDR) Event in Neratinib Arm Compared to Placebo Arm at Year 5", "Distant Disease-free Survival (DDFS) in Neratinib Arm Compared to Placebo Arm at Year 5", "Kaplan-Meier Estimates of Invasive Disease-free Survival (iDFS) at Year 2 by Treatment Arms", "Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2", "Overall Survival (OS)", "Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) in Neratinib Arm Compared to Placebo Arm at Year 2", "Kaplan-Meier Estimates of Time to Distant Recurrence (TTDR) Survival at Year 2 by Treatment Arms", "Kaplan-Meier Estimates of Distant Disease-free Survival (DDFS) at Year 2 by Treatment Arms", "Central Nervous System Recurrence in Neratinib Arm Compared to Placebo Arm at Year 2", "Percentage of Participants With Time to Distant Recurrence (TTDR) Event in Neratinib Arm Compared to Placebo Arm at Year 2", "Kaplan-Meier Estimates of Invasive Disease-free Survival (iDFS) at Year 5 by Treatment Arms", "Cumulative Incidence of Central Nervous System Recurrence (CNS) at Year 5", "Kaplan-Meier Estimates of Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) at Year 2 by Treatment Arms", "Cumulative Incidence of Central Nervous System Recurrence (CNS) at Year 2", "Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) in Neratinib Arm Compared to Placebo Arm at Year 5"], "outcome-Measure": ["Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 5", "Distant Disease-free Survival (DDFS) in Neratinib Arm Compared to Placebo Arm at Year 2", "Percentage of Participants With Time to Distant Recurrence (TTDR) Event in Neratinib Arm Compared to Placebo Arm at Year 5", "Distant Disease-free Survival (DDFS) in Neratinib Arm Compared to Placebo Arm at Year 5", "Kaplan-Meier Estimates of Invasive Disease-free Survival (iDFS) at Year 2 by Treatment Arms", "Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2", "Overall Survival (OS)", "Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) in Neratinib Arm Compared to Placebo Arm at Year 2", "Kaplan-Meier Estimates of Time to Distant Recurrence (TTDR) Survival at Year 2 by Treatment Arms", "Kaplan-Meier Estimates of Distant Disease-free Survival (DDFS) at Year 2 by Treatment Arms", "Central Nervous System Recurrence in Neratinib Arm Compared to Placebo Arm at Year 2", "Percentage of Participants With Time to Distant Recurrence (TTDR) Event in Neratinib Arm Compared to Placebo Arm at Year 2", "Kaplan-Meier Estimates of Invasive Disease-free Survival (iDFS) at Year 5 by Treatment Arms", "Cumulative Incidence of Central Nervous System Recurrence (CNS) at Year 5", "Kaplan-Meier Estimates of Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) at Year 2 by Treatment Arms", "Cumulative Incidence of Central Nervous System Recurrence (CNS) at Year 2", "Disease-free Survival Including Ductal Carcinoma in Situ (DFS-DCIS) in Neratinib Arm Compared to Placebo Arm at Year 5"]}, "NCT00049829": {"age": ["65 Years", "89 Years"], "eligibility": ["No history of severe liver, kidney or eye disease", "Female, 65-89 years old", "Using hip protectors", "Current bisphosphonate users such as Aredia\u00ae (pamidronate), Didronel\u00ae (etidronate), Fosamax\u00ae (alendronate), Actonel\u00ae (risedronate), Skelid\u00ae (tiludronate)"], "condition": ["Osteoporosis"], "location": ["Sioux Falls", "Naples", "Clinical Pharmacology Study Groups", "Nuremberg", "Osteoporosis Prevention Center", "Walnut Creek", "Norfolk", "Worcester", "CRA Research", "Spokane", "Newark", "Oregon Health and Science University", "Rhode Island Hospital, Osteoporosis Research/ Bone Density Unit", "Richmond", "Providence", "Oakland", "University of Tennessee Health Science", "Mercerville", "Wichita", "Palm Beach Research Center", "Boston", "Winthrop U Hospital", "VA Commonwealth University", "West Palm Beach", "Southern Arizona VA", "Chicago", "Avera Research Institute", "Cincinnati", "Radiant", "Sarasota", "Munster", "Diablo Clinical Research, Inc", "Einstein", "Memphis", "Osteoporosis Clinical Trial Center", "Osteoporosis Medical Center", "Arizona Arthritis Research", "McGuire Veterans Affairs Medical Center", "Pittsburgh", "Orthopaedic Hospital", "Birmingham", "Roger William Medical Center", "Beverly Hills", "Comprehensive Clinical Trials, LLC", "Endwell", "University of Cincinnati Bone Health and Osteoporosis Center", "Germany", "School of Medicine", "Altoona Center for Clinical Research", "New Mexico Clinical Research and Osteoporosis Center, Inc", "Phoenix OB-GYN Associates, LLC", "Wyomissing", "Maine Center for Osteoporosis Research and Education", "Cleveland", "Tucson", "United Osteoporosis Centers (UOC)", "Tyler", "Heartland Research Associates, LLC", "Colorado Center for Bone Research", "Internal Medicine Associates", "Hagerstown", "Albuquerque", "Medical Specialists", "Fort Lauderdale", "Paradise Valley", "Seattle", "Los Angeles", "Gainesville", "Anchor Research Center", "Osteoporosis Research Unit", "University of California Davis- Gen Med Research", "Radiant Research- San Diego", "Northeast Clinical Research", "Stuart", "Novartis", "Moorestown", "Philadelphia", "Duncansville", "University of Pittsburgh", "Lakewood", "The Foundation for Osteoporosis Research and Education", "Little Rock", "Cleveland Clinic Foundation", "San Antonio", "The Physicians Clinic", "Indianapolis", "Washington University School of Medicine", "United States", "Thomas Jefferson University Hospital", "University of Alabama at Birmingham", "San Diego", "Portland", "Sarasota Arthritis Center", "Center for Arthritis and Osteoporosis", "Hamden", "Longmont", "West Cancer Clinic", "Midland", "University of Texas Health Center at Tyler -Center for Clinical Research", "Mineola", "Hampton Roads Center for Clinical Research, Inc", "Northwestern University Center for Clinical Research", "Elizabethtown", "Bangor", "St Louis", "Fargo", "Longmont Medical Research Network", "University of Arkansas for Medical Science", "Sacramento", "Brigham and Women's Hospital", "Arthritis Regional Research Center", "Sam Clinical Research Center", "Health Core", "Endwell Family Physicians", "Diabetes Regional Research Center"], "intervention": ["Zoledronic Acid"], "outcome": ["Incidence of new vertebral fxs", "New and/or worsening vertebral fxs", "All clinical fxs", "Percent change in hip BMD", "Incidence of hip fxs"]}, "NCT02030353": {"age": ["18 Years"], "eligibility": ["Health problems which preclude ability to walk for physical activity (e.g., lower limb amputation)", "Treatment of diabetes with insulin, due to the concerns about hypoglycemia", "Possession and usage of an Internet e-mail address or willingness to sign up for a free email account", "Plans for major surgery (including breast reconstruction) during the intervention time frame", "Report a past diagnosis of or treatment for a Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR) eating disorder (anorexia nervosa or bulimia nervosa)", "Currently using prescription weight loss medications", "Self-identify as African American or black", "Untreated hypertension, hyperlipidemia, or diabetes, unless permission is provided by their health care provider", "Physician approval to participate", "Currently pregnant, pregnant within the past 6 months, or planning to become pregnant within the next 6 months", "History of heart attack or stroke within past 6 months", "Report a diagnosis of psychiatric diseases (schizophrenia, bipolar disorder, depression leading to hospitalization in the past year), drug or alcohol dependency.", "No evidence of progressive disease or second primary cancers", "Willing to be randomized", "Female, age 18 or older", "Diagnosed with stage I-IIIA breast cancer within the last 10 years", "Completed cancer treatment (except endocrine treatment) with full recovery of any treatment associated toxicities to <= Grade 1 or baseline", "Have access to the Internet and a computer on at least a weekly basis", "Have the ability to read, write and speak English", "Body mass index of 20-45 kg/m\u00b2", "Inability to attend 3 assessment visits (baseline, 3 months, and 6 months) at the University of North Carolina Weight Research Program center"], "condition": ["Body Weight Changes", "Breast Neoplasms"], "location": ["Chapel Hill", "University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center", "United States"], "control": ["Delayed intervention control"], "intervention": ["Self-regulation plus activity monitoring"], "outcome": ["Change in cholesterol", "Change in waist circumference", "Change in blood pressure", "Change in physical activity", "Change in triglycerides", "Proportion of participants with completed assessments at 3 months", "Proportion of participants with completed assessments at 6 months", "Weight change", "Change in hemoglobin A1c", "Change in dietary intake"]}, "NCT04255225": {"age": ["18 Years"], "eligibility": ["women over the age of 18", "pregnant", "under 18 years of age", "history of dementia or organic brain syndrome", "non-consent of physician", "reported trouble with memory/concentration", "fluent in English", "unable to walk unassisted", "physician's consent", "no longer undergoing treatment", "male", "not currently pregnant", "inability to communicate in English", "no diagnosis of breast cancer", "no health reasons that would prevent ability to exercise", "currently undergoing treatment for breast cancer", "no reported trouble with memory or concentration", "diagnosis of breast cancer", "able to walk unassisted", "no history of dementia or organic brain syndrome"], "condition": ["Breast Cancer", "Cognitive Impairment", "Cancer-related Problem/Condition", "Physical Activity"], "intervention": ["Walking for 10 minutes"], "outcome": ["Change in working memory by walking as a function of walking duration (10, 20 or 30 minutes)", "Change in attention by walking as a function of walking duration (10, 20 or 30 minutes)", "Change from baseline in anxiety levels after one bout of exercise as assessed by the Hospital Anxiety and Depression Scale (HADS) questionnaire.", "Change in cognitive flexibility by walking as a function of walking duration (10, 20 or 30 minutes)", "Change in processing speed by walking as a function of walking duration (10, 20 or 30 minutes)", "Mental health as a predictor of change in cognitive function (executive function domains: working memory, attention/inhibition/cognitive flexibility and processing speed) after acute exercise", "Body mass index as a predictor of change in cognitive function (executive function domains: working memory, attention/inhibition/cognitive flexibility and processing speed) after acute exercise", "Lifestyle physical activity as a predictor of change in cognitive function (executive function domains: working memory, attention/inhibition/cognitive flexibility and processing speed) after acute exercise"]}, "NCT02620735": {"age": ["75 Years", "18 Years"], "eligibility": ["Current pregnancy or planned pregnancy within 9 months)", "Planned surgery during study; 4) not willing to be randomized.", "Plans to join a weight-loss or exercise program within 9 months)", "Baseline participation of < 60 min of weekly pre-planned PA", "Within 2 years of completion of adjuvant therapy, with the exception of hormone therapy, for early stage (0-IIIA) BrCa", "Physician permission for moderate PA participation 4)Able to read and write English", "Able to attend in-person exercise training sessions and physiologic assessments at prescribed intervals."], "condition": ["Breast Neoplasms"], "location": ["Toronto", "Canada", "ELLICSR, Toronto General Hospital 200 Elizabeth St."], "intervention": ["Fit bit Device"], "outcome": ["Recruitment Rate", "Group cohesion measure - Physical Activity Group Environment Questionnaire (PAGEQ)", "Change in quality of life - Functional Assessment of Cancer Therapy-Breast (FACT-B)", "Change in breast cancer related physical symptoms - The Breast Cancer Prevention Trial (BCPT) Symptoms Scale", "Change in Cardiorespiratory fitness - \"VO2\"(oxygen consumption) Peak (mlO2/kg/min)", "Acceptability:Participants perceptions regarding their experience of the study and if they liked it", "Change in state of depressive symptoms - The Center for Epidemiological Studies-Depression Scale Short Form (CESD-SF)", "Change in waist circumference (WC) (cm)", "Change in breast cancer related fatigue - Functional Assessment of Cancer Therapy-Fatigue (FACT-F) subscale", "Change in grip strength (kg of force)", "Change in body mass index (kg/m2)", "Change in fear of recurrence - Fear of Recurrence Questionnaire (FRQ)", "Change in body fat percentage (%)", "Change in indices of anxiety - Spielberger's State-Trait Anxiety Inventory-State (STAI-S)", "Change in exercise frequency - Leisure-Time Exercise Questionnaire (LTEQ)", "Retention Rate", "Treatment Implementation and Fidelity - length, number and quality of health coaching phone sessions", "Capture of Outcomes - proportion of participants from whom complete information is derived on clinical outcomes."]}, "NCT02162667": {"iv-bin-abs": ["84.27", "39.92", "51.61", "41.41", "4.84", "46.77", "4.69", "50.39", "55.08", "83.98"], "iv-cont-number": ["0.99", "0.96", "0.98", "1.00", "41", "35", "0.95"], "iv-cont-mean": ["186.428", "18.915", "178.567", "18.905"], "age": ["18 Years"], "eligibility": ["Patient who has histologically confirmed and newly diagnosed breast cancer", "Patient who has clinical stage I, II, or IIIa operable breast cancer according to AJCC (American Joint Committee on Cancer) Breast Cancer Staging 7th edition", "Patient who has bilateral breast cancer", "Patient who has HER2-positive status confirmed locally, defined as 3+ score by IHC (immuno-histochemistry)."], "condition": ["HER2-positive Carcinoma of Breast"], "intervention": ["CT-P6", "Trastuzumab", "Herceptin"], "outcome": ["Disease-free Survival", "Maximum Serum Concentration After Administration (Cmax) in Each Cycle", "The Percentage of Patients Achieving Pathological Complete Response (pCR) of the Breast Regardless of DCIS With Positive or Unknown Nodal Status", "The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)", "Overall Response Rate (ORR) From Local Review", "The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes With Absence of DCIS", "Trough Serum Concentration (Ctrough) in Each Cycle", "The Number of Patients Who Had Progressive Disease or Recurrence", "Overall Survival", "Progression-Free Survival"], "outcome-Measure": ["Disease-free Survival", "Maximum Serum Concentration After Administration (Cmax) in Each Cycle", "The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes Regardless of DCIS", "The Percentage of Patients Achieving Pathological Complete Response (pCR) of the Breast Regardless of DCIS With Positive or Unknown Nodal Status", "The Percentage of Patients Achieving Pathological Complete Response Defined as the Absence of Invasion Tumor Cells in the Breast and in Axillary Lymph Nodes, Regardless of Ductal Carcinoma in Situ (DCIS)", "Overall Response Rate (ORR) From Local Review", "The Percentage of Patients Achieving Pathological Complete Response of the Breast and Axillary Nodes With Absence of DCIS", "Trough Serum Concentration (Ctrough) in Each Cycle", "The Number of Patients Who Had Progressive Disease or Recurrence", "Overall Survival", "Progression-Free Survival"]}, "NCT01148823": {"age": ["70 Years", "18 Years"], "eligibility": ["presence of skin lesions on the surgical site", "use of antibiotics at the time of the operation", "body mass index over 35Kg/m2", "\u2022candidate to immediate or delayed breast reconstruction after mastectomy or segmental mastectomy", "hard smoking"], "condition": ["Surgical Site Infection"], "location": ["Hospital das Clinicas Samuel Lib\u00e2nio, Universidade do Vale do Sapuca\u00ed", "Pouso Alegre", "Brazil"], "intervention": ["Incisions covered for 1 day", "PO6", "Incisions covered for 6 days", "PO1"], "outcome": ["Skin colonization", "Surgical site infection (SSI)", "Patients self assessments"]}, "NCT01480869": {"age": ["18 Years"], "eligibility": ["Hypervitaminosis D", "Legal inability or restricted legal ability. Medical or psychological conditions not allowing proper study completion or informed consent signature", "Known severe hypersensitivity to vitamin D or to calcium supplementation or to one of the excipients.", "trait\u00e9s dans les 5 ans pr\u00e9c\u00e9dents.", "Affiliation to a social security regime or beneficiary of equivalent social protection", "Written informed consent provided before any study specific procedures", "Complementary inclusion criterion for randomization", "WHO performance status 0-1", "Disease and/or medical conditions accompanied by hypercalcaemia and/or hypercalciuria", "Calcium lithiasis and tissue calcification", "i) Uncontrolled endocrine disease ii) Known disorders of calcium phophorus laboratory testing iii) Proved osteopenia or osteoporosis requiring vitamin D and calcium supplements", "Age >=18 years old", "\\- Proved vitamin D deficiency as defined by serum vitamin D level lower than 30 ng/ml (75 nmol/L).", "Pregnancy, breastfeeding or of reproductive potential not using an effective contraceptive method", "Metastatic disease", "Contraindication to calcium or cholecalciferol"], "condition": ["Breast Cancer"], "location": ["France", "CRLC Val d'Aurelle-Paul Lamarque", "Montpellier"], "intervention": ["calcium and cholecalciferol"], "outcome": ["Clinical and biological tolerance profile", "Normalization rate of serum 25-OHD level", "Quality of life", "Impact of study treatments on bone and joint pains induced by aromatase inhibitors", "Normalization rate of serum 25-OHD level in control patients who shift to experimental strategy", "Baseline vitamin D/calcium status in this patient population", "Treatment compliance", "Predictive value of individual biomarkers", "Changes in vitamin and calcium biological markers", "To evaluate the increase in normalization of serum vitamin D level"]}, "NCT03148886": {"age": ["78 Years", "18 Years"], "eligibility": ["pregnancy", "medical certificate of no contraindications to exercise physical activity", "able to complete questionnaires and follow instructions in French", "unable to be followed for medical, social, familial, geographical or psychological reasons over the study duration,", "valid health insurance affiliation.", "aged 18 to 78 years old,", "deprivation of liberty by court or administrative decision", "untreated brain metastases", "newly diagnosed with a metastatic breast cancer (i.e. within the last 3 months)", "being French-speaking", "uncontrolled cardiac disease,", "contraindications to PA,", "ECOG Performance status <2,"], "condition": ["Metastatic Breastcancer"], "location": ["France", "Centre L\u00e9on B\u00e9rard", "Lyon"], "intervention": ["PA intervention"], "outcome": ["Variation of oxidative stress", "Investigate the effects of a PA intervention on quality of life", "Investigate the barriers and facilitators of adherence to a PA program", "Proportion of patients achieving the physical activity program recommendations", "Investigate the effects of a PA intervention on fatigue", "Investigate the effects of a PA intervention on changes in anthropometrics", "Investigate the effects of a PA intervention on social deprivation", "Investigate the effects of a PA intervention on fitness level"]}, "NCT00769470": {"age": ["70 Years", "18 Years"], "eligibility": ["Bilateral invasive breast cancer", "ECOG performance status 0-1 Adequate organ function (ejection fraction>- lower limit of normal) as determined by MUGA or echocardiogram.", "HER2/neu-positivity by fluorescence in situ hybridization (FISH)", "Adequate organ function as defined by the following laboratory values", "pre-existing motor or sensory neurotoxicity >= grade 2 by NCI NTCAE version 3.0", "Estrogen receptor- and progesterone receptor-negative", "New York Heart Association class II-IV congestive heart failure", "AP <= 2.5 times ULN AND ALT/AST <= 1.5 times ULN", "Histologically or cytologically confirmed adenocarcinoma of the breast", "If female of childbearing potential, pregnancy test is negative and is willing to use effective contraception while on treatment and for at least 3 months after the last dose of study therapy.", "patient is willing to provide written informed consent prior to performance of any study-related procedure.", "Inflammatory breast cancer, defined as the presence of erythema or induration involving > 1/3 of the breast", "patient is accessible and willing to comply with treatment, tissue acquisition and follow up.", "Women aged 18 to 70 years, inclusive", "active, uncontrolled infection requiring parenteral antimicrobials", "Estrogen and progesterone receptor status known prior to study entry.", "Myocardial infarction within the past 6 months", "Creatinine < 1.5 mg/dL", "Grade > 1", "Unstable angina", "Metastatic disease", "AP <= 5 times ULN AND AST/ALT normal", "Age <= 35 years", "Absolute neutrophil count >= 1,500/mm\u00b3", "pregnant or lactating subjects", "Hemoglobin >= 9.0 g/dL", "male subjects", "AP normal AND AST/ALT <= 2.5 times upper limit of normal (ULN)", "Platelet count >= 100,000/mm\u00b3", "concurrent ovarian hormonal replacement therapy. Prior treatment must be stopped prior to first baseline biopsy.", "Total bilirubin <= 1.0 times upper limit of normal (ULN) (< 3 times ULN in patients with Gilbert's syndrome confirmed by genotyping or Invader UGTIA1 molecular assay)"], "condition": ["Breast Cancer"], "location": ["Cancer Institute of Florida, PA - Orlando", "Wilshire Oncology Medical Group, Incorporated - Pomona", "Henderson", "Northridge", "Orlando", "Santa Maria", "Bakersfield", "St. Jude Heritage Medical Group at Virginia K. Crosson Cancer Center", "Hematology and Oncology Consultants, PA - Orlando", "Pomona", "Haute Terre", "Comprehensive Cancer Centers of Nevada - Henderson", "New Mexico Cancer Center", "Santa Barbara Hematology Oncology - Solvang", "Providence Medical Group", "Torrance", "Fullerton", "Comprehensive Blood and Cancer Center", "Solvang", "Cancer Care Associates Medical Group, Incorporated - Redondo Beach", "United States", "Sansum Medical Clinic", "Central Coast Medical Oncology Corporation", "North Valley Hematology-Oncology Medical Group", "Central Hematology Oncology Medical Group, Incorporated - Alhambra", "Santa Barbara", "Alhambra", "Albuquerque", "Florida Hospital Cancer Institute"], "intervention": ["trastuzumab"], "outcome": ["Pathologic complete response (pCR)", "Comparison of pCR rates"]}}